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Abstract 
Neisseria meningitidis is an important cause of meningitis and septicaemia 
worldwide. Invasive meningococcal disease (IMD) is cyclical and varies by age 
group, being more common in children, especially those under 5 years. However, 
IMD is a rare outcome relative to asymptomatic carriage of the organism by the 
host and disease-causing isolates represent the tip of the iceberg in terms of the 
overall meningococcal population biology. The emphasis of previous research 
into N. meningitidis has rested firmly on the study of IMD isolates. In more 
recent times, however, there has been a more conscious effort to re-dress this 
balance to aid in our understanding of the relationship between carriage and 
disease.  
The Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus 
Reference Laboratory (SHLMPRL) have accrued an extensive isolate archive 
dating back to the 1960s. Only recently with the expansion of molecular 
techniques has the SHLMPRL begun to investigate this valuable resource. For 
around a decade or more the SHLMPRL have routinely used genotyping 
techniques to characterise all IMD isolates it receives. However, these methods 
have hitherto not been employed to investigate isolates of the archive not 
obtained from cases of IMD. 
This study sought to characterise a collection of carried meningococci assembled 
from the isolate archive of the SHLMPRL that was obtained during the 31-year 
period, 1974 – 2004. Multi-locus sequence typing (MLST), porA Variable Region 
(VR) subtyping and a panel of genogrouping PCRs was used to characterise 791 
carriage isolates. Temporal analyses of the data revealed how the presence of 
individual serogroups, clonal complexes, Sequence Types (STs), PorA subtypes 
and individual strain types in carried meningococci had changed in Scotland. 
Furthermore, these data were used in a comparison with a previously 
characterised collection of IMD isolates obtained during the same 31-year period 
to investigate the association of individual serogroups, clonal complexes, STs, 
PorA subtypes and individual strain types either with a carriage phenotype or 
with invasive disease. 
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Nongroupable isolates [Odds Ratio: OR 17.66; 95% Confidence Interval: CI (12.71 
to 24.54)] and those of serogroups W135 [OR 2.49; 95% CI (1.72 to 3.60)], Y [OR 
6.26; 95% CI (4.18 to 9.39)], X [OR 3.13; 95% CI (1.20 to 8.14)], Z [OR 131.89; 
95% CI (18.00 to 960.76)] and 29E [OR 21.30; 95% CI (4.76 to 95.36)] were 
significantly associated with a carriage phenotype. In contrast, serogroups A [OR 
3.64; 95% CI (1.96 to 6.76)], B [OR 2.65; 95% CI (2.25 to 3.12)] and C [OR 1.92; 
95% CI (1.58 to 2.33)] were significantly associated with invasive disease. 
The carriage strain collection reported herein was also observed to be highly 
diverse with the majority of STs identified only once.  This diversity observed 
within the carriage strain collection [0.981; 95% CI (0.955, 1.006)] was 
significantly greater than the diversity within an IMD strain collection [0.938; 
95%CI (0.934, 0.942)] from the same period. Temporal changes in the most 
prevalent clonal complexes (ccs) were observed throughout the 31-year period 
with increases in cc22, cc41/44 and cc269 and decreases in cc1, cc5, cc8, cc11, 
cc32, cc35, cc37, cc254, cc334 and cc364. Furthermore, for several ccs a 
significant association with a carriage phenotype (cc22, cc23, cc35, cc92, cc167, 
cc174, cc212, cc213, cc254, cc461, cc750, cc1157 and meningococci unassigned 
to a clonal complex) or with invasive disease (cc1, cc8, cc11, cc32, cc41-44 and 
cc269) was observed. Four lineages were identified amongst capsule null locus-
containing meningococci, two of which, cc53 and cc1117, contained a unique 
allele (cnl-8) that was distinct from isolates of these lineages reported 
elsewhere. 
Despite significant associations at the level of cc, distinct differences in those 
associations were apparent for individual STs within a given clonal complex; 
most notably the significant association of ST41 and both ST43 and ST44 with 
invasive disease and a carriage phenotype, respectively. A feature of the 
carriage strain collection was the concentration of cc8 isolates during the period 
1984 – 1986 and the high proportion of isolates obtained from individuals 
resident in Lanarkshire at a time when an episode of increased disease was 
experienced within that region. In this study, cc8 was found to be significantly 
associated with invasive disease. Furthermore, whilst ST8 was also significantly 
associated with invasive disease the most common strain type within cc8, 
C:8:8:5,2,36-2, [OR 1.68; 95% CI (1.25, 2.27)] was however, significantly 
associated with a carriage phenotype. The strain types B:213:22,14,36 [OR 2.38 
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(95% CI 1.40, 4.07)] and B:43:19,15-1,36 [OR 2.88 (95% CI 1.42, 5.88)] were also 
significantly associated with a carriage phenotype. 
Due to the heterogeneity of PorA subtypes in meningococci in Scotland the 
potential coverage by experimental or licensed PorA-based OMV vaccines would 
be limited. Therefore the introduction of monovalent or multivalent PorA-based 
vaccines in Scotland may be of little benefit. Improved strain coverage as a 
whole, not just against those of serogroup B, may require the addition of other 
vaccine antigens. Several other vaccine targets, including factor H-binding 
protein, are currently under investigation to improve coverage. Surveillance of 
these antigens and of the different lineages and serogroups in carriage and IMD 
isolates is essential to accurately monitor the effects that future vaccines will 
have on the meningococcus. We must remain vigilant despite a downward trend 
in cases of meningococcal disease in more industrialised countries. 
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1 Introduction 
1.1 Neisseria meningitidis - the meningococcus 
Neisseria meningitidis, the meningococcus, is a Gram negative diplococcus that 
colonises the human nasopharynx. The meningococcus can be carried 
asymptomatically by up to 30% of the general population and infrequently will 
invade the host and cause disease. Of the Neisseria spp. only N. meningitidis and 
N. gonorrhoeae are considered pathogenic and their only known host is man. 
Meningococci are transmitted directly by person-to-person contact or close 
contact via aerosols. 
N. meningitidis is an important cause of meningitis and septicaemia worldwide. 
Invasive meningococcal disease (IMD) is cyclical and varies by age group, being 
more common in children, especially those under 5 years. A further peak in 
disease occurs in adolescence and rates decline during early adulthood and 
subsequently increase in older age groups (van Deuren, Brandtzaeg et al. 2000; 
Rosenstein, Perkins et al. 2001). The prevalence of different serogroups changes 
over time and can vary by geographic location. In temperate climates most cases 
of meningococcal disease occur during the winter or early spring, while in the 
“meningitis belt” in sub-Saharan Africa, the incidence of meningococcal 
infection rises sharply towards the end of the dry and dusty season (the 
harmattan) and falls with the onset of the rains (Jones 1995). 
Diagnosis of IMD is problematical as initial symptoms are often non-specific and 
resemble other respiratory illnesses. The progression of disease is rapid, case-
fatality rates exceed 10% and permanent sequelae are even more common. 
Isolation of the causative organism is not always possible, particularly if 
antibiotics have been administered prior to hospital admission, and laboratory-
confirmed cases of IMD are increasingly being diagnosed by non-culture methods. 
Vaccination remains the best form of disease prevention. However, currently 
licensed vaccines do not offer broad protection against all serogroups, or are not 
immunogenic in those individuals most at risk of IMD (i.e. infants <2 years). 
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The meningococcus currently remains an important pathogen of man despite the 
best efforts of the medical and scientific communities over the preceding two 
centuries and longer. The potential of genomic sequencing offers exciting 
prospects for the future of meningococcal research and as the complexity of this 
bacterium is unravelled perhaps a more potent method for the eradication of 
meningococcal disease can be discovered. Meanwhile, current strategies to 
control the burden of N. meningitidis should not be taken for granted; 
vaccination and antibiotic use has been shown to be effective in high-risk 
populations. However, continued surveillance is required to establish the long-
term effect on individual lineages should they undergo genetic changes that 
render a particular vaccine or antibiotic ineffective. 
 
1.2 Historical perspectives 
Although it is thought that the English physician Thomas Willis (1621-75) was 
probably first to report an outbreak of cerebrospinal fever, Vieusseux is usually 
credited with the first clear account of epidemic meningitis with his description 
of an outbreak during March 1805 in Geneva, Switzerland. This was soon 
followed by the first formal description of an outbreak in the USA. Consequently 
over the next decade reports of meningococcal disease spread throughout the 
eastern United States and Canada. Descriptions on both sides of the Atlantic 
soon followed. During the first half of the 19th century the clinical 
characteristics were clearly recognised: its contagious nature (although the 
cause was unknown at the time); the predilection of the disease for the military; 
sudden onset of meningococcal disease; extremely high mortality and the 
capacity to infect most members of a family within a few days. It was not until 
1887 that Anton Weichselbaum first isolated an organism (which he called 
diplococcus intracellularis meningitidis) from the meningeal exudates of six out 
of eight cases of primary, sporadic meningitis. The first demonstration that 
patients with meningococcal meningitis could also carry the bacteria in the 
oropharynx came around the same time (Cartwright 1995a). 
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Formal notification systems were in place in many UK cities not long after the 
start of the 20th Century. At this time meningococcal disease in the UK appeared 
to be a particular problem in large cities, perhaps associated with poverty and 
overcrowding. Substantial outbreaks of cerebrospinal fever in Glasgow in 1906-7 
and in Belfast in 1907-8 were documented. Compulsory notification of many 
infectious diseases, including cerebrospinal fever, was introduced in Britain in 
September 1912. During the following three years (1912-14) notified cases in 
England & Wales varied from 87 to 315. In contrast, the first full year of World 
War I (1915) saw 3496 notified cases. Numerous outbreaks in British and colonial 
army recruits began to occur and investigations by Captain JA Glover of the 
Royal Army Medical Corps (RAMC) at the Guards Depot Caterham, London found 
a close correlation between periods of severe overcrowding and the 
meningococcal carrier rate (Cartwright 1995a). 
The first group of specific antimicrobial agents, the sulphonamides, became 
widely available in time to be used in large outbreaks of meningococcal 
meningitis which occurred in combatant countries during mobilisation at the 
outset of World War II. In 1940, for example, there were more than 12,000 
notified cases in Britain. The introduction of sulphonamides had a dramatic 
effect on mortality in meningococcal meningitis, and they were also first used 
during the war to successfully treat carriage. Later in World War II, penicillin 
became available following Fleming’s 1929 discovery and the subsequent 
purification of the active agent by Florey and Chain (Cartwright 1995a). During 
the latter part of the 20th Century, progress in reducing mortality rates has 
slowed somewhat despite improvements in the recognition and diagnosis of 
meningococcal disease and early intervention with antimicrobials. 
 
1.3 Characterisation of Meningococci  
1.3.1 Introduction 
The meningococcus has on its surface several structures including outer 
membrane proteins (OMPs) and capsular polysaccharide that have been used as a 
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means of characterising strains. OMPs can be differentiated into five classes 
(Class 1-5) according to molecular weight. The meningococcus has several OMPs 
including PorA (Class 1), PorB (Class 2/3), Rmp (Class 4) (which has homology to 
E. coli OmpA) and the Class 5 Opa and Opc proteins. Other proteins involved in 
meningococcal pathogenesis include iron limitation-induced OMPs i.e. FetA 
(previously known as FrpB), the transferrin-binding proteins, Tbp-1, Tbp-2 and 
37kDa Fe-binding protein, Fbp. FetA is an iron-regulated OMP that is also a 
vaccine target. However, its antigenic diversity may limit its usefulness or 
require the inclusion of multiple variants (Thompson, Feavers et al. 2003; Urwin, 
Russell et al. 2004). The PorA and FetA proteins are European Monitoring Group 
for Meningococci (EMGM)-recommended typing targets (Jolley, Brehony et al. 
2007). 
N. meningitidis can be classified serologically using antisera raised by 
immunising lab animals: into serogroups on the basis of structural differences in 
their capsular polysaccharide; into serotypes according to variation in their Class 
2 or 3 OMPs (PorB) and into serosubtypes according to variation in their Class 1 
OMPs (PorA) (Frasch, Zollinger et al. 1985; Abdillahi and Poolman 1988). 
Lipopolysaccharide can also be used to define immunotypes. Serological 
classification methods are phenotypically based and suffer from the deficiency 
that groupings based on them may contain strains that are genotypically 
dissimilar. Furthermore, the panel of monoclonal antibodies (MAbs) is not 
exhaustive nor do isolates always react, resulting in many nongroupable (NG), 
nontypeable (NT) or nonsubtypeable (NST) strains (Brooks, Fallon et al. 1995; 
van der Ende, Hopman et al. 1995; Feavers, Fox et al. 1996). Consequently, 
molecular typing schemes are increasingly replacing phenotypically-based 
techniques (Russell, Jolley et al. 2004). Numerous different methodologies have 
been published in the peer-reviewed literature; each has its own advantages and 
disadvantages. 
Several molecular typing techniques have been used to characterise 
meningococcal isolates. This list is by no means complete but has included 
Multilocus Enzyme Electrophoresis (MLEE) (Selander, Caugant et al. 1986), 
Multilocus Sequence Typing (MLST) (Maiden, Bygraves et al. 1998), Pulsed-Field 
Gel-Electrophoresis (PFGE) (Bygraves and Maiden 1992; Yakubu, Abadi et al. 
1994; Bevanger, Bergh et al. 1998), Polymerase Chain Reaction-Restriction 
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Fragment Length Polymorphism (PCR-RFLP) have been used to discriminate 
between serogroup (Borrow, Claus et al. 1998) or class 1 OMP (Speers and Jelfs 
1997; Stefanelli, Fazio et al. 2001) and class 2/3 OMP PorB (Stefanelli, Fazio et 
al. 2001), Amplified Fragment Length Polymorphism (AFLP), Ribotyping (Woods, 
Helsel et al. 1992; Verdu, Coll et al. 1999), Variable Number Tandem Repeat 
(VNTR) (Yazdankhah, Kesanopoulos et al. 2005; Yazdankhah, Lindstedt et al. 
2005), Single-Stranded Conformation Polymorphism (SSCP) (Newcombe, Dyer et 
al. 1997; Kesanopoulos, Tzanakaki et al. 2005), Matrix-Assisted Laser 
Desorption/Ionization – Time Of Flight (MALDI-TOF) analysis for genotyping 
(Lowe, Diggle et al. 2004; Honisch, Chen et al. 2007) and pyrosequencing to 
discriminate between strains (Diggle and Clarke 2004) or in determining reduced 
susceptibility to antibiotics (Thulin, Olcen et al. 2008). Various reviews and 
comparisons of the merits, or otherwise, of many of these methods have been 
published in the literature (Swaminathan, Matar et al. 1996; Yakubu, Abadi et 
al. 1999; Diggle and Clarke 2006). 
 
1.3.2 Polysaccharide capsule: (sero)group 
1.3.2.1 Introduction 
Meningococci can be divided into twelve serogroups; A, B, C, H, I, K, L, W-135, 
X, Y, Z and Z’(29-E), on the basis of structural differences in their capsular 
polysaccharide (Liu, Gotschlich et al. 1971a; Liu, Gotschlich et al. 1971b; 
Bundle, Jennings et al. 1973; Bundle, Smith et al. 1974; Bhattacharjee, Jennings 
et al. 1975; 1976; Bhattacharjee, Jennings et al. 1978; Jennings, Lugowski et al. 
1983; van der Kaaden, van Doorn-van Wakeren et al. 1984; van der Kaaden, 
Gerwig et al. 1985). However, the majority of disease is caused by serogroups A, 
B, C, W-135, Y and more recently X, although this varies geographically (Jones 
1995; Rosenstein, Perkins et al. 1999; Djibo, Nicolas et al. 2003). Capsular 
polysaccharide of the disease-associated serogroups B, C, W-135 and Y are 
composed of sialic acid (Liu, Gotschlich et al. 1971a). Sialic acid is an N-
acetylated nine-carbon acidic ketose (N-acetyl neuraminic acid; NeuNAc or 
NANA) that results from the condensation of pyruvic acid and N-acetyl 
mannosamine (ManNAc). The serogroup B and C capsules are homopolymers of 
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sialic acid linked α2-8 and α2-9, respectively. The α2-9 polysialyl capsule 
(serogroup C) is variously O-acetylated; the α2-8 polymer (serogroup B) is not. 
The serogroup Y and W-135 capsules are co-polymers of NeuNAc linked α2-6 to 
glucose (serogroup Y) or galactose (serogroup W-135) and both are variously O-
acetylated. The serogroup B capsule is poorly immunogenic and is known to be 
structurally homologous with sialic acid in human cell lines (Neural cell adhesion 
molecule; NCAM) (Finne, Leinonen et al. 1983; Finne, Bitter-Suermann et al. 
1987). Consequently, alternative means must be sought when developing 
vaccines to target serogroup B meningococcal disease. Serogroup A meningococci 
have a polymer of (alpha 1-6)-linked N-acetyl-D-mannosamine-1-phosphate 
(ManNAc-P) for a capsule (Liu, Gotschlich et al. 1971b). 
 
1.3.2.2 Capsule biogenesis 
The genetic basis of capsular polysaccharide synthesis, transport and expression 
has been studied extensively. The region of the chromosome responsible is 
termed the capsule locus (cps) and can broadly be divided into three regions; A, 
B, C, that contain the genes responsible for synthesis, modification and 
transport, respectively (Figure 1.1). 
 
 
Figure 1.1 - Schematic of the cps complex of Neisseria meningitidis 
Region A, capsule synthesis operon (synXBCD; also known as siaABCD); Region B, transport 
(lipA/B or ctrE/D); Region C, capsule transport operon (ctrABCD); Region D, LOS synthesis; 
Region E, regulation; P, divergent promoter (Swartley, Marfin et al. 1997) 
 
 
 
 
 
 
Figure 1.1 has been removed due to copyright restrictions 
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Early studies cloning the cps from Group B meningococci into Escherichia coli 
revealed that a 24kb fragment was required for expression on the cell surface 
(Frosch, Weisgerber et al. 1989). This region showed homology to some or all 
other N. meningitidis capsular serogroups or Neisseria species depending on the 
region studied (Frosch, Weisgerber et al. 1989; Frosch, Edwards et al. 1991; 
Swartley, Ahn et al. 1996). Subsequently it has been shown that the capsule 
transport operon, ctrABCD (region C), and capsule synthesis operon, 
siaABCD/synxBCD (region A), are divergently transcribed from a shared 134bp 
promoter region (Swartley, Ahn et al. 1996; Tzeng, Swartley et al. 2001). 
Enzymes encoded by siaA-C synthesise sialic acid (CMP-NANA) and are conserved 
among sialic acid-producing serogroups B, C, W-135 and Y (Ganguli, Zapata et al. 
1994; Swartley, Marfin et al. 1997). Sialyltransferases, which catalyzes the 
serogroup-specific linkage of sialic acid homopolymers or sialic acid with glucose 
or galactose is encoded by the fourth gene of the sia operon, siaD and is unique 
for each serogroup (Claus, Vogel et al. 1997). Serogroup A capsular 
polysaccharide is composed of (alpha 1-6)-linked N-acetyl-D-mannosamine-1-
phosphate (Liu, Gotschlich et al. 1971b) and the genes encoding this capsule 
operon, mynA-D, are unique to this serogroup. Novel capsule biosynthesis genes 
are also present in serogroup X meningococci (Tzeng, Noble et al. 2003). Some 
homology has been suggested between xcbA (serogroup X), sacB (serogroup A) 
and lcbA (serogroup L) (Tzeng, Noble et al. 2003), however the cps of the less 
common serogroups has not been described in the literature. 
The capsule transport operon, ctrABCD, is highly conserved amongst serogroups 
B, C, W-135, Y, and A. The proteins encoded form a predicted ABC transporter 
that translocates capsular polysaccharide chains from the cytoplasm to the 
surface of the meningococcus (Frosch, Edwards et al. 1991; Frosch, Muller et al. 
1992; Frosch and Muller 1993). The ctrA gene has been used as a non-specific 
target to identify meningococcal DNA in clinical specimens from individuals 
suspected of having meningococcal disease (Corless, Guiver et al. 2001) and as a 
serogroup-specific target to identify serogroups A, H, X, Z or 29E strains (Sadler, 
Fox et al. 2003; Bennett, Mulhall et al. 2004). 
Chapter 1                                                                                                                                          36 
Flanking ctrABCD and siaABCD are tex (Region E) and galE or galU (Region D) 
which are located 5’ and 3’ respectively. Nucleotide sequences between siaD 
and galE/U vary depending on the strain sequenced. The nucleotide sequence of 
the tex gene is highly similar to hypothetical proteins of unknown function in E. 
coli and Haemophilus influenzae (Frosch, Edwards et al. 1991; Petering, 
Hammerschmidt et al. 1996) while in Bordetella pertussis the tex gene locus 
negatively affects toxin expression (Fuchs, Deppisch et al. 1996). Upstream of 
tex are lipA and lipB (Region B), which were originally proposed to be involved 
in cytoplasmic phospholipid substitution of the capsular polysaccharide chains 
(Frosch and Muller 1993), but more recently have been found to be involved in 
translocation and surface expression of the lipidated polymer (Tzeng, Datta et 
al. 2005). Furthermore, the authors proposed renaming LipA and LipB as CtrE 
and CtrF, respectively, to reflect their roles in capsule translocation, not 
lipidation (Tzeng, Datta et al. 2005). LipA and LipB are present in encapsulated 
N. meningitidis but not found in N. gonorrhoeae or N. lactamica. In N. 
gonorrhoeae and N. lactamica, tex and galE are adjacent to each other. These 
species are acapsulate and the genes responsible for synthesis and transport of 
capsule polysaccharide in N. meningitidis are absent from other members of the 
genus Neisseria (Frosch, Muller et al. 1992; Claus, Maiden et al. 2002). 
 
1.3.2.3 Capsule switching 
The exchange of DNA coding for the sialyltransferase by meningococci enables 
clones to express different capsular polysaccharide (Swartley, Marfin et al. 
1997). Reports from continental Europe describing capsule switching in clinical 
isolates of N. meningitidis (Stefanelli, Fazio et al. 2003; Lancellotti, Guiyoule et 
al. 2006) is of particular importance to countries like the UK who have, since 
1999, been using the Meningococcal serogroup C polysaccharide-protein 
conjugate (MCC) vaccine. Fortunately capsule switching has not been reported 
as yet in the UK (Maiden and Stuart 2002; Mooney, Christie et al. 2004; Diggle 
and Clarke 2005). Beddek and colleagues provided evidence that an invasive 
meningococcal strain may have acquired an entire capsule locus from a carriage-
associated strain (Beddek, Li et al. 2009). Molecular surveillance data from 
Portugal during 2002 – 2006 indicates that C-to-B capsule switching has occurred 
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in some invasive lineages (Simoes, Cunha et al. 2009). The authors also 
highlighted the emergence of a number of B:2b:P1.5,2 strains (based on current 
nomenclature, rather than that used by the authors) in neighbouring Spain 
following an epidemic wave due to C:2b:P1.5,2 strains during 1996-7 (Alcala, 
Arreaza et al. 2002a; Alcala, Salcedo et al. 2002b).  
The epidemic strain in Spain pre-dates those reported by Simoes et al 2009 
Rather than the Portuguese B:2b:P1.5,2 strain arising as a result of capsule 
switching from a Portuguese C:2b:P1.5,2 strain it may be the case that the 
B:2b:P1.5,2 strain that emerged in Spain may have dispersed into, and become 
maintained in, the Portuguese population. Furthermore, the Spanish B:2b:P1.5,2 
strain was thought to have arisen due to strain displacement rather than a 
detectable capsule-switching event (Alcala, Arreaza et al. 2002a; Alcala, 
Salcedo et al. 2002b). Subsequent surveillance data in Spain observed a further 
serogroup C epidemic after 1999 due to the C:2a:P1.5 ST-11 strain. Following 
mass vaccination in 2002 with the MCC vaccine dramatic reductions in serogroup 
C disease in Spain were observed (Salleras, Dominguez et al. 2003). However, 
cases of meningococcal disease due to the B:2a:P1.5 strain that may have 
undergone a recombination event involving the cps have been reported (Castilla, 
Vazquez et al. 2009). 
Reports of possible capsule switching have not been restricted to continental 
Europe. In Canada, it is possible that strains may have undergone a Y-to-B 
capsule switch (Tsang, Law et al. 2005). Active Bacterial Core surveillance 
(ABCs) data from the United States seems to indicate that transformation events 
leading to capsule switching may not be rare; particularly among serogroup C 
isolates (Harrison 2008; Harrison, Shutt et al. 2010). In their study of 1,180 
isolates from the period 2000 – 2005, Harrison and colleagues observed that 518 
(43.9%), 281 (23.8%) and 319 (27.0%) isolates were of serogroup B, C and Y, 
respectively. A further 62 (5.3%) were of other serogroups or NG. Isolates of 
serogroup B (n=8, 1.5%), C (n=32, 11.4%) and Y (n=2, 0.6%) (Harrison 2008) or, in 
an updated report on 1,160 isolates, eight of serogroup B, three of serogroup Y 
and 36 of serogroup C  showed evidence of capsule switching (Harrison, Shutt et 
al. 2010). Evidence for capsule switching in an isolate was defined “as the 
presence of an unusual ST-serogroup combination; specifically a genetic 
sequence type (ST)/clonal complex in an isolate of a serogroup more generally 
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associated with another serogroup” (Harrison 2008). The authors presented data 
indicating 35 B-to-C, seven C-to-B, two W-135-to-Y and one W-135-to-B capsule 
switching events (Harrison 2008; Harrison, Shutt et al. 2010). 
 
1.3.2.4 Capsule-deficient meningococci 
Rates of carriage of meningococci in more industrialised countries are typically 
around 10% (Jolley, Kalmusova et al. 2000; Claus, Maiden et al. 2005). A high 
proportion of carriage isolates are unencapsulated and are defined as NG. In a 
study of carriage strains from the Czech Republic nearly half the isolates were 
NG (Jolley, Kalmusova et al. 2000). The genetic basis for this has been 
investigated; often unencapsulated strains possess the genes necessary for 
capsule synthesis and transport but one or more genes can be inactivated by a 
variety of mechanisms (Jolley, Kalmusova et al. 2000; Claus, Maiden et al. 2002; 
Dolan-Livengood, Miller et al. 2003; Weber, Claus et al. 2006). Some isolates 
have been shown to harbour one or two homopolymeric tracts, exhibiting length 
variation in the serogroup B, W-135 and Y polysialyltransferase genes, as well as 
in the siaA gene, which could be phase variable (Weber, Claus et al. 2006). 
Irreversible mutation of the cps complex by one-base pair deletions, insertions 
of 1-34bp, or single nucleotide polymorphisms leading to premature stop codons 
can occur in some isolates (Weber, Claus et al. 2006). Insertion sequence (IS) 
elements, including IS1301 which is often found in the same position in the siaA 
gene,  or others found at various positions of the cps complex, can also lead to 
loss of encapsulation (Arreaza, Alcala et al. 2001; Dolan-Livengood, Miller et al. 
2003; Weber, Claus et al. 2006). 
Alternatively, unencapsulated strains lack the genes required for capsule 
synthesis (siaA-D) and transport (ctrA-D) (Claus, Maiden et al. 2002); regions A 
and C in Figure 1.1, respectively. Characterisation of the meningococcal 
capsule-synthesis cluster in carried meningococci isolated from healthy subjects 
in Bavaria, Germany has shown that a significant proportion of isolates harbour a 
non-coding intergenic region of either 113 or 114bp in length, termed the 
capsule null locus (cnl) (Claus, Maiden et al. 2002). The cnl of a subset of the 
Bavarian isolates was sequenced and compared to different strains of N. 
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lactamica and N. gonorrhoeae, which are acapsulate. This identified six 
different alleles; some alleles were found in more than one of the three species 
(Claus, Maiden et al. 2002). Additionally the cnl was associated with particular 
lineages. This may suggest a reduced  dependence on expression of a capsule for 
transmission in meningococci possessing the cnl, compared to other 
meningococci (Claus, Maiden et al. 2002). 
Interestingly, there have been reports in the literature of cnl-possessing 
meningococci causing disease in immunocompromised and, more remarkably, 
immunocompetent individuals (Vogel, Claus et al. 2004b; Hoang, Thomas et al. 
2005; Findlow, Vogel et al. 2007). It has been demonstrated that polysaccharide 
capsule promotes survival in extracellular fluids like the bloodstream, mediating 
resistance to phagocytosis and complement-mediated bacteriolysis (serum 
resistance) (Vogel, Weinberger et al. 1997; Kahler, Martin et al. 1998) and also 
aids in intracellular survival in vitro (Spinosa, Progida et al. 2007). However, our 
understanding has been challenged by these reports of capsule-deficient strains 
causing IMD. 
Other normally encapsulated bacterial species, such as Streptococcus 
pneumoniae and H. influenzae, are also frequently characterised as nontypeable 
(NT) or unencapsulated. Unencapsulated S. pneumoniae can be isolated from 
disease and carriage, particularly in association with epidemics of conjunctivitis 
among healthy young people. Characterisation of a collection of genuine NT 
pneumococci isolated from carriage and acute otitis media among children in 
Finland identified a lineage of NT pneumococci that had lost its capsular locus 
(Hanage, Kaijalainen et al. 2006). Moreover, H. influenzae that lack capsular 
polysaccharides are referred to as nontypeable (NTHi). Although NTHi are most 
commonly associated with asymptomatic colonisation, they are also pathogenic. 
H. influenzae is frequently associated with otitis media, chronic bronchitis, and 
community-acquired pneumoniae, and the strains associated with these mucosal 
infections are NTHi (Erwin, Nelson et al. 2005; Erwin and Smith 2007). 
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1.3.3 Neisserial Porins: PorB (sero)type & PorA (sero)subtype  
Neisserial porins function as pores and are essential for bacterial survival as they 
modulate the exchange of ions between the bacterium and its surroundings. N. 
meningitidis expresses two porin proteins, PorA and PorB, on its outer 
membrane. Topology models of neisserial porins predicts PorA to be composed 
of highly conserved transmembrane sequences that form a β-sheet structure 
with eight surface exposed loops (Loops I-VIII) (Figure 1.2) (van der Ley, Heckels 
et al. 1991). 
 
Figure 1.2 - Schematic of the N. meningitidis class 1 OMP PorA 
VR, variable region; (Derrick, Urwin et al. 1999) 
 
Three dimensionally, PorA forms a trimer (Figure 1.3) and all but two of the 
loops vary extensively in both length and sequence (Derrick, Urwin et al. 1999). 
One loop, Loop II, is important in monomer-monomer interactions, while Loop III 
is proposed to lie inside the pore of each monomer, potentially influencing pore 
function (Derrick, Urwin et al. 1999). 
 
 
 
 
 
 
 
 
 
Figure 1.2 has been removed due to copyright restrictions 
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Figure 1.3 - Three-dimensional structure of monomeric and trimeric PorA 
A, cross-sectional view of monomeric PorA; B, aerial view of trimeric PorA; roman numerals 
correspond to the individual loops as indicated in Figure 1.2 (Derrick, Urwin et al. 1999) 
 
Traditionally, serotyping (PorB) and serosubtyping (PorA) were performed using a 
panel of monoclonal antibodies (MAbs) (Abdillahi and Poolman 1988), however 
meningococci are often only partially serosubtyped or increasingly, are classified 
as non-serosubtypable either because a variant is not recognised by MAbs or 
because PorA is not expressed (Jelfs, Munro et al. 2000; Devoy, Dyet et al. 
2005). To overcome these problems nucleotide sequencing of porB (Abad, Alcala 
et al. 2006) and porA VR1 (Loop I) and VR2 (Loop IV) is now becoming the 
method of choice. This allows VR families and variants to be assigned on the 
basis of amino acid sequence relationships rather than their reactivity with 
MAbs. The nomenclature was revised and family groupings were determined with 
≥ 80% amino acid identity as a guide, or where amino acid identity was slightly 
below 80%, the presence of a particular motif representative of the family 
(Russell, Jolley et al. 2004). Furthermore, sequencing of VR3 (Loop V) has shown 
that strains possessing identical VR1 and VR2 can have a different VR3, although 
variation is less diverse (Molling, Unemo et al. 2000; Molling, Backman et al. 
2001; Clarke, Diggle et al. 2003b). 
PorA is also a target for meningococcal vaccines (Devoy, Dyet et al. 2005; Oster, 
Lennon et al. 2005; Martin, Ruijne et al. 2006); therefore it is important to 
monitor the evolution of variation within this protein in the meningococcal 
population to inform vaccine policy and monitor the effects of strain specific 
 
 
 
 
 
Figure 1.3 has been removed due to copyright restrictions 
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vaccines or multivalent vaccines based on PorA subtypes, should they be 
introduced. This is also particularly relevant following the reports of a PorA-
deficient invasive meningococcal strain isolated during an outbreak (van der 
Ende, Hopman et al. 2003) and a porA-negative strain isolated from a sporadic 
case (van der Ende, Hopman et al. 1999) given that the stable expression of PorA 
would be required for a PorA-based vaccine to be fully efficacious.  
Variable expression of PorA can be caused by guanidine residue insertion and/or 
deletion due to slipped-strand mispairing on the polyguanidine stretch within the 
intervening sequence of the -35 and -10 regions of the promoter (van der Ende, 
Hopman et al. 1995; van der Ende, Hopman et al. 2000; Devoy, Dyet et al. 
2005). Additionally, it seems variation due to mutations in the VR2 epitope that 
compromises recognition by the serosubtypes-specific MAbs is more common 
(Jelfs, Munro et al. 2000; Devoy, Dyet et al. 2005). The insertion element IS1301 
has been found to lead to insertional inactivation of the porA gene (Newcombe, 
Cartwright et al. 1998). As mentioned previously, IS1301 has been shown to 
mediate capsule phase variation in N. meningitidis by reversible insertional 
inactivation of the siaA gene (Arreaza, Alcala et al. 2001; Dolan-Livengood, 
Miller et al. 2003; Weber, Claus et al. 2006) and is widely distributed in 
meningococci, but varies with serotype in the isolates studied (Hilse, 
Hammerschmidt et al. 1996; Hilse, Stoevesandt et al. 2000). Given that IS1301 
was found in multiple copies in N. meningitidis of different serogroups (Hilse, 
Hammerschmidt et al. 1996; Hilse, Stoevesandt et al. 2000) it would be of 
interest to discover the location of the other insertion sites in the genome and 
what effects they may have on meningococcal pathogenesis. 
 
1.3.4 Multilocus Enzyme Electrophoresis (MLEE) and Multilocus 
Sequence Typing (MLST): Electrophoretic Type (ET) and 
Sequence Type (ST) 
MLEE determines the mobility of a selection of constitutive metabolic enzymes 
in a starch gel or polyacrylamide gel matrix. Changes in the mobility of enzymes 
are caused by charge differences due to amino acid substitutions in the 
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polypeptide sequence (Selander, Caugant et al. 1986). MLEE has been widely 
used to study genetic relationships among strains of meningococci for over 20 
years (Caugant, Bovre et al. 1986; Caugant, Froholm et al. 1986; Caugant, Mocca 
et al. 1987; Caugant, Hoiby et al. 1994). However, it is a labour-intensive and 
time-consuming technique. Furthermore, MLEE detects only those alleles with 
differences in coding sequences that lead to replacement of a differently 
charged amino acid and hence a change in electrophoretic mobility.  
Multilocus sequence typing (MLST) was developed and validated on N. 
meningitidis in 1998 (Maiden, Bygraves et al. 1998) and since then it has been 
applied to many other organisms, including other encapsulated bacteria such as 
S. pneumoniae (Enright and Spratt 1998) and H. influenzae (Meats, Feil et al. 
2003). Typically this procedure involves sequencing internal fragments of around 
500 base pairs of seven housekeeping genes; in the meningococcus the 
housekeeping genes are abcZ (putative ABC transporter), adk (adenylate kinase), 
aroE (shikimate dehydrogenase), fumC (fumarate hydratase), gdh (glucose-6-
phosphate dehydrogenase), pdhC (pyruvate dehydrogenase subunit) and pgm 
(phosphoglucomutase). MLST was adapted from MLEE and identifies alleles 
directly from nucleotide sequence rather than comparing the electrophoretic 
mobility of the enzymes they encode. This is advantageous as it allows more 
allelic variation to be detected and therefore distinguishes more alleles per 
locus, thus permitting a higher level of discrimination between isolates. Strain 
associations shown by MLST were consistent with clonal groups previously 
established by MLEE (Maiden, Bygraves et al. 1998).  
Nucleotide sequence data is unambiguous and electronically portable thus 
comparison between laboratories is easy. The exchange of molecular typing data 
is centrally located on a curator-controlled global database accessed via the 
internet (http://pubmlst.org/neisseria/). MLST can be used for strain 
surveillance, for monitoring individual clones as they spread or for the 
identification of unique lineages. This can be applied to short term or local 
epidemiology in the case of disease outbreaks (Feavers, Gray et al. 1999; Birtles, 
Hardy et al. 2005) and even when isolates are not available MLST can be 
performed directly on clinical material e.g. blood or CSF (Diggle, Bell et al. 
2003; Birtles, Hardy et al. 2005). MLST can also be useful for long term or global 
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epidemiology to allow geographical or temporal comparisons to be made 
(Yazdankhah, Kriz et al. 2004; Zhang, Shao et al. 2008). 
Typically, bacterial pathogens consist of large heterogeneous collections of 
isolates that rarely cause disease and a small number of groups of closely related 
strains (clones or lineages) that are particularly associated with outbreaks of 
disease. So called “Hypervirulent” lineages or clones which have the same allele 
at all seven housekeeping loci are frequently isolated and have an increased 
capacity to cause disease. Strains can be grouped into a clonal complex on the 
basis that they share five out of the seven alleles. Each complex is then 
designated STn-complex (n being the founder ST). MLST has the potential to 
identify existing and newly emerging hypervirulent lineages and to monitor their 
global spread. This is of particular importance if a clone acquires the ability to 
be antibiotic non-susceptible (McGee, McDougal et al. 2001). Recently 
recommendations by the European Meningococcal Disease Society (EMGM) for 
the typing of N. meningitidis isolates were proposed to include serogroup, PorA 
VRs 1 & 2, FetA VR, sequence type (clonal complex); i.e. C:P1.5,2-1:F5-4:ST-
11(cc11) (Jolley, Brehony et al. 2007). 
 
1.4 Interactions of N. meningitidis with the human host 
1.4.1 Exposure 
Exposure to the meningococcus requires the inhalation of infected aerosols from 
a previously colonised individual. This person-to-person transmission requires 
frequent or close contact. Colonisation itself is not dangerous; between 25% and 
40% of young adults in temperate climates carry the meningococcus in their 
throat in the absence of disease. The non-carrier is potentially at risk since their 
ability to establish a commensal relationship with a newly acquired strain is not 
known. Additionally, certain circumstances, in which populations coming 
together from diverse geographic locations and where overcrowding may be a 
problem, are known to predispose to meningococcal carriage, infection and 
disease outbreaks. These include new military recruits, pilgrims, boarding 
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school, new university students, prisoners and even close contact within a 
discotheque (Jones and Sutcliffe 1990; Cartwright 1995a; 1995b; Cookson, 
Corrales et al. 1998; Gilmore, Jones et al. 1999; Neal, Nguyen-Van-Tam et al. 
1999; Ala'Aldeen, Neal et al. 2000; Neal, Nguyen-Van-Tam et al. 2000; Nelson, 
Charlett et al. 2001; Aguilera, Perrocheau et al. 2002; Hahne, Gray et al. 2002; 
Grecki and Bienias 2006; Tully, Viner et al. 2006). 
 
1.4.2 Adherence and Invasion 
Following exposure to the bacterium, adhesion to host cells is the critical first 
stage in the sequence of events necessary for colonisation of the nasopharynx 
(and the possible subsequent dissemination throughout the body). Damage to the 
ciliated epithelial layer is believed to be a contributing risk factor towards 
meningococcal infection. This may be due to preceding viral infection or active 
or passive smoking (Cartwright 1995b; Fischer, Hedberg et al. 1997; Yusuf, 
Rochat et al. 1999; Kriz, Bobak et al. 2000; MacLennan, Kafatos et al. 2006). At 
6am on the 26th March 2006 Scotland became the first country in the United 
Kingdom to implement a smoking ban in enclosed public spaces. The Smoking, 
Health and Social Care (Scotland) Bill came into force making it illegal to smoke 
in restaurants, bars, cafes, hotels, theatres, bingo halls, church halls, sports 
centres, shopping centres, public transport, schools, hospitals, clubs and 
workplaces, including lorries and vans (Anonymous 2005). Acts in Wales, 
Northern Ireland and England (Health Act 2006) banning smoking in public spaces 
came into force as of 2nd April, 30th April and 1st July 2007 respectively 
(Department of health www.dh.gov.uk). It is difficult to speculate how this new 
legislation may impact on the transmission and carriage of N. meningitidis and 
the incidence of meningococcal disease in Scotland. Would a change in smoking 
habits affect exposure to cigarette smoke in a household setting and, in turn, 
impact on transmission amongst the household?  
Initial attachment to epithelial cells in the nasopharyngeal mucosa is mediated 
by Type IV pili. Neisserial pili are composed of repeating polypeptide subunits 
called pilin (Pil) and are subject to phase variation (on/off) and antigenic 
variation. Fifteen Pil proteins (including the major subunit PilE) are responsible 
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for Pilin biogenesis in N. meningitidis and mutational analysis of their 
corresponding genes has attempted to define at which step of the process each 
acts (Carbonnelle, Helaine et al. 2006). Contact by pili with the host cell is via 
the membrane cofactor protein (MCP or CD46) (Kallstrom, Liszewski et al. 1997). 
Type IV pili induce signal transduction pathways in host cells (Kallstrom, Islam et 
al. 1998). Type IV pilus appears to be absolutely required for adhesion to host 
cells by encapsulated meningococci (Meyer, Pohlner et al. 1994). Capsulate Nm 
lacking assembled pili did not adhere efficiently and expression of Opa or Opc 
did not alter the adherence of these bacteria (Virji, Kayhty et al. 1991). Pilus-
facilitated adherence in capsule-deficient bacteria, but not capsulate bacteria, 
may result in internalisation. 
A secondary, more intimate interaction with host cells is achieved via class 5 
OMPs, such as Opa and Opc. In the absence of pili and capsule, opa or opc 
variants are sufficient to confer adhesive and, under some conditions, invasive 
phenotypes. Opa protein binds to the N-terminal domain of CEACAM1/CD66a 
adhesion molecule (Virji, Watt et al. 1996) and Opc binds to heparan-sulphate 
proteoglycans (Gray-Owen 2003). In vitro, meningococci and gonococci have 
been shown to induce localised rearrangement of the cortical actin cytoskeleton 
at the sites of bacterial adhesion (Merz and So 1997). Signal transduction events 
induced by pili, Opa, and Opc culminate in cytoskeletal rearrangements and 
engulfment of meningococci by epithelial cells and transcellular traversal (Merz 
and So 1997; Gray-Owen 2003; Plant and Jonsson 2003). Data from Virji et al 
1992 suggests that bacteria expressing opc might colonise and invade the 
mucosal epithelium more efficiently than other bacteria if the local conditions 
down-regulate capsule production (Virji, Makepeace et al. 1992). 
 
1.4.3 Carriage of N. meningitidis 
The association of N. meningitidis with the human nasopharynx has been 
recognised for over a century. In recent decades investigations into 
meningococcal carriage has focused on closed or semi-closed populations i.e. 
military recruits (Caugant, Hoiby et al. 1992; Andersen, Berthelsen et al. 1998; 
Jones, Christodoulides et al. 1998; Riordan, Cartwright et al. 1998; Block, 
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Gdalevich et al. 1999) or in higher-risk groups such as university students 
(Gilmore, Jones et al. 1999; Ala'Aldeen, Neal et al. 2000; Neal, Nguyen-Van-Tam 
et al. 2000) or religious pilgrims (Balkhy, Memish et al. 2003; Wilder-Smith 2003; 
Wilder-Smith, Barkham et al. 2003a; Wilder-Smith, Barkham et al. 2003b; 
Wilder-Smith, Paton et al. 2003; Balkhy, Memish et al. 2004; Nicolas, Ait M'barek 
et al. 2005) or in household contacts of patients with meningococcal disease 
(Marks, Frasch et al. 1979; Olcen, Kjellander et al. 1981; Frasch and Mocca 
1982; Cartwright, Stuart et al. 1991; Cardenosa, Dominguez et al. 2001) or in 
communities where a recent outbreak has occurred (Cartwright, Stuart et al. 
1987; Stuart, Cartwright et al. 1987; Davies, O'Flanagan et al. 1996; Conyn-van 
Spaendonck, Reintjes et al. 1999; Gilmore, Jones et al. 1999; Fitzpatrick, 
Salmon et al. 2000). A few studies have focused on randomly sampled groups to 
determine genetic lineages (Caugant, Kristiansen et al. 1988; Caugant, Hoiby et 
al. 1994; Jolley, Kalmusova et al. 2000; Claus, Maiden et al. 2005; Caugant, Fogg 
et al. 2006) or to identify risks associated with carriage (Davies, O'Flanagan et 
al. 1996; Tayal, Rashid et al. 1997; Kremastinou, Tzanakaki et al. 1999; 
Fitzpatrick, Salmon et al. 2000; Bakir, Yagci et al. 2001; Dominguez, Cardenosa 
et al. 2001; Pavlopoulou, Daikos et al. 2004; Bogaert, Hermans et al. 2005; 
MacLennan, Kafatos et al. 2006). Carriage has also been assessed to evaluate the 
effects of conjugate vaccination in teenagers in the UK (Maiden and Stuart 
2002). 
Carriage of the meningococcus is known to vary in relation to the age-group of 
the population sampled;  rates of carriage are low in young children, particularly 
under 2 years where disease rates are highest, and peak in teenagers (Gold, 
Goldschneider et al. 1978; Cartwright, Stuart et al. 1987; Caugant, Kristiansen 
et al. 1988; Caugant, Hoiby et al. 1994; Pavlopoulou, Daikos et al. 2004; 
Bogaert, Hermans et al. 2005; Claus, Maiden et al. 2005; Maiden, Ibarz-Pavon et 
al. 2008) and these isolates are frequently NG (Young, Harris et al. 1983; 
Cartwright, Stuart et al. 1987; Caugant, Kristiansen et al. 1988; Caugant, Hoiby 
et al. 1994; Ala'Aldeen, Neal et al. 2000; Jolley, Kalmusova et al. 2000; Maiden, 
Ibarz-Pavon et al. 2008). In the three years of the UK carriage study conducted 
to monitor the effects of the MCC vaccination campaign carriage prevalence 
among 15 – 19 year olds were 16.7%, 17.7% and 18.7% respectively (Maiden, 
Ibarz-Pavon et al. 2008). MacLennan and colleagues suggest that it is the social 
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behaviour that greatly influences the risk of carriage rather than age per se. 
Attendance at pubs or clubs, intimate kissing and cigarette smoking were all 
independently and strongly associated with increased risk of carriage; carriage in 
those with none of the risk factors was 7.8% compared to 32.8% in those with all 
three. Passive smoking was also linked to higher risk for carriage (MacLennan, 
Kafatos et al. 2006). 
In multi-centre studies, carriage has been found to vary across different 
locations at the regional, city or institutional level (Maiden and Stuart 2002; 
Glitza, Ehrhard et al. 2008). Carriage is higher among family members or 
caregivers of individuals with meningococcal disease and often the strains they 
carry are phenotypically (Frasch and Mocca 1982) or genotypically (Cardenosa, 
Dominguez et al. 2001; Tzanakaki, Urwin et al. 2001) indistinguishable from the 
patient isolates. However, carriage of disease-associated or outbreak-associated 
strains in the wider community does not appear to be high (Kellerman, McCombs 
et al. 2002). Increased rates of carriage were observed in situations of 
overcrowding or the recent coming together of individuals i.e. military recruits 
(Caugant, Hoiby et al. 1992), religious pilgrimage or university students (Neal, 
Nguyen-Van-Tam et al. 2000).  
The majority of carriage studies can be termed “point-prevalence” or “cross-
sectional” studies as they provide information on the rate of carriage at a given 
time in a defined place/population i.e. in a population of n = x individuals n = y 
individuals will carry N. meningitidis. This contrasts with “longitudinal” studies 
which investigate the duration of carriage of N. meningitidis strains in 
individuals by repeated swabbing at timed intervals (Andersen, Berthelsen et al. 
1998; Ala'Aldeen, Neal et al. 2000; Glitza, Ehrhard et al. 2008).  
Uncertainty remains regarding the optimal sampling method to identify 
meningococcal carriage. Different carriage studies often use different methods 
and, as such, are difficult to compare. The choice of sampling site, transport 
medium versus direct plating of swabs, single versus multiple swabs and length 
of time between swabbing and plating can influence the level of carriage. The 
sensitivity of swabbing in detecting carriage is variable, 60-83% (Trotter and Gay 
2003) and must influence the interpretation of the results of carriage studies. A 
recent review by Roberts and colleagues (Roberts, Greenwood et al. 2009) of the 
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published literature concluded that meningococcal carriage would be best 
assessed by swabbing the posterior pharyngeal wall through the mouth with 
direct plating or keeping transport time to below 5 hours. Additionally the use of 
charcoal swabs was recommended. Furthermore; it is recommended to use 
selective antibiotics to inhibit the growth of non-meningococcal bacteria and 
thus improve the yield of meningococci in the sample (Caugant, Hoiby et al. 
1992).  
 
1.4.4 Symptoms and the spectrum of meningococcal disease 
The diagnosis of meningococcal disease is problematic due to the spectrum of 
clinical manifestations involved, some of which are difficult to differentiate 
from those due to less life-threatening but more common illnesses. One or more 
of the following may be present in an individual person; meningococcal 
meningitis, meningococcal septicaemia, meningococcemia (purpura fulminans 
and the Waterhouse-Friderichsen syndrome), respiratory tract infections 
(pneumonia, epiglottitis, and otitis media), focal infections (conjunctivitis, 
septic arthritis, urethritis, purulent pericarditis) and chronic meningococcemia 
(van Deuren, Brandtzaeg et al. 2000; Rosenstein, Perkins et al. 2001). In 
children, the most common form of disease is meningococcal meningitis; 
symptoms more commonly associated with older children are high fever, 
vomiting, drowsiness and headache, stiff neck and photophobia. In infants and 
younger children symptoms may be more subtle and more non-specific; fever, 
vomiting, irritability, drowsiness and confusion, or in more severe cases, 
declining consciousness and convulsions leading to coma. The presence of a rash 
is more indicative of meningitis caused by N. meningitidis however this is more 
common in patients with meningococcal septicaemia. This form of 
meningococcal infection is associated with greater mortality and presenting 
features include high fever, vomiting, muscle aches, shivering, and confusion. A 
petechial or purpuric rash is usually present; however the severity of rash does 
not correlate with the degree of circulatory failure (Brandtzaeg 1995; Nadel, 
Levin et al. 1995; Steven and Wood 1995). Interestingly, in meningococcal 
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disease, bacterial load is associated with likelihood of death, permanent 
sequelae and prolonged hospitalisation (Darton, Guiver et al. 2009). 
 
1.5 Global epidemiology of meningococcal disease 
1.5.1 Introduction 
Historically, serogroup A, B, C, W-135 and Y have been responsible for most 
endemic and epidemic meningococcal disease, although this varies with 
geographic location (Figure 1.4) and seasonality. Serogroup A was responsible for 
outbreaks of disease in the more industrialised countries in the early 1900s, but 
cases with this serogroup have been rare since World War II. Serogroup B and C 
are responsible for most cases of meningococcal disease in the more 
industrialised countries (Clarke, Reid et al. 2002a; Gray, Trotter et al. 2006). 
However serogroups W-135 and Y have been emerging as the cause of disease 
outbreaks in Africa, serogroup W-135 has emerged in the middle east (WHO 
2006) and serogroup Y in North America (Rosenstein, Perkins et al. 2001; Pollard 
2004). 
 
 
 
Figure 1.4 - Geographic distribution of IMD due to individual meningococcal serogroups  
(Stephens 2007) 
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Chapter 1                                                                                                                                          51 
 
1.5.2 Meningococcal disease in Scotland & the Meningococcus 
Reference Laboratory 
Laboratory isolations of meningococci were first notified to the Communicable 
Diseases (Scotland) (CDS) Unit in February 1967 and meningococcal isolates were 
sent to the Meningococcus Reference Laboratory (Scotland) (MRLS), as it was 
known at the time, at Ruchill Hospital, Glasgow for determination of serogroup, 
serotype and sulphadiazine sensitivity. Five years later in 1972, details of age, 
sex, nature of disease and outcome were sought for all patients to determine 
mortality and morbidity associated with infection (Fallon, Brown et al. 1984). 
Isolates of N. meningitidis were obtained from patients with meningitis or 
septicaemia without meningitis in Scotland during 1972 – 1982. In that eleven 
year period, 1185 strains of N. meningitidis were isolated; of these 927 were 
examined at the MRLS. 19.3%, 63%, 9.6% and 6% were of serogroup A, B, C and 
W-135, respectively. A further 1.6% were of other serogroups and NG strains 
were rare (Fallon, Brown et al. 1984). Group B meningococci predominated 
through the 1970s but, by 1985, were virtually equalled in number by serogroup 
C; the trend was maintained in the first half of 1986. Throughout most of the 
1970s serogroup A meningococci outnumbered serogroup C however by the mid-
1980s serogroup A had fallen to a very low level (Fallon 1986a; 1986b; 1986c). 
During the late 1970s and early 1980s the proportion of two predominant 
serotypes, types 2 and 15, of serogroup B meningococci fluctuated. The 
proportion of these two types displayed an inverse relationship so that when 
type 15 formed a small proportion of serotypes type 2 dominated and vice versa 
(Fallon and Morris 1986). 
During the eleven year period, 1972 - 82, 1156 strains of meningococci isolated 
from carriers were also forwarded to the reference laboratory; many from a 
study of meningococcal carriage in patients attending a department for sexually 
transmitted diseases. Most strains were isolated from the respiratory tract, and 
many were isolated from genital sources. Serogroup distribution differed from 
that in disease; 2.9% were of serogroup A and 40% were of serogroup B. 32% 
Chapter 1                                                                                                                                          52 
were NG as opposed to 0.4% in cases. Meningococci of serogroup Z’ (29E) were 
only seen in carriers (Young, Harris et al. 1983). This study concluded that 
among patients attending a clinic for sexually transmitted diseases, women 
without gonorrhoea were significantly less likely to be colonised with 
meningococci than were women with gonorrhoea and men with or without 
gonorrhoea. Women without gonorrhoea were also significantly less likely to be 
colonised with groupable meningococci but there were no significant differences 
in carriage rates of NG meningococci.  
The authors discussed the effect of behavioural differences and therefore 
relative-risk on the different groups based on their results. Many of the women 
from which throat swabs were taken were asymptomatic contacts (of men with 
gonorrhoea) while the vast majority of males from whom throat swabs were 
taken attended the clinic with symptomatic urethritis. It was suggested that a 
higher incidence of meningococcal colonisation of the pharynx appears to be 
associated with the greater rate of recent mouth-to-mouth contact in the more 
sexually active and hence ‘high-risk’ patients rather than directly correlated 
with gonococcal infection. Furthermore, the authors suggested that these results 
may be explained if predominantly different transmission routes for groupable 
and NG isolates were to exist. If NG isolates were primarily spread via droplet 
spray then most individuals would be exposed to a similar extent. In contrast, if 
groupable meningococci were primarily spread from direct salivary spread then 
they would be expected to be of higher incidence in their ‘high risk’ patients by 
virtue of their greater degree of mouth-to-mouth contact. 
The years 1984 – 1986 saw an upward trend in meningococcal isolations and 
disease cases. This was first noted in Lanarkshire in 1984 (Thomson and Jackson 
1987) and was also noted in both east and west Scotland. However, unlike in 
England and Wales there were no reported local outbreaks of disease. 
Furthermore; around this time notification of serogroup C disease, and strain 
isolations, increased and subsequently predominated for the first time in 
Scotland since laboratory surveillance of infections commenced. 
For a short period, serogroup C was dominant but then declined over the next 10 
years to the mid 1990s (Mooney and McMenamin 2004). During the 1990s it was 
evident that the most common serotype was changing whereby C:2b declined 
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and C:2a increased (Smart 1997; 1999; Clarke 1999b; 2001). The most common 
serogroup B strains were also undergoing a change; the decline of B:2b:- ,P1.10,- 
and B:15:1.7,P1.16, - began around 1992 and by ’98-‘99 none had been received 
and characterised by the Scottish Meningococcus and Pneumococcus Reference 
Laboratory (SMPRL) (as the reference laboratory had come to be known since its 
move to Stobhill Hospital in 1992) (Smart 1997; 1999; Clarke 1999b; 2001). This 
coincided with the emergence of B:4:-, P1.4,- strains from around 1994 
becoming the most dominant through to the year 2000 and beyond (Smart 1997; 
1999; Clarke 1999b; 2001; 2002c; 2003a; 2003c; Mooney and McMenamin 2004; 
Clarke 2005; Hopkins and McMenamin 2005). 
During the late 1990s, serogroup C disease began increasing again, prompting 
the introduction of the MCC vaccine in November 1999, initially targeting those 
less than 18 years for vaccination. The following year, a decrease in serogroup C 
disease was observed in those age groups targeted. In 2002, vaccination was 
extended to include 20-24 year olds. Year-on-year from 1999 there has been a 
decrease in the percentage of disease caused by serogroup C meningococci 
(Clarke 2001; 2002c; 2003a; 2003c; 2005; Hopkins and McMenamin 2005); in 2002 
the majority of serogroup C cases occurred in those over 25 years (Clarke 
2003c). By 2003 90% of all isolates were serogroup B (Clarke 2005). 
Overall, disease incidence increased from 4.1 cases per 100,000 population in 
1996 to 6.7 cases per 100,000 population in 2000 (Smart 1997; 1999; Clarke 
1999b; 2001; 2002c), and since then has decreased yearly to 3 cases per 100,000 
population (Clarke 2003a; 2003c; Mooney and McMenamin 2004; Clarke 2005; 
Hopkins and McMenamin 2005). This can be partly attributed to the dramatic 
reduction of serogroup C disease following the introduction of the MCC vaccine 
in the age groups targeted (Mooney, Christie et al. 2004; Diggle and Clarke 
2005). Only three cases of serogroup C IMD were reported in each of 2003, 2004, 
2006 and 2007; with one case in 2005 (Ure 2008). In 2002 the annual incidence 
was 3.5 cases per 100,000 population (n=178), falling to 3.07 cases per 100,000 
population (n=155) in 2007. The annual incidence of disease has remained fairly 
stable since then (Figure 1.5) and the latest surveillance data in Scotland puts 
the rate for 2009 at 2.69 cases per 100,000 population (McDonald 2010a). For 
the last two calendar years, 2008-2009, no cases of serogroup C disease have 
been reported to HPS (McDonald 2010a). 
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Figure 1.5 - Cases of meningococcal disease reported to HPS, 1998 - 2008* 
*, weeks 1-26 only; (Shakir, Cameron et al. 2008) 
 
Enhanced surveillance of meningococcal disease (MD) in Scotland, through the 
Meningococcal Infectious Disease Augmented Surveillance (MIDAS) scheme, was 
implemented in November 1999 (Clarke 1999a) to coincide with the MCC 
immunisation campaign and the SHLMPRL1 maintains a record of all patients 
notified as having MD. In 1999 the Enhanced Surveillance of Meningococcal 
Disease (ESMD) was established in England, Wales and Northern Ireland to obtain 
accurate incidence data and develop a robust surveillance system (Shigematsu, 
Davison et al. 2002). ESMD was established to monitor the impact of the MCC 
vaccine during and following its introduction in the UK from November 1999. The 
scheme included improved case ascertainment data for meningococcal infection 
directly from clinical specimens. 
 
                                         
1 In late 2009 the SMPRL merged with the Scottish Legionella Reference Laboratory (SLRL) and is 
currently known as the Scottish Haemophilus, Legionella, Meningococcus & Pneumococcus 
Reference Laboratory (SHLMPRL) 
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1.5.3 Epidemiology of meningococcal disease in England, Wales 
& Northern Ireland 
Laboratory-confirmed cases of meningococcal disease rose from 1,448 in 1995 to 
peak at 2,804 in 1999 falling to 1,233 in 2008. An increase in serogroup C cases 
from 1995-9 prompted the introduction of the serogroup C conjugate MCC 
vaccine into the UK population. The proportion of disease attributed to 
serogroups B, C, Y or W-135 altered markedly following the MCC introduction. In 
2008, 90% of all confirmed cases were serogroup B, 3% were serogroup Y, and 
serogroup C and W-135 comprised just 2% each. Transient changes in W-135 
infections in 2000-1 were associated with Hajj pilgrims and their contacts in the 
UK. Phenotypic and genotypic shifts have been observed; specifically the 
relative proportions of MLST clonal complexes ST-41/44, ST-269, ST-32, ST-213 
and ST-11 (Gray, Campbell et al. 2009). Disease incidence during the 
epidemiological year July 2002 – June 2003 based on laboratory-confirmed cases 
only was reported as being 2.8 per 100,000 (Anonymous 2003). 
 
1.5.4 Continental Europe 
In recent years, a downward trend in cases of IMD has been occurring across the 
continent, irrespective of serogroup and with or without the introduction of 
serogroup C conjugate vaccination campaigns. Undoubtedly MCC vaccination 
campaigns have reduced the burden of disease due to this serogroup in the 
countries where the vaccine has been implemented. In countries using the MCC 
vaccine around 80% or more of disease is now due to serogroup B. Several 
countries not using the MCC vaccine are doing so because the actual numbers of 
disease cases due to this serogroup are low.  
Surveillance of bacterial infection is vital so that the epidemiology can be 
monitored accurately and the impact of immunisation campaigns can be 
measured. Since IMD is relatively uncommon (particularly after vaccination has 
been introduced), pooling data across European countries should increase the 
power of any epidemiological analysis. With this in mind, the European Union 
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Invasive Bacterial Infections Surveillance Network (EU-IBIS) was established in 
1999 with the following aims; to improve the epidemiological information on 
invasive disease caused by N. meningitidis and H. influenzae within the EU; to 
improve the laboratory capacity to accurately characterise the isolates of N. 
meningitidis and H. influenzae using standardised methods; to evaluate the 
impact of vaccination with conjugate vaccines on the epidemiology of N. 
meningitidis and H. influenzae; to compare the impact of vaccination with 
conjugate vaccines produced by different manufacturers and according to 
different schedules; to form a focus for wider collaboration with non-EU 
countries and candidate EU countries. 
In 2007 the project was transferred to the European Centre for Disease 
Prevention and Control (ECDC). In a recent ECDC report on data from 2007 of 
5,586 cases (5,180 confirmed) the highest notification rates with 3.8 and 2.5 per 
100,000 were observed in Ireland and the UK, respectively. Contrastingly, the 
lowest notification rate was observed in Italy (0.3 per 100,000). Of 4,993 cases 
with known age data, 44% were reported in children under 5 years old. This age 
group had the highest notification rate at 8.6 per 100,000, followed by the 15 – 
24 year olds (1.6 per 100,000). The notification rate peaked in winter and fell 
during spring to a low during the summer period (June to September). Serogroup 
B (77%) and C (16%) remain the major cause of IMD in Europe. Serogroup B 
predominates in all age groups, but is especially dominant in the under 10 year 
olds, while serogroup C was more evident in the age groups over 10 years old, 
especially the groups 10-14 and 25-44 years. The case fatality ratio was highest 
in serogroup C (13%) and Y (13%), the latter is most likely because it mainly 
affects the older age group 45 – 64 years (ECDC 2009). It should be noted that 
disease incidence rates may be affected by any differences between the 
surveillance systems in place in each country. 
The recent epidemiology of IMD in Europe and North America is summarised in 
Table 1.1. Most countries are experiencing a reduction in disease incidence, 
irrespective of conjugate vaccination campaigns. In Austria during 2008 there 
were 95 cases of meningococcal disease; an incidence of 1.14 per 100,000. Of 
the 84 laboratory-confirmed cases 69.1%, 28.6%, 1.2% and 1.2% were serogroup 
B, C, Y and W-135 respectively. A reported rise in incidence, solely due to 
serogroup B cases, has followed the previous two years where the incidence was 
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<1.0 per 100,000 (Heuberger, Mikula et al. 2009). In the Czech Republic the 
incidence of IMD has been stable since 2005 at around 0.8 per 100,000. 
Serogroups B, C and Y accounted for 67.4%, 20.9% and 9.3% respectively. 
Predominant clonal complexes were cc11, cc18, cc41/44 and cc32; 18.6%, 
13.9%, 9.3% and 9.3%, respectively (Kriz, Klamusova et al. 2009). In Denmark 
during the past 20 years the incidence of IMD has continued to decline from 
around 5 per 100,000 to 1.4 per 100,000 in 2007 and 1.2 per 100,000 in 2008 (St-
Martin, Christensen et al. 2009).  
France has experienced local outbreaks of both serogroup B and C recently 
which has prompted intervention with targeted vaccine campaigns (Parent du 
Chatelet, Taha et al. 2009). In Greece serogroup B is responsible for around 80% 
of cases of meningococcal disease during 2007-8, followed by serogroup C; 8.1% 
in 2007 and 7.8% in 2008 (Tzanakaki and Kremastinou 2009). In Finland, following 
a period of higher incidence in 1995-6 caused by serogroup B and C, the 
incidence of IMD has fluctuated at low levels between 0.5 – 1.1 per 100,000. 
Most cases were due to serogroup B (73%) and C (16.4%). Since 1996 the 
incidence of serogroup C has remained low, 0.02 – 0.17 per 100,000. There are 
currently no plans to introduce the MCC vaccine (Toropainen, Kayhty et al. 
2009). 
In Ireland the incidence rate of IMD notification continues to decline from the 
peak in 1999 (14.8 per 100,000) down to 179 cases (4.8 per 100,000) and 169 
cases (4.0 per 100,000) in 2007 and 2008 respectively. Since introduction of the 
MCC in 2000 the incidence of serogroup C disease has declined from 3.9 per 
100,000 (1999) to 0.07 per 100,000 (2008); a 98% reduction. During the same 
period meningococcal B disease had declined from 8.1 per 100,000 to 3.3 per 
100,000, a 59% reduction. In 2008, 82% of IMD cases were due to serogroup B, 3 
cases serogroup C IMD (1.8%) and other serogroups accounted for 3.6% of cases 
(Cotter, O'Lorcain et al. 2009). In Italy, despite the recent introduction of the 
MCC vaccine, serogroup C is still responsible for a considerable proportion of 
disease; with clonal outbreaks of disease still being experienced (Stefanelli, 
Fazio et al. 2009). 
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Table 1.1 – Epidemiological summary of Invasive Meningococcal Disease in Europe & North America 
 
Country 
Disease Incidence per 100,000/Year MCC2 
Y/N 
(Year) 
Common 
serogroups ≤1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
Austria           <1.0 <1.0 1.14  N B = 69%  C = 28.6% 
Belgium      3.7       1.0  Y (2002) B (C) 
Croatia             0.6  N B = 85.7% 
Czech Rep          0.8 since 2005  N B = 67%, C = 21%, Y = 9.3% 
Denmark 5.0 (~1980)           1.4 1.2  N 
B = 69% 
C = 29% 
E + W1          2.8        Y (1999) B = 90% 
Estonia 0.4 – 1.0  N B 
Finland Higher in 1995-96; 0.5 – 1.1 since then  N B = 73%  C = 16% 
France                 1.0 – 2.0 for the past 20 years 1.3 1.2  Y* B = 67%  C = 24% 
Germany      0.9 0.7 0.5 0.5  Y (2006) B (C) 
Greece            0.95 0.67  Y B = >80%  C <8% 
Ireland    14.8        4.8 4.0  Y (2000) B = 82% 
Italy            0.3 0.3  Y B = 55.7% C = 36.45 
Poland  0.37          1.03   N B = 51.6% C = 44% 
Russia          1.92 1.7 1.56   N 
A = 36% 
B = 24% 
C = 18.5% 
Scotland 4.1 (1996)    6.7  3.5     3.07  2.69 Y (1999) B >85% 
Sweden             0.54  N B, C, Y 
USA   0.93  0.78     0.33  0.33   MCV4
3 
2006 
Y = 37%, C = 
30% B = 25% 
Canada       0.62    0.42    Y (2002-2005) 
B (children) C & 
Y(adults) 
 
1 E+W, England and Wales; 2 MCC, meningococcal conjugate serogroup C vaccine; 3 MCV4, meningococcal conjugate quadrivalent vaccine; *, Local outbreaks only 
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Furthermore, in Poland disease incidence has increased overall from 0.37 per 
100,000 in 1997 to 1.03 per 100,000 in 2007. Since 2002 serogroup C has been 
increasingly isolated from cases of sporadic infections and in outbreaks of 
disease (Kadlubowski, Skoczynska et al. 2008). The epidemiology of IMD in Russia 
is particularly variable according to geographic area. The national mean 
incidence declined from 1.92 per 100,000 in 2005 to 1.56 per 100,000 in 2007. 
Regionally the incidence varied from 0 – 6.0 per 100, 000 with most regions 
within 0 – 3 per 100,000. Nationally the serogroup prevalence was 36.1%, 24.1% 
and 18.5% for serogroups A, B and C, respectively. However, in Central and 
Southern regions of Russia serogroup A largely predominated whereas in North-
Western and Eastern regions serogroup B predominated (Koroleva, Beloshitskij et 
al. 2009). 
 
1.5.5 North America 
In the United States, since World War II, the annual incidence of meningococcal 
disease has varied from 0.5 to 1.5 cases per 100,000 population. During the past 
three decades, the incidence has increased and decreased in multi-year cycles. 
The most recent peak in incidence occurred during the mid 1990s. As is the case 
in many European countries, a downward trend in IMD cases has also been 
observed in the United States; decreasing to 0.33 cases per 100,000 in 2007 
(Table 1.1). While undoubtedly due in part to the introduction of conjugate 
vaccines (MCV4 in 2004 and MCC in 1999 in the US and UK, respectively), 
surveillance data suggest the downward trend had begun already; caused by 
decreases in the three most common serogroups in the United States: B, C and Y 
(Harrison 2010). Furthermore, disease cases due to serogroup B meningococci 
have been in decline despite not being included in either of the conjugate 
vaccines (Cohn, MacNeil et al. 2010; McDonald 2010a). Serogroup Y accounted 
for only 2% of meningococcal infections during 1989-1991 (Jackson and Wenger 
1993). However, by the mid-1990s, the incidence increased and serogroup Y 
strains accounted for one-third of meningococcal infections (Rosenstein, Perkins 
et al. 1999).  
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Active Bacterial Core surveillance (ABCs) is a core component of CDC’s Emerging 
Infections Programs network (EIP), involving a collaboration between CDC, state 
health departments, and universities. ABCs is an active laboratory- and 
population-based surveillance system for invasive bacterial pathogens of public 
health importance. ABCs was initially established in four states in 1995. It 
currently operates among 10 EIP sites across the United States, representing a 
population of approximately 41 million persons. However, most areas restrict 
the population further for certain pathogens to ensure complete reporting and 
good audit data. At this time, ABCs conducts surveillance for six pathogens: 
group A and group B Streptococcus (GAS, GBS), H. influenzae, N. meningitidis, S. 
pneumoniae, and methicillin-resistant Staphylococcus aureus (MRSA). 
In 2007, data from the ABCs indicated that 25%, 30% and 37% of cases were due 
to serogroups B, C and Y, respectively, with a further 9% of cases being caused 
by serogroup W-135, other serogroups and NG strains (CDC 2008). County-wide 
surveillance of bacterial infectious disease is not practical due to the size of the 
USA. Subsequently, surveillance data may be skewed by any geographical or 
demographical change in disease epidemiology; evidence for this has occurred in 
recent years in the form of a prolonged serogroup B outbreak in the state of 
Oregon which has warranted separate data analyses by the CDC, or its 
collaborators, in recent publications (CDC 2008; 2010b).  
In Canada, surveillance data from 2002-2007 (IMPACT; Immunization Monitoring 
Program, Active) revealed that disease incidence has also been declining; from 
0.62/100,000 in 2002 to 0.42/100,000 in 2006 (Table 1.1). Serogroups B, C and Y 
caused the majority of IMD in Canada but the distribution of serogroups varied 
among adults and children and by province. Serogroup B occurred more 
frequently in children while serogroups C and Y occurred more frequently among 
adults. The incidence of serogroup C disease declined over the 5 year period; 
mostly attributable in provinces (British Columbia, Alberta and Quebec) that had 
started earlier (2002-2003 versus 2005) MCC vaccination campaigns. The 
incidence of serogroups B, Y and W-135 remained stable (Bettinger, Le Saux et 
al. 2008). 
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1.5.6 Africa and the meningitis belt 
In the meningitis belt in Africa, most disease is caused by serogroup A 
meningococci, predominantly of ST-5 and ST-7 (Nicolas, Norheim et al. 2005), 
which differ only at the pgm locus. It is thought that ST-5 strains were 
introduced prior to 1988. In one study characterising meningococcal isolates 
from cases of meningitis between 1988 and 2003 in 13 countries of the African 
meningitis belt, most cases between 1988 and 2001 were due to ST-5 (Nicolas, 
Norheim et al. 2005). Sequence Type 7 is reported to have been identified for 
the first time in Algeria in 1995 (Nicolas, Decousset et al. 2001) and has gone on 
to replace ST-5 strains in many countries of Africa (Nicolas, Decousset et al. 
2001; Nicolas, Norheim et al. 2005). 
Recently, a cause for concern has been the serogroup W-135 strains of the ST-
11/ET-37 complex. Sporadic cases have been increasing since 2000 and the first 
epidemic in Africa was seen in Burkina Faso in 2002. The majority of W-135 cases 
in Africa are due to ST-11 complex strains and, more recently, a new ST-2881 
clone has emerged in several countries (Nicolas, Djibo et al. 2005; Nicolas, 
Norheim et al. 2005). Any possible effect that this new W-135 clone may have on 
the whole ST-11 complex will need to be monitored. During the first 10 weeks of 
the 2006 meningitis season, two main outbreaks were observed; in the west 
caused predominantly by serogroup A meningococci, and in the east caused 
predominantly by serogroup W-135 meningococci (WHO 2006). Historically, cases 
in two provinces have accounted for the majority of IMD in South Africa 
predominantly caused by serogroup B and serogroup A in the Western Cape and 
Gauteng, respectively. In recent years, the W-135 ST-11 complex has become 
more prevalent, particularly in Gauteng province (von Gottberg, du Plessis et al. 
2008). 
 
1.5.7 Asia 
In China, serogroup A is responsible for around 95% of cases of meningococcal 
disease, whereas serogroups B and C only cause sporadic cases (Zhu, Hu et al. 
1995). However, recently in one province there has been an increase in 
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outbreaks due to serogroup C meningococci. Molecular characterisation of 
selected isolates revealed a dominant clone that was unique to China (Shao, Li 
et al. 2006). Furthermore this clone did not belong to any clonal complex, 
including the hypervirulent ST-11/ET37 or ST-8 lineages, responsible for most 
serogroup C disease in North America, Europe and Africa (Achtman 1995). In 
Taiwan, molecular characterisation of meningococcal disease isolates revealed 
the recent emergence of serogroups A, C and Y belonging to the major 
worldwide epidemic clones currently circulating. This partly contributed to an 
increase in cases of meningococcal disease in 2001-2002 (Chiou, Liao et al. 
2006). 
 
1.5.8 Latin & South America 
Since 2001, serogroup B had been isolated most commonly in cases of IMD in 
Argentina, representing 72% of all isolates in 2006 (Sorhouet, Regueira et al. 
2008). An epidemic wave at the end of the 1990s due to serogroup C accounted 
for around 20% of cases until 2005. Serogroup W-135 isolates began increasing to 
13% in 2007 and 27.7% during the first 5 months of 2008. A selected number of 
strains genotyped as ST-11 and had the porA 5,2 (Efron, Sorhouet et al. 2008). 
Characterisation of 46 serogroup B isolates from 2006 by MLST revealed the 
majority of isolates grouped into four complexes. PorA VR sequencing identified 
17 subtypes, three of which accounted for over 60% of all isolates. Isolates with 
the subtypes P1.21,16-36 and P1.22-1,14 all belonged to the ST-865 complex and 
ST-35 complex, respectively. The ST-41-44/Lineage 3 complex was identified ten 
times with heterogeneous porA subtypes (Sorhouet, Regueira et al. 2008).  
 
1.5.9 New Zealand and Australia 
Historical trends in meningococcal disease in Australia have followed a similar 
pattern to other industrialised countries; characteristic epidemics during the 
two World Wars, a rise in disease during the 1950s and a subsequent period of 
endemicity. During the second half of the 20th Century, serogroup A has been 
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replaced by serogroups B and C, particularly as a result of the spread of 
hypervirulent lineages of meningococci across the globe. Following successful 
campaigns in Europe the serogroup C conjugate vaccine was introduced in 
Australia in 2003 (Patel 2007). 
From 1991, New Zealand experienced an epidemic of IMD, which peaked in 2001, 
predominantly caused by the strain type B:4:P1.7-2,4 (Martin, Walker et al. 
1998; Baker, Martin et al. 2001; Devoy, Dyet et al. 2005). This prompted the 
mass vaccination with a strain-specific outer membrane vesicle (OMV) vaccine in 
2004. A large reduction in disease due this strain was observed. However, the 
success of this vaccine campaign has been debated; disease-burden may already 
have been in decline and the suitability of methods used to assess vaccine 
efficacy have been disputed. Moreover, as of July 2008, the vaccination 
campaign was controversially terminated (Martin and Lopez 2008) and data on 
any long-term impact is awaited. 
 
1.6 Treatment & prevention of meningococcal disease 
1.6.1 Antibiotic therapy 
Rapid admission to hospital is of highest priority when meningococcal disease is 
suspected. In the UK in suspected cases of IMD (meningitis or septicaemia) 
general practitioners are recommended to give intra-muscular (i.m.) or intra-
venous (i.v.) benzylpenicillin (Adult, 1.2g; Infant <1yr, 300mg; Child 1-9yr, 
600mg; 10 years or over, as adult) before urgent transfer to hospital. If there is 
penicillin allergy, cefotaxime may be used as an alternative or chloramphenicol 
may be used if there is a history of anaphylaxis to penicillins or to 
cephalosporins. For meningitis caused by meningococci, it is recommended to 
treat with benzylpenicillin or cefotaxime for 5 days, or alternatives as above 
(BNF 2010). Additionally, it is advised to use rifampicin treatment for two days 
to eliminate nasopharyngeal carriage. For the prevention of secondary cases it is 
recommended to give rifampicin 600mg every 12 hours for 2 days; child – 
10mg/kg (under 1 yr, 5 mg/kg) every 12 hours for 2 days (BNF 2010).  
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1.6.2 Vaccines for the prevention of meningococcal disease 
1.6.2.1 Introduction 
The first meningococcal vaccines were available during the 1970s and 1980s. 
These were bivalent and quadrivalent polysaccharide vaccines targeting 
serogroup A & C and A, C, Y and W-135, respectively. They were proven to be 
safe, with good efficacy in older children and adults. However, the level of 
protection was variable for the different polysaccharides (particularly serogroup 
C) and was not long-term. In the last decade, polysaccharide-conjugate vaccines 
have been licensed in Europe (serogroup C) and the US (serogroups A, C, Y, W-
135). Vaccines for serogroup B strains have, since the 1980s, focused on OMV and 
have been employed successfully in Norway, Cuba and New Zealand to curb 
strain-specific outbreaks of disease in those countries. Genome-sequencing 
projects have facilitated the identification of potential vaccine antigen targets, 
irrespective of serogroup (Pizza, Scarlato et al. 2000; Rappuoli 2001; 2008). 
 
1.6.2.2 Plain polysaccharide vaccines 
In the UK, the quadrivalent (ACYW-135) polysaccharide vaccine (manufactured 
by GlaxoSmithKline) is recommended for use in children over three months and 
less than 2 years of age and the primary course is given as two doses 3 months 
apart. In children over 2 years and in adults the primary course consists of one 
dose. A booster dose should be given every 5 years to those at continued risk, or 
every 2-3 years in children receiving their first dose under the age of five (DoH 
2006a; 2006b). The quadrivalent polysaccharide vaccine is also recommended for 
individuals who are travelling or going to reside abroad. Large epidemics due to 
serogroup A, and more recently, serogroup W-135 occur throughout tropical 
Africa, particularly during the dry season in sub-Saharan Africa. Large epidemics 
of serogroup A and serogroup W-135 have been associated with Hajj pilgrimages 
to Saudi Arabia. Immunisation with A & C polysaccharide vaccines was a visa 
requirement before Hajj 2000 and 2001 when subsequently the quadrivalent 
vaccine was required of visiting pilgrims by the Saudi authorities (DoH 2006b; 
K.S.A. 2010). In the United States, a quadrivalent meningococcal polysaccharide 
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vaccine MPSV4 has been licensed for use since 1981. The vaccine is 
recommended for use in persons aged 2 – 55 years if MCV4 is unavailable, in 
children aged 2 - 10 years with a history of Guillain-Barré syndrome and in 
persons over 55 years (Poland 2010). 
 
1.6.2.3 Polysaccharide-protein conjugate vaccines 
1.6.2.3.1 Serogroups A, C, Y & W-135 
 
In 1999, the UK was the first country to implement the use of the MCC (Miller, 
Salisbury et al. 2001). Initial observations have seen a considerable decrease in 
serogroup C disease in the age groups targeted (Balmer, Borrow et al. 2002; 
Maiden and Stuart 2002; Mooney, Christie et al. 2004) and a decade of 
surveillance data from MIDAS (Scotland) and from England & Wales (ESMD) has 
demonstrated the longevity of this successful vaccination campaign (McDonald 
2010a). Herd immunity has also been observed (Ramsay, Andrews et al. 2003). In 
Scotland, a substantial decline of serogroup C ET-37/ST11 strains and no 
corresponding increase in serogroup B ET-37/ST-11 strains was observed, as yet, 
providing no evidence for the occurrence of capsule switching (Diggle and Clarke 
2005). This was also the case in England and Wales (Trotter, Ramsay et al. 
2006). 
In the UK, since September 2006, the childhood immunisation schedule for 
prevention of meningococcal disease recommends vaccination with 3 doses of 
the meningococcal serogroup C conjugate vaccine at 3, 4 and 12 months of age. 
The MCC is recommended for use in persons under the age of 25 years and in 
older adults at elevated risk from meningococcal C disease (Health 2006b; a). 
The vaccines in use are conjugated with either CRM197 (non-toxic variant of 
diphtheria toxin) or tetanus toxoid. A number of other (western) European 
countries including Ireland, Spain, the Netherlands, Germany and Luxembourg, 
as well as Canada and Australia, have followed the UK in implementing 
conjugate meningococcal C vaccination programmes (Cohen 2003; de Wals, 
Deceuninck et al. 2004; Welte, van den Dobbelsteen et al. 2004; Larrauri, Cano 
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et al. 2005; de Greeff, de Melker et al. 2006; Wiese-Posselt, Hellenbrand et al. 
2006; DoH 2006b; Booy, Jelfs et al. 2007).  
Several manufacturers produce the MCC vaccine for use in the UK: Meningitec® 
(Wyeth Pharmaceuticals); Menjugate® (Novartis Vaccines); NeisVac-C® (Baxter 
Healthcare; and Menitorix (Hib/MenC) (GlaxoSmithKline). In the US, the FDA 
licensed the Meningococcal (Groups A, C, Y and W-135) Conjugate Vaccine (MCV-
4) marketed as Menactra (Sanofi Pasteur) in January 2005 for use in all 
adolescents 11-18 years of age and persons aged 2-55 years who are at increased 
risk of IMD (Poland 2010). Unfortunately, vaccine coverage targets in adolescents 
have yet to be met; only a third of adolescents had received one dose of the 
MCV4 during 2007 (Poland 2010). 
The Novartis Vaccines’ Investigational MenACWY-CRM quadrivalent conjugate 
vaccine has undergone Phase II and III studies and has equivalent safety and 
tolerability as well as equivalent or superior immune responses compared with 
currently available vaccines (Dull, Gill et al. 2009; Jackson, Baxter et al. 2009; 
Reisinger, Baxter et al. 2009) and was licensed for use in the US in 2010 (CDC 
2010a). Meanwhile a conjugate serogroup A vaccine is currently being developed 
and trialled for use in Africa (Jodar, LaForce et al. 2003; Kshirsagar, Mur et al. 
2007; Hodgson, Forgor et al. 2008; Lee, Kuo et al. 2009; Okoko, Idoko et al. 
2009). 
1.6.2.3.2 Serogroup B 
 
Currently there is no vaccine effective against serogroup B meningococci 
licensed in the UK or in the US. Strategies to develop vaccines against serogroup 
B disease have focused on sub-capsular antigens using OMV preparations (native 
or detergent-treated), recombinant proteins alone or in combination (Granoff 
2010). 
1.6.2.3.2.1 PorA-based OMV vaccines 
 
In New Zealand, where an epidemic due to serogroup B meningococci has been 
ongoing since 1991 (Martin, Walker et al. 1998; Baker, Martin et al. 2001; Devoy, 
Dyet et al. 2005), a strain specific OMV vaccine against B:4:P1.7-2,4 
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meningococci has been evaluated for safety and immunogenicity in clinical trials 
(Oster, Lennon et al. 2005). The VR2 P1.4 epitope was subsequently 
demonstrated to be immunodominant (Martin, Ruijne et al. 2006). Similarly, 
clonal epidemics in Norway and Cuba have been targeted by the use of 
monovalent PorA-based OMV vaccines (Bjune, Hoiby et al. 1991; Rodriguez, 
Dickinson et al. 1999). 
The Netherlands Vaccine Institute (NVI) has produced a hexavalent OMV vaccine 
containing six different PorA subtypes. This vaccine, HexaMen, contains the 
subtypes P1.7,16; P1.5-1,2-2 and P1.19,15-1 on one OMV preparation and the 
subtypes P1.5-2,10; P1.12-1,13 and P1.7-2,4 on another OMV preparation. The 
NVI has also recently conducted Phase I trials to investigate the safety of a 
nonavalent outer membrane vesicle (OMV) vaccine containing nine different 
PorA subtypes. This vaccine, NonaMen, was based on the six subtypes of the 
HexaMen OMV vaccine with the addition of the subtypes P1.22,14, P1.7-1,1 and 
P1.18-1,3 to improve the potential immunisation coverage of serogroup B 
disease. Results indicated the vaccine was well tolerated with no major safety 
concerns (Rots and Kleijne 2008). 
1.6.2.3.2.2 Alternative antigens for serogroup B vaccines 
 
Currently, the Novartis 5 Component Vaccine against Meningococcus B (5CVMB) 
is being examined in clinical trials. This vaccine is composed of the New Zealand 
OMV (Oster, Lennon et al. 2005) plus five other antigens: Factor H-binding 
protein (fHbp; Genome-derived Neisserial antigen; GNA 1870: LP2086) variant 1; 
Neisserial adhesion A (NadA, GNA 1994); GNA 2091; GNA 2132; and GNA 1030. 
Factor H-binding protein (fHbp) is a ~ 28kDa surface lipoprotein that was 
originally described by Fletcher et al. as LP2086 (Fletcher, Bernfield et al. 2004) 
and by Masignani et al. as GNA 1870 (Masignani, Comanducci et al. 2003). 
Following the discovery that the protein GNA 1870 was able to bind complement 
factor H (Madico, Welsch et al. 2006) it was re-named. A number of prevalence 
and sequence analyses of fHbp from a variety of serogroup B N. meningitidis 
lineages indicates that all isolates have a fHbp gene and that variants so far 
identified can be classified into two or three distinct groups; subfamilies A and B 
(Fletcher, Bernfield et al. 2004; Murphy, Andrew et al. 2009) or groups 1, 2 and 
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3 (Masignani, Comanducci et al. 2003; Brehony, Wilson et al. 2009), 
respectively, in all countries surveyed. 
Neisseria adhesion A (NadA) or GNA 1994 is a novel surface antigen that is 
thought to be involved in adhesion to, and invasion of, epithelial cells 
(Comanducci, Bambini et al. 2002; Comanducci, Bambini et al. 2004; Capecchi, 
Adu-Bobie et al. 2005). Four variants have been described; variants 1-3 are 
predominantly present in invasive isolates (Comanducci, Bambini et al. 2002), 
whereas variant 4 is only found in carrier isolates (Comanducci, Bambini et al. 
2004). Only around 50% of meningococcal isolates harbour the nadA gene 
(Comanducci, Bambini et al. 2004). It is almost always present in three clonal 
complexes (cc); ST-32 (cc32), cc11 and cc8. Disappointingly however it has not 
been identified in cc41/44 (Comanducci, Bambini et al. 2002) and is seldom 
found in cc269 (Lucidarme, Comanducci et al. 2009); two ccs which account for 
the majority of IMD due to serogroup B strains in the UK (Gray, Trotter et al. 
2006; Ure 2008; Gray, Campbell et al. 2009). 
GNA 2132, also known as Neisseria Heparin-binding antigen (NHBA), is a surface-
exposed lipoprotein that is able to bind heparin, is found in all strains studied 
and was also present in strains of N. gonorrhoeae and N. lactamica (Pizza, 
Scarlato et al. 2000; Jacobsson, Thulin et al. 2006; Jacobsson, Hedberg et al. 
2009; Lucidarme, Comanducci et al. 2009). GNA 2132, along with GNA 1030 (a 
periplasmic protein involved in quinine metabolism) and GNA 2091 (a predicted 
periplasmic and or secreted lipoprotein and a putative haemolysin) are other 
components of the Novartis vaccine composed of the MeNZB OMV plus 
recombinant antigens (Jacobsson, Hedberg et al. 2009). 
Wyeth is also currently investigating a bivalent fHbp vaccine (based on one 
family A and one family B variant) in clinical trials. Early results indicate that 
the vaccine is able to elicit antibodies that are broadly bactericidal against 
epidemiologically diverse invasive meningococcal serogroup B disease isolates 
(Jansen, McNeil et al. 2008; Marshall, Nissen et al. 2008; Richmond, Marshall et 
al. 2008; Anderson, Jones et al. 2009). 
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1.7 Neisserial genome sequences and their application  
A number of strains of N. meningitidis have been fully sequenced: the serogroup 
B strain MC58; the serogroup A strain Z2491; the serogroup C strain FAM18; and 
the serogroup C strain 053442 (Parkhill, Achtman et al. 2000; Tettelin, Saunders 
et al. 2000; Bentley, Vernikos et al. 2007; Peng, Yang et al. 2008). Analyses of 
these genome sequences has highlighted the abundance and variety of repetitive 
or mobile DNA elements that contribute towards genome variability such as DNA 
uptake sequences (DUS), Correia-repeat enclosed elements (CREE), dRS3, IS 
elements, prophages and islands of horizontal transfer (Claus, Vogel et al. 2007). 
Furthermore, whole-genome sequences of three isolates obtained during a 
carriage study; α 14: cnl ST-53(cc53), α 153: 29E ST-60(cc60) and α 275: W-135 
ST-22(cc22), have recently been completed (Schoen, Blom et al. 2008). In turn, 
whole-genome comparisons between these three carriage isolates and three 
disease-associated strains showed that there is no consistent difference in the 
distribution of candidate virulence genes between carriage and disease isolates. 
The majority of candidate virulence genes found in N. meningitidis can also be 
found in the carriage isolates studied (Schoen, Blom et al. 2008). 
Attempts to identify virulence gene candidates that were restricted to invasive 
isolates from Neisserial genome comparisons has been performed using 
microarray hybridisation experiments. Differences in the pathogenic potential of 
different meningococci (carried or invasive), gonococci or other Neisseria spp. 
were measured by the mere presence/absence of a particular genetic 
determinant. Conflicting results regarding the association of a filamentous phage 
Nf1 (MDA) with invasive isolates suggests this phage is not a characteristic of all 
invasive meningococcal strains (Bille, Zahar et al. 2005; Hotopp, Grifantini et al. 
2006). 
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1.8 Project background and rationale 
In Scotland, a reference laboratory for N. meningitidis has existed, in one guise 
or another, for around half a century. Over the decades the laboratory has 
accrued a considerable isolate collection and only in recent years with the 
expansion of molecular biology has it been possible to take advantage of this 
untapped resource. The reference laboratory has, for the best part of a decade, 
utilised molecular typing methods to characterise meningococcal isolates 
routinely isolated from cases of IMD. Furthermore, investigations have previously 
been conducted to characterise invasive meningococci from the reference 
laboratory isolate archive. However, to date sequence typing methods have not 
been applied to large-scale studies of carried meningococci from Scotland. The 
present study sought to characterise further a panel of carried meningococci 
from the isolate archive of the SHLMPRL with the purpose of gaining further 
understanding on the genetic structure of the N. meningitidis population in 
Scotland over a 31-year period.  
What is the level of genetic diversity in carried meningococcal isolates in 
Scotland? 
Has the diversity of carried meningococcal isolates in Scotland changed during 
the study period? 
How does this level of genetic diversity compare with that of invasive 
meningococcal isolates in Scotland? 
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2 Materials and Methods 
2.1 Handling of bacterial isolates, COSHH and Health & 
Safety 
The Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus 
Reference Laboratory (SHLMPRL) is a fully accredited laboratory via the Clinical 
Pathology Accreditation (UK) Ltd. (CPA). All work undertaken in the laboratory 
was performed following the designated Standard Operating Procedures (SOPs) 
in place at the SHLMPRL and in compliance with the Control of Substances 
Hazardous to Health Regulations 2002 (COSHH) and the appropriate Procedure 
Risk Assessment. Neisseria meningitidis is classified as a Hazard Group 2 
Pathogen by the Advisory Committee on Dangerous Pathogens (ACDP) and as 
such work with N. meningitidis isolates was carried out in a class 1 exhaust 
protective cabinet (model 20270, serial no. 111944). Live suspensions were kept 
in racks to reduce the likelihood of spillage and protective gloves were worn at 
all times. 
 
2.2 Chemicals, Reagents and Buffers 
2.2.1 0.85% Saline (2ml) 
0.85% saline was used as a suspension medium for serogrouping isolates of N. 
meningitidis. 8.5g of sodium chloride (VWR International Ltd., Poole, Dorset, 
UK) was added to 1 litre of de-ionised water (SHLMPRL). This was distributed 
into glass bijoux bottles in 2ml amounts and sterilised by autoclaving at 121°C 
for 15 minutes. 
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2.2.2 ELFO Buffer x50 & ELFO Buffer x1 
ELFO buffer was used in the preparation of agarose gels and in the gel 
electrophoresis tanks. ELFO buffer x50 was made by adding 242g of Tris (Trizma 
Base) (Sigma-Aldrich Co. Ltd., Dorset, UK) and 18.61g of EDTA 
(Ethylenediaminetetraacetic acid disodium salt dihydrate) (Sigma-Aldrich Co. 
Ltd., Dorset, UK) to 900ml of de-ionised water (SHLMPRL). The pH was adjusted 
to 7.7 with approximately 50ml of glacial acetic acid (McQuilkin & Co. Ltd., 
Glasgow, UK) and made up to a final volume of 1 litre with de-ionised water 
(SHLMPRL). For use, ELFO buffer x50 was diluted 1 in 50 with de-ionised water 
(SHLMPRL). 
 
2.2.3 Ethidium bromide 1mg/ml 
Ethidium bromide was used to visualise DNA products in agarose gels following 
amplification by PCR. In a sterile glass universal, 1ml of ethidium bromide 
aqueous solution 10mg/ml (Sigma-Aldrich Co. Ltd., Dorset, UK) was diluted 1 in 
10 with 9ml of de-ionised water (SHLMPRL). 
 
2.2.4 Hydrochloric acid 15% 
Hydrochloric acid 15% was used in conjunction with sodium bicarbonate to 
produce an atmosphere of carbon dioxide (CO2) suitable for the growth of N. 
meningitidis. 1,190ml of de-ionised water (SHLMPRL) was added to a 2 litre 
conical flask. 820ml of a 37% solution of Hydrochloric acid (McQuilkin & Co. Ltd., 
Glasgow, UK) was added slowly to the water while gently mixing. This was 
allowed to cool before transferring to a 5 litre container. 
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2.2.5 Meningococcal co-agglutinating reagents 
Meningococcal co-agglutinating reagents were used to serogroup isolates of N. 
meningitidis into the 6 serogroups; A, C, Y, W135, X and Z. A 1:5 or a 1:10 
dilution was prepared by adding 20μl or 10μl of each N. meningitidis 
agglutinating serum (Remel Europe Ltd., Dartford, Kent, UK) to 80μl or 90μl of 
Pansorbin® Cells (Merck Chemicals Ltd., Nottingham, UK) respectively in a 2ml 
micro tube (Sarstedt Ltd., Leicester, UK). Each new batch of co-agglutination 
reagents was tested against the 7 N. meningitidis serogroup A, B, C, W135, X, Y 
and Z control organisms (See Table 2.1).  
In the class 1 safety cabinet, using a sterile cotton swab (McQuilkin & Co. Ltd., 
Glasgow, UK) for each isolate, a few colonies were picked from an overnight 
culture plate to make a suspension in 2ml of 0.85% saline (SHLMPRL) to give a 
McFarland standard of approximately 2. On a glass microscope slide (VWR 
International Ltd., Poole, Dorset, UK) using 1μl disposable loops (VWR 
International Ltd., Poole, Dorset, UK) a loop-full of control suspension was mixed 
with a loop-full of corresponding co-agglutination reagent. This was mixed with 
a wooden cocktail stick and the slide was gently tilted. The slide was observed 
for evidence of clumping indicative of a positive agglutination reaction. If the 
mixed suspensions remained milky in appearance this was indicative of a 
negative reaction. Each co-agglutinating reagent was tested against all the 
control isolates to ensure no cross reaction. Any reagents that did cross react 
were discarded. The two dilutions of co-agglutinating reagent was compared and 
the highest dilution giving good agglutination results with no cross reaction was 
used in subsequent testing of N. meningitidis isolates. 
 
2.2.6 Mueller-Hinton Broth 
Mueller-Hinton broth was used as a suspension medium when re-suspending 
lyophilised freeze-dried N. meningitidis isolates. 21g of powdered Mueller-
Hinton broth (Oxoid, Basingstoke, Hamps., UK) was added to 1 Litre of de-
ionised water (SHLMPRL) and mixed to dissolve. This was distributed in 2ml 
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amounts into glass bijou bottles and sterilised at 121°C for 15 minutes in a 
Priorclave Autoclave (Model No. PS/LAC/EV100). 
 
2.3 Neisseria meningitidis isolates 
All strains included in this study were received by the SHLMPRL between 1972 
and 2004. Isolates were identified following consultation of the SHLMPRL N. 
meningitidis isolate database using the criteria defined below. Carried 
meningococci were defined as N. meningitidis strains isolated from throat or 
nasopharyngeal samples from asymptomatic individuals with no epidemiological 
link to an invasive meningococcal disease case. Table 2.1 lists the control strains 
used in this study. 
Table 2.1 – N. meningitidis control strains 
 
Organism Serogroup designation Source 
ATCC 13077 A NCTC, HPA, Colindale, UK 
ATCC 13090 B NCTC, HPA, Colindale, UK 
ATCC 13102 C NCTC, HPA, Colindale, UK 
ATCC 35561 Y NCTC, HPA, Colindale, UK 
NCTC 11203 W135 NCTC, HPA, Colindale, UK 
NCTC 10790 X NCTC, HPA, Colindale, UK 
NCTC 10792 Z NCTC, HPA, Colindale, UK 
NCTC 11202 29E NCTC, HPA, Colindale, UK 
GL0101366 NG (non-serogroupable) 
Capsule null locus-positive 
Dr M. A. Diggle, UK Carriage Study, 
SHLMPRL, Glasgow, UK 
GL0103161 NG (non-serogroupable) 
Capsule null locus-positive 
Dr M. A. Diggle, UK Carriage Study, 
SHLMPRL, Glasgow, UK 
 
 
2.3.1 Resuscitation and recovery of bacterial strains 
N. meningitidis isolates were recovered from either ProtectTM beads (isolates 
from 1996 – 2004) stored at -80°C or from freeze-dried ampoules (isolates from 
1972 – 1995) stored at room temperature at the SHLMPRL. For isolates recovered 
from ProtectTM beads; one or two beads were used to inoculate a single plate of 
Columbia agar with horse blood (Oxoid, Basingstoke, Hamps., UK). Isolates were 
incubated overnight at 37°C in an atmosphere of 5.0% v/v CO2.  
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For isolates resuscitated from freeze-dried ampoules; 500μl of either Meuller-
Hinton broth (SHLMPRL) or 18MΩ H2O (ELGA Process Water, High Wycombe, 
Bucks., UK) was used to re-suspend the culture. Using a sterile graduated 
pipette (Alpha Laboratories Ltd, Eastleigh, UK) 2 or 3 drops of the re-suspended 
isolate was used to inoculate a single plate of Columbia agar with horse blood 
(Oxoid, Basingstoke, Hamps., UK). Isolates were incubated for either 24 or 48 
hours at 37°C in an atmosphere of 5.0% v/v CO2.  
 
2.3.2 DNA extraction of N. meningitidis isolates 
From an overnight pure culture plate meningococcal DNA was extracted by 
inoculating 500μl of 18MΩ H2O (ELGA Process Water, High Wycombe, Bucks., UK) 
in a 2ml microfuge tube (Sarstedt Ltd., Leicester, UK) and heating at 80°C for 15 
minutes in a water bath (Grant Instruments Ltd., Sherpeth, Cambs., UK). 
Following a five minute centrifugation at 15000 rpm (Biofuge Primo, Heraeus 
Instruments), 200μl of the supernatant containing the DNA was added to a fresh 
2ml microfuge tube (Sarstedt Ltd., Leicester, UK) and stored at -80°C until 
required for all further PCR and sequencing reactions. 
 
2.3.3 Non-culture DNA extraction of re-suspended freeze-dried 
isolates prior to incubation 
Re-suspended freeze-dried isolates underwent a non-culture DNA extraction 
using the remaining fluid by addition to a further 500μl of 18MΩ H2O (ELGA 
Process Water, High Wycombe, Bucks., UK) in a 2ml microfuge tube (Sarstedt 
Ltd., Leicester, UK) and used as for extraction of isolates that were successfully 
sub-cultured. In some instances isolates failed to grow on sub-culture and the 
non-culture extract was used as template for all further PCR and sequencing 
reactions. 
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2.3.4 DNA extraction from reconstituted freeze-dried specimens 
of N. meningitidis using FTA® Elute Cards 
FTA Elute Cards (Whatman International Ltd., Maidstone, Kent, UK) are designed 
for room temperature collection, shipment, archiving and purification of nucleic 
acids from biological samples for PCR analysis. FTA Elute Cards are impregnated 
with a patented chemical formula that lyses cells and denatures proteins upon 
contact. For each sample an individual FTA Elute Card was labelled with the 
appropriate sample identification number. Using a P200 Gilson pipette (Anachem 
Ltd., Luton, Beds., UK) and 1-200μl barrier tips (Starlab UK Ltd., Milton Keynes, 
UK) 40μl of each reconstituted freeze-dried specimen was added to its 
corresponding FTA Elute Card within the printed circle area.  
The samples were either left to dry completely at room temperature for at least 
3 hours or, to reduce drying time, the spotted FTA Elute Card was placed in a 
heated drier (Thermo Fisher Scientific, Epsom, Surrey, UK) set to 50°C for 1 
hour. Once the samples had completely dried, a 3mm disk was cut from the 
centre of the spotted circle using a 3mm Harris Uni-Core device (Whatman 
International Ltd., Maidstone, Kent, UK) and transferred to a 1.5ml microfuge 
tube (McQuilkin & Co. Ltd., Glasgow, UK). Next 500μl of 18MΩ H2O (ELGA Process 
Water, High Wycombe, Bucks., UK) was added to the tube and immediately 
pulse-vortexed three times for a total of 15 seconds using a WhirliMixerTM (Fisons 
Scientific Equipment).  
The disk was immediately transferred to a second 1.5ml microfuge tube 
(McQuilkin & Co. Ltd., Glasgow, UK) containing 100μl of 18MΩ H2O (ELGA Process 
Water, High Wycombe, Bucks., UK) ensuring the disk was completely immersed 
in the 18MΩ H2O. The tube was then incubated in a water bath (Type JB2, Grant 
Instruments Ltd., Sherpeth, Cambs., UK) at 90°C for 30 minutes. At the end of 
the incubation period the tube was briefly pulse-vortexed and placed in the 
centrifuge for 30 seconds to separate the matrix from the eluate and the disk 
was removed using a sterile pipette tip and discarded. The eluate contains the 
purified DNA. Eluted DNA was stored at -20°C until required. 
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2.4 Phenotypic procedures 
2.4.1 Production of a 5% v/v CO2 environment 
To produce an atmosphere of 5% v/v carbon dioxide (CO2) suitable for the 
growth of N. meningitidis approximately 10ml of hydrochloric acid 15% w/v 
(SHLMPRL) was dispensed into a glass universal and placed in a polypropylene jar 
with a suitable universal holder. Inoculated Columbia agar plates with horse 
blood were placed inside the jar, one sodium bicarbonate 600mg tablet (Norton 
Healthcare, London, UK) was added to the universal of hydrochloric acid 15% 
w/v and the lid of the jar was promptly closed. The jar was placed into an LTE 
Scientific, Raven 2 Incubator set to 37°C for at least 12 hours or overnight. 
 
2.4.2 Serogrouping of N. meningitidis isolates by latex 
agglutination 
The Wellcogen N. meningitidis B/E. coli K1 (Remel Europe Ltd., Dartford, Kent, 
UK) and Wellcogen N. meningitidis ACYW135 (Remel Europe Ltd., Dartford, 
Kent, UK) kits were used for the qualitative detection of specific antigen in a 
live suspension from an overnight culture plate. To initially serogroup 
encapsulated meningococci, Wellcogen latex particles coated with monoclonal 
antibodies specific to serogroup B or coated with polyclonal antibodies specific 
to serogroup A, C, Y, W135 (Remel Europe Ltd., Dartford, Kent, UK) are used in 
a slide agglutination technique. The following was performed in a class 1 safety 
cabinet. Using a sterile cotton tipped swab (McQuilkin & Co. Ltd., Glasgow, UK) 
a few colonies of the N. meningitidis isolate to be tested were picked from an 
overnight culture plate and used to make a suspension in 2ml of 0.85% saline 
(SHLMPRL) to give a McFarland standard of approximately 2. On a glass 
microscope slide (VWR International Ltd., Poole, Dorset, UK) using 1μl disposable 
loops (VWR International Ltd., Poole, Dorset, UK) a loop-full of the suspension 
was mixed with a drop of polyvalent Wellcogen N. meningitidis A, C, Y, W135 
test latex reagent and a second loop-full of the suspension was mixed with a 
drop of Wellcogen N. meningitidis Group B/E. coli K1 test latex reagent. The 
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glass slide was gently tilted to and fro for up to 3 minutes and observed for an 
agglutination reaction; clumping of the latex particles was indicative of an 
agglutinated pattern and therefore a positive result. 
In a negative reaction the latex does not agglutinate and a milky appearance 
remains. If a positive reaction was observed with the Group B/E. coli K1 latex 
suspension then the isolates is serogroup B positive. If a positive reaction was 
observed with the N. meningitidis A, C, Y, W135 polyclonal latex reagent the 
individual meningococcal co-agglutinating reagents A, C, Y and W135 were used 
to test the isolate further (see below). If a negative reaction was observed with 
both Wellcogen latex reagents then the meningococcal co-agglutinating reagents 
X and Z were used to test the isolate further. A negative reaction with all the 
latex and co-agglutination reagents indicates that either the N. meningitidis 
isolate is phenotypically capsule negative or the organism may lack the genes 
required for synthesis and transport of capsular polysaccharide. When this 
occurred isolates were tested further by genotypic PCR to amplify DNA specific 
for individual capsular polysaccharides or the capsule null locus (see genotypic 
procedures section). 
 
2.4.3 Serogrouping of N. meningitidis isolates by co-agglutination 
Following a positive reaction with the polyclonal Wellcogen N. meningitidis 
ACYW135 latex reagent (Remel Europe Ltd., Dartford, Kent, UK) the serogroup 
was determined using the panel of monoclonal co-agglutination reagents for 
serogroup A, C, Y and W135. Using the previously prepared suspension of the 
test strain that gave a positive reaction with the polyclonal latex reagent, with a 
sterile 1µl disposable loop (McQuilkin & Co. Ltd., Glasgow, UK) 6 loop-fulls of 
suspension were spotted onto a glass slide, or slides (VWR International Ltd., 
Poole, Dorset, UK). With a sterile 1µl disposable loop (McQuilken & Co. Ltd., 
Glasgow, UK) a loop-full of each individual monoclonal co-agglutination reagent 
was also spotted to the glass microscope slide(s) (VWR International Ltd., Poole, 
Dorset, UK) adjacent to a separate spot of the live suspension of the test strain. 
The adjacent spots of suspended organism and co-agglutination reagent were 
mixed gently and the glass slide was tilted to and fro and examined for 
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agglutination. The serogroup was then determined by a positive agglutination 
with only one corresponding co-agglutination reagent. 
 
2.4.4 Storage of N. meningitidis isolates 
Isolates of N. meningitidis that were grown successfully (from the archived 
isolate on ProtectTM bacterial preservation beads or freeze-dried ampoules) were 
stored on a new vial of ProtectTM bacterial preservation beads (Technical Service 
Consultants Ltd., Heywood, Lancs., UK). From a pure overnight culture plate N. 
meningitidis was recovered using a sterile cotton swab (Medical Wire Equipment 
Co., Corsham, Wilts., UK) and this was used to inoculate a vial of ProtectTM 
bacterial preservation beads (Technical Service Consultants Ltd., Heywood, 
Lancs., UK). The inoculated vial was mixed and the excess fluid was removed 
using a sterile plastic pipette (McQuilkin & Co. Ltd., Glasgow, UK). The vial was 
stored in the freezer at    -80°C until required. 
 
2.5 Genotypic procedures 
2.5.1 Genotypic serogrouping PCR 
Oligonucleotide primers were obtained by ordering online from www.vhbio.com 
(VH Bio Ltd., Gateshead, UK); or www.eurogentec.com (Eurogentec Ltd., 
Southampton, Hamps., UK); or www.eurofinsdna.com/home (Eurofins MWG 
Operon, Ebersberg, Germany). Unless stated, PCR was carried out to a final 
volume of 25µl using the following; 1µl of each oligonucleotide primer at 
5µM/ml, 20µl of 1.1x ReddymixTM PCR Master Mix (1.5mM MgCl2) (Thermo Fisher 
Scientific, Epsom, Surrey, UK) and 3µl template DNA. Primers used for genotypic 
serogrouping PCR are listed in Table 2.2. PCR products were confirmed by 
agarose gel electrophoresis as described later; using the appropriate control 
organism (Table 2.1) as a positive control. Negative controls were performed 
using control organisms of a serogroup different to the serogroup being tested. A 
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negative control was also performed using 18MΩ H2O (ELGA Process Water, High 
Wycombe, Bucks., UK) instead of bacterial DNA. 
Table 2.2 – Oligonucleotides used in the capsular characterisation of NG meningococci 
 
Primer Name Primer Sequence 5’ – 3’ Reference 
siaD B-F TGC ATG TCC CCT TTC CTG A (Guiver, Borrow et al. 2000) 
siaD B-R AAT GGG GTA GCG TTG ACT AAC AA (Guiver, Borrow et al. 2000) 
siaD C-F GAT AAA TTT GAT ATT TTG CAT GTA GCT TTC (Guiver, Borrow et al. 2000) 
siaD C-R TGA GAT ATG CGG TAT TTG TCT TGA AT (Guiver, Borrow et al. 2000) 
siaDY/W135-F CAA ACG GTA TCT GAT GAA ATG CTG GAA G (Borrow, Claus et al. 1998) 
siaDY/W135-R TTA AAG CTG CGC GGA AGA ATA GTG AAA T (Borrow, Claus et al. 1998) 
ctrA 29E-F ATT ACG CTG ACG GCA TGT GGA (Bennett, Mulhall et al. 2004) 
ctrA Z-F TAT GCG GTG CTG TTC GCT ATG (Bennett, Mulhall et al. 2004) 
ctrA X-F GTC TTT GTA TAA GGC CCA AG (Bennett, Mulhall et al. 2004) 
ctrA U-R TTG TCG CGG ATT TGC AAC TA (Corless, Guiver et al. 2001) 
ctrA F GCT GCG GTA GGT GGT TCA A (Corless, Guiver et al. 2001) 
cnl-F GGA TTG GAC GAG CGA GAC (Claus, Maiden et al. 2002) 
cnl-R GGT CGT GTG AAA GCT TGC CTT GCT C (Claus, Maiden et al. 2002) 
HC287 CGC GCC ATT TCT TCC GCC (Claus, Maiden et al. 2002) 
mynA-F GTC TTA ACC GTC TTT GGC ACT (Diggle, Smith et al. 2003) 
mynA-R TGA GGC ATT ACC TAT CCC GTA (Diggle, Smith et al. 2003) 
 
 
2.5.1.1 Serogroup B (siaD B) and Serogroup C (siaD C) 
Amplification of the siaD gene specific for the production of serogroup B or 
serogroup C capsular polysaccharide was performed using primers siaD B-F and 
siaD B-R or siaD C-F and siaD C-R, respectively (Table 2.2). Both were amplified 
under the same thermal conditions; firstly, denaturation at 95°C for 10 minutes 
was followed by 35 cycles of denaturation at 95°C for 15 seconds, annealing at 
60.4°C for 1 minute and extension at 72°C for 30 seconds. This was followed by 
an extension step at 72°C for 5 minutes. 
 
2.5.1.2 Serogroup Y/W135 (siaD Y/W135)  
The high degree of similarity between the DNA sequence of the siaD gene 
encoding for the serogroup Y and serogroup W135 polysaccharide requires that 
detection of these serogroups is performed in two steps. Firstly, PCR using 
common primers that amplify both sequences, followed by a restriction digest of 
the amplified product to distinguish between the two serogroups. This PCR was 
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carried out at the same thermal conditions as the serogroup B (siaD B) and 
serogroup C (siaD C) PCR above using primers siaD Y/W135-F and siaD Y/W135-R 
(Table 2) to a final volume of 50µl (i.e. double volumes). 
To distinguish between serogroups Y and W135 the following restriction digest 
was performed in either a 96-well plate (Web Scientific Ltd., Crewe, UK) or a 
0.2ml microfuge tube (Thermo Fisher Scientific, Epsom, Surrey, UK). 15µl of 
amplified product was combined with 1µl of the restriction enzyme XbaI 
(Promega UK Ltd., Southampton, Hamps., UK), 3µl of 10X restriction digest 
buffer (Promega UK Ltd., Southampton, Hamps., UK) and 11µl 18MΩH2O (ELGA 
Process Water, High Wycombe, Bucks., UK) and incubated for 6 hours at 37°C in 
a water bath (Type JB2; Grant Instruments Ltd., Sherpeth, Cambs., UK) or 
thermal cycler (Aviso, Germany). Digests were then analysed by agarose gel 
electrophoresis (see section 2.5.2). An XbaI site is unique to the serogroup Y siaD 
gene and the digest reaction produces DNA fragments of 438bp and 92bp, whilst 
the serogroup W135 amplicon remains intact (Borrow, Claus et al. 1998). 
 
2.5.1.3 Serogroup A (mynA) 
Amplification of the mynA gene specific for the production of the serogroup A 
polysaccharide was performed using primers mynA-F and mynA-R (Table 2.2). 
Firstly, denaturation at 95°C for 15 minutes was followed by 35 cycles of 
denaturation at 95°C for 15 seconds, annealing at 53°C for 30 seconds and 
extension at 72°C for 30 seconds. This was followed by an extension step at 
72°C for 3 minutes. 
 
2.5.1.4 Serogroup X (ctrA X), serogroup Z (ctrA Z) and serogroup 29E (ctrA 
29E) 
A slightly different approach was used to identify serogroup X, Z or 29E; the ctrA 
gene was used to differentiate between these serogroups. This PCR used a 
universal upstream primer ctrA U-R and a downstream primer specific to each 
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serogroup; ctrA X-F, ctrA Z-F and ctrA Z-F for serogroup X, Z and 29E 
respectively (Table 2.2). Firstly, denaturation at 95°C for 5 minutes was 
followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 
62.5°C for 1 minute and extension at 72°C for 30 seconds. This was followed by 
an extension step at 72°C for 5 minutes. 
 
2.5.1.5 Capsule null locus (cnl)  
Some N. meningitidis isolates lack the genes required for capsule synthesis 
(siaABCD) and transport (ctrABCD) and as such the serogrouping by latex or co-
agglutination and the genotypic serogrouping PCR tests outlined above will yield 
a negative result. The intergenic region between the region E and the region D 
of the cps cluster containing the capsule null locus was amplified by PCR using 
primers cnl-F and cnl-R  or cnl-R and HC287 (Table 2.2). Firstly denaturation at 
95°C for 2 minutes was followed by 40 cycles of denaturation at 95°C for 25 
seconds, annealing at 53°C for 20 seconds and extension at 72°C for 30 seconds. 
This was followed by an extension step at 72°C for 5 minutes. 
 
2.5.1.6 Serogroup non-specific ctrA PCR  
Where NG N. meningitidis isolates yielded a negative result with the serogroup-
specific PCRs and the cnl PCR, the serogroup non-specific ctrA PCR assay used in 
the SHLMPRL for the detection of meningococcal DNA in clinical specimens in 
suspected cases of meningococcal disease (Corless, Guiver et al. 2001) was used 
to confirm that isolates were N. meningitidis.  The PCR used the ctrA-U and 
ctrA-F primers (Table 2.2). Firstly denaturation at 95°C for 2 minutes was 
followed by 10 cycles of denaturation at 95°C for 20 seconds, annealing at 55°C 
for 20 seconds and extension at 72°C for 10 seconds. This was followed by a 
further 10 cycles where the extension step was increased to 12 seconds.  This 
was subsequently followed by a further 10 cycles with the extension step 
increased to 15 seconds. 
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2.5.2 Confirmation of PCR products by agarose gel 
electrophoresis 
‘Hi-Pure’ Low EEO Agarose (Biogene Ltd, Kimbolton, Cambs., UK) was added to 
1x ELFO buffer (SHLMPRL) to make a 1.5 % (w/v) gel and heated until molten 
using a standard microwave. 4μl of 1mg/ml ethidium bromide (SHLMPRL) was 
added to the molten gel and this was poured into a gel cast and allowed to set. 
Once the gel had set, 5μl - 10μl of each PCR product was used for agarose gel 
electrophoresis and visualised using a UV transilluminator (VWR International 
Ltd., Poole, Dorset, UK) or Bio-Rad gel doc 2000 gel analysis system and Quantity 
One 1-D analysis software (Bio-Rad Laboratories Ltd, Hemel Hempsted, UK). The 
ReddyMix PCR Master Mix w/ 1.5mM MgCl2 (Thermo Scientific, Epsom, Surrey, 
UK) used in all PCR reactions contains a dye and a precipitant to facilitate gel 
loading. Agarose gels were disposed of following the standard operating 
procedures in place at the SHLMPRL (designated Ethidium bromide agarose gel 
waste bins were used and these were uplifted by an outside contractor for safe 
disposal).  Examples of agarose gel electrophoresis pictures for the genotypic 
serogrouping PCRs, porA and MLST gene amplification are shown in the 
Appendix, section 9.3 (Figures 9.1 – 9.8). 
 
2.5.3 Multi-locus sequence typing (MLST) 
2.5.3.1 Amplification reaction primers and conditions 
MLST was performed using semi-automated methods as described previously 
(Sullivan, Jefferies et al. 2006). Amplification of the MLST gene fragments was 
performed using the oligonucleotide primer pairs abcZ-M-AF and abcZ-M-AR, 
adk-M-AF and adk-M-AR, aroE-M-AF and aroE-M-AR, fumC-M-AF and fumC-M-AR, 
gdh-M-AF and gdh-M-AR, pdhC-M-AF and pdhC-M-AR, pgm-M-AF and pgm-M-AR as 
listed in Table 2.3. In addition, primer pairs ending in -SF and -SR were used for 
amplification if a particular gene fragment was unsuccessfully amplified using 
the -AF and -AR primer pairs. Amplification of the gene fragments was carried 
out to a final volume of 25µl using the following: 1µl of each primer (forward 
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and reverse) + 20µl of 1.1x ReddymixTM PCR Master Mix (1.5mM MgCl2) (Thermo 
Fisher Scientific, Epsom, Surrey, UK) + 3µl of template DNA. 
Table 2.3 – Oligonucleotides used for DNA amplification and sequencing of MLST alleles 
 
Primer Name Primer Sequence 5’ – 3’ 
abcZ-M-AF  TGT TCC GCT TCG ACT GCC AAC 
abcZ-M-AR  TCC CCG TCG TAA AAA ACA ATC 
adk-M-AF CCA AGC CGT GTA GAA TCG TAA ACC 
adk-M-AR TGC CCA ATG CGC CCA ATA C 
aroE-M-AF TTT GAA ACA GGC GGT TGC GG 
aroE-M-AR CAG CGG TAA TCC AGT GCG AC 
fumC-M-AF TCC CCG CCG TAA AAG CCC TG 
fumC-M-AR GCC CGT CAG CAA GCC CAA C 
gdh-M-AF CTG CCC CCG GGG TTT TCA TCT 
gdh-M-AR TGT TGC GCG TTA TTT CAA AGA AGG 
pdhC-M-AF CCG GCC GTA CGA CGC TGA AC 
pdhC-M-AR GAT GTC GGA ATG GGG CAA ACA 
pgm-M-AF CTT CAA AGC CTA CGA CAT CCG 
pgm-M-AR CGG ATT GCT TTC GAT GAC GGC 
abcZ-M-SF  AAT CGT TTA TGT ACC GCA GR 
abcZ-M-SR  GAG AAC GAG CCG GGA TAG GA 
adk-M-SF AGG CWG GCA CGC CCT TGG 
adk-M-SR CAA TAC TTC GGC TTT CAC GG 
aroE-M-SF GCG GTC AAY ACG CTG RTK 
aroE-M-SR ATG ATG TTG CCG TAC ACA TA 
fumC-M-SF TCC GGC TTG CCG TTT GTC AG 
fumC-M-SR TTG TAG GCG GTT TTG GCG AC 
gdh-M-SF CCT TGG CAA AGA AAG CCT GC 
gdh-M-SR RCG CAC GGA TTC ATR YGG 
pdhC-M-SF TCT ACT ACA TCA CCC TGA TG 
pdhC-M-SR ATC GGC TTT GAT GCC GTA TTT 
pgm-M-SF CGG CGA TGC CGA CCG CTT GG 
pgm-M-SR GGT GAT GAT TTC GGT YGC RCC 
All sequences obtained from http://pubmlst.org/neisseria/ 
 
In addition, primer pairs ending in -SF and -SR were used for amplification if a 
particular gene fragment was unsuccessfully amplified using the -AF and -AR 
primer pairs. Amplification of the gene fragments was carried out to a final 
volume of 25µl using the following: 1µl of each primer (forward and reverse) + 
20µl of 1.1x ReddymixTM PCR Master Mix (1.5mM MgCl2) (Thermo Fisher 
Scientific, Epsom, Surrey, UK) + 3µl of template DNA. 
Firstly denaturation at 95°C for two minutes was followed by ten cycles of 
denaturation at 95°C for 30 seconds, annealing at 58°C for 40 seconds and 
extension at 72°C for 1 minute 30 seconds. Subsequently, twelve cycles with an 
altered annealing step at 55°C and extension step of 1 minute 35 seconds and a 
further fourteen cycles with an altered annealing step at 50°C and extension 
Chapter 2  85 
step of 1 minute 40 seconds. Finally this was completed by an extension step at 
72°C for five minutes. PCR products were confirmed by agarose gel 
electrophoresis as described earlier. 
2.5.3.2 Sequencing reaction primers and conditions 
Sequencing of the MLST gene fragments was performed as described in (Sullivan, 
Jefferies et al. 2006). Briefly; each fragment was sequenced on both strands 
using 1µl of each of the corresponding -SF and -SR primers at 5µM/ml (Table 
2.3), 4µl of DYEnamic ET TerminatorTM (GE Healthcare, Little Chalfont, UK) and 
6µl of clean DNA. The sequencing reaction was performed using thirty cycles at 
the following thermal parameters; denaturation at 95°C for 20 seconds, 
annealing at 50°C for 15 seconds and extension at 60°C for 60 seconds. 
Following the sequencing reaction; sequencing products were prepared using 
MultiScreen®384-SEQ filter plates (Millipore Ltd., Watford, Herts., UK) and a 
TheOnyx liquid handling system (Aviso, GmbH, Germany) according to the 
manufacturers’ instructions. DNA sequencing was performed using the MegaBACE 
1000 DNA Analysis System (GE Healthcare, Little Chalfont, UK) according to the 
manufacturers’ instructions. 
 
2.5.3.3 MegaBACE 1000 automated DNA sequencer 
Operation of the MegaBACE 1000 automated DNA sequencer was conducted 
following standard operating procedures in place at the SHLMPRL. In the 
Electrophoresis parameters tab within the Instrument Control Manager the 
standard sequencing run parameters were entered at the following settings; 
Sample Injection Voltage = 3KV; Sample Injection Time = 38 seconds; Run 
Voltage = 9KV; Run Time = 120 minutes.  On occasion these settings were altered 
to improve the sequencing read length where there was evidence of late 
injection or over injection of a sample. 
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2.5.4 PorA genotypic characterisation 
The amplification conditions, confirmation of PCR products, sequencing 
reactions, preparation of sequencing products and DNA sequencing of PorA 
variable regions were performed as for the MLST gene fragments with the 
exception of using the primers listed in Table 2.4. Amplification was performed 
primarily using porA-M-AF(210) and porA-M-AR(211). In instances where 
amplification was unsuccessful, primers porA-M-AF(AU) and porA-M-AR(AL) were 
used together or in combination with the aforementioned pair. DNA sequencing 
of VR1, VR2 and VR3 on both strands was performed using the primers listed in 
Table 2.4. 
 
Table 2.4 – Oligonucleotides used for PCR and sequencing of PorA variable regions 
 
Primer Name Primer sequence 5’ – 3’ VR
1; direction 
sequenced Reference 
porA-M-AF(210) ATG CGA AAA AAA CTT ACC GCC CTC VR1; 5’-3’ (Feavers and Maiden 1998) 
porA-M-AR(211) AAT GAA GGC AAG CCG TCA AAA ACA ND2 (Feavers and Maiden 1998) 
porA-M-AF(AU) GCA CGA GGT CTG CGC ND (Molling, Unemo et al. 2000) 
porA-M-AR(AL) ATT AAT TTG AGT GTA GTT GCC ND (Molling, Unemo et al. 2000) 
porA-M-SF(103L) AAC GGA TAC GTC TTG CTC VR1; 3’-5’ (Suker, Feavers et al. 1994) 
porA-M-SR(8U) TCC GTA CGC TAC GAT TCT CC VR2/3; 5’-3’ (Maiden, Suker et al. 1991) 
porA-M-SF(21U) GCG AAA TCA AAG CCG GCG T VR2/3; 5’-3’ (Maiden, Suker et al. 1991) 
porA-M-SR(122L) GGC GAG ATT CAA GCC GCC VR2/3; 3’-5’ (Suker, Feavers et al. 1994) 
1 VR, variable region; 2 ND, not determined 
 
 
2.5.5 DNA sequencing of the capsule null locus 
DNA sequencing of the capsule null locus was performed following the method of 
Claus et al 2002 with modifications. The preparation of amplified DNA and 
sequencing reaction mixes and the sequencing reaction for nucleotide 
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sequencing of the cnl was performed as for MLST and PorA sequencing using the 
equivalent primer pair as used in the amplification reaction to obtain the 
nucleotide sequences for both strands. 
 
2.5.6 DNA sequence analysis 
For MLST, sequence data analysis was performed as described previously (Diggle 
and Clarke 2002). The sequence data were read automatically from the 
sequencer using the integrated image analysis and data collection software. DNA 
sequence data were analyzed using the MegaBACE Sequence Analysis Software, 
Version 2.4, Build 20010115, Molecular Dynamics © 1996 – 2001, using the 
Cimarron 2.19 Slim Phredify or Cimarron 1.53 Slim Phredify Base caller). MLST 
allele sequences were downloaded in FASTA format from the MLST database 
website and generated sequences were compared using the DiscoverIR software, 
version 1, Build 1.19, LI-COR Inc, Michigan, USA. New allelic variants and new 
sequence types were submitted to the N. meningitidis MLST database curator for 
assignment (http://pubmlst.org/neisseria/).  
For porA genosubtyping, the sequence data were read automatically from the 
sequencer using the integrated image analysis and data collection software. The 
nucleotide sequences were translated into amino acid sequences using the 
Translate program (http://expasy.cbr.nrc.cu/tools/dna.html) and compared to 
known variants on the PorA database (www.neisseria.org/nm/typing) or directly 
using the PorA web-site database for VR1 and VR2. For VR3 subtyping the 
nucleotide sequences were translated into amino acid sequences using the 
Translate program and compared with those previously sequenced by the 
SHLMPRL or other collaborators (Molling, Unemo et al. 2000; Molling, Backman 
et al. 2001; Molling, Jacobsson et al. 2002; Clarke, Diggle et al. 2003b). 
Sequence analysis of the capsule null locus was performed using the sequence 
trace files (SCF) from the integrated MegaBACE software and imported directly 
into the CLC DNA Workbench 3.6.2 (CLC bio A/S, Aarhus, Denmark) for reverse 
complementation (where required) and alignment with published sequences of 
cnl alleles; see Table 2.5. cnl alleles were aligned using ClustalX version 2.0 
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(Larkin, Blackshields et al. 2007). New DNA sequences were submitted to 
GenBank. 
 
Table 2.5 – Capsule null locus allele sequences used for cnl DNA sequence comparison 
 
Capsule null 
locus allele 
Source strain description Accession 
number 
cnl-1 N. meningitidis ST-53 tex/galE intergenic sequence replacing the 
regions A + C of cps locus 
AJ308327 
cnl-2 N. meningitidis tex/galE intergenic sequence, strain α30 AM086166 
cnl-3 N. meningitidis tex/galE intergenic sequence, strain α627 AM086167 
cnl-4 N. lactamica tex/galE intergenic sequence, strain β154 AM086168 
cnl-5 N. lactamica tex/galE intergenic sequence, strain β270 AM086169 
cnl-6 N. gonorrhoeae tex/galE intergenic sequence, strain FA1090 AM086170 
cnl-7 N. lactamica tex/galE intergenic sequence, strain 10618 V1 AM086171 
 
 
 
2.5.7 Analysis of MLST alleles and sequence types 
MLST allelic profiles were analysed using eBURSTv3 (Feil, Li et al. 2004; Spratt, 
Hanage et al. 2004). The algorithms employed in the eBUSRTv3 software allow 
STs to be grouped based on relatedness at individual gene loci. BURST, unlike 
cluster diagrams, trees or dendograms, uses a simple but appropriate model of 
bacterial evolution in which an ancestral (or founding) genotype increases in 
frequency in the population and, while doing so, begins to diversify to produce a 
cluster of closely-related genotypes that are all descended from the founding 
genotype. This cluster of related genotypes is often referred to as a “clonal 
complex”. eBURSTv3 has been developed and is hosted at Imperial College 
London. The prevalence of sequence types within carriage and invasive 
meningococcal disease (IMD) isolate datasets was compared using the 
comparison tool in the eBURSTv3 software to identify STs unique to each dataset 
or shared between the two datasets. 
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Sequence Type Analysis and Recombinational Tests  version 2 (STARTv2), written 
by Keith Jolley (Jolley, Feil et al. 2001), was used to perform a number of 
analyses on the carried N. meningitidis strain collection dataset generated 
during this study and on the invasive meningococcal disease isolate dataset 
(covering the same temporal period) that was kindly provided by the SHLMPRL. 
Within the software the MLST scheme for N. meningitidis was defined and known 
allelic profiles and allele sequences were imported from the N. meningitidis 
PubMLST website (www.pubmlst.org/data). The individual data sets containing 
the allelic profiles and STs for the carried specimens sequenced in this study and 
for the IMD dataset obtained from the SHLMPRL were entered. Allele and ST 
frequencies were calculated for each dataset from the corresponding allelic 
profiles. The number of polymorphic sites was calculated from the concatenated 
sequences. Lineage assignment was investigated using the BURST method from 
the allelic profiles and using the UPGMA and Neighbor-joining methods from the 
concatenated sequences. 
 
2.6 MLST clonal complexes 
As of May 2010 the defined clonal complexes listed on the Neisseria MLST 
website were as follows: ST-11 complex/ET-37 complex, ST-8 complex/Cluster 
A4, ST-41/44 complex/Lineage 3, ST-32 complex/ET-5 complex, ST-1 
complex/subgroup I/II, ST-4 complex/subgroup IV, ST-5 complex/subgroup III, 
ST-106 complex, ST-116 complex, ST-18 complex, ST-198 complex, ST-23 
complex/Cluster A3, ST-231 complex, ST-254 complex, ST-292 complex, ST-334 
complex, ST-35 complex, ST-364 complex, ST269 complex, ST-376 complex, ST-
53 complex, ST-549 complex, ST-92 complex, ST-22 complex, ST-162 complex, 
ST-213 complex, ST-461 complex, ST-226 complex, ST-60 complex, ST-174 
complex, ST-103 complex, ST-167 complex, ST-750 complex, ST-1157 complex, 
ST-865 complex, ST-4821 complex, ST-37 complex, ST-175 complex, ST-1117 
complex, ST-1136 complex, ST-212 complex, ST-178 complex and ST-282 
complex.  In this publication, the author used a modified version of these clonal 
complexes.  For some MLST clonal complexes that have dual names to reflect 
the groupings defined by MLEE, those MLEE designations were, for the most part, 
Chapter 2  90 
dropped from the text.  Additionally, for convenience, the word “complex” was 
dropped from the name and the prefix “ST-” was replaced with “cc” denoting 
“clonal complex”. For example, “ST-11 complex/ET-37 complex” became “cc11” 
and “ST-213 complex” was modified to “cc213”. 
 
2.7 Measurement of genetic diversity, D 
Simpson’s index of diversity (D) was used to assess the level of diversity of 
sequence types or PorA subtypes within the carriage and IMD strain collections as 
a whole, or in part to compare temporal distribution, diversity within serogroup 
or geographic region. It gives the probability that any two randomly selected 
individuals drawn from an infinitely large community belong to two different 
species, or in the case of this study, isolates drawn from a population belong to 
different MLST types (Hunter and Gaston 1988). The value of the index ranges 
from zero to one, meaning the nearer the value to one the greater the diversity 
and the nearer to zero the less the diversity. The 95% confidence intervals (CIs) 
for these indices were calculated following the method of Grundmann and 
colleagues (Grundmann, Hori et al. 2001). Non-overlapping 95% CIs indicate a 
significant difference in D.  
 
2.8 Phylogenetic inference of PorA subtypes (VR1, VR3 & 
VR3) based on concatenated amino acid sequences 
A Pearson (FASTA) file containing the concatenated amino acid sequences of the 
PorA subtypes (VR1,VR2,VR3) of the carriage strain collection was uploaded into 
ClustalW2 (Larkin, Blackshields et al. 2007) available at 
www.ebi.ac.uk/clustalw/ and a multiple alignment of the concatenated amino 
acid sequences was first generated using the default settings. The multiple 
alignment was subsequently used to construct a phylogenetic tree based on the 
neighbor-joining (NJ) method (Saitou and Nei 1987). 
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A phylogram is a branching diagram (tree) that is assumed to be an estimate of a 
phylogeny. The branch lengths are proportional to the amount of inferred 
evolutionary change. A cladogram is a branching diagram (tree) assumed to be 
an estimate of a phylogeny where the branches are of equal length. Therefore, 
cladograms show common ancestry, but do not indicate the amount of 
evolutionary "time" separating taxa. 
 
2.9 Estimation of the association of meningococcal 
serogroups, clonal complexes, STs and PorA 
subtypes with invasive disease or with a carriage 
phenotype 
An empirical odds ratio (OR) was directly calculated to compare the probability 
of invasive disease (or carriage), on the basis of individual meningococcal strain 
characteristics; i.e. serogroup, clonal complex, sequence type or PorA subtype. 
Where a is the number of invasive ‘A’ serogroups; b is the number of carried ‘A’ 
serogroups, c is the number of invasive non-‘A’ serogroups and d is the number 
of carried non-‘A’ serogroups, the odds ratio is calculated using the equation OR 
= (ad)/(bc). This was repeated for clonal complexes, STs and PorA VR1,2 
subtypes. An OR > 1 indicates that a particular meningococcal serogroup, clonal 
complex, ST or subtype is associated with invasive disease, whilst an OR < 1 
indicates that a particular meningococcal serogroup, clonal complex, ST or 
subtype is associated with carriage. Where an OR indicated carriage the 
reciprocal OR was calculated in each case. To assess the significance of the ORs, 
95% CIs were calculated; if the confidence interval does not include the value 1 
then the OR is statistically significant. Furthermore, a narrow confidence 
interval implies high precision, while a wide confidence interval implies poor 
precision. 
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2.10 Invasive meningococcal disease isolate dataset 
The meningococcal isolate database at the SHLMPRL was examined to identify 
invasive meningococcal disease isolates. An invasive meningococcal disease 
isolate is one which has been grown from a normally sterile site. For the 
purposes of this study only blood or CSF isolates were considered. IMD isolates 
were matched temporally to the carriage strain collection; IMD isolates were 
also received by the reference laboratory during the same period, 1st January 
1974 – 31st December 2004. Furthermore, IMD isolates were also matched 
geographically on the basis that the isolates had been obtained from the same 
population, i.e. Scotland. The reference laboratory often receives isolates from 
other locations; therefore isolates were excluded if the submitting laboratory 
was not located in Scotland. Isolates that had been fully characterised by MLST 
were selected from the meningococcal isolate database for analysis. 
This identified 2,772 invasive isolates, comprising 1,264 blood isolates and 1,508 
CSF isolates. This strain collection was designated as the invasive meningococcal 
disease strain collection; and from this point onwards may be referred to as 
simply the IMD strain collection or IMD isolates. It should be noted that analysis 
of the IMD strain collection dataset with STARTv2 (Jolley, Feil et al. 2001) 
identified five duplicate records and ten typographical errors relating to miss-
matching ST:allelic profiles. The five duplicate records were removed and the 
miss-matching ST:allelic profile combinations were re-assigned on the basis that 
the allelic profile was correct. This gave a final number of isolates in the IMD 
strain collection of 2,767 from which data were used for all comparisons with 
the carriage strain collection described herein. 
 
2.11 Meningococcal strain designation 
The recommended strain designation for meningococci includes the serogroup, 
PorA VRs 1 & 2, FetA VR, MLST sequence type and clonal complex (Brehony, 
Jolley et al. 2007). An example being: C: P1.5, 2-1: F5-4: ST-11 (cc11). At the 
time this project commenced FetA VR sequencing was not employed by the 
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reference laboratory in Scotland as a means to characterise strains of 
meningococci, and as such FetA VR sequencing was not included as part of this 
study. For the purposes of this study in Chapter 6, strain types were designated 
in the format: sero/geno-group:CC:ST:VR1,VR2,VR3.  For example, C:8:8:5,2,36-
2. 
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3 Epidemiological summary and capsular 
characterisation of the carried meningococci in 
Scotland, 1974 – 2004 
3.1 Introduction 
Many of the specimens pre-date the use of electronic data recording by the 
reference laboratory; any accompanying documentation (i.e. letters or specimen 
information documents) were archived and a meningococcal isolate register was 
maintained by the reference laboratory summarising basic information on each 
specimen. Following the re-location of the reference laboratory to its current 
location at Stobhill Hospital, epidemiological information recorded in the 
meningococcal isolate register and any accompanying documentations was 
compiled onto an electronic database which was examined to identify isolates, 
based upon the previously mentioned criteria, for inclusion into this study. The 
serogroup of each isolate included in the study was recorded when the 
specimens were first processed by the reference laboratory. Unless stated 
otherwise, only isolates whose serogroup was initially recorded as non-groupable 
were re-checked by latex- and co-agglutination. A range of serogroup-specific 
and non-serogroup-specific PCR targets were used to further characterise carried 
meningococcal specimens. 
 
3.2 Examination of the Reference Laboratory strain 
archive and the meningococcal isolate database 
The project proposal stated that the SHLMPRL isolate archive contained 2091 
carried meningococci, of which, 1460 were reportedly carried throat isolates. On 
commencement of the project the isolate database at the SHLMPRL was 
examined to identify carried meningococcal throat isolates from the isolate 
archive. Limited information was available on many of the specimens in the 
isolate database; particularly for specimens from earlier years. As outlined in 
Chapter 2 a carriage isolate was defined as coming from an asymptomatic 
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individual with no epidemiological link to an invasive meningococcal disease 
case. Based upon these criteria some 523 isolates were included for further 
study. A considerable number of specimens were initially excluded as limited 
information was available based upon the “diagnosis” or “clinical details” 
recorded for the specimen or individual sampled. 
Following further investigation and discussion it was decided that we could seek 
assistance from Health Protection Scotland (HPS) and/or the regional NHS health 
boards regarding background epidemiological information on the specimens 
which lacked full details. Following initial contact with HPS it was advised that 
my request would require a combined approach between the senior management 
of SHLMPRL and HPS. However no further background information on the 
specimens was obtained via this route. In addition we also contacted the 
regional NHS health boards to obtain updated information regarding the 
specimens listed on the SHLMPRL isolate database.  
The isolate database at SHLMPRL was re-examined for isolates for inclusion in 
this study. The database contained 2,214 upper respiratory tract isolates during 
the period 1974 – 2004; comprising of 2,006 “throat isolates”, 160 “sputum 
isolates”, 23 “nasal isolates”, six “nasopharyngeal isolates”, six “mouth wash 
isolates”, two “tracheal secretion isolates” and one “bronchial aspirate isolate”. 
Specimens were excluded from the study for various reasons; 588 specimens 
were not found or the isolate was never archived at the time of receipt; 131 
isolates were identified as being from a contact of a notified case of invasive 
meningococcal disease (IMD), 76 specimens did not yield viable meningococci 
after 48 hours and were discarded, 30 specimens were from an individual 
confirmed as having IMD and four specimens were PCR negative for all MLST loci 
and porA. In addition, one isolate was identified as Neisseria flava and one was 
identified as N. lactamica; these were also excluded. 
The isolate archive at SHLMPRL consisted of isolates stored as freeze-dried 
(lyophilised) cultures (1972-1996) or isolates stored at -80°C on ProtectTM 
bacterial preservation beads and/or in 5% v/v glycerol (1996 onwards). When 
isolates were originally archived as freeze-dried (lyophilised) specimens, in some 
cases, multiple specimens were often stored; for example more than one 
individual glass vial of freeze-dried (lyophilised) specimen had been prepared. 
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Where multiple vials existed for individual isolates consecutive vials were 
prepared for resuscitation and recovery until a viable meningococcal isolate was 
obtained, or until all vials had been exhausted. In contrast, specimens archived 
from 1996 onwards were usually stored in pairs using one vial of ProtectTM beads 
and one vial containing 5% glycerol. Furthermore, these specimens were also 
repeatedly sub-cultured using two beads at a time and each plate was incubated 
for up to 48 hours until colonies of meningococci had grown. When a sub-culture 
did not yield any viable meningococci the process was repeated until viable 
meningococci were obtained or until the vial of ProtectTM beads (or 5% glycerol 
stock) was exhausted. Often it was required to take a single colony pick from the 
original culture plate for sub-culture either to improve the yield of the culture 
or to obtain a pure culture; this was more frequent with older specimens. 
Successful recovery of isolates from freeze-dried vials was lower than expected 
during this study. Each vial contained the lyophilised specimen and a strip of 
paper with the Reference Laboratory specimen number. Specimens more likely 
to yield viable meningococci were more milky-white in colour, denser and of a 
powdery consistency. In contrast, the condition of specimens less likely to yield 
viable meningococci could be described as ranging from yellowish to brown in 
colour; often they were more transparent and took on a frothy, bubble-like 
appearance (perhaps due to over-heating during the preparation of the samples). 
As the project progressed the decision was taken to exclude a further 470 
specimens from the study. Due to the visibly poor quality of the specimen in the 
glass vials it was thought unlikely that any viable meningococci could be 
recovered from these sub-standard specimens and to attempt to do so would 
have been a waste of both time and resources. Attempts were made on 695 
isolates from 1972 – 1995 using in excess of 1060 individual freeze-dried vials. Of 
these, 271 isolates failed to grow on sub-culture and no more vials remain in the 
isolate archive for these isolates. 
Many specimens required sub-culturing for purity or for improved growth. 
Specimens were discarded when significant contamination by another organism 
had occurred. Initially, when a specimen was resuscitated and no viable 
meningococci were recovered after incubation for 48 hours the specimen was 
discarded. However, due to the unexpectedly high number of non-viable 
specimens being encountered during the resuscitation and recovery process it 
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was subsequently decided that, for specimens processed thereafter, a portion of 
any re-suspended specimen be retained should the specimen not yield viable 
meningococci. Those portions, if required, subsequently underwent the DNA 
extraction procedure listed in section 2.3.3 or 2.3.4 of Chapter 2 prior to 
amplification and sequencing. Limited success was achieved however; some 162 
specimens were non-viable, while the remaining 629 isolates were successfully 
sub-cultured from ProtectTM beads, 5% v/v glycerol, or freeze-dried (lyophilised) 
specimens. In total 791 meningococcal specimens plus four ATCC and four NCTC 
control isolates (see Chapter 2) were included in the study. 
The SHLMPRL isolate database was examined for any other relevant information 
relating to clinical details or any symptoms of the individual sampled. For 
approximately half of all specimens (n=402; 50.8%) ‘Unknown’ was recorded in 
the database and no further information was available. For 294 (37.2%) 
specimens ‘Asymptomatic’ or ‘(Staff) Screen(ing)’ was recorded in the database. 
Several samples (n=58; 7.3%) were recorded as originating from individuals with 
flu-like or non-specific symptoms (i.e. one or more of ‘headache’, ‘fever’, ‘neck 
stiffness’, ‘rash’, ‘photophobia’, ‘pyrexia’, ‘febrile’, ‘sore throat’, ‘pharyngitis’, 
‘tonsillitis’, ‘drowsy’, ‘nausea’). A further 23 (2.9%) samples had originated from 
individuals screened whilst attending a sexually-transmitted infections or genito-
urinary medicine facility. Eight (1.0%) more specimens were obtained from 
individuals recorded as having ‘viral illness’ or ‘encephalitis’, or ‘anal HSV’, 
‘herpes’, ‘HIV-positive’, ‘HPV’ or ‘measles’. Six (0.8%) more specimens had 
other details recorded; one each stated ‘diabetic’, ‘pneumonia’, ‘PUO’, 
‘vomiting’, ‘student’ and ‘study’. No accompanying information was available to 
suggest that any of the source individuals were a contact of a notified case of 
IMD, or were indeed a notified case themselves and these specimens were 
accepted into the study. 
 
3.3 Year of isolation  
The 791 carried meningococcal specimens included in this study were received 
by the SHLMPRL during 1st January 1972 – 31st December 2004. Figure 3.1 
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indicates the number of carried meningococcal specimens per each calendar 
year was highly variable; from zero in 1991 and 1993 to 234 in 1985. One 
hundred and thirty (16.4%), 450 (56.9%) and 211 (26.7%) meningococcal 
specimens were received by the SHLMPRL during the periods 1974 – 1983, 1984 – 
1993 and 1994 – 2004, respectively. The carriage strain collection was broadly 
clustered into three periods; a smaller cluster in the late 1970s, a large cluster 
from 1996 onwards, and a larger cluster during the mid 1980s that is dominated 
by the large number of isolates from 1985. In comparison the distribution of the 
IMD strain collection was more uniform throughout the 31-year period comprising 
of an average of 89 or 90 fully characterised isolates per calendar year; although 
this ranged from twenty in 1983 to 144 in 1991 (Figure 3.1). 
 
 
 
Figure 3.1 - Temporal distribution of meningococci in Scotland, 1974 – 2004 
NIV, non-invasive meningococci; IMD, invasive meningococcal disease 
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3.4 Geographic area (health board)  
The NHS health board, under whose jurisdiction each sending laboratory 
belonged, was used as a predictor of the geographic area of residence of the 
individual from which each isolate was obtained. In 2006 the NHS health board 
‘Argyll & Clyde’ was sub-divided and the ‘Argyll’ region was combined with NHS 
Highland health board to form NHS Highland & Argyll. The ‘Clyde’ region was 
combined with Greater Glasgow to form the NHS Greater Glasgow & Clyde health 
board. Given that the specimens in this study pre-date the re-organisation of 
those health boards for the purposes of this study the health board names, as 
defined prior to the re-organisation, were used throughout. This subdivided 
Scotland into fifteen geographic areas; NHS Argyll & Clyde (AC), NHS Ayrshire & 
Arran (AA), NHS Borders (BR), NHS Dumfries & Galloway (DG), NHS Fife (FF), NHS 
Forth Valley (FV), NHS Grampian (GR), NHS Greater Glasgow (GG), NHS Highland 
(HG), NHS Lanarkshire (LN), NHS Lothian (LO),  NHS Orkney (OR), NHS Shetland 
(SH), NHS Tayside (TY) and NHS Western Isles (WI) (Figure 3.2). 
                
 
Figure 3.2 - Map of Scotland divided into NHS Health Boards1 
1 Correct at the point of commencement of the study (2006); AA = Ayrshire & Arran; AC = Argyll & 
Clyde; BR = Borders; DG = Dumfries & Galloway; FF = Fife; FV = Forth Valley; GG = Greater 
Glasgow; GR = Grampian; HG = Highland; LN = Lanarkshire; LO = Lothian; OR = Orkney; SH = 
Shetland; TY = Tayside; WI = Western Isles.  
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Figure 3.3 shows the geographic distribution of the carriage strain collection. No 
specimens were isolated from individuals predicted to reside in the Orkney or 
Shetland NHS Health board areas. The number of isolates in each geographic 
area varied between one from the NHS Western Isles health board area to 273 
from the NHS Lanarkshire health board area.  
 
 
 
Figure 3.3 - Geographic distribution of meningococci in Scotland, 1974 – 2004 
NIV, non-invasive; IMD, invasive meningococcal disease; AA, Ayrshire & Arran; AC, Argyll & Clyde; 
BR, Borders; DG, Dumfries & Galloway; FF, Fife; FV, Forth Valley; GG, Greater Glasgow; GR, 
Grampian; HG, Highland; LN, Lanarkshire; LO, Lothian; OR, Orkney, SH, Shetland; TY, Tayside, 
WI, Western Isles; * One isolate in the IMD strain collection (equivalent to <0.1%) was obtained 
from individuals resident in each of the Orkney and Shetland NHS Health board regions; ** One 
isolate in the non-invasive strain collection (equivalent to 0.1%) was obtained from an individual 
resident in the Western Isles NHS health board region. 
 
Twelve (1.5%) specimens were isolated from individuals predicted to reside in 
the NHS Ayrshire & Arran Health board area; eight (1.0%) specimens were 
isolated from individuals predicted to reside in the NHS Argyll & Clyde Health 
board area; sixteen (2.0%) specimens were isolated from individuals predicted to 
reside in the NHS Borders Health board area; twenty-two (2.8%) specimens were 
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isolated from individuals predicted to reside in NHS Dumfries & Galloway Health 
board area; 140 (17.7%) specimens were isolated from individuals predicted to 
reside in the NHS Fife Health board area; fifty-seven (7.2%) specimens were 
isolated from individuals predicted to reside in the NHS Forth Valley Health 
board area and 141 (17.8%) specimens were isolated from individuals predicted 
to reside in the NHS Greater Glasgow Health board area. A further three (0.4%) 
specimens were isolated from individuals predicted to reside in the NHS 
Grampian Health board area; ten (1.3%) specimens were isolated from 
individuals predicted to reside in the NHS Highland Health board area; 273 
(34.5%) specimens were isolated from individuals predicted to reside in the NHS 
Lanarkshire Health board area; 102 (12.9%) specimens were isolated from 
individuals predicted to reside in the NHS Lothian Health board area; three 
(0.4%) specimens were isolated from individuals predicted to reside in the NHS 
Tayside Health board area and one (0.1%) isolate was received from an individual 
predicted to reside in the NHS Western Isles Health board area. In addition, 
three specimens were coded as being received from BAN:HOS however it was 
unclear which NHS Health board this submitting laboratory belonged. To 
summarise, the vast majority (n=613; 77.5%) of carried meningococcal specimens 
were isolated from individuals predicted to reside in five NHS Health Board areas 
located across the ‘central belt’, and hence, the most populated areas of 
Scotland (FF, FV, GG, LN and LO; shaded grey in Figure 3.2). 
Using the data recorded in the SHLMPRL meningococcal isolate database the 
same fifteen geographic areas based on the NHS health boards were also used to 
differentiate the IMD strain collection. The number of isolates in each 
geographic area varied from one each in Orkney and Shetland NHS Health boards 
to 711 in NHS Greater Glasgow (Figure 3.3). One hundred and ninety-nine (7.2%) 
specimens were isolated from individuals resident in the Ayrshire & Arran region; 
212 (7.6%) specimens were isolated from individuals resident in the Argyll & 
Clyde region; 21 (0.8%) specimens were isolated from individuals resident in the 
Borders; 76 (2.7%) specimens were isolated from individuals resident in Dumfries 
& Galloway; 137 (4.9%) specimens were isolated from individuals resident in the 
Fife region; 119 (4.3%) specimens were isolated from individuals resident in the 
Forth Valley region; 711 (25.6%) specimens were isolated from individuals 
resident in the Greater Glasgow region, 221 (8.0%) specimens were isolated from 
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individuals resident in the Grampian region; 128 (4.6%) specimens were isolated 
from individuals resident in the Highland region; 325 (11.7%) specimens were 
isolated from individuals resident in the Lanarkshire region; 384 (13.9%) 
specimens were isolated from individuals resident in the Lothian region; one 
(<0.1%) specimen was isolated from an individual resident in NHS Orkney region;  
one (<0.1%) specimen was isolated from an individual resident in NHS Shetland 
region; 230 (8.3%) specimens were isolated from individuals resident in the 
Tayside region and seven (0.3%) specimens were isolated from individuals 
resident in the NHS Western Isles region. 
In comparison with the carriage strain collection characterised during this study 
a larger proportion of isolates in the IMD strain collection was obtained from 
individuals from Ayrshire & Arran, Argyll & Clyde, Greater Glasgow, Grampian, 
Highland and Tayside NHS health board regions (Figure 3.3). In contrast, a larger 
proportion of isolates in the carriage strain collection was obtained from 
individuals resident in the Fife, Forth Valley and Lanarkshire NHS health board 
regions. A similar proportion of isolates in each strain collection was obtained 
from individuals resident in the Borders, Dumfries & Galloway and Lothian NHS 
health board regions. 
 
3.5 Age of individuals sampled 
The SHLMPRL meningococcal isolate database was examined for information on 
the age of the individual sampled. This was available for 459 (58%) specimens of 
the carriage strain collection. For convenience, specimens were grouped 
according to age (Figure 3.4). Carried meningococci were isolated from nine 
(1.1%) persons < 1 year, 14 (1.8%) persons aged 1-4 years, 16 (2.0%) persons aged 
5-9 years, 13 (1.6%) persons aged 10-14 years, 181 (22.9%) persons aged 15-19 
years, 118 (14.9%) persons aged 20-24 years, 58 (7.3%) persons aged 25-34 years, 
33 (4.2%) persons aged 35-44 years, seven (0.9%) persons aged 45-54 years, six 
(0.8%) persons aged 55-64 years, three (0.4%) persons aged 65-74 years, zero 
persons aged 75-84 years and one (0.1%) person aged >85yrs. ‘Unknown’ was 
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recorded for 326 (41.2%) specimens and for six (0.8%) specimens the age-group 
field was blank. 
 
 
 
Figure 3.4 - Distribution by age group of the source individual of meningococci in Scotland, 
1974 - 2004  
NIV, non-invasive; IMD, invasive meningococcal disease; NK, not known; * zero isolates in the non-
invasive strain collection were obtained from individuals age 75-84 years; ** one isolate in the non-
invasive strain collection (equivalent to 0.1%) was obtained from an individual ≥ 85 years of age 
 
For the IMD strain collection the SHLMPRL isolate database was also examined 
for information on the age of the individual sampled. This was available for 
2,311/2,772 (83.4%) IMD isolates. For convenience, samples were grouped 
according to age (Figure 3.4). IMD isolates were obtained from 648 (23.4%) 
persons < 1 year, 662 (23.9%) persons aged 1-4 years, 162 (5.8%) persons aged 5-
9 years, 142 (5.1%) persons aged 10-14 years, 207 (7.5%) persons aged 15-19 
years, 107 (3.9%) persons aged 20-24 years, 77 (2.8%) persons aged 25-34 years, 
65 (2.3%) persons aged 35-44 years, 73 (2.6%) persons aged 45-54 years, 58 
(2.1%) persons aged 55-64 years, 55 (2.0%) persons aged 65-74 years, 40 (1.4%) 
persons aged 75-84 years and fifteen (0.5%) person aged >85yrs. ‘Unknown’ was 
recorded for 453 (16.3%) isolates and for a further eight (0.3%) isolates the age-
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group field was blank. Nearly half of the IMD strain collection is composed of 
meningococci isolated from paediatric cases of IMD. Whereas, the majority of 
the carriage collection is composed of meningococci isolated from individuals in 
adolescence or early adulthood. It should be noted that for a considerable 
proportion of the strain collections, more so for the carriage strain collection, 
information on the age of the individual sampled was unavailable. 
 
3.6 Sex of individuals sampled 
For the carriage strain collection examination of the SHLMPRL database showed 
that information on the sex of the individual sampled was recorded for 303 
(38.3%) specimens. 111 (14.0%) and 192 (24.2%) were isolated from females and 
males respectively. ‘Unknown’ was recorded for 482 (60.9%) specimens and six 
(0.8%) were blank. For the IMD strain collection examination of the SHLMPRL 
database showed that information on the sex of the individual sampled was 
recorded for 2,511/2,767 (90.7%) isolates. One thousand one hundred and fifty 
(41.6%) and 1,361 (49.2%) were isolated from females and males respectively. 
‘Unknown’ was recorded for 253 (9.1%) isolates and for eight (0.3%) isolate the 
‘sex’ field in the database was blank. In both strain collections a larger 
proportion of isolates was also obtained from males compared to females. 
However, for the majority of isolates (61.7%) in the carriage strain collection 
this information was not available. 
 
3.7 Serogrouping data 
Figure 3.5 shows the serogrouping results for the carried meningococci isolated 
in Scotland during the period 1974 - 2004. Isolates were characterised into eight 
distinct serogroups; A (11/791; 1.4%), B (269/791; 34.0%), C (152/791; 19.2%), Y 
(65/791; 8.2%), W135 (50/791; 6.3%), X (8/791; 1.0%), Z (36/791; 4.6%) and Z’ 
(12/791; 1.5%). The remaining meningococcal isolates were recorded as non-
groupable (188/791; 23.8%) in the SHLMPRL meningococcal isolate database. 
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Also included in Figure 3.5 are each of the eight ATCC/NCTC isolates (one each 
of serogroups A, B, C, W135, Y, X, Z and 29E). 
 
 
Figure 3.5 - Serogroup prevalence identified in meningococci in Scotland, 1974 – 2004 
NIV, non-invasive; IMD, invasive meningococcal disease; NG, non-groupable; * one isolate 
(equivalent to <0.1%) in the IMD strain collection was of serogroup Z and one isolate (equivalent to 
<0.1%) was of serogroup Z’; ** one isolate (equivalent to <0.1%) in the IMD strain collection and 
zero isolates in the non-invasive strain collection were of serogroup 29E 
 
For the IMD strain collection the SHLMPRL meningococcal isolate database was 
examined for information on the serogroup result recorded at the time each 
isolate was processed by the reference laboratory. Almost 90% of the IMD strain 
collection were of serogroup B (n=1597; 57.6%) or serogroup C (n=868; 31.3%) 
(Figure 3.5). Almost 5% were of serogroup A (n=135), with a further 2.6% (n=73) 
and 1.4% (n=39) of serogroup W135 and Y, respectively. Nine isolates were 
serogroup X, and there were one each of serogroups Z, Z’ and 29E. For three 
isolates N/A was recorded in the serogroup field. Nongroupable (NG) was 
recorded for 45 (1.6%) of the invasive isolates; however genotypic serogrouping 
PCR had previously characterised 37 of these as B (n=26), C (n=9), A (n=1) or 
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W135 (n=1) while eight isolates were negative by PCR for serogroup A, B, C, 
W135 and Y (data not shown). 
The most striking difference between the two strain collections is the greater 
proportion of nongroupable isolates in the carriage strain collection (Figure 3.5). 
The proportion of meningococci of serogroups W135, Y, X, Z and Z’(29E) is 
somewhat more pronounced in the carriage strain collection. Contrastingly, the 
proportion of meningococci of serogroups A, B and C is lower amongst the 
carriage strain collection. Meningococci of serogroups A, B and C were more 
likely to be isolated from cases of invasive disease in Scotland during the period 
1974 – 2004, as indicated by the odds ratios in Table 3.1. In contrast, 
meningococci of serogroups W135, Y, Z and 29E were more likely to be found in 
the carriage strain collection; however, it should be noted that the large odds 
ratios determined for serogroups Z and 29E were less precise, as indicated by the 
wide 95%CIs (Table 3.1). Non-groupable meningococci were also more likely to 
be found in the carriage strain collection. 
Table 3.1 – Association of meningococcal serogroups identified in Scotland, 1974 – 2004 
with invasive disease or with a carriage phenotype 
 
Invasive 
Serogroup 
n1 
(IMD2) 
n 
(NIV3) 
OR4 95% CI5 
A 135 11 3.64 1.96 to 6.76 
B 1597 269 2.65 2.25 to 3.12 
C 868 152 1.92 1.58 to 2.33 
     
carriage 
Serogroup 
n 
(NIV) 
n 
(IMD) 
OR 95% CI 
W135 50 73 2.49 1.72 to 3.60 
Y 65 39 6.26 4.18 to 9.39 
X 8 9 3.13 1.20 to 8.14 
Z 36 1 131.89 18.00 to 960.76 
29E 12 2 21.30 4.76 to 95.36 
NG 188 48 17.66 12.71 to 24.54 
1 n, number of isolates; 2 IMD, invasive meningococcal disease strain collection; 3 carriage, carriage 
strain collection; 4 OR, odds ratio; 5 CI, confidence interval 
 
The serogrouping data was divided into three broadly equal time periods to 
investigate if any temporal changes had occurred in the prevalence of the 
individual serogroups (Table 3.2). Differences are apparent in the temporal 
distribution of prevalent serogroups in the carriage strain collection. Serogroup A 
was most prevalent during 1974 - 1983 (5.4%), decreasing to 0.9% during 1984 – 
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1993; no serogroup A isolates were found amongst the carriage strain collection 
beyond 1988. Serogroup B prevalence was similar during the first and third 
periods, 36.9% vs. 36.0% respectively, and was only slightly lower during 1984 – 
1993 (32.2%). The prevalence of serogroup C was distinctly different across the 
three time periods; during 1974 – 1983 prevalence was 6.9%, however serogroup 
C accounted for just over 30% of isolates during 1984 – 1993 compared with only 
1.9% of isolates during 1994 – 2004 (Table 3.2). The prevalence of serogroup Y 
increased overall, however it was highest during 1984 – 1993. The prevalence of 
serogroup X increased overall in contrast with serogroups Z and Z’(29E) which 
decreased overall. The prevalence of nongroupable isolates was high overall, as 
noted earlier. During 1974 – 1983 nongroupable isolates accounted for nearly 30% 
of the carriage strain collection; however these isolates were most prevalent 
during 1994 – 2004 (46.5%) compared with only 11.6% during 1984 – 1993 (Table 
3.2). 
Table 3.2 – Temporal analysis of serogroup prevalence amongst meningococci in Scotland, 
1974 - 2004 
 
  carriage1  IMD2 
Serogroup  1974-1983 1984-1993 1994-2004  1974-1983 1984-1993 1994-2004 
  No. (%)3 No. (%)3 No. (%)3  No. (%)3 No. (%)3 No. (%)3 
A  7 (5.4) 4 (0.9) -  123 (17.9) 9 (0.8) 2 (0.2) 
B  48 (36.9) 145 (32.2) 76 (36.0)  414 (60.3) 603 (53.9) 577 (60.0) 
C  9 (6.9) 139 (30.9) 4 (1.9)  62 (9.0) 483 (43.2) 332 (34.6) 
W135  11 (8.5) 30 (6.7) 9 (4.3)  38 (5.5) 13 (1.2) 22 (2.3) 
Y  4 (3.1) 45 (10.0) 16 (7.6)  12 (1.8) 8 (0.7) 19 (2.0) 
X  1 (0.8) 1 (0.2) 6 (2.8)  - 2 (0.2) 7 (0.7) 
Z  6 (4.6) 29 (6.4) 1 (0.5)  1 (0.2) - - 
Z’  6 (4.6) 5 (1.1) 1 (0.5)  - 1 (0.1) - 
NG4  38 (29.2) 52 (11.6) 98 (46.5)  34 (5.0) - 11 (1.1) 
ND5  - - -  3 (0.4) - - 
Total No.  130 450 211  687 1119 961 
1 carriage, carriage strain collection; 2 IMD, invasive meningococcal disease strain collection; 3, 
expressed as the percentage of isolates of a given serogroup within each time period; 4 ND, not 
determined; 5 NG, nongroupable  
 
Temporal analysis of the serogrouping data for the IMD strain collection also 
indicates changes in the prevalence of different serogroups (Table 3.2). The 
prevalence of serogroup A decreased from 17.9% during 1974 – 1983 to 0.2% 
during 1994 – 2004; indeed no serogroup A isolates within the IMD strain 
collection were isolated after 1995. Serogroup B isolates accounted for just over 
60% of the IMD strain collection during 1974 – 1983, decreasing to 54% during 
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1984 -1993 before increasing again to 60% during 1994 - 2004. The prevalence of 
serogroup C showed the most variation across the three periods; during 1974 – 
1983 serogroup C isolates accounted for only 9.0%. The prevalence of serogroup 
C isolates rose dramatically peaking at 43.2% during 1984 – 1993, before falling 
during 1994 – 2004 to 34.5%. 
Over the 31-year period the prevalence, in the IMD strain collection, of 
serogroup W135 declined; prevalence was highest during 1974 – 1983 (5.5%), 
decreasing during 1984 – 1993 (1.2%), before increasing slightly again during 1994 
– 2004 to 2.3%. Similarly the prevalence of serogroup Y was lowest during 1984 – 
1993 (0.7%) after decreasing compared with 1974 – 1983 (1.8), before recovering 
again to a similar level during 1994 – 2004 (2.0%). Only a handful of isolates were 
of any other serogroup. Somewhat surprisingly, a small number of isolates in the 
IMD strain collection were nongroupable. 
The panel of tests available to the reference laboratory would have changed 
over the years in response to advances in technology (especially molecular 
biology) and with increased understanding of meningococcal biology. Moreover, 
carriage studies have shown that meningococci are often serologically non-
groupable and that capsular polysaccharide is not transported and/or expressed 
by strains of meningococci. In order to further characterise non-groupable 
specimens, some of which were non-viable, different genogrouping PCR tests 
were used to detect serogroup-specific gene targets. 
 
3.8 Genotypic capsular characterisation of 
phenotypically nongroupable meningococci 
3.8.1 Serogroup-specific genotypic PCR 
The encapsulated NCTC and ATCC meningococci (see Table 2.1) were used as 
positive controls for their respective serogroup-specific genotypic PCR and as 
negative controls in other serogroup-specific genotypic PCR tests. As a negative 
control, 18MΩ H2O was used in each genotypic serogrouping PCR. Figure 3.6 
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shows the genotypic PCR results for the 188 phenotypically nongroupable carried 
meningococci.  
 
 
Figure 3.6 - Genogrouping of non-serogroupable carried meningococci in Scotland, 1974 – 
2004 
cnl, capsule null locus; Z/29E POS, one specimen tested positive for both PCR tests; PCR NEG, 
samples tested negative for all genogrouping PCR tests; ND, not determined 
 
Serogroup-specific genotypic PCR further characterised phenotypically 
nongroupable isolates into genogroup A (1/188; 0.5%), B (62/188; 33.0%), C 
(11/188; 5.9%), Y (12/188; 6.4%), W135 (6/188; 3.2%), X (3/188; 1.6%), Z 
(12/188; 6.4%) and 29E (24/188; 12.8%). Four NG specimens were not tested 
fully using the panel of genogrouping PCRs as the specimens were no longer 
available (recorded as ND in Figure 3.6). Fifty-two (27.7%) meningococcal 
isolates were negative for all serogroup-specific genogrouping PCR tests and 
these were tested further for the presence of the cnl (see section 3.8.2 below). 
Due to their relatively low prevalence it was decided to test carried 
meningococcal specimens recorded as serogroup X, serogroup Z and serogroup Z’ 
using the ctrA-X, ctrA-Z and ctrA-29E PCRs to confirm the serogrouping results. 
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Eight of eight (100%) serogroup X isolates and the serogroup X NCTC 10790 tested 
positive for ctrA-X PCR, and negative for the ctrA-Z and ctrA-29E PCRs. Nine of 
nine (100%) serogroup Z’ isolates and the serogroup 29E NCTC 11202 isolate 
tested positive for ctrA-29E PCR and negative for ctrA-X and ctrA-Z PCR. The 
serogroup Z NCTC 10792 isolate tested positive for the ctrA-Z PCR and negative 
for the ctrA-X and ctrA-29E PCRs. However, of 36 isolates recorded as serogroup 
Z nine (25%) isolates tested positive for ctrA-Z PCR and negative for ctrA-X and 
ctrA-29E PCRs. A further 26 (72.2%) serogroup Z isolates tested positive for ctrA-
29E PCR and negative for the ctrA-X and ctrA-Z PCRs. Furthermore, a cross-
reaction was observed for one (2.8%) isolate which tested positive for both the 
ctrA-Z and ctrA-29E PCRs and negative for the ctrA-X PCR. 
 
3.8.2 Capsule null locus PCR 
Often, carried meningococci lack the genes responsible for the synthesis and 
transport of capsule polysaccharide and instead posses the capsule null locus 
(Claus, Maiden et al. 2002). Forty (21.3%) nongroupable carried meningococcal 
specimens tested positive for the capsule null locus by PCR (Figure 3.6) while a 
further twelve (6.4%) nongroupable carried meningococcal specimens tested 
negative for the cnl. Of these twelve specimens, seven were viable and the 
organism had been stored on ProtectTM beads following initial sub-culture. These 
seven viable isolates were re-tested phenotypically by agglutination for the 
presence of capsule and they did not react with the available agglutination 
reagents. All twelve carried meningococcal specimens were tested genotypically 
by using the ctrA PCR (see section 3.8.3 below) that is routinely used at 
SHLMPRL to detect meningococcal DNA in clinical specimens from patients with 
suspected meningococcal disease (Corless, Guiver et al. 2001). 
 
3.8.3 ctrA PCR of phenotypically & genotypically NG specimens 
The ATCC 13077 serogroup A, ATCC 13090 serogroup B, ATCC 13102 serogroup C, 
ATCC 35561 serogroup Y,  NCTC 11203 serogroup W135, NCTC 10790 serogroup X, 
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NCTC 10792 serogroup Z and NCTC 11202 serogroup 29E meningococcal isolates 
were used as positive controls and a cnl isolate from the UK carriage study was 
used as a negative control. As expected, all the encapsulated ATCC and NCTC 
isolates tested positive for the non-serogroup-specific ctrA PCR. cnl-positive 
meningococci lack the capsule transport operon (and the capsule synthesis 
operon) and as expected this isolate tested negative for the ctrA PCR. One of 
five non-culture carried meningococcal specimens and five of seven viable 
carriage isolates tested negative for the ctrA PCR. Five out of six non-culture 
carried meningococcal specimens and two out of seven viable carriage isolates 
tested positive for the ctrA PCR (data not shown). 
 
3.9 DNA sequencing of the capsule null locus (cnl) 
Two different cnl alleles, cnl-2 and a unique allele, were detected amongst cnl 
meningococci in this study. The new cnl allele sequence was submitted to 
GenBank; accession number EU872189, and named as cnl allele 8 (cnl-8). Figure 
3.7 shows the alignment of the cnl-8 allele with the available cnl sequences from 
GenBank.  
 
Figure 3.7 - DNA sequence alignment of cnl alleles 
An * underneath the alignment denotes consensus sequence; a space underneath the alignment 
denotes a polymorphic site; - within the aligned sequences denotes a nucleotide deletion 
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Capsule null locus allele 8 is different from cnl-1 at positions 90 and 91; in allele 
1 position 90 and position 91 are occupied by an adenine and a cytosine residue 
respectively, whereas in cnl-8 there is an inversion of the same two nucleotides 
at these positions. Furthermore cnl-8 is only one nucleotide different from cnl-4; 
cnl-4 has a guanidine deletion at position 14. Table 3.3 shows the cnl PCR-
positive isolates and the cnl allele sequenced. 
Table 3.3 – Capsule null locus-containing meningococci identified in Scotland, 1974 – 2004 
 
Year 
 
cc1 ST2 PorA Subtype 
3VR 1, 2, 3 
cnl 
allele 
No. of 
isolates 
1975 ND4 ND ND cnl-2 1 
1978 N. lactamica N. lactamica N. lactamica cnl-7 1 
1984 cc198 ST-198 18, 25-25, 38-1 cnl-2 1 
cc53 ST-53 7, 30, 38 cnl-8 1 
1986 cc198 ST-198 18, 25, 38-1 cnl-2 1 
1987 cc198 ST-198 18, 25-1, 38-1 cnl-2 1 
cc198 ST-198 18, 25-7, 38-1 cnl-2 1 
1988 cc198 ST-7782 7-2, 13-5, 35-1 cnl-2 1 
1996 cc53 ST-53 7, 30-3, 38 cnl-8 1 
cc53 ST-53 7, 30, 38 cnl-8 1 
1997 cc53 ST-53 7, 30, 38 cnl-8 1 
cc53 ST-53 7, 30-2, 38 cnl-8 1 
cc53 ST-53 7, 30-3, 38 cnl-8 1 
1998 cc53 ST-53 7, 30, 38 cnl-8 1 
1999 cc53 ST-53 7, 30, 37-1 cnl-8 1 
cc53 ST-5950 7, 30, 38 cnl-8 1 
2000 cc53 ST-53 7, 30-1, 38 cnl-8 1 
cc53 ST-53 7, 30-2, 38 cnl-8 1 
cc53 ST-53 7, 30-3, 38 cnl-8 1 
cc1136 ST-8635 18-4, 25, 38-1 cnl-2 1 
2001 cc53 ST-53 7, 30, 38 cnl-8 4 
cc53 ST-53 7, 30-3, 38 cnl-8 3 
cc1117 ST-1117 18-1, 30-3, 38 cnl-8 1 
2002 cc53 ST-53 7, 30, 38 cnl-8 3 
cc53 ST-53 7-2, 30, 38 cnl-8 1 
cc53 ST-53 7, 30-1, 38 cnl-8 1 
cc53 ST-53 7, 30-2, 38 cnl-8 1 
cc53 ST-53 7, 30-3, 38 cnl-8 1 
cc198 ST-198 18, 25-1, 38-1 cnl-2 1 
cc198 ST-823 7-2, 13-15, 35-1 cnl-2 1 
2003 cc53 ST-53 7, 30, 38 cnl-8 2 
1 cc, MLST clonal complex; 2 ST, Sequence Type; 3 VR, variable region; 4 ND, not determined 
 
 
One N. lactamica isolate from 1978 was also included for cnl sequencing as N. 
lactamica is known to possess the cnl. With the exception of one specimen all 
remaining carried meningococcal specimens in this study were characterised by 
MLST and porA VR sequencing. Seven different STs were identified; ST-53 (30 
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isolates), ST-198 (5 isolates), and a single isolate of the STs 823, 1117, 5950, 
7782 and a new ST. These seven STs belonged to four distinct clonal complexes; 
cc53 (ST-53 and the Single-Locus Variant; SLV ST-5950), cc198 (ST-198 the SLV 
ST-823 and Double-Locus Variant; DLV ST-7782), cc1117 (ST-1117) and cc1136 
(ST-8635; with a new allele at the pgm locus is a SLV of ST-1136). Two new STs 
were identified in this collection of cnl-containing meningococci; ST-7782 which 
had a new aroE allele, aroE-525, and ST-8635 which had a new pgm allele, pgm-
580.  
The cnl-2 allele was identified in all cc198 isolates and in the new ST (cc1136). 
The cnl-7 allele was identified in a N. lactamica isolate from 1978 and has 
previously been described only in N. lactamica (Claus, Maiden et al. 2002). MLST 
was not performed on the N. lactamica isolate. The new cnl allele was identified 
in all twenty-eight cc53 isolates and in the single ST-1117 isolate and in each of 
these twenty-nine strains the new allele was identical. 
Four reports from three different continents were identified in a review of the 
literature for evidence of other lineages of capsule null locus-containing 
meningococci (Table 3.4). In meningococci isolated from carriage or from cases 
of invasive disease, researchers in Europe, North America and Africa identified a 
total of twenty-eight STs, accounting for seven distinct lineages of meningococci 
that have so far been found to contain the cnl instead of the genes responsible 
for polysaccharide capsule synthesis and transport (Claus, Maiden et al. 2002; 
Vogel, Claus et al. 2004b; Hoang, Thomas et al. 2005; Findlow, Vogel et al. 
2007). Four of these lineages were identified amongst the carriage isolate 
collection in Scotland; cc53, cc198, cc1117 and cc1136 (Table 3.4). 
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Table 3.4 – Comparison of capsule null locus-positive meningococci in Scotland with the 
published literature 
 
cc1 
(cnl allele) 
 
ST 
n 
C2 
n 
D3 
MLST loci 
Reference abcZ adk aroE fumC gdh pdhC pgm 
53 (cnl-1) 53 51 - 16 2 6 25 17 25 22 a 
122 2 - 16 2 6 25 8 25 22 a 
931 1 - 16 2 6 13 17 25 22 a 
932 1 - 16 2 6 25 17 9 22 a 
1115 1 - 16 2 6 13 17 25 20 a 
1118 1 - 16 2 6 2 17 25 22 a 
53 (cnl-8) 53 24 - 16 2 6 25 17 25 22 b 
5950 1 - 16 2 346 25 17 25 22 b 
1117 (cnl-1) 1117 14 - 16 2 159 92 77 25 112 a 
1114 2 - 16 2 159 39 77 25 22 a 
1116 1 - 16 2 12 92 77 25 112 a 
1119 1 - 16 2 159 92 77 25 2 a 
1117 (cnl-8) 1117 1 - 16 2 159 92 77 25 112 b 
198 (cnl-2) 198 26 - 5 4 17 15 14 7 12 a 
198 5 - 5 4 17 15 14 7 12 b 
39 4 - 5 4 17 15 14 7 16 a 
822 3 - 5 4 17 15 14 125 12 a 
823 7 - 5 4 17 15 30 7 12 a 
823 1 - 5 4 17 15 30 7 12 b 
7782 1 - 5 4 525 15 30 7 12 b 
824 1 - 5 4 17 15 30 114 12 a 
827 1 - 5 79 17 15 14 133 12 a 
968 1 - 103 4 17 15 14 7 12 a 
1107 1 - 114 4 17 15 14 7 140 a 
198 (ND) 198 - 1 5 4 17 15 14 7 12 c 
1136 (cnl-2) 1136 3 - 5 4 38 15 22 40 13 a 
 8635 1 - 5 4 38 15 22 40 580 b 
 825 1 - 5 4 38 15 8 40 13 a 
845 (cnl-2) 845 7 - 6 41 108 15 9 6 9 a 
845 - 1 6 41 108 15 9 6 9 d 
847 3 - 6 41 108 118 9 6 9 a 
848 1 - 6 41 108 136 9 6 9 a 
1138 1 - 6 41 108 15 3 6 9 a 
44 (cnl-3) 43 1 - 12 6 9 9 9 6 9 a 
UA (cnl-3) 192 14 3 35 24 15 48 6 48 41 e 
1 cc, MLST clonal complex; 2 number of carriage isolates; 3 number of disease isolates; ND, not 
determined; UA, unassigned to a clonal complex; a (Claus, Maiden et al. 2002); b This study, 
highlighted;  c (Hoang, Thomas et al. 2005); d (Vogel, Claus et al. 2004b); e (Findlow, Vogel et al. 
2007) 
 
 
3.10 Discussion 
The carriage strain collection was assembled from the meningococcal isolate 
archive maintained by the SHLMPRL. During the study it became apparent that 
the SHLMPRL isolate database could not be fully cross-matched to the isolate 
archive as a listing on the database did not guarantee that a specimen or 
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specimens could be located in the isolate archive. Many meningococcal isolates 
recorded in the database were absent from the strain collection; presumably 
they may either have been expended or were never archived at the time the 
samples were originally processed. Somewhat disappointingly, a considerable 
number of the missing specimens were found to be NG isolates. Perhaps the 
isolates were not deemed worthy of further study at the time they were isolated 
or, due to some constraint, financial or otherwise, the isolates were not retained 
in the reference laboratory isolate archive. This is highlighted by the difference 
in prevalence of NG isolates in the temporal distribution of the strain collection.  
As a result, some bias may exist through the carriage strain collection. Further 
bias may have resulted from the exclusion of specimens deemed to be of poorer 
quality. These poorer quality specimens appeared to be more common during 
the early years of the 1980s and the early years of the 1990s (perhaps due to 
quality issues during their preparation). Epidemiological data indicate that 
isolates of the carriage strain collection were predominantly from males 
compared to females, of teenage or young adult age, resident in the central belt 
of Scotland; however the information regarding the sex (60.9%) and age group 
(42%) of the source individuals was often not known. 
Meningococci can currently be differentiated into twelve distinct serogroups 
based upon differences in polysaccharide capsule structure. A large proportion 
of carried meningococci in Scotland were found not to react with the available 
serogrouping antisera and the strains were designated as nongroupable. Carried 
meningococci are often found not to react with available antisera (Cartwright, 
Stuart et al. 1987; Maiden and Stuart 2002; Caugant, Fogg et al. 2006; Climent, 
Yero et al. 2010a). Moreover, a subset of these nongroupable strains in Scotland 
were found to possess the cnl, as previously reported elsewhere in carried 
meningococci (Claus, Maiden et al. 2002; Vogel, Claus et al. 2004a; Findlow, 
Vogel et al. 2007) and, in rare cases, from invasive meningococci (Vogel, Claus 
et al. 2004b; Hoang, Thomas et al. 2005; Findlow, Vogel et al. 2007). 
Previously, studies have indicated that meningococci of serogroup C are not 
isolated in high numbers in carriage studies (Cartwright, Stuart et al. 1987; 
Jolley, Kalmusova et al. 2000; Yazdankhah, Kriz et al. 2004; Claus, Maiden et al. 
2005); for example serogroup C carriage was found to be 2.7% during the UK 
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carriage study (Maiden and Stuart 2002), 3.3% in the Stonehouse survey 
(Cartwright, Stuart et al. 1987) and 4.8% in a study of carried meningococci 
isolated in the Czech Republic, Norway and Greece (Yazdankhah, Kriz et al. 
2004). However, in a separate study of carried meningococci from the Czech 
Republic serogroup C carriage was initially observed as 7.7% (associated with 
cc11 meningococci) (Jolley, Kalmusova et al. 2000) although this was later found 
to be much higher (11.1% in 15 to 19 year olds and 15.8% in 20 to 24 year olds for 
cc11 meningococci) (Jolley, Kalmusova et al. 2002). Our observation that 19.2% 
of carried meningococci in this study were serogroup C, associated mostly with 
cc8, whilst initially appearing to be somewhat unexpected, was similar to the 
amended report by Jolley and colleagues (Jolley et al., 2002). Furthermore, a 
report by Thomson & Jackson in 1987 described a period during 1984 – 1986 
where IMD cases increased to unusually high numbers; particularly characterised 
by a clustering of 40 cases over the winter of 1984/1985 (Thomson and Jackson 
1987). The report only gives details of the 7 cases where disease resulted in 
fatality, three of which were due to serogroup C.   
More significantly, Thomson and Jackson (1987) noted that routine swabbing of 
contacts revealed many asymptomatic carriers of N. meningitidis. It can only be 
assumed that these disease isolates and those from asymptomatic carriers were 
forwarded to the reference laboratory for analysis. Consequently, some of these 
carrier isolates may well be represented in the carriage isolate collection in this 
study; based on the observation that many carried isolates were obtained from 
1985 (Figure 3.1). In addition, 34.5% of the carriage isolate collection was 
obtained from individuals from Lanarkshire. The account by Mathew & Chaudhuri 
of the same period of increased disease adds further weight to these 
observations (Mathew and Chaudhuri 1986). The authors noted that of the 
twenty isolates in the outbreak, for which serogroups were available, fifteen 
were of serogroup C and five were of serogroup B. Strains of serogroup B 
predominated during October to December 1984, while cases from January 1985 
onwards were almost exclusively of serogroup C (Mathew and Chaudhuri 1986). 
When considered together, the reports by Mathew & Chaudhuri (1986), Thomson 
& Jackson (1987) and the data presented here regarding carriage and disease 
due to serogroup C meningococci, particularly associated with cc8, may indicate 
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the resurgence of this clonal complex following a period of transmission 
throughout central Scotland in particular. 
Five of the currently recognised serogroups (A, B, C, W135 and Y) are responsible 
for the majority of invasive disease cases globally (Rosenstein, Perkins et al. 
2001; Harrison, Trotter et al. 2009). Contrastingly, several of the remaining 
serogroups are rare and, as such, are seldom reported in the literature; 
consequently the genetics of those rare serogroups has not been described in 
great detail. The original serogrouping results recorded when isolates were 
originally processed was used to define meningococci phenotypically. From the 
SHLMPRL records it was not possible to ascertain the origins or availability of the 
agglutination reagents used when the isolates were first processed by the 
reference laboratory, nor is it evident how laboratory methods may have 
changed during the period 1974 - 2004. This may have a bearing on the 
characterisation of the isolates into known serogroups. The currently-available 
agglutination reagents may not be the same as those available at the time the 
isolates were originally processed and could potentially yield different results 
had all the isolates been re-tested during this study. A result of NG recorded 
against any isolate of the strain collection is indicative of that particular isolate 
not reacting with the particular reagents in use at the time the test was 
performed. The use of PCR tests to determine the presence of different 
serogroup-specific genes was used to further characterise the NG isolates by 
group genotypically. 
The rarity of serogroup X, Z and Z’(29E) amongst invasive disease isolates 
prompted further characterisation of isolates of these serogroups amongst the 
carriage strain collection. The published ctrA PCR (Bennett, Mulhall et al. 2004) 
was used to test isolates recorded as serogroup X, serogroup Z or serogroup Z’. 
The ctrA-X PCR results were concordant with the recorded phenotypic 
serogrouping result for isolates of serogroup X and the serogroup X NCTC 10790 
isolate. Serogroup Z’ is equivalent to serogroup 29E in current nomenclature; as 
expected the isolates recorded as serogroup Z’ tested positive for the ctrA-29E 
PCR, as did the serogroup 29E NCTC 11202 isolate. The results of the ctrA-Z PCR, 
however, were not in concordance with agglutination results determining 36 
isolates as serogroup Z. This may be indicative of a deficiency in the specificity 
of the ctrA-Z PCR; however only one cross-reaction was observed and the three 
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NCTC isolates tested positive only for their respective serogroup-specific ctrA 
PCR. More likely is the possibility that these results indicate a deficiency in the 
specificity of the agglutination reagents used at the time the isolates were 
originally processed; specifically in the miss-characterisation of 26 isolates as 
serogroup Z. These isolates were not re-tested using the agglutination reagents 
available during this study. MLST serves to further clarify the characterisation of 
these isolates. Interestingly, five out of nine serogroup Z’-ctrA-Z PCR-positive 
isolates were of ST-103, while 3 were unassigned to a defined clonal complex 
(see Chapter 6). The isolate that cross-reacted and tested positive for both ctrA-
Z and ctrA-29E PCR was also ST-103. However, none of the serogroup Z-ctrA-29E 
PCR-positive isolates was of ST-103. These isolates were of different lineages; 
cc60 (n=7), cc178 (n=5), cc212 (n=1), cc254 (n=12). One isolate was unassigned 
to a clonal complex. Furthermore, serogroup Z’-ctrA-29E isolates were also 
found to belong to cc60 (n=6) and cc254 (n=5); with one isolate belonging to 
cc35. 
Further characterisation of twelve phenotypically NG meningococci could not be 
achieved using the serogroup-specific PCR tests utilised during this study. The 
serogroup non-specific ctrA PCR used by the SHLMPRL did confirm that six of 
twelve phenotypically NG meningococci did possess one gene involved in capsule 
transport, thus supporting the possibility that these meningococci may produce 
an alternative capsular polysaccharide. The synthesis of capsular polysaccharide 
by these ctrA-positive meningococci may be achieved using genes encoding for 
one of the less prevalent serogroups or they may produce an unidentified 
capsular polysaccharide from a novel gene, or genes. However, as identified by 
Dolan-Livengood and colleagues, it is possible that strains of meningococci can 
posses the ctrABCD operon whilst lacking the siaABCD operon (Dolan-Livengood, 
Miller et al. 2003). 
Capsule genetics of meningococci of the most common disease-associated 
serogroups have been studied in more detail (Frosch, Weisgerber et al. 1989; 
Frosch, Muller et al. 1992; Hammerschmidt, Hilse et al. 1996; Hammerschmidt, 
Muller et al. 1996; Swartley, Ahn et al. 1996; Claus, Vogel et al. 1997; Swartley, 
Marfin et al. 1997; Swartley, Liu et al. 1998; Tzeng, Swartley et al. 2001; Von 
Loewenich, Wintermeyer et al. 2001; Claus, Maiden et al. 2002; Dolan-
Livengood, Miller et al. 2003; Sadler, Fox et al. 2003; Tzeng, Noble et al. 2003; 
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Tzeng, Datta et al. 2005; Weber, Claus et al. 2006). However, rarer serogroups 
are less well studied. In the early 1980s, three antigenically distinct serogroups, 
H, I and K, were described. This was followed soon after by the characterisation 
of their respective capsular polysaccharides (Ashton, Ryan et al. 1983; Jennings, 
Lugowski et al. 1983; van der Kaaden, van Doorn-van Wakeren et al. 1984; van 
der Kaaden, Gerwig et al. 1985). Since then, however, formal reports in the 
literature of meningococci of these serogroups have been limited. Neither have 
there been any reports describing new serogroups. One study investigating ctrA 
did however indicate partial homology between ctrA in serogroups X and L 
(Tzeng, Noble et al. 2003), while a high degree of homology was observed in the 
ctrA gene between isolates of serogroup H and isolates with sialic acid-
containing capsules (Sadler, Fox et al. 2003). 
There are several possibilities why meningococci in this study tested negative for 
the specific genotypic serogrouping PCRs and the serogroup non-specific ctrA 
PCR. Firstly there may be genetic polymorphisms at the primer-binding sites in 
these specimens that do not allow the primers to anneal adequately. However 
this seems less likely as most genetic polymorphism within the ctrA sequence is 
located at the 5’ end of the gene (Frosch, Muller et al. 1992; Sadler, Fox et al. 
2003). The primers used in the ctrA PCR amplify a small fragment of 110bp from 
positions 617 to 727 (Corless, Guiver et al. 2001) and thus anneal at positions 
internal to the beginning and end of the coding sequence which are downstream 
from the most variable region of sequence and in a region determined to have 
100% homology between the different serogroups (Sadler, Fox et al. 2003). The 
lack of amplified product in the ctrA PCR for some samples suggests the ctrA 
gene is absent in these specimens. Conflictingly, however, the cnl could not be 
amplified by PCR in these specimens either. Therefore it would seem plausible 
that these strains may contain genetic material encoding for alternative capsule 
transport and synthesis operons. 
In serogroup B meningococci, capsule expression of the ctrABCD and siaABCD 
operons is initiated by divergent promoters in a common 134bp intergenic region 
(Swartley, Ahn et al. 1996). It is not known whether the ctrA gene is being 
transcribed in the NG genotypic PCR-positive meningococci in this study. 
Sequencing of the ctrA promoter region may reveal whether this gene was being 
transcribed. A similar strategy has been used successfully to investigate the 
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promoter region of other genes in the meningococcal genome, such as porA (van 
der Ende, Hopman et al. 2000; Gorla, Lemos et al. 2003). Additionally, 
phenotypic analysis using a ctrA-specific monoclonal antibody followed by ELISA 
and OMP analysis using SDS-PAGE could be undertaken in parallel to establish if 
CtrA is being expressed by the NG genotypic PCR-positive meningococci in this 
study. 
The methods employed by Sadler and colleagues (Sadler, Fox et al. 2003) could 
be applied to these undefined specimens. In their study the siaA and ctrA genes 
were used to complement serogroup-specific PCR (for B, C, Y and W135). A ctrA 
PCR strategy was used to specifically distinguish non-sialic acid-containing 
serogroups (A, H, X, Z, 29E) from the sialic-acid containing serogroups (B or C or 
Y or W135). This identified 12/89 specimens that were ctrA positive which could 
not be characterised further using the specific ctrA PCRs. Furthermore, 28/89 
specimens were negative for ctrA PCR, possibly due to the replacement of the 
ctrABCD and siaABCD operons with the capsule null locus (Claus, Maiden et al. 
2002); although this was not determined by Sadler and colleagues (Sadler, Fox et 
al. 2003).  
Complete characterisation of the genes of the cps complex may reveal the 
underlying mechanisms responsible for loss of encapsulation in NG meningococci 
from Scotland. Weber and colleagues undertook PCR amplification and sequence 
analysis of the regions A, B and C of the cps gene cluster to identify the 
mechanism(s) responsible for inactivation of capsule expression (Weber, Claus et 
al. 2006). Insertion sequences (IS1016-like, IS1106 & IS1301), length variation in 
homopolymeric tracts (in siaA or siaD) or other irreversible mutations 
(insertions, deletions & base exchanges) were identified that could influence 
encapsulation in carried meningococci. Furthermore, irreversible inactivation 
events were proposed to be the result of short-term, within-host evolution and 
no association between genotype and the mechanism for loss of encapsulation 
was observed (Weber, Claus et al. 2006). 
The possibility that the genogrouping PCR-negative specimens were not 
meningococci, or not even Neisseria spp., can be ruled out as MLST (Chapter 4) 
and porA VR sequencing (Chapter 5) was successfully performed. The quality of 
the specimen DNA was also thought not to have affected the genotypic PCR 
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results since MLST and porA VR sequencing was successfully performed. This was 
further supported by the observation that genotypic serogrouping PCR-negative 
results were not restricted to non-viable meningococci as different extracted 
specimens of viable and non-viable meningococci failed to yield any positive 
result. 
We have shown that in Scotland cnl-containing carried meningococci belong to 
four different lineages. As highlighted in the published literature meningococci 
of other lineages can also contain the cnl. Furthermore, the Neisseria MLST 
website (http://pubmlst.org/neisseria) contains many more examples of NG 
meningococci of different STs assigned to these cnl-containing lineages that 
could potentially contain the cnl rather than the genes for capsule synthesis and 
transport. Previous studies on cnl-positive meningococcal isolates have 
highlighted that some cnl alleles appear to be restricted to particular lineages or 
Neisseria species (N. gonorrhoeae or N. lactamica); although the number of 
strains was small. The work of Claus and colleagues (Claus, Maiden et al. 2002) 
revealed the presence of three cnl alleles; cnl-1 (cc53 and cc1117 isolates), cnl-2 
(ST-198, cc1136 and cc845 isolates), and cnl-3 (cc44 isolates) in carried 
meningococci. While strains of N. lactamica possessed cnl-2, cnl-3, cnl-4 or cnl-5 
and strains of N. gonorrhoeae possessed either cnl-2 or cnl-6. Frosch and 
colleagues also reported that the ctrA gene was absent from other acapsulate 
Neisseria species including N. flava, N. perflava, N. subflava, N. mucosa, N. 
sicca and N. cinerea (Frosch, Muller et al. 1992); so it seems plausible that other 
Neisseria spp. may also possess the cnl. 
Sequencing of the cnl from carried strains isolated in Scotland has revealed both 
differences and similarities with the Bavarian cnl isolates (Claus, Maiden et al. 
2002). Scottish cnl strains of cc198 and cc1136 posses an identical allele (cnl-2) 
to that of Bavarian strains of the same clonal complexes. However, Scottish cnl 
strains of cc53 and cc1117 instead possess a unique allele (cnl-8) compared to 
that of Bavarian strains of the same clonal complex (cnl-1) (Figure 3.6 & Table 
3.4). cnl-8 is also similar to cnl-4 which has previously only been documented in 
Neisseria lactamica (Claus, Maiden et al. 2002). This unique allele may have 
evolved in these lineages from a previously identified cnl allele, i.e. cnl-1 or cnl-
4, or this allele was acquired from an independent meningococcal ancestor or 
from another Neisseria species and has subsequently been successfully 
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maintained within these lineages in Scotland. The question remains as to the 
significance of these results since the cnl is a region of non-coding DNA located 
between tex and galE in Neisseria spp. (Claus, Maiden et al. 2002; Dolan-
Livengood, Miller et al. 2003). 
It is widely accepted that the meningococcus requires a capsule to confer 
pathogenicity and to protect itself from opsonophagocytosis. Mutations in the 
capsule genes result in the abolishment of capsule production and impair 
bacterial survival in normal human serum (Kahler, Martin et al. 1998; Tzeng, 
Noble et al. 2003). Furthermore, acapsulate meningococci were believed to be 
incapable of causing invasive disease. However, our understanding has been 
challenged following reports of cnl-positive meningococci causing invasive 
disease in apparently immunocompetent as well as immunocompromised 
individuals. A cnl-positive isolate causing disease in an immunocompromised 
individual was shown to be sensitive in a serum killing assay (Vogel, Claus et al. 
2004b). More noteworthy was the description of cnl-positive isolates causing 
invasive disease in immunocompetent individuals (Hoang, Thomas et al. 2005; 
Findlow, Vogel et al. 2007). However, Hoang and colleagues did not test their 
isolate in a serum killing assay and Findlow and colleagues were unable to 
establish, retrospectively, whether the individuals with disease had any 
immunodeficiency. Findlow and colleagues were, however, able to show that 
two cnl-positive isolates were resistant in a serum killing assay and the levels 
were comparable to the fully capsulated serogroup B strain, MC58. The authors 
also state that the isolates may be virulent in immunocompetent individuals due 
to an alternative mechanism, to encapsulation, that allows them to survive in 
the bloodstream.  
The emergence of disease-causing cnl-positive meningococci could therefore 
impact greatly upon the ability of microbiology laboratories to accurately detect 
the presence of N. meningitidis in clinical specimens taken from individuals with 
suspected meningococcal disease. In the SHLMPRL, in such instances, clinical 
specimens are routinely tested by PCR for the presence of meningococcal DNA. 
The target of choice in our laboratory, and in others, is the ctrA gene (Taha, 
Alonso et al. 2005); the first of four genes in the ctrABCD operon involved in 
transport of capsule to the bacterial outer membrane and one of the genes that 
is absent in cnl meningococci (Claus, Maiden et al. 2002). The specificity of any 
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diagnostic test is fundamental to its utility; this would, however, be 
compromised as these isolates would give false negative results using the ctrA 
PCR. 
Moreover, currently licensed vaccines against meningococci target the capsular 
polysaccharide of serogroups A, C, W135 or Y in a single or multi combination 
formulation (either non-conjugated or conjugated). Again these vaccines would 
be ineffective in protecting against acapsulate strains. Fortunately, reports of 
cnl meningococci causing invasive disease are rare and none have been 
documented in Scotland2. Nevertheless, continued surveillance and improved 
diagnostic techniques are required to monitor these cnl lineages. Recently, 
Dolan and co-workers presented work on the evaluation of an alternative target 
for real-time PCR detection of N. meningitidis regardless of capsular status. 
Validation of the assay was performed on isolates of N. meningitidis and non-N. 
meningitidis organisms. The sodC gene was demonstrated to be highly sensitive 
and specific for identification and detection of the meningococcus in clinical 
samples (Dolan 2008; Dolan, Hatcher et al. 2009) and in a carriage study (Dolan, 
J., personal communication) and could be readily introduced into the repertoire 
of molecular tests utilised by the reference laboratory in Scotland. 
The carriage strain collection characterised during this study was compared with 
data on IMD isolates from Scotland obtained during the period 1974 - 2004. While 
differences are apparent in the relative distribution of isolates within different 
years and in different geographic areas, the two strain collections were 
adequately matched as they cover the same 31-year period and all isolates 
originated in Scotland. Differences in the age distribution are also apparent from 
the comparison above. This observation is not entirely unexpected; for more 
than one reason. Firstly, disease incidence is known to vary with age; it is 
highest in children, particularly those under 2 years of age and can be correlated 
with waning maternal antibody levels during the first year of life. An inverse 
relationship between anti-meningococcal antibody titres or the bactericidal 
activity of serum and the age-related incidence of meningococcal disease has 
been observed (Pollard and Frasch 2001). The relationship between disease 
                                         
2 Inspection of the SHLMPRL meningococcal isolate database revealed that cnl-meningococci 
have been cultured from eye swabs from individuals with infection of the conjunctiva. 
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incidence and age is reflected in this study by the observation that nearly 50% of 
the IMD strain collection has been isolated from individuals less than 5 years of 
age. 
Secondly, other studies have shown that carriage rates also vary with age; 
differently to the age prevalence of IMD isolates. Carriage studies have shown 
that the meningococcus is rarely carried in young children, particularly in the 
first one or two years of life (Cartwright, Stuart et al. 1987; Caugant, Kristiansen 
et al. 1988; Caugant, Hoiby et al. 1994; Bakir, Yagci et al. 2001), when carriage 
of N. lactamica is more prevalent (Cartwright, Stuart et al. 1987; Bakir, Yagci et 
al. 2001; Bennett, Griffiths et al. 2005). Carriage rates of N. meningitidis are 
highest in teenagers and young adults (Cartwright, Stuart et al. 1987; Caugant, 
Kristiansen et al. 1988; Caugant, Hoiby et al. 1994). While no age data was 
available for around 40% of the carriage strain collection in this study, most of 
the remaining isolates were obtained from individuals in their late-teens or early 
adulthood. In addition, data on the sex of the individuals sampled was not 
available for nearly two-thirds of the carriage strain collection whereas this 
information was lacking from only 10% of the IMD strain collection. 
This study has shown that differences are apparent in the serogroup composition 
of the carriage strain collection compared with an IMD strain collection isolated 
during the same 31-year period in Scotland. Serogroups A, B and C were more 
prevalent amongst the IMD strain collection, while sero- or genogroups W135, Y, 
X, Z, Z’(29E) and cnl-strains were more prevalent amongst the carriage strain 
collection. We have shown that meningococci isolated from the nasopharynx of 
otherwise healthy individuals are frequently nongroupable, as have others 
(Cartwright, Stuart et al. 1987; Jolley, Kalmusova et al. 2000; Yazdankhah, Kriz 
et al. 2004; Claus, Maiden et al. 2005). Unusually, for IMD isolates, NG was 
recorded for 45 isolates of the IMD strain collection. Thirty-seven were resolved 
by PCR as B, C, A or W135 however the genogroup of eight IMD isolates was not 
fully determined during work previously conducted by the SHLMPRL. The 
genotypic PCR tests performed on the carriage strain collection in this study 
were not all in use by the SHLMPRL at the time these NG isolates from the IMD 
strain collection were tested. Performing the other genogrouping tests (ctrA for 
serogroups X, Z and 29E or capsule null locus) or re-testing with the currently 
available agglutination reagents may provide further information on the eight NG 
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isolates, however it is possible these isolates may be of an unknown serogroup 
which cannot be tested for or they may be of another unidentified serogroup. 
Capsule expression is considered essential for the meningococcus to survive 
extracellularly in the bloodstream or CSF of the human host therefore; it seems 
unusual that any of the isolates obtained from cases of IMD should not express a 
capsule. It is possible that these NG IMD isolates may react with the available 
anti-sera currently used by the reference laboratory if they were to be re-
tested; however this was beyond the scope of this study. Alternatively, 
immunodeficiency or host genetic susceptibility can predispose an individual to 
meningococcal disease (Figueroa and Densen 1991; Emonts, Hazelzet et al. 2003; 
Vazquez-Bermudez, Barroso et al. 2003; Debard, Lamy et al. 2005) and the 
meningococcus may, or may not, require capsule to be expressed to cause 
infection in an immunodeficient individual. 
In Scotland during the 31-year period 1974 – 2004 serogroup B has been the most 
prevalent of the meningococcal serogroups isolated from cases of IMD and from 
the carriage strain collection. Moreover, in the years following this 31-year 
period (i.e. 2005 – to June 2010) the prevalence of serogroup B amongst IMD 
isolates in Scotland has increased to around 85% as cases of serogroup C disease 
are becoming more of a rarity following continued use of the MCC vaccine 
(Shakir, Cameron et al. 2008; Ure 2008; McDonald 2010a). The prevalence of 
serogroup C meningococci in Scotland has been variable over the past 30 years. 
In the mid 1970s, serogroup C strains accounted for only a few percent of 
disease isolates, increasing during the early 1980s to overtake serogroup B for a 
short while as the most prevalent serogroup. Serogroup C declined over the next 
few years before increasing again to overtake serogroup B as the most prevalent 
serogroup in the late 1990s (Fallon, Brown et al. 1984; Clarke 1999b; 2001; 
Clarke, Reid et al. 2002a; Clarke 2002c; 2003a; 2003c; 2005). 
Although few in number amongst the carriage strain collection, serogroup A 
isolates accounted for a large proportion of the IMD strain collection during 1974 
– 1983. This serogroup was not present in either strain collection beyond 1995. 
Subsequently, serogroup A has not been observed by the reference laboratory 
from cases of IMD in Scotland (Ure 2008). Similarly changes in serogroup 
prevalence have been observed in England and Wales (Gray, Trotter et al. 2006; 
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Russell, Urwin et al. 2008; Gray, Campbell et al. 2009) and in other countries 
around the globe (Rosenstein, Perkins et al. 1999; Rosenstein, Perkins et al. 
2001). Russell and colleagues observed that, over a 20-year period, the 
prevalence of serogroup B decreased, serogroup C increased and serogroup A 
disappeared altogether (Russell, Urwin et al. 2008). Today, serogroup A remains 
an important cause of meningococcal disease in Africa and in parts of Asia and 
Russia (Caugant and Nicolas 2007; Harrison, Trotter et al. 2009; Koroleva, 
Beloshitskij et al. 2009).
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4 Multi-locus Sequence Typing (MLST) of carried 
meningococci in Scotland, 1974 – 2004 
4.1 Introduction 
The following chapter details the frequency of MLST alleles, clonal complexes 
(ccs) and their associated sequence types (STs). This is followed by an analysis of 
the allelic profiles to identify lineages within the carriage strain collection and a 
discussion of the prevalence of these STs and lineages within data from other 
countries. Throughout this chapter the carriage strain collection is compared to 
data on the IMD strain collection mentioned previously. The relationships of STs 
with serogroup and PorA subtype is discussed later (Chapter 6). 
As outlined in the Neisseria Multi Locus Sequence Typing website, sequence 
types are grouped into clonal complexes by their similarity to a central allelic 
profile (genotype). The central genotypes are identified by a number of heuristic 
means, including BURST and split decomposition, along with feedback from 
public health laboratories and epidemiologists. For the Neisseria database, once 
a central genotype has been identified, clonal complexes are defined as 
including any sequence type (ST) that matches the central genotype at four or 
more loci unless it more closely matches another central genotype. STs are 
assigned to clonal complexes automatically by a Perl script that runs against the 
database each evening. The management committee for the Neisseria MLST 
website and databases is responsible for the designation of clonal complexes; as 
recently as 21/04/2010 the ST-1117, ST-1136, ST-212, ST-178 and ST-282 
complexes were defined. 
 
4.2 Frequency of Multi-locus Sequence Typing alleles  
Initial analysis of the carriage strain MLST data set was performed using STARTv2 
to identify MLST allele frequencies. This identified 34 unique abcZ alleles, 22 
unique adk alleles, 50 unique aroE alleles, 45 unique fumC alleles, 46 unique gdh 
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alleles, 49 unique pdhC alleles and 36 unique pgm alleles (Table 4.1). This 
included 35 newly identified alleles that were submitted to the N. meningitidis 
MLST database curator for assignment. These were abcZ-454, abcZ-462, abcZ-
474, abcZ-475, abcZ-486, adk-307, adk-322, adk-325, adk-327, aroE-513, aroE-
514, aroE-519, aroE-525, aroE-532, aroE-533, fumC-468, fumC-476, fumC-477, 
fumC-483, fumC-497, fumC-498, gdh-496, gdh-498, gdh-502, gdh-508, gdh-525, 
pdhC-475, pdhC-477, pdhC-478, pdhC-481, pdhC-506, pgm-497, pgm-498, pgm-
499, pgm-501 and pgm-580. STARTv2 was also used to determined the number of 
polymorphic sites from the allele sequences of the carriage strain collection as 
85, 43, 188, 56, 86, 90 and 93 for abcZ, adk, aroE, fumC, gdh, pdhC and pgm 
respectively (Table 4.1). 
Table 4.1 – Diversity in MLST alleles in carried meningococci in Scotland, 1974 – 2004 
 
allele n1 Psites2 dN/dS3 Top 5 (%)4 Top 10 (%)4 
abcZ 34 85 0.0467 57.1 79.2 
adk 22 43 0.0190 83.0 95.9 
aroE 50 188 0.2699 58.2 82.7 
fumC 45 56 0.0217 63.8 82.9 
gdh 46 86 0.0478 68.1 85.9 
pdhC 49 90 0.0653 50.7 73.0 
pgm 36 93 0.1115 57.6 80.9 
1 n, number of allelic variants; 2 Psites, polymorphic sites; 3 dN/dS, ratio of non-synonymous to 
synonymous sites ; 4 percentage of isolates covered by the most common allelic variants   
 
 
4.3 Frequency of Sequence Types 
STARTv2 calculated 297 distinct allelic profiles (i.e. STs) corresponding to the 
791 carried meningococci and eight control strains. This did not include 11 
incomplete profiles in the dataset. Table 4.2 shows the prevalence of individual 
STs identified in the carriage strain collection. The twenty most frequently 
identified STs accounted for 46.2% (369/799) of carried meningococci. In rank 
order these were; ST-8 (77/799; 9.6%), ST-22 (36/799; 4.5%), ST-53 (31/799; 
3.9%), ST-23 (29/799; 3.6%), ST-213 (24/799; 3.0%), ST-457 (22/799; 2.8%), ST-43 
(16/799; 2.0%), ST-11 (15/799; 1.9%), ST-254 (14/799; 1.8%), ST-289; 12/799; 
1.5%), ST-334 (12/799; 1.5%), ST-60 (11/799; 1.4%), ST-167 (10/799; 1.3%), ST-
269 (9/799; 1.1%), ST-44 (9/799; 1.1%), ST-577 (9/799; 1.1%), ST-41 (8/799; 
1.0%), ST-178 (8/799; 1.0%), ST-103 (8/799; 1.0%) and ST-114 (8/799; 1.0%). 
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Table 4.2 – Prevalence of sequence types identified in carried meningococci in Scotland, 
1974 – 2004 
 
Frequency 
(%) 
Sequence Type(s) % of 
Specimens 
77 (9.64) 8 9.64 
36 (4.51) 22 4.51 
31 (3.88) 53 3.88 
29 (3.63) 23 3.63 
24 (3.00) 213 3.00 
22 (2.75) 457 2.75 
16 (2.00) 43 2.00 
15 (1.88) 11 1.88 
14 (1.75) 254 1.75 
12 (1.50) 289, 334 3.00 
11 (1.38) 60 1.38 
10 (1.25) 167 1.25 
9 (1.13) 44, 269, 577 3.39 
8 (1.00) 41, 103, 114, 178 4.00 
7 (0.88) 198, 259, 1162 2.64 
6 (0.75) 32, 33, 750, 1157, 1574, 4221 4.50 
5 (0.63) 1, 212, 1251, 6657 2.52 
4 (0.50) 153, 206, 461, 472, 766, 1034, 1455, 2154, 2520, 3296  5.00 
3 (0.38) 136, 168, 283, 336, 413, 437, 468, 1097, 7409 3.42 
2 (0.25) 5, 35, 170, 189, 275, 284, 288, 344, 1031, 1117, 1218, 1224, 1466, 
1655, 1710, 2415, 2514, 2532, 2552, 2875, 3294, 3676, 4650, 6654, 
6660, 6911, 6913, 7264, 7407, 7731, 7781  
7.75 
1 (0.125) 13, 15, 24, 42, 67, 94, 162, 180, 183, 185, 278, 337, 340, 352, 460, 
462, 464, 473, 479, 482, 492, 571, 823, 833, 835, 865, 961, 1011, 
1057, 1161, 1197, 1220, 1226, 1229, 1246, 1273, 1284, 1292, 1361, 
1362, 1416, 1433, 1489, 1650, 1651, 1780, 1794, 1802, 1811, 1839, 
1908, 1915, 1947, 1953, 2002, 2104, 2120, 2152, 2155, 2166, 2239, 
2380, 2433, 2508, 2526, 2528, 2534, 2539, 2547, 2549, 2592, 2631, 
2701, 2803, 3258, 3278, 3285, 3286, 3287, 3293, 3295, 3464, 3621, 
3866, 4037, 4053, 4385, 4597, 4677, 4874, 4878, 4881, 5120, 5471, 
5544, 5945, 5946, 5947, 5948, 5949, 5950, 5951, 5952, 5953, 5984, 
6031, 6032, 6033, 6034, 6402, 6403, 6430, 6655, 6656, 6658, 6659, 
6661, 6662, 6663, 6800, 6903, 6904, 6905, 6906, 6907, 6908, 6909, 
6910, 6912, 6914, 6915, 7203, 7265, 7266, 7267, 7268, 7269, 7270, 
7271, 7272, 7398, 7399, 7404, 7405, 7406, 7408, 7410, 7411, 7412, 
7413, 7618, 7619, 7620, 7621, 7622, 7624, 7720, 7721, 7722, 7723, 
7724, 7725, 7726, 7727, 7728, 7729, 7730, 7732, 7733, 7782, 7797, 
7798, 7799, 7800, 7801, 7802, 7803, 7903, 7904, 7905, 7927, 7930, 
7964, 7965, 7966, 7967, 7968, 7969, 7970, 7971, 7973, 7974, 7975, 
7987, 7988, 7989, 7990, 7991, 7992, 7997, 7998, 7999, 8000, 8001, 
8002, 8003, 8066, 8220, 8221, 8222, 8231, 8232, 8635, 8646, 8647 
26.90 
 
Sequence Types in bold face were identified as new during this study 
 
The prevalence of the remaining STs were each individually less than 1.0% (or 
fewer than eight in number); three STs were identified seven times accounting 
for 2.6% of specimens; six STs were identified six times accounting for 4.5% of 
specimens; four STs were identified five times accounting for 2.5% of specimens; 
ten STs were identified four times accounting for 5.0% of specimens; nine STs 
were identified three times accounting for 3.4% of specimens and thirty-one STs 
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were identified twice accounting for 7.8% of specimens. The remaining 215 STs 
were each identified once, accounting for over a quarter (26.9%) of specimens 
(Table 4.2).  
During this study 125 new allelic profiles were sequenced and submitted to the 
N. meningitidis MLST database curators for assignment of the new ST. The STs 
were STs-5945-5953, STs-6031-6034, STs-6402-6403, STs-6654-6663, STs-6903-
6915, ST-7203, STs-7264-7272, STs-7398-7399, STs-7404-7413, STs-7618-7622, 
ST-7624, STs-7720-7733, STs-7781-7782, STs-7797-7803, STs-7903-7905, ST-7930, 
STs-7964-7975, STs-7987-7992, STs-7997-8003, ST-8066, STs-8220-8222 and STs-
8231-8232, ST-8635 and ST-8646-8647 (in bold face in Tables 4.2 - 4.4). 
 
4.4 Frequency of MLST clonal complexes 
Seven hundred and one (87.7%) carried meningococci were assigned to thirty-
four ccs (Table 4.3) while the remaining 12.3% could not be assigned to a known 
cc (Table 4.4). Twenty-five ccs contained the central genotype after which the 
cc was named, whilst eight did not. In twenty-two ccs the central genotype was 
the most prevalent ST. Nine ccs were comprised of a single ST, while twenty-five 
ccs comprised greater than one ST. The five most common ccs accounted for 
45.9% (367/799) of carriage isolates, while the ten most common ccs accounted 
for 65.1% (520/799) of carriage isolates. The ten most common ccs, in rank 
order, were cc41-44 complex/Lineage 3 (n=113; 14.1%), cc8/Cluster A4 (n=82; 
10.3%), cc22 (n=65; 8.1%), cc35 complex (n=65; 8.1%), cc23/Cluster A3 (n=43; 
5.4%), cc254 complex (n=35; 4.4%), cc269 complex (n=33; 4.1%), cc53 complex 
(n=32; 4.0%), cc213 complex (n=27; 3.4%) and cc334 complex (n=26; 3.3%). 
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Table 4.3 – Clonal complexes and STs identified in carried meningococci in Scotland, 1974 – 
2004 
 
cc nI nST Sequence Type (nI) 
cc41/44 113 51 41 (8), 42 (1), 43 (16), 44 (9), 136 (3), 170 (2), 180 (1), 206 (4), 337 (1), 340 
(1), 437 (3), 464 (1), 482 (1), 571 (1), 577 (9), 833 (1), 835 (1), 1097 (3), 
1361 (1), 1362 (1), 1433 (1), 1489 (1), 1574 (6), 1908 (1), 1915 (1), 1947 (1), 
2120 (1), 2433 (1), 2459 (1), 2514 (2), 2532 (2), 2631 (1), 3278 (1), 3296 (4), 
3866 (1), 5120 (1), 5471 (1), 6034 (1), 6655 (1), 6657 (5), 6909 (1), 7266 (1), 
7270 (1), 7621 (1), 7624 (1), 7720 (1), 7728 (1), 7730 (1), 7799 (1), 7971 (1), 
8220 (1) 
cc8 82 2 8 (77), 153 (4), incomplete (1) 
cc22 65 9 22 (36), 114 (8), 289 (12), 1224 (2), 1226 (1), 2878 (1), 5948 (1), 7409 (3), 
7904 (1) 
cc35 65 33 35 (2), 278 (1), 457 (22), 472 (4), 1197 (1), 1292 (1), 1651 (1), 1710 (2), 
2380 (1), 3295 (1), 3676 (2), 5945 (1), 6033 (1), 6402 (1), 6658 (1), 6660 (2), 
6904 (1), 6905 (1), 6907 (1), 6911 (2), 6913 (2), 7264 (2), 7271 (1), 7408 (1), 
7410 (1), 7797 (1), 7798 (1), 7903 (1), 7969 (1), 7988 (1), 7997 (1), 8001 (1), 
8232 (1), incomplete (1) 
cc23 43 12 23 (29), 183 (1), 1655 (2), 1794 (1), 1811 (1), 5544 (1), 6800 (1), 7406 (1), 
7731 (2), 7781 (2), 7973 (1), 8002 (1) 
cc254 35 16 254 (14), 468 (3), 1839 (1), 1953 (1), 2520 (4), 2701 (1), 3294 (2), 4881 (1), 
6914 (1), 6915 (1), 7203 (1), 7964 (1), 7968 (1), 7991 (1), 8221 (1), new (1) 
cc269 33 22 13 (1), 269 (9), 275 (2), 283 (3), 352 (1), 479 (1), 492 (1), 1161 (1), 1273 (1), 
1284 (1), 1416 (1), 2166 (1), 2239 (1), 2592 (1), 2803 (1), 3286 (1), 5984 (1), 
6908 (1), 7269 (1), 7992 (1), 8000 (1), 8231 (1) 
cc53 32 2 53 (31), 5950 (1) 
cc213 27 3 213 (24), 1218 (2), 5951 (1) 
cc334 26 9 189 (2), 334 (12), 1031 (2), 1034 (4), 2508 (1), 2526 (1), 2552 (2), 3285 (1), 
3464 (1) 
cc167 21 6 167 (10), 168 (3), 766 (4), 2415 (2), 6031 (1), 7803 (1) 
cc11 20 6 11 (15), 67 (1), 473 (1), 1246 (1), 4037 (1), 4677 (1) 
cc32 19 3 32 (6), 33 (6), 259 (7) 
cc60 19 8 60 (11), 1650 (1), 1780 (1), 2002 (1), 2104 (1), 2155 (1), 6903 (1), 7724 (1), 
incomplete (1) 
cc178 14 7 178 (8), 5949 (1), 6662 (1), 6912 (1), 7974 (1), 7987 (1), new allele (1) 
cc364 11 8 15 (1), 413 (3), 462 (1), 2534 (1), 4650 (2), 7725 (1), 7733 (1), 7965 (1) 
cc198 9 3 198 (7), 823 (1), 7782 (1) 
cc103 8 1 103 (8) 
cc461 8 5 461 (4), 6403 (1), 6430 (1), 6910 (1), 7972 (1) 
cc174 7 6 185 (1), 1057 (1), 1466 (2), 2547 (1), 3293 (1), 7930 (1) 
cc212 7 3 212 (5), 1229 (1), 7618 (1) 
cc750 7 2 24 (1), 750 (6) 
cc1157 7 2 1157 (6), 7619 (1) 
cc1 5 1 1 (5) 
cc92 4 4 94 (1), 7721 (1), 7722 (1), 7966 (1) 
cc5 2 1 5 (2) 
cc376 2 2 7265 (1), 7405 (1) 
cc865 2 2 460 (1), 865 (1) 
cc1117 2 1 1117 (2) 
cc162 1 1 162 (1) 
cc175 1 1 7800 (1) 
cc231 1 1 1011 (1) 
cc282 1 1 1802 (1) 
cc1136 1 1 8635 (1) 
 
cc, clonal complex; nI, number of isolates; nST, number of sequence types; Sequence Types in bold 
face were identified as new during this study 
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Twenty-two new STs were assigned to the cc35 while a further thirteen new STs 
were assigned to the cc41-44/Lineage 3 (Table 4.3). Seven new STs were 
assigned to the cc254, while 5 new STs were assigned to each of the cc23/A3, 
cc178 and cc269. Three new STs were assigned to each of the cc22, cc92, cc364 
and cc461 while two new STs were assigned to each of the cc60, cc167 and 
cc376. A single new ST was also assigned to each of the clonal complexes cc53, 
cc174, cc175, cc198, cc212, cc213 and cc1157. Forty-two new STs were not 
assigned to a known MLST clonal complex (Table 4.4). 
Table 4.4 – Sequence Types identified in carried meningococci in Scotland, 1974 – 2004 not 
assigned to a defined clonal complex 
 
ST1 n2 ST n ST n ST n ST n ST n ST n 
284 2 2154 4 4597 1 6659 1 7407 2 7732 1 7999 1 
288 2 2528 1 4874 1 6661 1 7411 1 7801 1 8003 1 
336 3 2539 1 4878 1 6663 1 7412 1 7802 1 8066 1 
344 2 2875 2 5946 1 6906 1 7413 1 7905 1 8222 1 
961 1 3258 1 5947 1 7267 1 7620 1 7967 1 8646 1 
1162 7 3287 1 5952 1 7268 1 7622 1 7970 1 8647 1 
1220 1 3621 1 5953 1 7272 1 7723 1 7975 1   
1251 5 4053 1 6032 1 7398 1 7726 1 7989 1   
1455 4 4221 6 6654 2 7399 1 7727 1 7990 1   
2152 1 4385 1 6656 1 7404 1 7729 1 7998 1   
1 ST, Sequence Type; 2 n, number of isolates; STs in bold face were identified as new during this 
study; three additional isolates had a new gdh allele; two additional isolates had an incomplete 
allelic profile 
 
Inspection of the SHLMPRL isolate database revealed that isolates of the IMD 
strain collection could be assigned to thirty-one of the currently defined N. 
meningitidis clonal complexes (ccs). One hundred and sixty-five (6.0%) isolates 
were not assigned to a known clonal complex (cc). The five most common ccs 
accounted for 71.5% (n=1,981) of invasive isolates, while the ten most common 
ccs accounted for 85.2% (n=2364; 85.3%). The ten most common ccs were ST-
8/Cluster A4 (n=547; 19.7%), ST-41/-44/Lineage 3 (n=493; 17.8%), ST-11/ET-37 
(n=491, 17.7%), ST-32/ET-5 (n=262; 9.5%), ST-269 (n=188; 6.8%), ST-1/subgroup 
I/II (n=125; 4.5%), ST-334 (n=95; 3.4%), ST-60 (n=74; 2.7%), ST-213 (n=45; 1.6%) 
and ST-35 (n=44; 1.6%). 
Figure 4.1 shows a comparison of the prevalence of ccs identified in the IMD and 
carriage strain collections. Amongst the two strain collections there were 
similarities and differences in the prevalence of particular ccs. Moreover the 
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comparison highlights that some ccs are more prevalent in one strain collection 
than the other. Specifically, cc18, cc37 and cc549 were present in the IMD strain 
collection, but absent from the carriage strain collection. Contrastingly, cc53, 
cc175, cc178 and cc198 were present in the carriage strain collection, but 
absent from the IMD strain collection. 
 
 
 
Figure 4.1 - Prevalence of clonal complexes identified in invasive meningococcal disease 
and carried meningococcal strain collections in Scotland, 1974 – 2004 
NIV, non-invasive (carried meningococci); IMD, invasive meningococcal disease; UA, unassigned 
 
Furthermore, cc1, cc8, cc11, cc32, cc41/44 and cc269 were all more prevalent 
amongst the IMD strain collection than the carriage strain collection. Whereas, 
cc22, cc23, cc35, cc167, cc174, cc212, cc254, cc461 and isolates not assigned to 
a clonal complex were all more prevalent amongst the carriage strain collection 
than the IMD strain collection. A few clonal complexes, cc5, cc60, cc103, cc334 
and cc364, were found in similar proportions amongst the two strain collections.  
An odds ratio was calculated for each clonal complex to estimate the probability 
of invasive disease or a carriage phenotype (i.e. carriage) due to individual ccs 
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(Table 4.5). Invasive disease due to cc1, cc8, cc11, cc32, cc41-44 and cc269 was 
estimated to be a more likely outcome; whereas cc22, cc23, cc35, cc92, cc167, 
cc174, cc212, cc213, cc254, cc461, cc750, cc1157 and meningococci unassigned 
to a clonal complex were more likely to be associated with a carriage 
phenotype. A varied range of confidence intervals for ccs more likely to be 
associated with a carriage phenotype indicates that for some ccs this association 
is less precise. For example, the widest confidence intervals were observed for 
ccs isolated less frequently over the course of the study, i.e. cc212 (Table 4.5).  
Table 4.5 – Association of meningococcal clonal complexes identified in Scotland, 1974 – 
2004 with invasive disease or with a carriage phenotype 
 
Invasive 
cc1 
n2 
(IMD3) 
n 
(carriage4) OR
5 (95% CI6) 
cc1 124 5 7.45 (3.04 to 18.28) 
cc8 547 82 2.15 (1.68 to 2.76) 
cc11 490 18 9.30 (5.77 to 14.98) 
cc32 262 17 4.81 (2.93 to 7.91) 
cc41-44 491 113 1.31 (1.05 to 1.63) 
cc269 188 33 1.69 (1.16 to 2.47) 
    
carriage 
cc 
n 
(carriage) 
n 
(IMD) 
OR 
(95% CI) 
cc22 65 36 6.72 (4.43 to 10.18) 
cc23 43 17 9.20 (5.22 to 16.23) 
cc35 64 43 5.52 (3.71 to 8.19) 
cc92 4 2 6.96 (1.27 to 38.05) 
cc167 21 23 3.22 (1.77 to 5.85) 
cc174 7 4 6.11 (1.78 to 20.91) 
cc212 7 1 24.45 (3.00 to 199.00) 
cc213 27 45 2.12 (1.30 to 3.43) 
cc254 35 26 4.83 (2.89 to 8.07) 
cc461 8 11 2.53 (1.02 to 6.34) 
cc750 7 4 6.11 (1.78 to 20.91) 
cc1157 7 2 12.22 (2.53 to 58.94) 
UA 93 165 2.08 (1.59 to 2.71) 
1 cc, clonal complex; 2 n, number of isolates; 3 IMD, invasive meningococcal disease isolates; 4 
carriage, carriage strain collection; 5 OR odds ratio; 6 CI confidence interval 
 
Approximately 70% of the STs identified in the carriage strain collection were 
unique to the carriage strain collection, whereas just fewer than 30% of the STs 
were present in both the IMD and carriage strain collections. The shared STs 
corresponded to less than one third of the total number of STs identified in the 
carriage strain collection and around one fifth of the STs identified in the IMD 
strain collection. This corresponded to approximately 60% and 81% of isolates 
from the carriage and IMD strain collections, respectively (Table 4.6). 
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Simpsons’ index of diversity, D, was used to assess the genetic diversity of the 
two strain collections on the basis of sequence type. This was calculated on the 
strain collections as a whole and when split into three roughly equal time 
periods, 1974-1983, 1984-1993 and 1994-2004 (Table 4.6). The indices were 
calculated as 0.981 (95% confidence interval, CI; 0.955, 1.006) for the full 
carriage strain collection and 0.989 (95%CI 0.878, 1.100), 0.960 (95%CI 0.929, 
0.991) and 0.964 (95%CI 0.899, 1.028), respectively, for the three periods (Table 
4.6). This does not indicate any significant difference in the diversity of the 
strain collection over the 31 year period, given the overlapping 95% CIs. 
Table 4.6 – Summary of the genetic diversity in meningococci in Scotland, 1974 – 2004 
 
  carriage1  IMD2 
  ‘74-‘83 ‘84-‘93 ‘94-‘04 ALL  ‘74-‘83 ‘84-‘93 ‘94-‘04 ALL 
Isolates  127a 445b 208c 780d  687 1119 961 2767 
           
Alleles           
abcZ  20 31 20 34 (11)g  20 23 26 34 (11)g 
adk  17 18 14 22 (7)  11 13 19 24 (9) 
aroE  25 36 28 50 (20)  19 33 30 46 (16) 
fumC  24 34 28 45 (13)  20 35 31 43 (11) 
gdh  21 30 26 47 (19)  16 28 33 44 (16) 
pdhC  30 36 26 49 (17)  26 34 30 44 (12) 
pgm  23 29 20 36 (14)  17 24 21 28 (6) 
           
STs           
Total  89 153 97 294  96 198 195 406 
Uniquee     209 
(71.1%) 
    321 
(79.1%) 
Sharede     85 
(28.9%) 
    85 
(20.9%) 
% of 
isolatesf 
    60.3     80.6 
Dh  0.989 0.960 0.964 0.981  0.900 0.938 0.892 0.938 
95% CIsi  (0.878, 
1.100) 
(0.929, 
0.991) 
(0.899, 
1.028) 
(0.955, 
1.007) 
 (0.892, 
0.907) 
(0.929, 
0.946) 
(0.881, 
0.903) 
(0.934, 
0.942) 
1 carriage, carriage strain collection; 2 IMD, invasive meningococcal disease strain collection;  a 
Three incomplete isolates/profiles not included; b Five incomplete isolates/profiles not included; c 
Three incomplete isolates/profiles not included; d Eight NCTC/ATCC isolates and eleven 
incomplete isolates/profiles not included; e Represented as the number & percentage of STs in the 
strain collection; f Represented as the percentage of the strain collection characterised by the 
shared STs; g number of alleles unique to each strain collection in parentheses; h D, Simpson’s 
index of diversity (Hunter & Gaston 1988); i 95% confidence intervals calculated as described in 
Grundmann et al 2001. 
 
Genetic diversity of the IMD strain collection was 0.938 (95%CI 0.934, 0.942) in 
comparison with the carriage strain collection and the non-overlapping 95% CIs 
suggests that the level of genetic diversity of the two strain collections is 
significantly different (Table 4.6). Furthermore, the level of genetic diversity 
within the IMD strain collection is different across the different time periods. D 
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was calculated to be 0.900 (95% CI 0.892, 0.907) for the period 1974-1983; 
compared to 0.938 (95% CI 0.929, 0.946) for the period 1984-1993; and 0.892 
(95% CI 0.881, 0.903) for the period 1994-2004 (Table 4.6). The 95% CIs for the 
periods 1974-1983 and 1994-2004 both overlap with each other, however the 95% 
CIs for the period 1984-1993 does not overlap with the 95% CI of either of the 
other two periods. Hence, the level of diversity, D, of the IMD strain collection 
for the periods 1974-1983 and 1994-2004 can be said to be significantly less 
compared with that for the period 1984-1993. 
To assess the probability of invasive disease or carriage by individual STs, odds 
ratios were again calculated (Table 4.7).  
Table 4.7 – Association of meningococcal Sequence Types identified in Scotland, 1974 – 
2004 with invasive disease or with a carriage phenotype 
 
Invasive 
ST1 
n2 
(IMD3) 
n 
(carriage4) OR
5 (95% CI6) 
ST1 120 5 7.20 (2.93, 17.67) 
ST8 356 77 1.38 (1.07, 1.80) 
ST11 468 15 10.64 (6.32, 17.90) 
ST32 106 6 5.26 (2.30, 12.03) 
ST33 79 6 3.88 (1.69, 8.94) 
ST41 242 8 9.48 (4.66, 19.25) 
ST153 133 4 10.04 (3.70, 27.22) 
ST180 29 1 8.45 (1.15, 62.15) 
ST206 50 4 3.66 (1.32, 10.16) 
ST269 77 9 2.51 (1.25, 5.03) 
    
carriage 
ST 
n 
(carriage) 
n 
(IMD) OR (95% CI) 
ST22 36 13 10.00 (5.27, 18.94) 
ST23 29 15 6.91 (3.69, 12.95) 
ST43 16 21 2.67 (1.39, 5.15) 
ST44 9 10 3.14 (1.27, 7.76) 
ST136 3 1 10.42 (1.08, 100.36) 
ST167 10 8 4.37 (1.72, 11.11) 
ST213 24 38 2.22 (1.33, 3.73) 
ST254 14 15 3.27 (1.57, 6.81) 
ST289 12 9 4.67 (1.96, 11.13) 
ST336 3 1 10.42 (1.08, 100.36) 
ST457 22 25 3.11 (1.74, 5.54) 
ST577 9 1 31.51 (3.99, 249.11) 
ST750 6 3 6.97 (1.74, 27.94) 
ST1157 6 2 10.46 (2.11, 51.93) 
1 ST, sequence type; 2 n, number of isolates; 3 IMD, invasive meningococcal disease strain 
collection; 4 carriage, carriage strain collection; 5 OR, odds ratio; 6 CI, confidence interval 
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Founder STs of the ccs significantly associated with invasiveness (Table 4.5) were 
also shown to be significantly associated with invasiveness in addition to a 
second ST belonging to cc8 (ST-153) and two other STs belonging to cc41-44 
(ST180 & ST206) (Table 4.7). Founder STs of seven of twelve ccs previously 
shown to be associated with a carriage phenotype; cc22, cc23, cc167, cc213, 
cc254, cc750 and cc1157 had significant ORs indicating association with a 
carriage phenotype (Table 4.7).  
Interestingly, ORs of four STs (ST-43, -44, -136 & -577) belonging to cc41-44 
were shown to be significant for association with a carriage phenotype (more so 
for ST43 and ST44 which had much narrower 95% CIs than that calculated for 
ST136 and ST577) despite this clonal complex being significantly associated with 
an invasive phenotype (Table 4.5). A second ST belonging to cc22 (ST-289) was 
significantly associated with a carriage phenotype. ST457 (cc35) was also shown 
to be significantly associated with a carriage phenotype, as was one ST not 
assigned to a clonal complex (ST-336); although the wide 95% CI indicates the OR 
is less precise (Table 4.7). 
 
4.5 Temporal trends in the prevalence of MLST clonal 
complexes  
Data on the prevalence of the MLST clonal complexes was examined for evidence 
of any temporal changes (Table 4.8). Temporal variation in the prevalence of ccs 
was observed in the carriage strain collection. Ten ccs were observed during one 
of the three time periods only; cc5, cc92, cc162, cc175, cc213, cc231, cc282, 
cc750, cc1117 and cc1136. Nine ccs were observed during two of the three time 
periods; cc1, cc8, cc53, cc103, cc167, cc198, cc376, cc865 and cc1157. The 
remaining fifteen ccs were observed during all three time periods; cc11, cc22, 
cc23, cc32, cc35, cc41-44, cc60, cc174, cc178, cc212, cc254, cc269, cc334, 
cc364 and cc461.  
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Table 4.8 – Temporal analysis of clonal complexes identified in meningococci in Scotland, 
1974 - 2004: carriage strain collection versus invasive meningococcal disease isolates 
 
cc1 
 carriage3  IMD4 
 ‘74 – ‘83 
No. (%) 
‘84 – ‘93 
No. (%) 
‘94 – ‘04 
No. (%) 
 ‘74 – ‘83 
No. (%) 
‘84 – ‘93 
No. (%) 
‘94 – ‘04 
No. (%) 
cc1  4 (3.1) 1 (0.2) -  118 (17.1) 6 (0.5) - 
cc5  2 (1.5) - -  5 (0.7) 2 (0.2) 2 (0.2) 
cc8  2 (1.5) 80 (17.8) -  168 (24.5) 329 (29.4) 50 (5.2) 
cc11  6 (4.6) 10 (2.2) 2 (0.95)  44 (6.4) 159 (14.2) 287 (29.9) 
cc18  - - -  - 2 (0.2) 25 (2.6) 
cc22  12 (9.2) 42 (9.3) 11 (5.2)  5 (0.7) 11 (1.0) 20 (2.1) 
cc23  2 (1.5) 34 (7.6) 7 (3.3)  8 (1.6) 6 (0.5) 3 (0.3) 
cc32  3 (3.1) 13 (2.9) 2 (1.0)  76 (11.1) 121 (10.8) 65 (6.8) 
cc35  17 (13.1) 39 (8.7) 8 (3.8)  23 (3.3) 14 (1.3) 6 (0.6) 
cc37  - - -  7 (1.0) 3 (0.3) - 
cc41-44  15 (11.5) 64 (14.2) 34 (16.1)  83 (12.1) 211 (18.9) 197 (20.5) 
cc53  - 4 (0.9) 28 (13.3)  - - - 
cc60  2 (1.5) 11 (2.4) 5 (2.4)  14 (2.0) 33 (3.0) 27 (2.8) 
cc92  4 (3.1) - -  1 (0.2) - 1 (0.1) 
cc103  - 5 (1.1) 3 (1.4)  - 14 (1.3) 2 (0.2) 
cc162  - - 1 (0.5)  - 1 (0.1) - 
cc167  - 11 (2.4) 10 (4.7)  4 (0.6) 5 (0.5) 14 (1.5) 
cc174  1 (0.8) 4 (0.9) 2 (1.0)  1 (0.2) 1 (0.1) 2 (0.2) 
cc175  - 1 (0.2) -  - - - 
cc178  1 (0.8) 10 (2.2) 3 (1.4)  - - - 
cc198  - 7 (1.6) 2 (1.0)  - - - 
cc212  1 (0.8) 2 (0.4) 4 (1.9)  - 1 (0.1) - 
cc213  - - 27 (12.8)  - - 45 (4.7) 
cc231  - 1 (0.2) -  3 (0.5) 1 (0.1) - 
cc254  15 (11.5) 19 (4.2) 1 (0.5)  11 (1.6) 11 (1.0) 4 (0.4) 
cc269  5 (3.9) 10 (2.2) 18 (8.5)  11 (1.6) 56 (5.0) 121 (12.6) 
cc282  - 1 (0.2) -  - 3 (0.3) 3 (0.3) 
cc334  5 (3.9) 19 (4.2) 2 (1.0)  50 (7.3) 44 (3.9) 1 (0.1) 
cc364  6 (4.6) 4 (0.9) 1 (0.5)  17 (1.5) 10 (0.9) 2 (0.2) 
cc376  1 (0.8) 1 (0.2) -  1 (0.2) 1 (0.1) - 
cc461  1 (0.8) 4 (0.9) 3 (1.4)  - - 11 (1.1) 
cc549  - - -  3 (0.5) 5 (0.5) - 
cc750  - - 7 (3.3)  - 1 (0.1) 3 (0.3) 
cc865  - 1 (0.2) 1 (0.5)  1 (0.2) 3 (0.3) 1 (0.1) 
cc1117  - - 2 (1.0)  - - - 
cc1136  - - 1 (0.5)  - - - 
cc1157  1 (0.8) - 6 (2.8)  - - 2 (0.2) 
UA2  22 (16.9) 52 (11.6) 19 (9.0)  33 (4.8) 65 (5.8) 67 (7.0) 
1 cc, clonal complex; 2 UA, unassigned; 3 carriage, carriage strain collection; 4 IMD, invasive 
meningococcal disease strain collection 
 
Furthermore, differences were observed in the trend in prevalence of particular 
ccs; cc1, cc5, cc8, cc92 and cc376 would appear to have disappeared from the 
carriage strain collection given that they were not observed during at least the 
most recent time period. Whilst being observed through all three time periods 
several ccs, cc11, cc32, cc35, cc254, cc334 and cc364, have declined in 
prevalence across the whole period covered by the carriage strain collection. 
The prevalence of other ccs would appear to have increased across the whole 
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period covered by the carriage strain collection; cc22, cc41/44, cc60 and cc269. 
Moreover, a few ccs would appear to have emerged during the period covered by 
the carriage strain collection as they were absent from at least the earliest time 
period; cc53, cc103, cc162, cc167, cc198, cc213, cc750, cc865 and cc1117. 
However, for some of these lineages the numbers are small, with the exception 
of cc53 and cc213. The remaining ccs were observed either sporadically or they 
persisted at fairly low levels (Table 4.8). 
In the IMD strain collection, the prevalence of cc1, cc5, cc32, cc35, cc37, cc254, 
cc334 and cc364 have all decreased over the three time periods. Moreover, cc1 
and cc37 were not present in the final period, 1994 – 2004. Furthermore, despite 
being prevalent during 1994 – 2004, cc5 was not present beyond 1995. Cc8 
accounted for nearly a quarter of IMD strains in the first period and subsequently 
increased by 5% during the second time period; however this lineage appears to 
have rapidly declined, only accounting for approximately 5% of IMD strains during 
the final period. Indeed cc8 was not present beyond 2001. Cc334 also declined 
steadily over the three periods and was not present amongst the IMD strain 
collection beyond 1996.  
Conversely three clonal complexes, cc11, cc41-44 and cc269, increased 
substantially over the three time periods. Cc11 increased from 6.4% during 1974 
– 1983 to 14.2% during 1984 – 1993, and further to nearly 30% in the final time 
period. Cc41-44 accounted for a modest 12% of the IMD isolates during 1974 – 
1983, increasing to almost 19% during 1984 – 1993 and increasing by a further 2% 
during 1994 – 2004. Cc269 accounted for only 1.6% of IMD isolates during 1974 – 
1983 increasing to 5% during 1984 – 1993 and increasing in prevalence by more 
than double to 12.6% during 1994 – 2004. The table also indicates the emergence 
of one clonal complex, cc213, which was absent during the first two periods but 
was found to account for nearly 5% of isolates of the IMD strain collection and 
nearly 13% of the carriage strain collection during the period 1994 – 2004. 
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4.6 Analysis of MLST allelic profiles using eBURST 
The eBURST software was used to compare the IMD and carriage strain 
collections. The two datasets gave a total of 3558 isolates, comprising of 615 
STs. eBURST identified 85 STs that were common to both strain collections, 214 
STs were unique to the carriage strain collection and 321 STs were unique to the 
IMD strain collection. Lineage analysis of allelic profiles of the 791 carried 
meningococci and the eight NCTC/ATCC isolates were performed using BURST, 
implemented in STARTv2 (Jolley, Feil et al. 2001) with the group definition set 
such that each ST in a group matches at least one other ST in the group at five 
or more loci. BURST analysis categorised the dataset into 37 groups and 49 
singletons. Group 1 consisted of three STs assigned to cc213; ST-213 was 
predicted as the central genotype with two SLVs of ST-1218 and ST-5951 (Figure 
4.2).  
                                      
 
Figure 4.2 - Representation of BURST Group 1 of carried meningococci in Scotland, 1974 – 
2004 
Numbers refer to sequence types; ST within black circle is the founder genotype; an ST within red 
circle is a single-locus variant (SLV) of the founder genotype. 
 
Group 2 consisted of 20 STs belonging to cc269 (ST-13, -269, -275, -283, -352, -
479, -492, -1161, -1273, -1284, -1416, -2166, -2592, -2803, -3286, -5984, -7411, -
7992, -8000 and -8231) with ST-269 as the predicted central genotype; whilst ST-
6906 was not assigned to a known cc (Figure 4.3). In addition two other STs 
belonging to cc269 (ST-2239 & ST-6908) were assigned to a different group by 
BURST; Group 36. Furthermore a third ST assigned to cc269, ST-7269, was 
designated a singleton by BURST. Within this BURST group, a number of other 
STs (ST-275, ST-352 & ST-7411), besides the predicted central genotype ST-269, 
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have a number of SLVs of their own and as such are depicted as subgroups 
(Figure 4.3). 
 
 
Figure 4.3 - Representation of BURST Group 2 of carried meningococci in Scotland, 1974 – 
2004 
Numbers refer to sequence types; ST within a black circle is the founder genotype or the subgroup 
founder genotype; an ST within a red circle is a single-locus variant (SLV) of the founder genotype; 
an ST within a blue circle is a DLV of the founder genotype; A faint red line connecting a satellite 
ST with an ST within a group, or subgroup, indicates they are SLVs of each other. 
 
Group 3 consisted of 48 STs almost completely of cc41-44/Lineage 3 with ST-206 
as the predicted central genotype. The 48 STs were ST-41, -42, -43, -44, -136, -
170, -180, -206, -337, -340, -437, -464, -482, -571, -577, -833, -835, -1097, -
1361, -1362, -1433, -1489, -1908, -1915, -2120, -2433, -2459, -2514, -2532, -
2631, -3278, -3296, -3866, -5120, -5471, -6034, -6655, -6909, -7266, -7270, -
7398, -7624, -7720, -7728, -7730, -7799 and ST-7971 (Figure 4.4). As defined by 
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the N. meningitidis MLST website ST-7398 is not assigned to a known MLST 
complex, however BURST analysis placed this ST alongside 47 other STs of cc41-
44/Lineage 3. Furthermore four STs assigned to cc41-44/Lineage 3 (STs-1574, -
1947, -7621 and -8220) were not assigned to this group using BURST and were 
designated as singletons. Within this BURST group a number of other STs (ST-41, 
ST-43, ST-180, & ST-2532), besides the predicted central genotype ST-206, have 
a number of SLVs of their own and as such are depicted as subgroups (Figure 
4.4). 
 
 
Figure 4.4 - Representation of BURST Group 3 of carried meningococci in Scotland, 1974 – 
2004 
Numbers refer to sequence types; ST within a black circle is the founder genotype or the subgroup 
founder genotype; an ST within a red circle is a single-locus variant (SLV) of the founder genotype; 
an ST within a blue circle is a DLV of the founder genotype; A faint red line connecting a satellite 
ST with an ST within a group, or subgroup, indicates they are SLVs of each other; A grey line 
connecting a satellite ST with a ST within a group, or subgroup, indicates these STs are DLVs of 
each other. A grey line connecting central genotypes within different subgroups indicates these STs 
are SLVs of each other. 
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Group 4 consisted of six STs assigned to cc167 with ST-766 as the predicted 
central genotype. The six STs were ST-766, four SLVs (ST-167, -168, -6031 and -
7803) and the DLV ST-2415 (Figure 4.5).  
 
                          
 
Figure 4.5 - Representation of BURST Group 4 of carried meningococci in Scotland, 1974 – 
2004 
Numbers refer to sequence types; ST within a black circle is the founder genotype; an ST within a 
red circle is a single-locus variant (SLV) of the founder genotype; an ST within a blue circle is a 
DLV of the founder genotype. 
 
Group 5 consisted of two STs, ST-24 and ST-750, which are SLVs of each other, 
belong to the cc750. Group 6 consisted of two STs, ST-53 and ST-5950, which are 
SLVs of each other and belong to cc53. Similarly Group 7 also consisted of two 
STs, ST-1157 and ST-7619, which are DLVs of each other and belong to cc1157. 
Group 8 consisted of 33 STs that almost completely assigned to cc35 with ST-472 
predicted as the central genotype (Figure 4.6). The 33 STs were, ST-35, -278, -
457, -472, -1197, -1292, -1651, -1710, -2380, -3295, -3676, -5945, -6033, -6402, -
6658, -6660, -6904, -6905, -6907, -6911, -6913, -7271, -7408, -7410, -7797, -
7798, -7802, -7903, -7988, -7969, -7997, -8001 and ST-8232. One ST, ST-7802, is 
currently not assigned to a known cc however it was assigned to this group using 
BURST. In addition, ST-7264 is part of the cc35 however BURST deemed this ST 
to be a singleton This BURST group also consisted of a subgroup with ST-457 
predicted as the subgroup founder (Figure 4.6). Group 9 consisted of 11 STs that 
mostly belonged to cc22 with ST-22 predicted as the central genotype (Figure 
4.7).  
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Figure 4.6 - Representation of BURST Group 8 of carried meningococci in Scotland, 1974 – 
2004 
Numbers refer to sequence types; ST within a black circle is the founder genotype or the subgroup 
founder genotype; an ST within a red circle is a single-locus variant (SLV) of the founder genotype; 
an ST within a blue circle is a DLV of the founder genotype; A grey line connecting a satellite ST 
with a ST within a group, or subgroup, indicates these STs are DLVs of each other. A grey line 
connecting central genotypes within different subgroups indicates these STs are SLVs of each 
other. 
 
                        
Figure 4.7 - Representation of BURST Group 9 of carried meningococci in Scotland, 1974 – 
2004 
Numbers refer to sequence types; ST within black circle is the founder genotype or the subgroup 
founder genotype; an ST within red circle is a single-locus variant (SLV) of the founder genotype. 
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A subgroup, with ST-1057 as its founder genotype, was also predicted. The STs 
were, ST-22, -114, -289, -1957, -1224, -1226, -2878, -3293, -5948, -7409 and ST-
7904. Interestingly, ST-1057 and ST-3293 belong to cc174 yet they were assigned 
to this group using BURST. Group 10 consisted of three STs; the central genotype 
ST-212 and two SLVs of ST-1229 and ST-7618 which belong to the recently 
assigned cc212 (Figure 4.8).  
 
                                  
 
Figure 4.8 - Representation of BURST Group 10 of carried meningococci in Scotland, 1974 – 
2004 
Legend as described in Figure 4.2 
 
Group 11 consisted of twelve STs assigned to cc23/A3 with ST-23 predicted as 
the central genotype (Figure 4.9).  
                        
 
Figure 4.9 - Representation of BURST Group 11 of carried meningococci in Scotland, 1974 – 
2004 
Numbers refer to sequence types; ST within a black circle is the founder genotype; an ST within a 
red circle is a single-locus variant (SLV) of the founder genotype; an ST within a blue circle is a 
DLV of the founder genotype; A grey line connecting a satellite ST with a ST within a group, or 
subgroup, indicates these STs are DLVs of each other.  
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The STs were, ST-23, -183, -1655, -1794, -1811, -5544, -6800, -7406, -7731, -
7781, -7973 and 8002 (Figure 4.9). Group 12 consisted of four STs that were not 
assigned to a known MLST complex; these were ST-336, -3621, -4221 and -7999. 
BURST predicted ST-336 to be the central genotype with the other three STs as 
SLVs of the central genotype (Figure 4.10).  
                                    
 
Figure 4.10 - Representation of BURST Group 12 of carried meningococci in Scotland, 1974 
– 2004 
Legend as described in Figure 4.2 
 
Group 13 consisted of three STs assigned to cc32/ET-5; the central genotype ST-
32 and two SLVs of ST-33 and ST-259 (Figure 4.11).  
                                 
 
Figure 4.11 - Representation of BURST Group 13 of carried meningococci in Scotland, 1974 
– 2004 
Legend as described in Figure 4.2 
 
Group 14 consisted of five STs assigned to cc461; the central genotype ST-461, 
three SLVs (STs-6430, -6910 and -7972) and a DLV of ST-6403 (Figure 4.12). 
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Figure 4.12 - Representation of BURST Group 14 of carried meningococci in Scotland, 1974 
– 2004 
Legend as described in Figure 4.5 
 
Group 15 consisted of 14 STs assigned to cc254 with BURST predicting ST-254 as 
the central genotype (Figure 4.13). Nine STs were SLVs (STs-1953, -2520, -2701, -
3294, -4881, -6914, -6915, -7203 and -7968); two STs were DLVs (ST-468 and ST-
7964) and two more were satellites (ST-7991 and ST-8221). 
 
                                
 
Figure 4.13 - Representation of BURST Group 15 of carried meningococci in Scotland, 1974 
– 2004 
Legend as described in Figure 4.9 
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Group 16 consisted of three STs assigned to cc198; STs-198, -823 and -7782. 
BURST predicted ST-823 to be the founding genotype; the other two STs being 
SLVs of ST-823 (Figure 4.14). Group 17 consisted of eight STs assigned to cc60; 
the central genotype ST-60, five SLVs (STs-1650, -2002, -2104, -2155 and -7724) 
and two DLVs (STs-1780 and -6903) (Figure 4.15). Group 18 consisted of three 
STs that were not assigned to a known cc; STs-5953, -5946 and -6663. BURST 
could not assign a central genotype. The former two STs are SLVs of each other, 
while the latter ST is a DLV of the former pair.  
                                    
 
Figure 4.14 - Representation of BURST Group 16 of carried meningococci in Scotland, 1974 
– 2004 
Legend as described in Figure 4.2 
 
 
                                   
 
Figure 4.15 - Representation of BURST Group 17 of carried meningococci in Scotland, 1974 
– 2004 
Legend as described in Figure 4.5 
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Group 19 consisted of eight STs assigned to cc334 with BURST predicting ST-334 
as the central genotype (Figure 4.16). These STs were ST-189, -334, -1031, -
1034, -2508, -2526, -3285 and -3464. Three STs, ST-189, -1034 and -2526, are 
SLVs of ST-334 while two more, ST-1031 and ST-3285, are DLVs of ST-334. ST-
2552 is also part of cc334 but was not assigned to this group by BURST.  
                            
 
Figure 4.16 - Representation of BURST Group 19 of carried meningococci in Scotland, 1974 
– 2004 
Numbers refer to sequence types; ST within a black circle is the founder genotype; an ST within a 
red circle is a single-locus variant (SLV) of the founder genotype; an ST within a blue circle is a 
DLV of the founder genotype; A faint red line connecting a satellite ST with an ST within a group, or 
subgroup, indicates these STs are SLVs of each other; A grey line connecting a satellite ST with a 
ST within a group, or subgroup, indicates these STs are DLVs of each other. 
 
Group 20 consisted of six STs assigned to cc11/ET-37 with ST-11 as the central 
genotype. Four STs, ST-67, -473, -1246 and -4677 are SLVs of ST-11 while ST-
4037 is a DLV (Figure 4.17).  
                                    
 
Figure 4.17 - Representation of BURST Group 20 of carried meningococci in Scotland, 1974 
– 2004 
Legend as described in Figure 4.5 
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Group 21 consisted of two STs, ST-7405 and ST-7265, assigned to cc376. Group 
22 consisted of two STs, ST-2552 and ST-4597, the former being assigned to 
cc334 while the latter was unassigned. Group 23 consisted of four STs, ST-94, -
7721, -7722 and -7966 assigned to cc92. ST-7966 was the predicted central 
genotype while the other three STs were DLVs (Figure 4.18). 
                                   
 
Figure 4.18 - Representation of BURST Group 23 of carried meningococci in Scotland, 1974 
– 2004 
Legend as described in Figure 4.2 
 
Group 24 consisted of two STs, ST-8 and ST-153 assigned to cc8. Group 25 
consisted of four STs, ST-2154, -4878, -7967 and -7801 which were not assigned 
to a known cc and BURST did not predict a central genotype. Group 26 consisted 
of eight STs assigned to cc364; however no central genotype was assigned. These 
STs were ST-15, -413, -462, -2534, -4650, -7725, -7733 and -7965. Group 27 
consisted of six STs assigned to cc178; however no central genotype was 
predicted by BURST. The six STs were ST-178, -5949, -6662, -6912, -7987 and -
7974. Group 28 consisted of three STs which are not assigned to a known cc; 
these were ST-2528, -3258 and -7267.  
Group 29 consisted of two STs; ST-185 assigned to cc174 and ST-1251 that is not 
assigned to a known cc. Group 30 consisted of three STs that are not assigned to 
a known cc; ST-3287, -7413 and -8222. Group 31 consisted of two more 
unassigned STs; ST-288 and ST-7970. Group 32 consisted of a further two 
unassigned STs; ST-961 and ST-5947. Group 33 also consisted of two STs; ST-2547 
assigned to cc174 and the unassigned ST-7930. Group 34 consisted of two more 
unassigned STs; ST-1162 and ST-7727. Group 35 consisted of two further 
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unassigned STs; ST-6661 and ST-7412. While Group 36 consisted of a pair of STs, 
ST-2239 and ST-6908, assigned to cc269 and Group 37 consisted of a pair of STs, 
ST-460 and ST-865, assigned to cc865.  
Many singleton STs (33/49) were not assigned to a known cc; these were ST-284, 
-344, -1220, -1455, -2152, -2539, -2875, -4053, -4385, -4874, -5952, -6032, -
6654, -6656, -6659, -7268, -7272, -7399, -7404, -7407, -7620, -7622, -7723, -
7726, -7729, -7732, -7905, -7975, -7989, -7990, -7998, -8003 and -8066. Twenty-
three of these singleton genotypes were assigned as new STs during this study.   
The N. meningitidis PubMLST website/database (www.pubmlst.org/neisseria) 
was inspected for further information regarding the remaining ten singletons not 
assigned to a known clonal complex. This identified that several of the singleton 
STs had previously been identified from carriage in the UK and Europe; some 
were identified as part of the UK carriage study investigating the effects of the 
meningococcal serogroup C polysaccharide-conjugate (MCC) vaccination 
campaign conducted during 1999 – 2001. Those STs previously identified from 
carriage were ST-1220, -2152, -4053 -4385 and ST-4874. A few singleton STs 
were previously identified from cases of IMD in the UK and Europe; STs- 284, -
1220, -1455 and -2539. Additionally, the ATCC 13090 serogroup B isolate 
sequenced in this study as ST-2875 matched one record on the website as this 
ST/serogroup combination was previously identified in the strain NCTC 10026. 
The N. meningitidis MLST website was also inspected for further information 
regarding the sixteen singleton STs assigned to known clonal complexes. ST-1 is 
the central genotype of cc1/subgroup I/II that has been a globally prevalent 
lineage of serogroup A responsible for causing invasive disease at least since the 
1960s. Also sampled in carriage, this lineage has at one time or another been 
prevalent in Europe, Africa, Asia, Australia and New Zealand. This lineage has 
become less prevalent in more industrialised countries however it currently 
remains a problem in the African continent. ST-5 is the central genotype of 
cc5/subgroup III that has been a globally prevalent lineage of serogroup A 
responsible for causing invasive disease at least since the 1960s. Occasionally 
isolated from carriers; this lineage has been prevalent in the African continent, 
Europe, Asia, Saudi Arabia and South America. ST-103 is the central genotype of 
cc103; particularly found in carriers associated with different serogroups (NG, B, 
C, Z, A, 29E) and found to cause invasive disease (serogroup B/C). Records on 
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the MLST website detail isolates originating from Norway, Greece, Czech 
Republic, Germany, Spain, Ireland, Israel, Cuba and Brazil. ST-162 is the central 
genotype of cc162 isolated from carriers (mostly B/NG; one A/W135) and 
invasive disease (mostly B, some NG). Records on the PubMLST website detail 
isolates originating from several European countries (Germany, Spain, Greece, 
France, Norway and Czech Republic), Taiwan and the USA during 1998 – 2010. 
ST-1011 is assigned to the cc231. Records on the PubMLST website indicate this 
lineage has been circulating in the Czech Republic since the early 1970s and has 
been found mainly in carriage; however it is capable of causing disease. These 
isolates were of serogroup B, C or were designated NG. ST-1117 is the central 
genotype of cc1117. This lineage has repeatedly been isolated from carriers in 
Europe during 1999 – 2009, particularly NG isolates during carriage studies in the 
UK, Germany and the Czech Republic. In addition, records describe isolates from 
Ireland, France, Norway and the USA. This lineage was also reportedly isolated 
from a case of invasive disease in the Czech Republic during 2005; the isolate 
was NG (ST-4788).   
Records on the PubMLST website indicate ST-1466 (cc174) has been identified in 
serogroup Y strains from cases of invasive disease in the UK and France during 
2001-2002. ST-1574 (cc41-44) has also been identified during 2001 in the UK 
from cases of serogroup B invasive disease. ST-1802 is assigned to the cc282 and 
was previously identified during the UK carriage study (Stockport; 1999) in a 
serogroup B isolate. Similarly, ST-1839 (cc254) was also identified in Stockport in 
1999, in a NG isolates, as part of the UK carriage study. Records on the PubMLST 
database indicate ST-1947 (cc41-44) was previously identified in Norway during 
1996 in carriage isolates of serogroup C or NG and in Cuba during 1998-1999 in 
carriage isolates of serogroup B or NG. This ST was also identified from strains of 
serogroup B causing invasive disease in Spain during 2001-2004. 
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4.7 Analysis of the concatenated MLST DNA sequences 
The eBURST algorithm allows lineage assignment on the basis of relatedness at 
the level of the allelic profile and, as such, any relationships inferred by this 
method are less reliable than that based upon the direct analysis of the DNA 
sequences themselves. For this reason, lineage assignment of the carriage strain 
collection was performed using the UPGMA algorithm in STARTv2 from the 
concatenated sequences (p-distances) of one isolate of each ST identified in the 
carriage strain collection in addition to the four ATCC and four NCTC isolates 
(Figure 4.19). Overlaid onto the UPGMA tree was information on the clonal 
complex to which each ST was assigned; cc1, solid red circle or sphere; cc5, 
solid orange circle or sphere; cc8, yellow solid circle or sphere; cc11, light green 
solid circle or sphere; cc22, dark green solid circle or sphere; cc23, blue solid 
circle or sphere; cc32, open square or rectangle; cc35, light blue solid circle or 
sphere; cc41/44, pink solid circle or sphere; cc53, purple solid circle or sphere; 
cc60, brown solid circle or sphere; cc92, black solid circle or sphere; cc103, light 
grey solid circle or sphere; cc162, dark grey solid circle or sphere; cc167, peach 
solid circle or sphere; cc174, pale green solid circle or sphere; cc175; red solid 
square or rectangle; cc178, red solid square or rectangle; cc198, yellow solid 
square or rectangle; cc212, bright green solid square or rectangle; cc213, dark 
green solid square or rectangle; cc231, blue solid square or rectangle; cc254, 
light blue solid square or rectangle; cc269, pink solid square or rectangle; cc282, 
purple solid square or rectangle; cc334, brown solid square or rectangle; cc364, 
black solid square or rectangle; cc376, light grey solid square or rectangle; 
cc461, dark grey solid square or rectangle; cc750, peach solid square or 
rectangle; cc865, pale green solid square or rectangle; cc1117 pale pink solid 
square or rectangle; cc1136, pale blue solid square or rectangle; cc1157, pale 
purple solid square or rectangle; UA, unassigned, open circle (Figures 4.20 – 
4.23). 
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Figure 4.19 - UPGMA tree generated from the concatenated MLST DNA sequences of carried 
meningococci in Scotland, 1974 – 2004 
a, area of UPGMA tree shown in Figure 4.20; b, area of UPGMA tree shown in Figure 4.21; c, area 
of UPGMA tree shown in Figure 4.22; d, area of UPGMA tree shown in Figure 4.23 
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Figure 4.20 - Enlargement of section a of the UPGMA tree in Figure 4.19 
For legend see the text on page 146 
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Figure 4.21 - Enlargement of section b of the UPGMA tree in Figure 4.19 
For legend see the text on page 146 
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Figure 4.22 - Enlargement of section c of the UPGMA tree in Figure 4.19 
For legend see the text on page 146 
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Figure 4.23 - Enlargement of section d of the UPGMA tree in Figure 4.19 
For legend see the text on page 146 
 
In the previous section (4.6), BURST was unable to group a few STs, known to be 
assigned to a particular MLST cc, with other members of the cc. For example, 
ST-2239 and ST-6908 were not grouped with other members of cc269 (BURST 
Group 2; Figure 4.3). However, they were placed together in Group 36. A third 
ST, ST-7269 was designated a singleton by BURST. In section a of the UPGMA tree 
of the concatenated MLST DNA sequences (Figure 4.20) we can see that the 
three aforementioned STs do indeed cluster with other STs of cc269. 
Furthermore, in the previous section (4.6) BURST was unable to group ST-1574, 
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ST-1947, ST-7621 and ST-8220 with other members of cc41/44 (BURST Group 3; 
Figure 4.4). Three of these aforementioned STs, ST-1574, ST-1947 and ST-8220, 
do however cluster together with other STs of cc41/44 in section c of the UPGMA 
tree of the concatenated MLST DNA sequences (Figure 4.22). ST-7621 does not 
cluster with the main group of cc41/44 STs but instead clusters in section a 
(Figure 4.20) next to ST-7720. Similarly, ST-7264 which did not group with other 
cc35 STs in BURST Group 8 (Figure 4.6) also did not cluster with the main group 
of cc35 STs in the UPGMA tree (section b; Figure 4.21). Instead, ST-7264 can be 
found in section a (Figure 4.20). In section 4.6, ST-2552 could not be assigned by 
BURST with other members of cc334 (Group 19; Figure 4.16). In the UPGMA tree, 
ST-2552 does cluster with ST-1031 in section a (Figure 4.20) however, neither of 
these STs cluster with the main group of cc334 STs in section b (Figure 4.21). If 
we consider STs unassigned to a clonal complex, several STs which had been 
grouped together by BURST also cluster together in the UPGMA tree of the 
concatenated MLST DNA sequences. For example, STs in BURST Group 12 (ST-
336, ST-3621, ST-4221 and ST-7999) cluster together in section a (Figure 4.20) as 
do STs in BURST Group 30 (ST-3287, ST-7413 and ST-8222).  STs in BURST Group 
31 (ST-288 and ST-7970) cluster together in section b (Figure 4.21). Furthermore, 
STs in BURST Group 32 (ST-961 and ST-5947), Group 34 (ST-1162 and ST-7727) 
and Group 35 (ST-6661 and ST-7412) all cluster in section c (Figure 4.22). 
In contrast, some STs assigned together in groups by BURST do not cluster 
together fully in the UPGMA tree of the concatenated MLST DNA sequences. In 
BURST Group 18, ST-6663 does not cluster together in section a (Figure 4.20) 
with ST-5953 and ST-5946. In BURST Group 25, ST-7801 (section c; Figure 4.22) 
does not cluster together with ST-2154, ST-4878 and ST-7967 (section b; Figure 
4.21). In BURST Group 28, ST-2528 does not cluster together with ST-3258 and 
ST-7267 in section a (Figure 4.20). In the UPGMA tree of the concatenated MLST 
DNA sequences, there are several examples of STs belonging to designated ccs 
which do not cluster together with other STs of the same designated cc. For 
example, ST-7408 (section a; Figure 4.20), ST-7264 (section a; Figure 4.20), ST-
3295 (section c; Figure 4.22), ST-2380 (section c; Figure 4.22), ST-7410 (section 
d; Figure 4.23) and ST-7988 (section d; Figure 4.23) cluster separately from the 
main cc35 cluster (section b; Figure 4.21). Furthermore, the main cc35 cluster is 
interrupted by two STs, ST-3286 and ST-7992, assigned to cc269. ST-6909, ST-
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6655 and ST-7624 cluster together, as do ST-7621 and ST-7720, in section a of 
the UPGMA tree (Figure 4.20) but not with the main cc41/44 cluster in section c 
(Figure 4.22). Furthermore, the main cc41/44 cluster is also interrupted by STs 
not assigned to this cc. Similarly, the main cc269 cluster in section a (Figure 
4.20) is interrupted by STs not assigned to this cc. 
 
4.8 Discussion 
This study is the first of its kind to characterise a collection of carried 
meningococci in Scotland spanning more than three decades. MLST of carried 
meningococci from Scotland over a 31-year period has identified unique allele 
sequences and unique allelic profiles. Predominantly, the new STs were not 
assigned to any of the currently defined clonal complexes, further indicating the 
extensive variation within circulating meningococcal strains that remains 
unidentified. Continued surveillance of circulating meningococcal lineages is of 
particular importance as this allows the identification of previously unrecognised 
clonal complexes, such as the recently defined cc1117, cc1136, cc212, cc178 and 
cc282. Furthermore, it enables the relative prevalence of lineages to be 
effectively monitored, at the national level, should any temporal changes occur.  
The majority of carriage isolates (87.7%) were assigned to a currently defined 
cc; a comparatively small proportion of isolates were not. Other studies have 
observed a higher proportion of unassigned sequence types. This may be due, in 
part, to the increasing number of defined ccs. In 2003 the ST-41 complex was 
expanded to include all STs that match ST-44 at four or more loci, and as such, 
was renamed the ST-41/44 complex. Since then a further nineteen ccs have been 
defined; one in 2003, one in 2004, nine in 2005, two in 2006, one in 2009 and 
five, so far, during 2010 (www.pubmlst.org/neisseria). It would seem unlikely 
that all the possible variation in meningococcal strains could be catalogued; 
however it may be possible that, in the future, fewer strains would be 
characterised as “unassigned” to a clonal complex as more laboratories adopt 
MLST as a typing tool. Many of the original MLST ccs were based on the clonal 
groupings assigned to strains on the basis of MLEE and its electrophoretic types 
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(ETs) such that these lineages are named using both nomenclature e.g. the ST-
11/ET-37 complex.  
Historically, studies of carried meningococci, based on MLEE studies conducted 
during the 1980s, found that the prevalence of particular clones responsible for 
the majority of systemic disease was greatly reduced in carried meningococci. 
Furthermore, the most prevalent clonal complex amongst carriage isolates had 
not previously been identified amongst disease-associated strains (Caugant, 
Bovre et al. 1986; Caugant, Kristiansen et al. 1988). It is particularly important, 
therefore, to monitor carried meningococci for the emergence of new lineages; 
especially STs not currently assigned to defined clonal complexes. While many of 
these STs are not related to defined ccs, groupings between these unassigned 
STs may still occur; it is also possible that any emergent lineages may come from 
this pool of unassigned STs. MLST has more commonly been applied to 
characterise invasive disease isolates. As the scientific community continues to 
characterise a greater proportion of carried meningococci other carriage-
associated lineages may be identified.  
Clonal complexes were identified at varying frequencies amongst the carriage 
strain collection. We have shown, as have others (Jolley, Kalmusova et al. 2000; 
Jolley, Kalmusova et al. 2002; Yazdankhah, Kriz et al. 2004; Climent, Yero et al. 
2010a; Climent, Urwin et al. 2010b), that “hyperinvasive” clonal complexes can 
be identified amongst meningococci isolated from healthy carriers. Jolley and 
colleagues, in their study of carried meningococci isolated in the Czech Republic 
in 1993, identified three hyperinvasive clonal complexes; cc41-44/Lineage 3, 
cc11/ET-37 and cc32/ET-5 (Jolley, Kalmusova et al. 2000; Jolley, Kalmusova et 
al. 2002). The prevalence of the cc41-44/Lineage 3 was remarkably similar in 
our study compared to Jolley et al. (2002). Cc11/ET-37 (15.2%) was the most 
prevalent cc amongst the Czech isolates, whereas this cc only accounted for 
2.5% of the carriage strain collection presented herein. Cc32/ET5 was identified 
in 2.4% of the carriage strain collection in this study while only one isolate was 
identified amongst the Czech carrier strain. Contrastingly, the prevalence of cc8 
was much higher in this study (8.0% versus 0.6%) compared to the Czech study 
(Jolley, Kalmusova et al. 2000; Jolley, Kalmusova et al. 2002). In the Czech 
study and in this study the prevalence of serogroup C was higher than expected; 
likely due to the recent spread of cc11/ET-37 in the Czech Republic in the early 
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1990s (Jolley, Kalmusova et al. 2000; Jolley, Kalmusova et al. 2002) and 
cc8/Cluster A4 in Scotland during the latter part of 1984 and early 1985 (Mathew 
and Chaudhuri 1986; Thomson and Jackson 1987).  
In a comparison of carried and disease isolates from the Czech Republic, Greece 
and Norway many carried isolates from all countries were not assigned to any of 
the clonal complexes defined at that time (Yazdankhah, Kriz et al. 2004). 
Geographic variation between countries in the prevalence of some ccs was also 
observed. In Greece cc162 was the most prevalent cc amongst carried 
meningococci, however this cc was absent from the carrier collections from 
Norway and the Czech Republic. Cc23 was absent from the Czech Republic 
carrier collection but was the second most prevalent cc amongst the carrier 
collections from Norway and Greece. Cc23 was previously found to be associated 
with carriage (Yazdankhah, Kriz et al. 2004). In the carriage strain collection in 
this study cc23 was the fifth most prevalent cc, and ST-23 was the fourth most 
prevalent ST. Cc92, cc106 and cc116 were only found in the Czech Republic 
carrier collection (Yazdankhah, Kriz et al. 2004). These three ccs were also 
common in the previously reported carrier collection from 1993 (Jolley, 
Kalmusova et al. 2000; Jolley, Kalmusova et al. 2002).  Cc11, however, was 
much less prevalent in the carrier collection (Yazdankhah, Kriz et al. 2004) 
despite accounting for the majority of the invasive disease collection during the 
same period (Yazdankhah, Kriz et al. 2004) or the Czech carrier isolate 
collection (Jolley, Kalmusova et al. 2000; Jolley, Kalmusova et al. 2002). 
We identified, in the carriage strain collection, STs belonging to four lineages, 
cc53, cc198, cc1117 and cc1136 previously identified in carried meningococci 
from Bavaria, Germany by Claus and colleagues to lack the genes for capsule 
synthesis and transport and instead possess the capsule null locus (cnl) (Claus, 
Maiden et al. 2002). The four lineages were also identified during the UK 
meningococcal carriage study in carried meningococci obtained from 16-18 year 
olds attending schools in Glasgow (Dr Mathew Diggle, personal communication). 
During the UK carriage study, 1256 meningococci isolated in Glasgow were 
characterised by MLST into 31 clonal complexes; 30 of which were identified 
amongst the carriage strain collection in this study. Fewer strains from the UK 
carriage study compared to the carriage collection described herein were not 
assigned to currently defined clonal complexes; 7.24% versus 12.3%. 
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In Cuba, from two recent studies comparing carried and disease isolates 
collected during 1983 – 2005, cc53 was associated with carriage (Climent, Yero 
et al. 2010a; Climent, Urwin et al. 2010b). Interestingly one disease isolate from 
Cuba was found to belong to the cc53. The Cuban studies also identified cc198 
among carrier isolates (Climent, Yero et al. 2010a; Climent, Urwin et al. 2010b) 
as did Yazdakhah and colleagues (Yazdankhah, Kriz et al. 2004). There have 
been three reports of cnl-containing lineages isolated from cases of IMD; two in 
immunocompromised individuals and one from an apparently immunocompetent 
individual (Vogel, Claus et al. 2004b; Hoang, Thomas et al. 2005; Findlow, Vogel 
et al. 2007). As yet, no reported cases of IMD in Scotland have been caused by 
cnl-containing meningococci (Dr. M. A. Diggle; personal communication). Climent 
and colleagues did not determine whether NG isolates possessed or lacked genes 
encoding for capsule polysaccharide synthesis nor did they determine the 
presence of the capsule null locus so it is unclear whether this isolate possessed 
the cnl or whether the strain had the genetic material to produce capsular 
polysaccharide but was unable to do so due to some unknown mutation that 
impaired synthesis or transport the capsular polysaccharide. 
Odds ratios were used to estimate the invasiveness of individual clonal 
complexes and STs identified in Scotland during 1974 – 2004 using the carriage 
strain collection described herein and data on invasive meningococcal disease 
isolates provided by the SHLMPRL. Cc1, cc8, cc11, cc32, cc41-44, and cc269 and 
their respective founder STs were identified as being significantly associated 
with invasive disease. In addition two more STs belonging to two of the 
aforementioned ccs were also associated with invasive disease. More recent data 
from the SHLMPRL indicates that cc269 and cc41-44 are most commonly 
observed ccs in case of invasive disease in Scotland (Ure 2008). In comparison, 
Climent and colleagues also found cc8, cc32 and cc41-44 were associated with 
disease in Cuba; cc32 was the most frequently identified in 61.4% of 373 isolates 
(163 cases, 210 carriers) over a 20 year period (Climent, Yero et al. 2010a). This 
was followed by cc53 (19.6%), cc41/44 (7.2%) and cc103 (2.7%). Furthermore, 
cc11/ET-37 was associated with disease in the Czech Republic, Greece and 
Norway (Yazdankhah, Kriz et al. 2004). In England and Wales, cc8, cc11, cc32, 
cc41-44 and cc269 were also significantly associated with invasive disease (Ure, 
Gray et al. 2004). 
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The observation that the “hyperinvasive” lineages were identified as being 
associated with invasive disease in Scotland is not unexpected. Of greater 
importance is knowledge of the STs and lineages found to be significantly 
associated with a carriage phenotype in Scotland; this included cc22, cc23, 
cc167, cc213, cc254, cc750 and cc1175 and their respective founder STs, in 
addition to other ccs and STs. Interestingly, two STs belonging to cc41-44 were 
significantly associated with a carriage phenotype despite the observation that 
cc41-44 was significantly associated with an invasive phenotype. This leads one 
to question why there should be such a difference in phenotype between 
members of the same genetic lineage.  
Ure and colleagues also observed that cc22, cc23, and cc213 were negatively 
associated with invasive disease (Ure, Gray et al. 2004) whilst Yazdankhah and 
colleagues also found the cc23 complex was associated with carriage 
(Yazdankhah, Kriz et al. 2004). Climent and colleagues reported that cc53 was 
associated with carriage (Climent, Yero et al. 2010a; Climent, Urwin et al. 
2010b) and while this lineage was prevalent amongst the carriage strain 
collection in this study, its absence from the IMD strain collection in Scotland 
prevents the calculation of an odds ratio; and hence an estimation of its invasive 
or carriage potential. This was also the case for several other STs or ccs.  Cc53 
cnl-positive meningococci are commonly carried and often described 
phenotypically as NG:NT:P1.7.  This lineage is clearly associated with carriage 
and not with IMD. 
Analysis of the dataset with eBURST revealed some discrepancies in the 
assignment of individual STs to particular groupings. Five STs assigned in this 
study were identified as members of assigned clonal complexes; ST-7264 (cc35), 
ST-7269 (cc269), ST-7621 (cc41-44), ST-7800 (cc175) and ST-8220 (cc41-44); 
however eBURST did not assign them to groupings containing other STs belonging 
to the same cc. eBURST was used with the group definition set where each ST in 
a group matches at least one other ST in the group at five or more loci. A small 
number of STs assigned to defined ccs were not grouped by eBURST as these STs 
had more than two differences in their allelic profile from other STs identified in 
this study that were assigned to known clonal complexes. Intermediary STs not 
sampled during this study would link those STs not grouped to the remaining 
members of the complex with the groupings defined by eBURST.  
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BURST uses a simple model of bacterial evolution in which an ancestral (or 
founding) genotype increases in frequency in the population, and while doing so, 
begins to diversify to produce a cluster of closely-related genotypes that are all 
descended from the founding genotype.  This cluster of related genotypes is 
referred to as a “clonal complex”.  The relationships inferred by BURST are 
based upon relatedness at the level of the allelic profile and not directly at the 
DNA sequence level.  Analysis of the concatenated MLST DNA sequences was 
undertaken to further examine the relationships between different 
meningococcal lineages identified during this study.  UPGMA is generally not 
considered a good algorithm for construction of phylogenetic trees as it relies on 
the rates of evolution among different lineages to be approximately equal.  In 
the study of bacterial population biology this is likely not to be the case, so the 
method should not be relied upon to cluster strains without artefacts. This was 
evident in the tree constructed from the concatenated MLST DNA sequences of 
the carried meningococcal strain collection characterised during this study. 
There were several examples of STs of different lineages clustering together 
with seemingly unrelated lineages belonging to different ccs (Figures 4.20 – 
4.23). There are clearly deficiencies with both BURST and UPGMA however, 
analysis of the MLST allelic profiles and the concatenated MLST DNA sequences 
required the use of both methods. 
Despite the observed temporal changes in the prevalence of individual clonal 
complexes, indices of diversity for the carriage strain collection during different 
time periods were not significantly different from each other or from the strain 
collection as a whole. However, the carriage strain collection was genetically 
more diverse than the IMD strain collection based on Simpson’s Index of 
diversity. Furthermore, measurement of D within the IMD strain collection also 
indicated significant temporal changes in genetic diversity. 
Analysis of the temporal distribution of ccs indicated major differences in the 
prevalence of certain clonal complexes, and trends in the data revealed whether 
ccs had increased, decreased or remained the same during the 31-year period 
covered by this study. For example, a dramatic reduction in cc1 has been 
observed and this lineage appears to have disappeared from the meningococcal 
population in Scotland. This contrasts with the recent emergence of cc213 
strains (Ibarz-Pavon, Brehony et al. 2004). Despite an apparent increase in 
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prevalence between the second and third time periods it should be noted, 
however, that the prevalence of cc11 lineage has actually declined; mostly as a 
result of the introduction of the serogroup C polysaccharide-conjugate vaccine 
into the UK childhood vaccination schedule in November 1999 due to the strong 
association of serogroup C with the ST-11/ET-37 complex. 
As previously discussed, comparisons of IMD and carriage strain collections in 
other countries have highlighted striking differences. Yazdankhah and colleagues 
presented a comparison of carried and disease-causing meningococci from three 
European countries; the Czech Republic, Greece and Norway (Yazdankhah, Kriz 
et al. 2004). However, the isolates studied were not appropriately matched 
temporally between countries or geographically within in any of the three 
countries. The carriage isolates were from only a few different distinct regions 
within the different countries while the disease isolates included represented 
only a subset of the total collection of disease isolates in each country 
(Yazdankhah, Kriz et al. 2004); as such there may be geographical bias or the 
isolates may not be entirely representative of the circulating strains within each 
country. 
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5 PorA variable region sequence analysis of 
carried meningococci in Scotland, 1974 - 2004 
5.1 Introduction 
The following chapter details the frequency of the PorA variable regions VR1, 
VR2 and VR3 deduced from the generated nucleotide sequences; the frequency 
of PorA subtypes using VR1 & VR2 data; the frequency of PorA subtypes inclusive 
of VR3 data; an examination of the temporal distribution of the major PorA 
subtypes (VR1,VR2) and an examination of the potential coverage of PorA 
subtypes in carried meningococci by licensed or experimental PorA-based OMV 
vaccines. This chapter also discusses data on PorA subtypes in the invasive 
meningococcal (IMD) strain collection. The relationship between PorA subtypes 
and data on serogroup, clonal complex or sequence type is presented later 
(Chapter 6).  PorA VR1, VR2 and VR3 are located on Loop I, Loop IV and Loop V 
of the PorA protein, respectively. VRs are grouped into families and variants 
within families are assigned on the basis of amino acid sequence relationships. 
Groupings are determined with 80% amino acid identity as a guide, or where 
identity is below 80%, the presence of a particular motif that is representative of 
a VR family (Russell, Jolley et al. 2004).  Variants were assigned in order of 
discovery following submission of DNA sequence trace files to the PorA database 
curator (www.pubmlst.org/neisseria).  For example, VR families have the prefix 
P1. , followed by a number corresponding to the family, e.g. P1.5. Each variant 
is prefixed by the number corresponding to the family, e.g. 5- , followed by a 
number corresponding to a particular variant, e.g. 5-24. 
 
5.2 Variable region 1 (VR1) 
Translation of the porA DNA sequences of carried meningococci identified 45 
individual variants of VR1 (Table 5.1) that could be grouped into nine of the 
currently defined VR1 families. Six of these variants had not previously been 
sequenced before and these were submitted to the PorA database curator for 
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verification and assignment of a new variant (Table 5.2). The new VR1 variants 
accounted for 13.3% of all VR1 variants sequenced; this was equivalent to 0.9% 
of specimens of the carriage strain collection. In eighteen specimens VR1 was 
not determined because a PCR product could not be amplified using the method 
outlined in section 2.5.4 (PorA genotypic characterisation). Seventeen (37.8%) 
VR1 variants were observed only once accounting for 2.4% of the carriage strain 
collection. This was in contrast with a further 17 variants which were observed 
over at least 20 years accounting for 719 (90%) of the carriage strain collection.   
 
 Table 5.1 – Frequency of PorA variable region peptides identified in carried meningococci in Scotland, 1974-2004 
 
VR1 Frequency  
(%) 
VR1 Frequency  
(%) 
 VR2 Frequency  
(%) 
VR2 Frequency  
(%) 
VR2 Frequency  
(%) 
 VR3 Frequency  
(%) 
5 101 (12.6) 5-4 2 (0.25)  2 95 (11.9) 16-3 4 (0.50) 9-14 1 (0.13)  36-2 221 (27.7) 
18-1 91 (11.4) 5-11 2 (0.25)  3 87 (10.9) 16-4 4 (0.50) 9-17 1 (0.13)  38 142 (17.8) 
19 87 (10.9) 17-1 2 (0.25)  15 66 (8.3) 9-5 3 (0.38) 10-12 1 (0.13)  35-1 139 (17.4) 
5-1 65 (8.1) 19-33 2 (0.25)  16 62 (7.8) 10-2 3 (0.38) 10-23 1 (0.13)  36 130 (16.3) 
7-2 61 (7.6) 20 2 (0.25)  13-1 53 (6.6) 13-7 3 (0.38) 10-81 1 (0.13)  37-1 74 (9.3) 
22 56 (7.0) 5-18 1 (0.13)  14 48 (6.0) 16-16 3 (0.38) 13-5 1 (0.13)  37 36 (4.5) 
7 53 (6.6) 5-24 1 (0.13)  2-2 37 (4.6) 30-1 3 (0.38) 13-6 1 (0.13)  38-1 18 (2.3) 
21 46 (5.8) 5-29 1 (0.13)  1 28 (3.5) 30-2 3 (0.38) 14-3 1 (0.13)  35 15 (1.9) 
22-1 34 (4.3) 5-31 1 (0.13)  10-4 28 (3.5) 34 3 (0.38) 15-10 1 (0.13)  36-1 5 (0.63) 
5-2 30 (3.8) 7-32 1 (0.13)  9 24 (3.0) 4-1 2 (0.25) 15-39 1 (0.13)  40 1 (0.13) 
7-1 22 (2.8) 12 1 (0.13)  15-1 21 (2.6) 9-7 2 (0.25) 15-41 1 (0.13)  newa 1 (0.13) 
12-1 20 (2.5) 12-16 1 (0.13)  30 21 (2.6) 10-3 2 (0.25) 16-5 1 (0.13)  ND 17 (2.1) 
18 19 (2.4) 18-4 1 (0.13)  4 18 (2.3) 10-8 2 (0.25) 16-13 1 (0.13)    
21-2 13 (1.6) 18-9 1 (0.13)  16-8 15 (1.9) 10-9 2 (0.25) 16-21 1 (0.13)    
17 11 (1.4) 19-2 1 (0.13)  28 15 (1.9) 13-15 2 (0.25) 16-93 1 (0.13)    
18-7 11 (1.4) 19-15 1 (0.13)  10 14 (1.8) 15-11 2 (0.25) 16-96 1 (0.13)    
19-1 10 (1.3) 19-32 1 (0.13)  13 12 (1.5) 23 2 (0.25) 16-102 1 (0.13)    
19-3 6 (0.75) 21-10 1 (0.13)  14-6 10 (1.3) 25-1 2 (0.25) 23-2 1 (0.13)    
21-1 5 (0.63) 21-13 1 (0.13)  30-3 10 (1.3) 25-6 2 (0.25) 23-3 1 (0.13)    
21-2 5 (0.63) 22-2 1 (0.13)  25 8 (1.00) 25-11 2 (0.25) 25-7 1 (0.13)    
7-4 4 (0.50) 22-11 1 (0.13)  26 8 (1.00) 2-5 1 (0.13) 25-9 1 (0.13)    
18-3 3 (0.38) 22-21 1 (0.13)  2-1 6 (0.75) 2-58 1 (0.13) 25-25 1 (0.13)    
5-3 2 (0.25) ND 18 (2.2)  10-1 6 (0.75) 3-1 1 (0.13) 30-14 1 (0.13)    
     10-57 6 (0.75) 4-2 1 (0.13) 44 1 (0.13)    
     13-2 5 (0.63) 9-3 1 (0.13) ND 17 (2.1)    
 
VR1, Variable region 1; VR2, Variable region 2; VR3, Variable region 3; ND, not determined; new VR1 and VR2 variants are highlighted in bold type; a, new VR3 peptide sequence 
LFGSTSDE 
Chapter 5                                                                                                                                        170 
The five and ten most common VR1 variants accounted for 50.6% and 78.1% of 
the carriage strain collection.  The ten most common VR1 variants were P1.5 
(n=101; 12.6%), P1.18-1 (n=91; 11.4%), P1.19 (n=87; 10.9%), P1.5-1 (n=65; 8.1%), 
P1.7-2 (n=61; 7.6%), P1.22 (n=56; 7.0%), P1.7 (n=53; 6.6%), P1.21 (n=46; 5.8%), 
P1.22-1 (n=34; 4.3%) and P1.5-2 (n=30; 3.8%). 
Table 5.2 – PorA Variable Region peptides identified as new variants during this study in 
carried meningococci in Scotland, 1974 – 2004 
 
Variable 
Region 
Peptide 
Family 
Peptide 
name 
Peptide Sequence 
VR1 P1.5 5-24 PPQNIQQPQVTKR 
VR1 P1.5 5-29 PLQNIQQPQVTKPQVTKR 
VR1 P1.5 5-31 PIPNIQPQVTKR 
VR1 P1.7 7-32 AQAANGGAGASAQVKVTKVTKA 
VR1 P1.19 19-32 PPSKSQPLVKVTKA 
VR1 P1.19 19-33 PPSKSQPPVKVTKA 
VR2 P1.2 2-58 HFVQQTLQSQPTLVP 
VR2 P1.9 9-14 YVDEQSEYPA 
VR2 P1.9 9-17 YVDEPSEYHA 
VR2 P1.10 10-81 HFVQNKQNKQNQQNQLPTLVP 
VR2 P1.15 15-41 HYTRQDNADVFVP 
VR2 P1.16 16-93 TKDKNDNLTLVP (missing YY motif) 
VR2 P1.16 16-96 YYTKDTNNNLTLVLTLVP 
VR2 P1.16 16-102 YYTKDTNNNLTLNNLTLVP 
VR2 P1.44 44 HFVQQLLKVSLLSF 
VR3 - - LFGSTSDE 
 
 
Ten variants belonging to the P1.5 family were identified; accounting for 206 
specimens (Table 5.1). Three variants were identified more than twice; in rank 
order these were variant 5 (n=101), variant 5-1 (n=65) and variant 5-2 (n=30). 
Variants 5-3, 5-4 and 5-11 were each identified twice while variants 5-18, 5-24, 
5-29 and 5-31 were identified only once. The latter three variants were newly 
characterised during this study (Table 5.2). Five variants belonging to the P1.7 
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family were identified; accounting for 141 specimens (Table 5.1). In rank order 
these were variant 7-2 (n=61), variant 7 (n=53), variant 7-1 (n=22), variant 7-4 
(n=4) and variant 7-32 (n=1). The latter variant was newly characterised during 
this study (Table 5.2). 
Three variants belonging to the P1.12 family were identified; accounting for 22 
specimens (Table 5.1). The most common variant was variant 12-1 (n=20). 
Variants 12 and 12-16 were each only identified only once during the study. Two 
variants belonging to the P1.17 family were identified; variant 17 and variant 17-
1 were identified eleven and two times, respectively (Table 5.1). Six variants 
belonging to the P1.18 family were identified; accounting for 127 specimens 
(Table 5.1). Four variants were identified more than once; these were variant 
18-1 (n=91), variant 18 (n=19), variant 18-7 (n=11) and variant 18-3 (n=3). 
Variants 18-4 and 18-9 were each identified once. Seven variants belonging to 
the P1.19 family were identified; accounting for 108 specimens (Table 5.1). Four 
variants were identified more than once; these were variant 19 (n=87), variant 
19-1 (n=10), variant 19-3 (n=6) and variant 19-33 (n=2). The three remaining 
variants, 19-2, 19-15 and 19-32 were each identified once. Variants 19-32 and 
19-33 were newly characterised during this study (Table 5.2). 
Only one variant, 20, belonging to the P1.20 family was identified in two 
specimens (Table 5.1). Six variants belonging to the P1.21 family were 
identified; accounting for 71 specimens (Table 5.1). Four variants were 
identified more than once; in rank order these were variant 21 (n=46), variant 
21-2 (n=13) and variants 12-1 and 12-7 (both n=5). Variants 12-10 and 12-13 were 
each identified once. Five variants belonging to the P1.22 family were 
identified; accounting for 93 specimens (Table 5.1). The two most common were 
variants 22 (n=56) and 22-1 (n=34). Three other variants, 22-2, 22-11 and 22-21 
were each identified once. 
 
5.3 Variable region 2 (VR2) 
Translation of the porA DNA sequences of carried meningococci identified 74 
individual VR2 variants that grouped into seventeen of the 20 currently defined 
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families (Table 5.1). Nine of these variants were had not previously been 
sequenced before and these were submitted to the PorA database curator for 
verification and assignment of a new variant name (Table 5.2). One of the new 
variants also defined a new family, P1.44. The new VR2 variants accounted for 
12.1% of all VR2 variants identified; this was equivalent to 1.1% of specimens of 
the carriage strain collection. For seventeen specimens VR2 could not be 
sequenced. Twenty nine (39.2%) VR2 variants were observed only once 
accounting for 3.6% of isolates of the carriage strain collection. In contrast, 19 
(25.7%) variants were observed over at least a 20 year period, accounting for 613 
(76.7%) of isolates of the carriage strain collection.  The five and ten most 
common VR2 variants accounted for 45.4% and 66.1% of the carriage strain 
collection, respectively.  The ten most common VR2 variants were P1.2 (n=95; 
11.9%), P1.3 (n=87; 10.9%), P1.15 (n=66; 8.3%), P1.16 (n=62; 7.8%), P1.13-1 
(n=53; 6.6%), P1.14 (n=48; 6.0%), P1.2-2 (n=37; 4.6%), P1.1 (n=28, 3.5%) and 
P1.10-4 (n=28, 3.5%). 
One variant, 1, belonging to the P1.1 family was identified in 28 specimens 
(Table 5.1). Five variants belonging to the P1.2 family were identified; 
accounting for 140 specimens (Table 5.1). Three variants were identified more 
than once; variant 2 (n=92), variant 2-2 (n=37) and variant 2-1 (n=6). Variants 2-
5 and 2-58 were each identified once; the latter variant was newly characterised 
during this study (Table 5.2). Two variants belonging to the P1.3 family were 
identified; accounting for 88 specimens (Table 5.1). All but one was variant 3, 
while the remaining specimens had variant 3-1. Three variants belonging to the 
P1.4 family were identified; accounting for 21 specimens (Table 5.1). The most 
common variant was variant 4 (n=18). Variants 4-1 and 4-2 were identified only 
twice and once, respectively. 
Six variants belonging to the P1.9 family were identified; accounting for 32 
specimens (Table 5.1). Two of these variants, 9-14 and 9-17 were newly 
characterised during this study. The most common variant was variant 9 (n=24). 
The remaining variants were seldom identified; 9-5 (n=3), 9-7 (n=2) and 9-3 
(n=1). Eleven variants belonging to the P1.10 family were identified; accounting 
for 66 specimens (Table 5.1). In rank order these were variant 10-4 (n=28), 
variant 10 (n=14), variants 10-1 and 10-57 (both n=6), variant 10-2 (n=3), 
variants 10-3, 10-8 and 10-9 (each n=2) and variants 10-12, 10-23 and 10-81 
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(each n=1). The latter variant was newly characterised during this study (Table 
5.2). 
Seven variants belonging to the P1.13 family were identified; accounting for 77 
specimens (Table 5.1). In rank order these were variant 13-1 (n=53), variant 13 
(n=12), variant 13-2 (n=5), variant 13-7 (n=3), variant 13-15 (n=2), and variants 
13-5 and 13-6 (both n=1). Three variants belonging to the P1.14 family were 
identified; accounting for 59 specimens (Table 5.1). In rank order these were 
variant 14 (n=48), variant 14-6 (n=10) and variant 14-3 (n=1). Six variants 
belonging to the P1.15 family were identified; accounting for 92 specimens 
(Table 5.1). The most common variants were variant 15 (n=66) and variant 15-1 
(n=21). The remaining four variants were seldom identified, variant 15-11 (n=2), 
and variants 15-10, 15-39 and 15-41 (each n=1). The latter variant was newly 
characterised during this study (Table 5.2). 
Eleven variants belonging to the P1.16 family were identified; accounting for 94 
specimens (Table 5.1). Five of these variants were identified more than once; in 
rank order these were variant 16 (n=62), variant 16-8 (n=15), variants 16-3 and 
16-4 (both n=4) and variant 16-16 (n=3). The other six variants, 16-5, 16-13, 16-
21, 16-93, 16-96 and 16-102, were each identified once. The latter three 
variants were newly characterised during this study (Table 5.2). Three variants 
belonging to the P1.23 family were identified, accounting for only four 
specimens (Table 5.1). Variant 23 was identified twice, while variants 23-2 and 
23-3 were each identified once. Seven variants belonging to the P1.25 family 
were identified; accounting for 16 specimens (Table 5.1). In rank order these 
were variant 25 (n=8), variants 25-1, 25-6 and 25-11 (each n=2) and variants 25-
7, 25-9 and 25-25 (each n=1). One variant, 26, belonging to the P1.26 family was 
identified in eight specimens (Table 5.1). 
One variant, 28, belonging to the P1.28 family was identified in fifteen 
specimens (Table 5.1). Five variants belonging to the P1.30 family were 
identified; accounting for 38 specimens (Table 5.1). In rank order these were 
variant 30 (n=21), variant 30-3 (n=10), variants 30-1 and 30-2 (both n=3) and 
variant 30-14 (n=1). One variant, 34, belonging to the P1.34 family was 
identified in three specimens (Table 5.1). Variant 44 was identified in one 
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specimen and was newly characterised during this study defining a new peptide 
family (Table 5.1 & Table 5.2). 
 
5.4 Variable region 3 (VR3) 
Translation of the porA DNA sequences of carried meningococci identified eleven 
individual VR3 variants that could be grouped into five families (Table 5.1). One 
hundred fifty-four (19.3%) specimens possessed a VR3 belonging to the P1.35 
Family. Three hundred fifty-six (44.6%) specimens possessed a VR3 belonging to 
the P1.36 Family. One hundred ten (13.8%) specimens possessed a VR3 belonging 
to the P1.37 Family. One hundred sixty-one (20.2%) specimens possessed a VR3 
belonging to the P1.38 Family. One specimen possessed a VR3 belonging to the 
P1.40 Family. One peptide sequence did not match any previously identified 
peptide sequence; peptide LFGSTSDE (Table 5.2). In rank order the VR3 peptides 
were variant 36-2 (n=221), variant 38 (n=142), variant 35-1 (n=139), variant 36 
(n=130), variant 37-1 (n=74), variant 37 (n=36), variant 38-1 (n=18), variant 35 
(n=15), variant 36-1 (n=5), variant 40 (n=1) and one new variant. For seventeen 
specimens VR3 was not sequenced. 
 
5.5 PorA variable region families 
Amongst the IMD strain collection 36 VR1 variants could be assigned to nine VR1 
Families and 46 VR2 variants could be assigned to fifteen VR2 Families. Figure 
5.1 shows the prevalence of the different PorA VR Families amongst the IMD 
strain collection compared with the carriage strain collection. Certain VR 
families were more prevalent in the IMD strain collection. Nearly half of the IMD 
strain collection possesses a VR1 variant belonging to the P1.5 family, compared 
with less than 30% of the carriage strain collection. The VR2 families P1.2 and 
P1.10 were also more prevalent in the IMD strain collection. While the VR3 is 
said to be less diverse than the other two VRs, it is clear from the comparison of 
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the two strain collections that the P1.38 family is considerably more prevalent 
amongst the carriage strain collection. 
 
 
 
Figure 5.1 - Prevalence of PorA VR Families identified in meningococci in Scotland, 1974 – 
2004 
NIV, non-invasive; IMD, invasive meningococcal disease; VR1, variable region 1; VR2, variable 
region 2; VR3, variable region 3 
 
 
5.6 PorA subtypes 
DNA sequencing of porA VR1 and VR2 identified 144 unique subtypes (Table 5.3); 
over half of which were identified only once in carried meningococci (n=77; 
53.5%). This accounted for 9.6% of the carriage strain collection. A further 49 
subtypes were identified between two and ten times in carried meningococci, 
accounting for 229 specimens. Nineteen subtypes were identified greater than 
ten times; in rank order these were subtype 5,2 (n=92), subtype 18-1,3 (n=80), 
subtype 19,15 (n=56), subtype 21,16 (n=39), subtype 5-1,2-2 (n=33), subtype 
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22,14 (n=30), subtype 7-2,13-1 (n=29), subtype 5-1,10-4 (n=25), subtype 19,15-1 
(n=21), subtype 7-1,1 (n=19), subtype 7,30 (n=17), subtype 7-2,4 (n=17), subtype 
22-1 (n=15), subtype 22-1,16-8 (n=15), subtype 5-2,10 (n=13), subtype 21-2,28 
(n=13), subtype 7,16 (n=12), subtype 12-1,13-1 (n=12) and subtype 22,9 (n=11). 
In thirteen specimens, including the ATCC13090 isolate, the PorA subtype could 
not be determined as no product could be amplified by PCR. Sixteen (10.4%) 
subtypes were observed over periods of at least 20 years, accounting for 
411/799 (51.4%) of the carriage strain collection. A further fourteen (9.7%) 
subtypes were observed over periods of 15-19 years, accounting for 132/799 
(16.5%) of the carriage strain collection. 
DNA sequencing of porA VR1, VR2 and VR3 identified 163 unique subtypes (Table 
5.4); over half of which were identified only once amongst carried meningococci 
(n=94; 57.7%). This accounted for 11.8% of the carriage strain collection. A 
further 51 subtypes were identified in more than two but fewer than ten carried 
meningococci, accounting for 170 specimens. Eighteen subtypes were identified 
in greater than ten carried meningococci; in rank order these were subtype 5, 2, 
36-2 (n=90); subtype 18-1, 3, 38 (n=80); subtype 19, 15, 36 (n=48); subtype 21, 
16, 37-1 (n=39); subtype 5-1, 2-2, 36-2 (n=33); subtype 22, 14, 36 (n=30); 
subtype 7-2, 13-1, 35-1 (n=29); subtype 5-1, 10-4, 36-2 (n=25); subtype 7-1, 1, 
35-1 (n=19); subtype 19, 15-1, 36 (n=17); subtypes 7, 30, 38 and 7-2, 4, 37 (both 
n=16); subtypes 22-1, 14, 38 and 22-1, 16-8, 36-2 (both n=15); subtypes 7, 16, 
35; 12-1, 13-1, 35-1 and 21-2, 28, 37 (each n=12) and subtype 22, 9, 35-1 (n=11).  
 
 Table 5.3 – Frequency of PorA subtypes (VR1, VR2) identified in carried meningococci in Scotland, 1974 – 2004 
 
PorA subtype 
(VR1, VR2) 
Frequency  
(%) 
PorA subtype 
(VR1, VR2) 
Frequency  
(%) 
PorA subtype 
(VR1, VR2) 
Frequency  
(%) 
PorA subtype 
(VR1, VR2) 
Frequency  
(%) 
PorA subtype 
(VR1, VR2) 
Frequency  
(%) 
5, 2 92 (11.5) 17, 16-4 4 (0.50) 19-33, 13-1 2 (0.25) 7, 16-21 1 (0.13) 18-7, 9-14 1 (0.13) 
18-1, 3 80 (10.0) 7, 16-16 3 (0.38) 20, 9 2 (0.25) 7-1, 14-6 1 (0.13) 18-7, 9-17 1 (0.13) 
19, 15 56 (7.0) 7, 30-2 3 (0.38) 21, 15 2 (0.25) 7-2, 4-2 1 (0.13) 18-9, 25-9 1 (0.13) 
21, 16 39 (4.9) 7-2, 1 3 (0.38) 21-1, 2-2 2 (0.25) 7-2, 13-2 1 (0.13) 19, 13-6 1 (0.13) 
5-1, 2-2 33 (4.1)  7-4, 14-6 3 (0.38) 21-1, 16 2 (0.25) 7-2, 13-5 1 (0.13) 19, 15-39 1 (0.13) 
22, 14 30 (3.8)  18, 3 3 (0.38) 22, 9-7 2 (0.25) 7-2, 13-7 1 (0.13) 19, 15-41 1 (0.13) 
7-2, 13-1 29 (3.6) 18-1, 34 3 (0.38) 22-1, 13-1 2 (0.25) 7-2, 13-15 1 (0.13) 19, 16 1 (0.13) 
5-1, 10-4 25 (3.1) 18-3, 1 3 (0.38) 5, 2-2 1 (0.13) 7-2, 16 1 (0.13) 19-1, 3 1 (0.13) 
19, 15-1 21 (2.6) 19, 13 3 (0.38) 5, 3 1 (0.13) 7-2, 16 1 (0.13) 19-1, 16 1 (0.13) 
7-1, 1 19 (2.4) 5-2, 10-2 2 (0.25) 5, 44 1 (0.13) 7-2, 30 1 (0.13) 19-2, 13-1 1 (0.13) 
7, 30 17 (2.1) 5-2, 10-3 2 (0.25) 5-1, 2-58 1 (0.13) 7-4, 13-7 1 (0.13) 19-3, 15-10 1 (0.13) 
7-2, 4 17 (2.1) 5-4, 2 2 (0.25) 5-1, 10-8 1 (0.13) 7-32, 13-1 1 (0.13) 19-15, 15 1 (0.13) 
22-1, 14 15 (1.9) 7, 1 2 (0.25) 5-1, 10-9 1 (0.13) 12, ND 1 (0.13) 19-32, 13 1 (0.13) 
22-1, 16-8 15 (1.9) 7, 9 2 (0.25) 5-2, 3 1 (0.13) 12-1, 13-2 1 (0.13) 21, 16-13 1 (0.13) 
5-2, 10 13 (1.6) 7, 30-1 2 (0.25) 5-2, 9-5 1 (0.13) 12-1, 13-7 1 (0.13) 21, 16-96 1 (0.13) 
21-2, 28 13 (1.6) 7-1, 4-1 2 (0.25) 5-2, 10-1 1 (0.13) 12-1, 23-3 1 (0.13) 21, 16-102 1 (0.13) 
7, 16 12 (1.5) 7-2, 9 2 (0.25) 5-2, 10-9 1 (0.13) 12-16, 13 1 (0.13) 21, 26 1 (0.13) 
12-1, 13-1 12 (1.5) 7-2, 13 2 (0.25) 5-2, 10-12 1 (0.13) 17, 4 1 (0.13) 21, 28 1 (0.13) 
22, 9 11 (1.4) 7-2, 16 2 (0.25) 5-2, 10-23 1 (0.13) 17, 16-93 1 (0.13) 21-1, 2-5 1 (0.13) 
7, 30-3 8 (1.00) 18, 25-1 2 (0.25) 5-2, 10-81 1 (0.13) 17, 23 1 (0.13) 21-10, 16-5 1 (0.13) 
18, 25 7 (0.88) 18, 25-6 2 (0.25) 5-3, 2 1 (0.13) 17-1, 23 1 (0.13) 21-13, 30-14 1 (0.13) 
5, 2-1 6 (0.75) 18, 25-11 2 (0.25) 5-3, 10-4 1 (0.13) 17-1, 23-2 1 (0.13) 22, 13-1 1 (0.13) 
5-2, 10-57 6 (0.75) 18-1, 30 2 (0.25) 5-11, 10-4 1 (0.13) 18, 13-2 1 (0.13) 22, 14-3 1 (0.13) 
18-7, 9 6 (0.75) 18-1, 30-3 2 (0.25) 5-11, 10-8 1 (0.13) 18, 25-7 1 (0.13) 22-1, 10-1 1 (0.13) 
22, 14-6 6 (0.75) 18-7, 9-5 2 (0.25) 5-18, 10-2 1 (0.13) 18, 25-25 1 (0.13) 22-1, 14 1 (0.13) 
12-1, 13 5 (0.63) 19, 13-1 2 (0.25) 5-24, 2-2 1 (0.13) 18-1, 1 1 (0.13) 22-2, 28 1 (0.13) 
19-3, 15 5 (0.63) 19, 13-2 2 (0.25) 5-29, 10-4 1 (0.13) 18-1, 3 1 (0.13) 22-11, 14 1 (0.13) 
21-7, 16 5 (0.63) 19-1, 15 2 (0.25) 5-31, 10 1 (0.13) 18-1, 3-1 1 (0.13) 22-21, 9 1 (0.13) 
22, 26 5 (0.63) 19-1, 13-1 2 (0.25) 7, 13-1 1 (0.13) 18-1, 30-1 1 (0.13) ND 16 (2.0) 
5-1, 10-1 4 (0.50) 19-1, 15-11 2 (0.25) 7, 14 1 (0.13) 18-4, 25 1 (0.13)   
17, 16-3 4 (0.50) 19-1, 26 2 (0.25) 7, 15 1 (0.13) 18-7, 9-3 1 (0.13)   
 
VR1, Variable Region 1; VR2, Variable region 2; VR3, Variable region 3; ND, not determined 
 
 Table 5.4 – Frequency of PorA subtypes (VR1, VR2 & VR3) amongst carried meningococci in Scotland, 1974 – 2004 
 
PorA subtype 
(VR1, VR2, VR3) 
Frequency  
(%) 
PorA subtype 
(VR1, VR2, VR3) 
Frequency  
(%) 
PorA subtype 
(VR1, VR2, VR3) 
Frequency  
(%) 
PorA subtype 
(VR1, VR2, VR3) 
Frequency  
(%) 
PorA subtype 
(VR1, VR2, VR3) 
Frequency  
(%) 
5, 2, 36-2 90 (11.3) 19, 15-1, 36-2 4 (0.50) 21-1, 2-2, 36-2 2 (0.25) 7-2, 4-2, 37 1 (0.13) 19, 13-2, 36 1 (0.13) 
18-1, 3, 38 80 (10.0) 5-2, 10, 36-2 3 (0.38) 22, 9-7, 35-1 2 (0.25) 7-2, 13-2, 35-1 1 (0.13) 19, 13-6, 36 1 (0.13) 
19, 15, 36 48 (6.0) 7, 16-16, 37-1 3 (0.38) 22-1, 13-1, 35-1 2 (0.25) 7-2, 13-5, 35-1 1 (0.13) 19, 15, 38 1 (0.13) 
21, 16, 37-1 39 (4.9) 7, 30-2, 38 3 (0.38) 5, 2, 36 1 (0.13) 7-2, 13-7, 35-1 1 (0.13) 19, 15, new 1 (0.13) 
5-1, 2-2, 36-2 33 (4.1) 7-2, 1, 35-1 3 (0.38) 5, 2, 36-1 1 (0.13) 7-2, 13-15, 35-1 1 (0.13) 19, 15-39, 36 1 (0.13) 
22, 14, 36 30 (3.8) 7-4, 14-6, 35-1 3 (0.38) 5, 2-2, 36-2 1 (0.13) 7-2, 16, 35 1 (0.13) 19, 15-41, 36 1 (0.13) 
7-2, 13-1, 35-1 29 (3.6) 18, 3, 38 3 (0.38) 5, 3, 36-2 1 (0.13) 7-2, 16, 37-1 1 (0.13) 19, 16, 37-1 1 (0.13) 
5-1, 10-4, 36-2 25 (3.1) 18-1, 34, 38 3 (0.38) 5, 44, 36-2 1 (0.13) 7-2, 30, 38 1 (0.13) 19-1, 3, 38 1 (0.13) 
7-1, 1, 35-1 19 (2.4) 18-3, 1, 35-1 3 (0.38) 5-1, 2-58, 36-2 1 (0.13) 7-4, 13-7, 35-1 1 (0.13) 19-1, 16, 37-1 1 (0.13) 
19, 15-1, 36 17 (2.1) 19, 13, 35-1 3 (0.38) 5-1, 10-8, 36-2 1 (0.13) 7-32, 13-1, 37-1 1 (0.13) 19-2, 13-1, 36 1 (0.13) 
7, 30, 38 16 (2.0) 5-2, 10-2, 36-1 2 (0.25) 5-1, 10-9, 36-1 1 (0.13) 12, ND, ND 1 (0.13) 19-3, 15-10, 36 1 (0.13) 
7-2, 4, 37 16 (2.0) 5-2, 10-3, 37-1 2 (0.25) 5-2, 3, 38 1 (0.13) 12-1, 13-2, 35-1 1 (0.13) 19-15, 15, 36 1 (0.13) 
22-1, 14, 38 15 (1.9) 5-4, 2, 36-2 2 (0.25) 5-2, 9-5, 35-1 1 (0.13) 12-1, 13-7, 35-1 1 (0.13) 19-32, 13, 36 1 (0.13) 
22-1, 16-8, 36-2 15 (1.9) 7, 1, 35-1 2 (0.25) 5-2, 10-1, 36-2 1 (0.13) 12-1, 23-3, 37 1 (0.13) 21, 16-13, 37-1 1 (0.13) 
7, 16, 35 12 (1.5) 7, 9, 35-1 2 (0.25) 5-2, 10-9, 36-2 1 (0.13) 12-16, 13, 35-1 1 (0.13) 21, 16-96, 37-1 1 (0.13) 
12-1, 13-1, 35-1 12 (1.5) 7, 30-1, 38 2 (0.25) 5-2, 10-12, 36-2 1 (0.13) 17, 4, 37 1 (0.13) 21, 16-102, 37-1 1 (0.13) 
21-2, 28, 37 12 (1.5) 7-1, 4-1, 37-1 2 (0.25) 5-2, 10-23, 36-2 1 (0.13) 17, 16-93, 36 1 (0.13) 21, 26, 35-1 1 (0.13) 
22, 9, 35-1 11 (1.4) 7-2, 9, 35-1 2 (0.25) 5-2, 10-81, 36-2 1 (0.13) 17, 23, 37 1 (0.13) 21, 28, 37 1 (0.13) 
5-2, 10, 37-1 10 (1.3) 7-2, 13, 35-1 2 (0.25) 5-3, 2, 36-2 1 (0.13) 17-1, 23, 37 1 (0.13) 21-1, 2-5, 36-2 1 (0.13) 
7, 30-3, 38 8 (1.00) 18, 25-1, 38-1 2 (0.25) 5-3, 10-4, 36-2 1 (0.13) 17-1, 23-2, 37 1 (0.13) 21-1, 16, 36-2 1 (0.13) 
18, 25, 38-1 7 (0.88) 18, 25-6, 38-1 2 (0.25) 5-11, 10-4, 36-2 1 (0.13) 18, 13-2, 35-1 1 (0.13) 21-1, 16, 37-1 1 (0.13) 
5, 2-1, 36-2 6 (0.75) 18, 25-11, 38-1 2 (0.25) 5-11, 10-8, 36-2 1 (0.13) 18, 25-7, 38-1 1 (0.13) 21-2, 28, 36-1 1 (0.13) 
5-2, 10-57, 36-2 6 (0.75) 18-1, 30, 38 2 (0.25) 5-18, 10-2, 36-2 1 (0.13) 18, 25-25, 38-1 1 (0.13) 21-10, 16-5, 37-1 1 (0.13) 
18-7, 9, 35-1 6 (0.75) 18-1, 30-3, 38 2 (0.25) 5-24, 2-2, 36-2 1 (0.13) 18-1, 1, 35-1 1 (0.13) 21-13, 30-14, 36-2 1 (0.13) 
22, 14-6, 36-2 6 (0.75) 18-7, 9-5, 35-1 2 (0.25) 5-29, 10-4, 36-2 1 (0.13) 18-1, 3, 40 1 (0.13) 22, 13-1, 36-2 1 (0.13) 
12-1, 13, 35-1 5 (0.63) 19, 13-1, 36 2 (0.25) 5-31, 10, 37-1 1 (0.13) 18-1, 3-1, 38 1 (0.13) 22, 14-3, 36-2 1 (0.13) 
19, 15, 35-1 5 (0.63) 19-1, 15, 36 2 (0.25) 7, 13-1, 35-1 1 (0.13) 18-1, 30-1, 38 1 (0.13) 22-1, 10-1, 36-2 1 (0.13) 
19-3, 15, 36 5 (0.63) 19-1, 13-1, 35-1 2 (0.25) 7, 14, 35 1 (0.13) 18-4, 25, 38-1 1 (0.13) 22-1, 14, 36-1 1 (0.13) 
21-7, 16, 37-1 5 (0.63) 19-1, 15-11, 36 2 (0.25) 7, 15, 36 1 (0.13) 18-7, 9-3, 35-1 1 (0.13) 22-2, 28, 37 1 (0.13) 
22, 26, 35-1 5 (0.63) 19-1, 26, 36-2 2 (0.25) 7, 16-21, 35 1 (0.13) 18-7, 9-14, 35-1 1 (0.13) 22-11, 14, 38 1 (0.13) 
5-1, 10-1, 36-2 4 (0.50) 19-33, 13-1, 36-2 2 (0.25) 7, 30, 37-1 1 (0.13) 18-7, 9-17, 35-1 1 (0.13) 22-21, 9, 35-1 1 (0.13) 
17, 16-3, 36 4 (0.50) 20, 9, 35-1 2 (0.25) 7-1, 14-6, 36-2 1 (0.13) 18-9, 25-9, 38-1 1 (0.13) ND 16 (2.0) 
17, 16-4, 36 4 (0.50) 21, 15, 36 2 (0.25) 7-2, 4, 37-1 1 (0.13) 19, 13-2, 35-1 1 (0.13)   
Legend as for Table 5.3; in addition subtypes in red type are those which have been differentiated by the inclusion of VR3 sequencing data
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The addition of VR3 sequencing data was able to re-characterise twelve PorA 
VR1,2 subtypes amongst the carriage strain collection into twenty-seven 
subtypes (Table 5.3 & Table 5.4). Ninety-two specimens with subtype 5, 2 were 
identified as having the one of three VR3 peptides; 36-2 (n=90), 36 (n=1) or 36-1 
(n=1). Thirteen specimens with subtype 5-2, 10 were identified as having one of 
two VR3 peptides; 37-1 (n=10) or 36-2 (n=3). Seventeen specimens with subtype 
7, 30 were identified as having one of two VR3 peptides; 38 (n=16) or 37-1 (n=1). 
Seventeen specimens with subtype 7-2, 4 were identified as having one of two 
VR3 peptides; 37 (n=16) or 37-1 (n=1). Two specimens with subtype 7-2, 16 were 
identified as having the VR3 peptide 35 or 37-1. Eighty-one specimens, including 
ATCC 13077, with subtype 18-1, 3 were identified as having one of two VR3 
peptides; 38 (n=80) or 40 (n=1). Two specimens with subtype 19, 13-2 were 
identified as having the VR3 peptide 35-1 or 36. Fifty-six specimens with subtype 
19, 15 were identified as having one of four VR3 peptides; 36 (n=48), 35-1 (n=5), 
38 (n=1) or a new VR3 peptide; LFGSTSDE (n=1). Twenty-one specimens with 
subtype 19, 15-1 were identified as having one of two VR3 peptides; 36 (n=17) or 
36-2 (n=4). Two specimens with subtype 21-1, 16 were identified as having VR3 
peptide 36-2 or 37-1. Thirteen specimens with subtype 21-2, 28 were identified 
as having on of two VR3 peptides; 37 (n=12) or 36-1 (n=1). Fifteen specimens 
with subtype 22-1, 14 were identified as having one of two VR3 peptides; 38 
(n=14) or 36 (n=1). 
The number of VR1 and VR2 variants and PorA subtypes identified amongst the 
carriage strain collection was greater than in the IMD strain collection (Table 
5.5). The five and ten most prevalent VR1 variants accounted for 69.5% and 
90.6% of isolates of the IMD strain collection, respectively. The ten most 
prevalent VR1 variants were 5 (n=557), 5-1 (n=450), 7-2, (n=364), 5-2 (n=301), 19 
(n=251), 22 (n=159), 7 (n=146), 21 (n=111), 7-1 (n=87) and 19-1 (n=82) (data not 
shown). The five and ten most prevalent VR2 variants accounted for 57.2% and 
80.7% of isolates of the IMD strain collection, respectively. The ten most 
prevalent VR2 variants were 2 (n=514), 4 (n=289), 10 (n=281), 2-2 (n=251), 16 
(n=248), 15 (n=213), 10-4 (n=124), 9 (n=114), 13-1 (n=107) and 14 (n=91) (data 
not shown). 
The most prevalent PorA subtypes (VR1, VR2) in the IMD strain collection were 
5,2 (n=478), 7-2,4 (n=279), 5-2,10 (n=275), 5-1,2-2 (n=232), 19,15 (n=206), 5-
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1,10-4 (n=114), 21,16 (n=109), 18-1,3 (n=75), 19-1,15-11 (n=74) and 7,16 (n=69). 
The five and ten most prevalent PorA subtypes accounted for 53.1% and 69.1% of 
isolates of the IMD strain collection, respectively. The inclusion of VR3 data re-
characterised 130 PorA VR1,VR2 subtypes into 169 PorA VR1,VR2,VR3 subtypes. 
Simpson’s index of diversity, D, was calculated for PorA subtype (VR1,VR2) 
across the full period of the IMD strain collection as 0.928 (95% CI 0.927, 0.928) 
(Table 5.5). In comparison, the level of D of PorA subtypes in the carriage strain 
collection was greater at 0.958 (95% CI 0.948, 0.968). Similarly, when VR3 data 
was included the level of D for PorA subtypes was greater in the carriage strain 
collection than in the IMD strain collection, respectively [0.961 (95% CI 0.949, 
0.973) vs. 0.931 (95% CI 0.930, 0.932)]. The non-overlapping 95% CIs indicate 
that the diversity of PorA subtypes is significantly different between the two 
strain collections. Therefore, with respect to PorA subtype, the diversity in the 
carriage strain collection is greater than the diversity in the IMD strain 
collection. 
Table 5.5 – Summary of antigenic diversity in carried and invasive meningococcal disease 
strain collections in Scotland, 1974 – 2004 
 
  carriage1  IMD2 
Isolates  780  2767 
     
PorA     
VR1 peptides  45  35 
VR2 peptides  74  46 
Subtypes (VR1, 2)   144  130 
D3  0.958  0.928 
95% CIs4  (0.948, 0.968)  (0.927, 0.928) 
     
VR3 peptides  10  10 
Subtypes (VR1,2,3)   163  169 
D  0.961  0.931 
95% CIs  (0.949, 0.973)  (0.930, 0.932) 
1 carriage, carriage strain collection; 2 IMD, invasive meningococcal disease strain collection; 3 D, 
Simpson’s index of diversity (Hunter and Gaston 1988); 4 95% confidence intervals calculated as 
described in (Grundmann, Hori et al. 2001). 
 
 
Figure 5.2 shows the ten most prevalent PorA subtypes (VR1,VR2) from the IMD 
strain collection, the ten most prevalent PorA subtypes (VR1,VR2) from the 
carriage strain collection and a comparison of their prevalence in the two strain 
collections. Subtypes 5,2; 5-1,2-2; 5-1,10-4; 18-1,3; 19,15 and 21,16 ranked in 
the top ten most prevalent subtypes in both strain collections; with subtype 5,2 
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the most prevalent in both strain collections. Subtypes 5-2,10; 7,16; 7-2,4 and 
19-1,15-11 ranked in the ten most prevalent subtypes of the IMD strain 
collection; but not in the carriage strain collection. In contrast, subtypes 7-1,1; 
7-2,13-1; 19,15-1 and 22,14 ranked in the ten most prevalent subtypes of the 
carriage strain collection but not in the IMD strain collection. Furthermore, 
subtypes 5,2; 5-1,2-2; 5-2,10; 7-2,4 and 19-1,15-11 were considerably more 
prevalent amongst the IMD strain collection. Whereas subtypes 7-1,1; 7-2,13-1; 
18-1,3 and 19,15-1 were considerably more prevalent amongst the carriage 
strain collection. Differences in prevalence of the other prevalent PorA subtypes 
amongst the two strain collections were less pronounced and tended to be 
within one percent. 
 
 
 
Figure 5.2 - Prevalence of the major PorA subtypes identified in meningococci in Scotland, 
1974 – 2004 
NIV, non-invasive; IMD, invasive meningococcal disease; numbers along the top of the figure 
correspond to the rank in prevalence of subtypes in each strain collection, NIV:IMD. 
 
For each PorA VR1,2 subtype an odds ratio was calculated to compare the 
probability of invasive disease by, or carriage due to, that individual PorA VR1,2 
subtype (Table 5.6). Whilst assessing invasiveness, subtypes 5,2; 5,2-1 and 7-2,4 
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were found to have ORs greater than 1 and the 95% CIs indicated significance. 
Whilst assessing a carriage phenotype, thirteen subtypes were found to have ORs 
greater than 1 and the 95% CIs indicated significance. There was, however, 
variation in the observed in range of the CIs for many subtypes. For example, 
subtype 7,30-2 had on OR of 10.43 but the wide range of the 95% CI (1.08 to 
100.36) indicates the OR to be less precise. In comparison, subtype 7-2,13-1 had 
an OR of 2.22 with a much narrower 95% CI (1.34 to 3.41) indicating greater 
precision for this OR. 
 
Table 5.6 – Association of PorA VR1,2 subtypes identified in meningococci in Scotland, 
1974 – 2004 with invasive disease or with a carriage phenotype 
 
“Invasive”  
Subtype 
n1 
(IMD2) 
n 
(carriage3) OR
4 95% CI5 
5,2 478 92 1.60 1.26 to 2.04 
5,2-1 66 6 3.23 1.39 to 7.48 
7-2,4 279 17 5.16 3.14 to 8.47 
     
“carriage” 
Subtype 
n 
(carriage) 
n 
(IMD) 
OR 95% CI 
7,30-2 3 1 10.43 1.08 to 100.36 
7-1,1 19 30 2.22 1.24 to 3.97 
7-2,13-1 29 48 2.13 1.34 to 3.41 
17,16-3 4 3 4.64 1.04 to 20.76 
18-1,3 81 75 4.05 2.93 to 5.60 
18-7,9 6 5 4.18 1.27 to 13.73 
19,15-1 21 21 3.53 1.92 to 6.50 
19-3,15 5 2 8.71 1.69 to 44.96 
21-2,28 13 4 11.43 3.72 to 35.14 
21-7,16 5 2 8.71 1.69 to 44.96 
22,26 5 4 4.35 1.17 to 16.24 
22-1,14 15 15 3.51 1.71 to 7.21 
22-1,16-8 15 3 17.63 5.09 to 61.05 
1 n, number of strains; 2 IMD, invasive meningococcal disease strain collection; 3 carriage, carriage 
strain collection; 4 OR, odds ratio; 5 CI; confidence interval 
 
Figure 5.3 shows the inferred phylogeny generated from the multiple alignments 
of concatenated amino acid sequences of the individual PorA subtypes identified 
during this study. The alignment was generated in ClustalW2 using the default 
settings with the neighbour-joining tree constructed from the alignment. Added 
to the phylogram is prevalence and temporal data which again highlights that 
the majority of PorA subtypes were only encountered sporadically while a 
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smaller number of subtypes are more prevalent and persist within the strain 
collection over long periods. Moreover, within groups of related subtypes a 
particular subtype tends to dominate over a number of other less frequently 
encountered variants. 
Chapter 5                                                                                                                                        184 
 
Figure 5.3 - Phylogenetic relationship of PorA subtypes identified in carried meningococci 
in Scotland, 1974 – 2004 
For legend see over page 
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See previous page 
Figure 5.3 - Phylogenetic relationship of PorA subtypes identified in carried meningococci 
in Scotland, 1974 – 2004 
Subtypes are defined by PorA VR1, VR2 and VR3; neighbour-joining tree constructed in ClustalW2 
using the pairwise differences from the multiple alignment of concatenated amino acid sequences 
using default settings. The number of dots is proportional to the number of times individual 
subtypes were sequenced in the carriage strain collection. Red, blue and green dots indicate the 
occurrence of a subtype during the period 1974 – 1983, 1984 – 1993 or 1994 – 2004, respectively. 
Black dots indicate an ATCC or NCTC strain. 
 
 
5.7 Temporal distribution of PorA subtypes 
PorA subtyping data (VR1,VR2) was examined for evidence of any changes in 
subtype prevalence over the 31 year period covered by the carriage strain 
collection. As previously, data was partitioned into three roughly equal time 
periods; 1974-1983, 1984-1993 and 1994-2004. The distribution of the most 
prevalent subtypes (sequenced in n>10 specimens; as listed in Table 5.3) was 
determined in each of the three time periods (Table 5.7).  
Table 5.7 – Temporal distribution of the major PorA subtypes identified in carried 
meningococci in Scotland, 1974 – 2004 
 
subtype 
(VR1,VR2) 
Prevalence (%) 
1974-1983 
(n=127)1 
1984-1993 
(n=445)1 
1994-2004 
(n=208)1 
5, 2  6 (4.7) 79 (17.8) 5 (2.4) 
18-1, 3 12 (9.4) 59 (13.3) 9 (4.3) 
19, 15 14 (11.0) 28 (6.3) 12 (5.8) 
21, 16 4 (3.1) 18 (4.0) 16 (7.7) 
5-1, 2-2 7 (5.5) 24 (5.4) 2 (1.0) 
22, 14 - 1 (0.2) 29 (13.9) 
7-2, 13-1 4 (3.1) 25 (5.6) - 
5-1, 10-4 4 (3.1) 10 (2.2) 10 (4.8) 
19, 15-1 2 (1.6) 15 (3.4) 4 (1.9) 
7-1, 1 7 (5.5) 11 (2.5) - 
7, 30 - 3 (0.7) 14 (6.7) 
7-2, 4 1 (0.8) 7 (1.6) 9 (4.3) 
22-1, 14 5 (3.9) 7 (1.6) 3 (1.4) 
22-1, 16-8 3 (2.4) 11 (2.5) 1 (0.5) 
5-2, 10 5 (3.9) 8 (1.8) - 
21-2, 28 3 (2.4) 6 (1.3) 4 (1.9) 
7, 16 1 (0.8) 10 (2.2) 1 (0.5) 
12-1, 13-1 4 (3.1) 7 (1.6) 1 (0.5) 
22, 9 1 (0.8) 4 (0.9) 6 (2.9) 
Total (%)2 83 (65.3) 327 (73.5) 126 (60.6) 
1 Number of fully subtyped isolates during each period; 2 major PorA subtypes as the number and 
percentage of fully subtyped isolates during each period 
 
Chapter 5                                                                                                                                        186 
The majority (14/19) of the subtypes persisted within the carriage strain 
collection throughout all time periods. Three subtypes were present during the 
earlier two periods but not in the third period; 7-2,13-1; 7-1,1 and 5-2,10. Two 
subtypes were absent from the earliest period but present in the latter two 
periods; 22,14 and 7,30. There was evidence to indicate changes in the 
distribution of persistent subtypes. The prevalence of five subtypes in the 
carriage strain collection has decreased; 5-1,2-2; 12-2,13-1; 19,15; 22-1,14 and 
22-1,16-8. The prevalence of a further three subtypes (5,2; 7,16 and 18-1,3), 
following increases from the first to second periods, have decreased to below 
their prevalence in the earliest period. The prevalence of three subtypes 
appears to have increased; 7-2,4; 21,16 and 22,9. 
 
5.8 Potential coverage of the carriage strain collection by 
currently licensed or experimental PorA-based outer-
membrane vesicle vaccines 
PorA-based OMV vaccines have been used for around two decades in targeted 
vaccination campaigns to limit the burden of large disease outbreaks in different 
parts of the world. The concept of designing vaccines that negate the use of 
capsular polysaccharide is an attractive one, particularly when trying to 
eradicate disease due to serogroup B meningococci. With this in mind the 
potential coverage of carried meningococci in Scotland by licensed or 
experimental PorA-based vaccines reported in the available literature was 
calculated from the aforementioned subtype frequencies. 
Table 5.8 shows the potential coverage of the carriage strain collection by six 
different PorA-based vaccine formulations reported in the literature; the Cuban 
VA-MENGOC-BC B: 4: P1.19,15 vaccine developed by the Finlay Institute (Holst, 
Feiring et al. 2003); the Norwegian P1.7, 16 vaccine developed by the Norwegian 
Institute of Public Health (NIPH) (Bjune, Hoiby et al. 1991); the New Zealand 
MeNZB P1.7-2,4 vaccine developed by the New Zealand Ministry of Health and 
Chiron (Oster, Lennon et al. 2005); the six-valent and nine-valent vaccines, 
developed by the Netherlands Vaccine Institute (NVI) HexaMen (Peeters, Rumke 
Chapter 5                                                                                                                                        187 
et al. 1996) and NonaMen (van den Dobbelsteen, van Dijken et al. 2007), 
respectively; and a bivalent vaccine (combined Cuban VA-MENGOC-BC & MeNZB) 
developed by the Finlay Institute and GSK (Boutriau, Poolman et al. 2007). 
Table 5.8 – Potential coverage of PorA VR1,2 subtypes identified in meningococci in 
Scotland, 1974 – 2004 by experimental or licensed PorA-based OMV vaccines 
 
Vaccine 
(Manufacturer) PorA subtype(s) 
Strain Coverage(%)1 
Carriage2 
all strains 
IMD3 
all strains 
Cuban  
VA-MENGOC-BC 
(Finlay Institute) 
P1.19,15 6.9% 7.5% 
Norwegian  
(NIPH)4 P1.7,16 1.5% 2.5% 
New Zealand MeNZB  
(NZMH5 & Chiron) P1.7-2,4 2.1% 10.1% 
Bivalent (Finlay 
Institute & GSK) 
P1.19,15 & 
P1.7-2, 4 9.0% 17.6% 
HexaMen 
(NVI)6 
P1.5-2,10; P1.12-1,13: P1.7-2,4; 
P1.19,15-1; P1.7,16 & P1.5-1,2-2 12.6% 31.9% 
NonaMen 
(NVI) 
HexaMen + P1.22,14;  
P1.7-1,1; P1.18-1,3 28.9% 38.1% 
1 Based on the prevalence of the homologous PorA subtype; 2 non-invasive strain collection; 3 
invasive meningococcal disease strain collection; 4 NIPH, Norwegian Institute of Public Health; 5 
NZMH, New Zealand Ministry of Health; 6 NVI, Netherlands Vaccine Institute 
 
 
Against the whole carriage strain collection the potential coverage by any of the 
three monovalent vaccines or the bivalent vaccine does not reach 10%. Even the 
six-valent vaccine only covers around an eighth of the strain collection. The 
addition of three more PorA subtypes in the NonaMen vaccine considerably 
improves coverage to between one quarter and one third; however this level is 
still disappointing. The potential coverage of the subtypes amongst the IMD 
strain collection by licensed or experimental PorA-based OMV vaccines was also 
assessed (Table 5.8). Each of the vaccines in Table 5.8 would cover a higher 
proportion of the IMD strain collection than the carriage strain collection. The 
coverage of each strain collection by the monovalent and bivalent vaccines was 
poor. A modest coverage could be achieved by the nonavalent vaccine; however 
this was still below 30% and 40% for the carriage and IMD strain collections, 
respectively. At best a potential hexavalent PorA-based OMV vaccine using the 
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six most prevalent subtypes identified in the whole carriage strain collection in 
this study could cover 41.3% of strains, rising to 50.6% using the nine most 
prevalent. At best a potential hexavalent PorA-based OMV vaccine using the six 
or nine most prevalent subtypes identified in the whole IMD strain collection in 
this study could cover 57.2% and 66.6% strains, respectively. 
 
5.9 Discussion 
The data indicates that within most PorA VR1 and VR2 families, one or two 
variants tended to predominant and any other variants were only identified 
sporadically. For example, six variants belonging to the P1.15 Family were 
identified; variant 15 was predominant (n=66), followed by variant 15-1 (n=22), 
while the remaining four variants were identified two times or fewer. In a few 
PorA VR1 and VR2 Families several variants were predominant in the carriage 
strain collection; i.e. three variants of the P1.5 Family were identified at least 
30 times. Furthermore, of the ten currently defined PorA VR1 families only five 
or six were identified in high numbers. Within PorA variable region families 
considerable variation has been documented, as evident on the PorA variable 
region database (http://pubmlst.org/neisseria/PorA/), yet only a comparatively 
small number of variants were identified in this strain collection. PorA subtyping 
of the carriage strain collection also identified several new VR sequences 
providing further evidence for the antigenic variability of the meningococcus. In 
twelve carried meningococci, and in the ATCC 13090 serogroup B isolate, DNA 
sequencing of PorA VRs1-3 was not determined because a PCR product could not 
be amplified using the porA-specific primers outlined in Chapter 2. 
A handful of laboratories, including the Scottish Haemophilus, Legionella, 
Meningococcus & Pneumococcus Reference Laboratory (SHLMPRL), perform DNA 
sequencing of PorA VR3 in addition to VRs 1 & 2. The inclusion of VR3 data has 
enabled further discrimination of meningococcal strains by characterising a 
larger number of subtypes. Despite this, however, PorA VR3 is not one of the 
typing targets recently recommended by the EMGM. The recommended strain 
designation for meningococci includes the serogroup, PorA VRs 1 & 2, FetA VR, 
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MLST sequence type and clonal complex (Brehony, Jolley et al. 2007). An 
example being: C: P1.5, 2-1: F5-4: ST-11 (cc11). At the time this project 
commenced FetA VR sequencing was not employed by the reference laboratory 
in Scotland as a means to characterise strains of meningococci, and as such was 
not included as part of this study.  
The data presented here provides evidence that a comparatively small number 
of dominant PorA VR1 variants, VR2 variants and PorA subtypes have been 
maintained over many years within carried meningococci from Scotland. In 
contrast, the majority of PorA subtypes were either short lived or occurred 
sporadically; supporting the findings of others (Buckee, Jolley et al. 2008; 
Buckee, Gupta et al. 2010). Despite the dominance of a few major subtypes, 
changes were observed in the prevalence of particular subtypes in carried 
meningococci and in IMD isolates in Scotland over the 31 year period. While none 
of the major PorA subtypes is exclusively present amongst only the IMD or only 
the carriage strain collection we have observed that particular subtypes are 
more prevalent in one strain collection versus the other, and subtypes are 
variable with respect to their temporal distribution.  
Previous work by the reference laboratory using phenotypic methods indicated 
the prevalence of serotypes and serosubtypes in IMD isolates had changed in 
Scotland during a 15-20 year period (Clarke 1999b). Amongst serogroup C strains 
serotype 2b strains decreased while 2a:P1.5 strains increased. Serogroup B 
strains are more diverse in their antigenic combinations; however 2b:P1.10 and 
15:P1.7,1.16 declined during the 1990s while 4:P1.4 increased (Clarke 1999b; 
Kyaw, Clarke et al. 2002). Similar observations were made in England and Wales 
around the same period; a decline in C:2b, B:2b and B:15:P1.7,16 strains and 
increases in B:4:P1.4 and B:NT:P1.9 strains during an eleven year period from 
1993-1994 onwards (Gray, Trotter et al. 2006). 
The carriage strain collection was genetically more diverse than the IMD strain 
collection based on Simpson’s Index of diversity. The observed heterogeneity of 
PorA subtypes in carried meningococci over the thirty-one year period 1974 - 
2004 indicates that monovalent PorA-based OMV vaccines would be of limited 
use against carried meningococci in Scotland. At the very least it would be 
necessary for a PorA-based OMV vaccine to include multiple subtypes to achieve 
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even moderate coverage. These moderate levels of coverage are to be expected 
given the observed diversity in PorA subtypes amongst the carriage strain 
collection. PorA-based OMV vaccines were developed to target predominant 
disease strains of serogroup B meningococci (Bjune, Hoiby et al. 1991; Sierra, 
Campa et al. 1991; Oster, Lennon et al. 2005) therefore one would expect that 
coverage would increase when assessing IMD strains from Scotland. Indeed, a 
previous study reported a higher level of coverage of invasive meningococcal 
isolates by PorA-based OMV vaccines; 65% of all isolates or 94.8% of serogroup B 
isolates across all age groups by the nine-valent vaccine (Sullivan 2008). 
Although the period assessed by Sullivan (1972-1998) was not identical to the 
period discussed in this report (1974-2004) there was considerable overlap and 
much of the IMD strain collection discussed herein uses data from the study by 
Sullivan. While one would expect some variation in coverage, the differences are 
too large to be explained by temporal variation alone. One can only assume 
differences must exist between the criteria chosen by Sullivan to define vaccine 
coverage compared with the criteria used herein. By relaxing coverage to 
include isolates possessing only one VR identical to the vaccine subtype(s), 
coverage of the two strain collections defined herein does increase (data not 
shown). 
Due to the temporal variation displayed by PorA subtypes it would be pertinent 
to discuss the most contemporary subtyping data available at the SHLMPRL. 
During the period 2003 to June 2008, 69 subtypes were identified amongst 384 
isolates from confirmed cases of meningococcal disease (R. Ure and B. Denham, 
personal communication). This PorA subtyping data from the SHLMPRL indicate 
that vaccine coverage has changed slightly providing further evidence of 
temporal changes in subtype prevalence. Based on these more recent data (data 
not shown), coverage across all strains from all ages was 1.3%, 3.4%, 18.0%, 
19.3%, 23.2% and 39.1% for the different vaccine preparations as listed in the 
order outlined in Table 5.8. Thus indicating increases in coverage by the NIPH 
monovalent, MeNZB monovalent, GSK & Finlay Institute bivalent and NVI 
nonavalent vaccines. Contrastingly, coverage by the Cuban monovalent and NVI 
hexavalent vaccines has actually reduced compared with the coverage data for 
the IMD collection. 
Chapter 5                                                                                                                                        191 
Undoubtedly, potential vaccine coverage is under-estimated as the data 
presented here only take into account strains with identical PorA subtypes. If 
PorA-related subtypes (based on one shared VR) or indeed heterologous strains 
(assuming cross-protection between subtypes of the same family) were taken 
into account perhaps the potential coverage may increase. Limited data exists 
on the precise bactericidal responses to the vast array of different VR1, VR2 or 
VR3 peptide epitopes within different PorA subtypes. Immunodominance of VR 
epitopes appears to be subtype-specific as immune responses due mainly to the 
VR1 or VR2 have been reported for different PorA subtypes; due to VR1 of 
subtypes P1.7,16 (van der Voort, van Dijken et al. 1997) and P1.12,13 (Wedege, 
Kolberg et al. 1995) or due to VR2 of subtypes P1.5,10 (van der Voort, van der 
Ley et al. 1996; van der Voort, van Dijken et al. 1997; Martin, Borrow et al. 
2000) and P1.7-2,4 (Martin, Ruijne et al. 2006). The VR2 epitope has been 
identified in clinical trials as the main target of vaccine-induced serum 
bactericidal antibodies. Modification or deletion of the VR2 epitope allowed 
strains to resist, to varying degrees, complement-mediated lysis (Martin, Ruijne 
et al. 2006). 
Due consideration must also be paid to the other antigenic components within 
these PorA-based OMV vaccines which could themselves be responsible for some 
part of the immune response generated within a potential recipient following 
vaccine administration. Other than PorA, OMVs contain multiple different 
membrane associated components which may elicit an immune response in vivo. 
Boutriau and colleagues reported some cross-protection against heterologous 
strains when using a bivalent OMV vaccine; however this cross-protection was 
variable and may be due to other antigens in the OMV preparation (Boutriau, 
Poolman et al. 2007). Investigations using various immunological assays has 
identified that multiple antigens gave rise to high levels of specific and cross-
reacting antibodies in vaccinees receiving MeNZB (7-2,4) or MenBvac (7,16) with 
no significant difference in post-vaccine responses of the two vaccine groups 
with each of the PorA antigens (Wedege, Hoiby et al. 1998). Proteomic analysis 
of the VA-MENGOC-BC OMV vaccine preparations identified at least 31 different 
proteins, of which five or six (FrpB, PorA, PorB, RmpM, Opa and OpcA) 
contribute 58-65% of the protein content depending upon vaccine batch (Uli, 
Castellanos-Serra et al. 2006). Vipond and colleagues also identified around 40 
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proteins in their analyses of batches of the MeNZB OMV vaccine, including 
proteins thought to be important in the development of protective immunity 
such as Omp85, FetA, PorA, PorB, RmpM, OpcA and NspA (Vipond, Wheeler et al. 
2005; Vipond, Suker et al. 2006). 
Presently, meningococcal disease is declining across much of Europe and, where 
countries have introduced MCC vaccination, the majority of disease cases are 
due to serogroup B strains (Trotter, Chandra et al. 2007). The publication of the 
genome sequences of a few meningococcal strains of different capsular 
serogroups from disease (Parkhill, Achtman et al. 2000; Tettelin, Saunders et al. 
2000; Bentley, Vernikos et al. 2007; Peng, Yang et al. 2008) or from carriage 
(Schoen, Blom et al. 2008) has paved the way for new approaches to vaccine 
antigen discovery (Pizza, Scarlato et al. 2000; Saunders and Butcher 2003; Kelly 
and Rappuoli 2005; Sardinas, Climent et al. 2009). Vaccine strategies targeting 
serogroup B strains are shifting focus towards a range of subcapsular antigens to 
improve strain coverage (Pizza, Donnelly et al. 2008; Bambini, Muzzi et al. 2009; 
Jacobsson, Hedberg et al. 2009). Several antigens, including factor H-binding 
protein (Masignani, Comanducci et al. 2003; Fletcher, Bernfield et al. 2004; 
Pizza, Donnelly et al. 2008), Neisseria adhesion A (NadA) or Genome-derived 
neisserial antigen (GNA) 1994 (Comanducci, Bambini et al. 2002), GNA2091, 
GNA2132 and GNA1030 are currently under investigation for use in various 
vaccine preparations (Rappuoli 2008; Snape 2008; Jacobsson, Hedberg et al. 
2009). To keep pace with new developments in vaccine research the SHLMPRL 
must consider expanding their repertoire of molecular surveillance targets 
should the efforts of the scientific and research community in producing a 
serogroup-independent vaccine reach fruition. 
193 
6 Strain types identified amongst carried 
meningococci in Scotland, 1974 - 2004: 
compilation of serogrouping, MLST & PorA data 
6.1 Introduction 
The data on sero- & geno-grouping, MLST, and PorA VR sequencing of carried 
meningococci from the preceding three chapters was combined to enable a more 
detailed analysis of the circulating carriage strain types in Scotland during the 
31-year period covered by the strain collection. The carriage strain collection 
was characterised into strain types on the basis of serogroup/genogroup: cc: ST: 
PorA subtype (VR1,VR2,VR3). Data on the most prevalent strain types amongst 
the carriage strain collection was studied for evidence of any temporal pattern 
in the distribution of clonal complexes; i.e. any pattern where the prevalence of 
a particular clonal complex may have altered throughout the period of time 
covered by the strain collection. The IMD strain collection was examined for the 
presence of the major strain types found in the carriage strain collection, and 
vice versa. 
 
6.2 Correlation of serogroup or genogroup with 
multilocus sequence types and clonal complexes 
Table 6.1 displays the prevalence of serogroup and clonal complex associations. 
Differences were evident in the diversity of lineages associated with particular 
serogroups, or vice versa. Some lineages were strictly associated to one 
serogroup while other lineages were associated with several different 
serogroups. Serogroup A was found to be associated with three clonal 
complexes; cc1/subgroup I/II, cc5/subgroup III and cc198. Four isolates of 
serogroup or genogroup A were not assigned to a known clonal complex. No 
other serogroup was associated with cc1 or cc5 strains. Serogroup B was 
associated with twenty-three distinct clonal complexes and with STs not 
assigned to any currently defined clonal complexes. No other serogroup or 
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genogroup was associated with cc32/ET-5, cc162, cc213, cc231, cc282, cc376 
and cc865. 
Table 6.1 – Correlation of the serogroup or genogroup with clonal complexes identified in 
carried meningococci in Scotland, 1974 – 2004 
 
 serogroup1/genogroup2  NG 
cc A B C W135 Y X Z 29E  cnl ctrA PCR NEG ND 
cc1 5/-             
cc5 2/-             
cc8  10/1 71/-           
cc11  3/- 9/- 5/- 1/-         
cc18              
cc22  6/- 8/- 37/6 6/1         
cc23     35/6      1 1  
cc32  19/-            
cc35  45/10 7/-  1/-      1   
cc37              
cc41-44  68/22 18/2  1/-       1  
cc53          31   1 
cc60  2/-      1/14      
cc92  -/1 1/-  -/1      1   
cc103       5/1     1  
cc162  1/-            
cc167  1/-   15/4      1   
cc174  2/- 2/- 1/- 2/-         
cc175   1/-           
cc178   -/1  1/-   -/12      
cc198 1/-   1/-      7    
cc212   2/3     -/2      
cc213  23/4            
cc231  1/-            
cc254  4/- 5/-    -/1 2/22    1  
cc269  24/7 -/1          1 
cc282  1/-            
cc334  4/- 21/1           
cc364  6/- 2/1 1/-          
cc376  1/1            
cc461  5/- 2/1           
cc549              
cc750      6/1        
cc865  1/1            
cc1117  -/1        1    
cc1136          1    
cc1157  -/1    -/1  -/5      
UA 4/1 42/13 4/1 5/-  2/1 3/10 -/3   2 2 2 
1 Number of strains of a particular serogroup; 2 Number of strains of a particular genogroup; cc, 
clonal complex; UA, unassigned; NG (NEG), strains were negative by all genogrouping PCR; NG 
(ND), strains were not fully characterised by genogrouping PCR 
 
 
Serogroup C was associated with fifteen distinct clonal complexes and with STs 
not assigned to any currently defined clonal complexes. Serogroup W135 was 
associated with just five distinct clonal complexes and with STs not assigned to 
any currently defined clonal complexes. Most specimens were predominantly of 
the cc22 lineage with a few of the cc11/ET-37 lineage. Serogroup Y was 
associated with nine distinct clonal complexes but was not associated with any 
STs not assigned to currently defined clonal complexes. Most specimens were 
predominantly of the cc23/Cluster A3 lineage, followed by the cc167 lineage. A 
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few specimens were associated with the cc22 lineage while the other six 
lineages were uncommon. Serogroup or genogroup X was associated with just 
two distinct clonal complexes, cc750 and cc1157, and with STs not assigned to 
any currently defined clonal complexes. 
Clonal complexes composed of isolates of more than one sero- or genogroup 
were inspected further to assess the correlation with individual STs. For the 
majority of clonal complexes individual STs were found to be of just a single 
serogroup (data not shown); however Table 6.2 shows those STs found to be 
associated with more than one sero- or genogroup. Twenty-one STs were 
associated with more than one sero- or genogroup; twenty of which were 
assigned to sixteen ccs. In most instances these STs were only associated with 
two different sero- or genogroups; with the exception of ST11 (serogroups B, C, 
W135 or Y), ST103 (Z, Z/29E or NEG) and ST198 (A, W135 or cnl). 
 
Table 6.2 – Sequence types identified in carried meningococci in Scotland, 1974 – 2004 
which are associated with multiple sero- or genogroups 
 
  serogroup1/genogroup2  NG 
cc ST A B C W135 Y Z 29E  Z/29E cnl ctrA (NEG) 
cc8 8  6/- 71/-          
cc11 11  2/- 7/- 3/- 1/-        
cc22 22  1/-  30/5         
 114   1/-  6/1        
 289  5/- 7/-          
cc23 23     26/2       1 
cc35 457  14/5 3/-          
 472  3/1     -/1      
cc41-44 206  1/- 3/-          
 1097  2/-   1/-        
cc60 60  1/-     1/9      
cc103 103      5/1   1   1 
cc167 167  1/-   8/-      1  
cc198 198 1/-   1/-      5   
cc212 212   2/2    -/1      
cc254 254   2/-    9/3      
cc269 283  1/- -/1          
cc334 334  1/1 10/1          
cc364 413  1/- 1/1          
cc461 461  3/- -/1          
UA 1162  5/- 2/-          
1 Number of strains of a particular serogroup; 2 Number of strains of a particular genogroup; cc, 
clonal complex; ST, sequence type; NG, non-groupable; Z/29E, cross-reaction with ctrA-Z and 
ctrA-29E PCR; cnl, capsule null locus; ctrA, positive by non-serogroup specific ctrA PCR; NEG, no 
positive reaction with any genotypic serogrouping PCR; UA, unassigned 
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6.3 Correlation of serogroup or genogroup and of clonal 
complex with PorA subtype 
Information relating to the serogroup or genogroup of carried meningococci was 
overlaid onto the phylogeny of the concatenated and aligned PorA VR1,2 and 3 
amino acid sequences (Figure 6.1). Few strict associations between serogroup 
and genogroup with PorA subtype were observed. Perhaps the most notable 
exception was strains of subtype 7n,30n,38n, where n represents any variant 
within that VR family, which were all non-groupable and tested positive for the 
capsule null locus by PCR (Figure 6.2). Strains of a particular serogroup could 
posses a variety of different PorA subtypes, and vice versa. Considering the more 
prevalent subtypes, strains of three or more serogroups could possess identical 
subtypes. 
With respect to PorA subtype, some clonal complexes were more diverse (Figure 
6.3), i.e. cc35 and cc41-44; whereas other ccs were less diverse i.e. cc22 
(mostly 18-1,3,38) (Figure 6.4) and cc8 (mostly 5,2,36-2) (Figure 6.5). 
Furthermore, the previously mentioned related subtypes 7n,30n,38n which were 
all non-groupable, cnl-positive (Figure 6.2) were all of cc53 (Figure 6.6). The 
subtypes 21,16,37-1 and 19,15,36 were associated with several distinct lineages; 
nine and seven respectively and with STs not assigned to currently-defined 
clonal complexes (Figure 6.7). 
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Figure 6.1 - Association of serogroup or genogroup with PorA subtypes identified in carried 
meningococci in Scotland, 1974 – 2004 
For Legend see over page 
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Figure 6.1 - Association of serogroup or genogroup with PorA subtypes identified in carried 
meningococci in Scotland, 1974 – 2004 
The number of circles is equivalent to the number of times a particular subtype was identified 
amongst carried meningococci; Red solid circles, serogroup or genogroup A; Orange solid circles, 
serogroup or genogroup B; Yellow solid circles, serogroup or genogroup C; Green solid circles, 
serogroup or genogroup W135; Dark blue solid circles, serogroup or genogroup Y; Light blue solid 
circles, serogroup or genogroup X; Pink solid circles, serogroup or genogroup Z; Purple solid 
circles, serogroup or genogroup 29E; Brown solid circles, capsule null locus; Grey solid circles, 
ctrA non-specific-PCR positive; Half pink & half purple solid circle, cross-reaction between ctrA Z 
and ctrA 29E PCR; Black solid circle, phenotypically NG & genotypic PCR negative; Black open 
circle, genogroup not determined; boxed area marked ‘a’ is shown in Figure 6.2. 
 
 
 
 
Figure 6.2 – Enlargement of section a of Figure 6.1 
The number of circles is equivalent to the number of times a particular subtype was identified 
amongst carried meningococci; Orange solid circles, serogroup or genogroup B; Yellow solid 
circles, serogroup or genogroup C; Green solid circles, serogroup or genogroup W135; Dark blue 
solid circles, serogroup or genogroup Y; Purple solid circles, serogroup or genogroup 29E; Brown 
solid circles, capsule null locus; Black open circle, genogroup not determined 
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Figure 6.3 - Association of clonal complex with PorA subtypes identified in carried 
meningococci in Scotland, 1974 - 2004 
For Legend see over page 
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Figure 6.3 - Association of clonal complex with PorA subtypes identified in carried 
meningococci in Scotland, 1974 - 2004 
The number of circles or squares is equivalent to the number of times a particular subtype was 
identified amongst carried meningococci; Red solid circle, cc1; Orange solid circle, cc5; Yellow 
solid circle, cc8; Bright green solid circle, cc11; Dark green solid circle, cc22; Dark blue solid circle, 
cc23; Black open squares, cc32; Light blue solid circle, cc35; Pink solid circle, cc41-44, Purple 
solid circle, cc53; Brown solid circle, cc60; Black solid circle, cc92; Light grey solid circle, cc103; 
Dark grey solid circle, cc162; Peach solid circle, cc167; Pale green solid circle, cc174; Red solid 
squares, cc175; Orange solid square, cc178; Yellow solid squares, cc198; Bright green solid 
square, cc212; Dark green solid square, cc213; Dark blue solid square, cc231; Light blue solid 
square, cc254; Pink solid square, cc269; Purple solid square, cc282; Brown solid square, cc334; 
Black solid square, cc364; Light grey solid square, cc376; Dark grey solid square, cc461; Peach 
solid square, cc750; Pale green solid square, cc865; Pale pink solid square, cc1117; Pale blue 
solid square, cc1136; Pale purple solid square, cc1157; Black open circle; Unassigned to a clonal 
complex; boxed area marked ‘a’ is shown in Figure 6.4; boxed area marked ‘b’ is shown in Figure 
6.5; boxed area marked ‘c’ is shown in Figure 6.6; boxed area marked ‘d’ is shown in Figure 6.7. 
 
 
 
 
 
 
Figure 6.4 – Enlargement of section a of Figure 6.3 
The number of circles or squares is equivalent to the number of times a particular subtype was 
identified amongst carried meningococci; Orange solid circle, cc5; Yellow solid circle, cc8; Bright 
green solid circle, cc11; Dark green solid circle, cc22; Dark blue solid circle, cc23; Light blue solid 
circle, cc35; Pink solid circle, cc41-44; Light grey solid circle, cc103; Dark grey solid circle, cc162; 
Peach solid circle, cc167; Pale green solid circle, cc174; Orange solid square, cc178; Yellow solid 
squares, cc198; Pink solid square, cc269; Brown solid square, cc334; Black solid square, cc364; 
Light grey solid square, cc376; Peach solid square, cc750; Pale green solid square, cc865; Pale 
pink solid square, cc1117; Pale blue solid square, cc1136; Pale purple solid square, cc1157; Black 
open circle; Unassigned to a clonal complex. 
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Figure 6.5 – Enlargement of section b of Figure 6.3 
The number of circles or squares is equivalent to the number of times a particular subtype was 
identified amongst carried meningococci; Red solid circle, cc1; Yellow solid circle, cc8; Bright green 
solid circle, cc11; Dark green solid circle, cc22; Dark blue solid circle, cc23; Light blue solid circle, 
cc35; Pink solid circle, cc41-44; Brown solid circle, cc60; Black solid circle, cc92; Peach solid circle, 
cc167; Red solid square, cc1; Orange solid square, cc178; Bright green solid square, cc212; Light 
blue solid square, cc254; Pink solid square, cc269; Brown solid square, cc334; Pale blue solid 
square, cc1136; Black open circle; Unassigned to a clonal complex. 
 
 
 
 
Figure 6.6 – Enlargement of section c of Figure 6.3 
The number of circles or squares is equivalent to the number of times a particular subtype was 
identified amongst carried meningococci; Light blue solid circle, cc35; Pink solid circle, cc41-44, 
Purple solid circle, cc53; Light blue solid square, cc254; Pink solid square, cc269; Black solid 
square, cc364; Black open circle; Unassigned to a clonal complex. 
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Figure 6.7 – Enlargement of section d of Figure 6.3 
The number of circles or squares is equivalent to the number of times a particular subtype was 
identified amongst carried meningococci; Orange solid circle, cc5; Bright green solid circle, cc11; 
Black open squares, cc32; Light blue solid circle, cc35; Pink solid circle, cc41-44, Brown solid 
circle, cc60; Light grey solid circle, cc103; Peach solid circle, cc167; Pale green solid circle, cc174; 
Orange solid square, cc178; Bright green solid square, cc212; Light blue solid square, cc254; Pink 
solid square, cc269; Brown solid square, cc334; Light grey solid square, cc376; Peach solid 
square, cc750; Pale green solid square, cc865; Pale pink solid square, cc1117; Pale blue solid 
square, cc1136; Black open circle; Unassigned to a clonal complex. 
 
 
6.4 Prevalence of strain types amongst carried 
meningococci in Scotland, 1974 – 2004 
The carriage isolate collection was characterised into 438 strain types on the 
basis of serogroup/genogroup:cc:ST:PorA subtype (VR1,VR2,VR3) (Table 6.3). 
The vast majority of these strain types were identified in four carried 
meningococci or fewer while twenty-six strain types were identified in five or 
more carried meningococci, accounting for 290 specimens or 36.3% of the 
carriage isolate collection.  
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Table 6.3 – Prevalence of strain types identified in carried meningococci in Scotland, 1974 - 
2004 
 
Group  cc1 ST2 VR13 VR24 VR35 Frequency
6 
(Phenotypic/PCR) 
A cc1/subgroup I/II 1 5-2 10 36-2 3/- 
   5-2 10 37-1 1/- 
   ND ND ND 1/- 
 cc5/subgroup III 5 20 9  35-1 2/- 
 cc198 198 18-9 25-9 38-1 1/- 
 Unassigned 3287 18-1 3 18 1/- 
  7413 22-1 16-8 36-2 -/1 
  8222 5-2 9-5 35-1 1/- 
  8646 5-2 10 37-1 1/- 
  8648 18-1 3 38 1/- 
B cc5/subgroup III 153 5-2 10 37-1 1/- 
 cc11/ET-37 11 5 2 36-2 1/- 
 cc8/Cluster A4 8 5 2 36-2 4/- 
   5 2 36 1/- 
   7-2 13-1 35-1 1/- 
  153 5-2 10 37-1 2/- 
   5 2-1 36-2 1/- 
   5-31 10 37-1 -/1 
  4037 5 2 36-2 1/- 
 cc22 22 18-1 3 38 1/- 
  289 18-1 3 38 5/- 
 cc32/ET-5 32 7 16 35 4/- 
   7 16-21 35 1/- 
   7-2 16 35 1/- 
  33 19 15 36 5/- 
   19 15-39 36 1/- 
  259 7 16 35 7/- 
 cc35 35 22 14 36 1/- 
   22-1 14 38 -/1 
  278 7-2 13-7 35-1 1/- 
  457 22-1 14 38 5/- 
   22-1 16-8 36-2 4/2 
   19 15 36 3/3 
   19-1 15 36 1/- 
   21-1 16 36-2 1/- 
  472 21-2 28 37 3/- 
  1197 21 28 37 1/- 
  1292 22-2 28 37 1/- 
  1651 22-11 14 38 -/1 
  1710 22-1 13-1 35-1 2/- 
  2380 21-2 28 37 -/1 
  3295 22-1 14 38 1/- 
  5945 21-2 28 37 1/- 
  6033 21-2 28 37 1/- 
  6402 19 15 36 1/- 
  6658 22-1 14 38 1/- 
  6660 22-1 16-8 36-2 2/- 
  6904 22-1 14 38 -/1 
  6905 5-3 10-4 36-2 1/- 
  6907 22-1 16-8 36-2 1/- 
  6911 22-1 16-8 36-2 2/- 
  6913 19 15 36 2/- 
  7271 21-2 28 37 1/- 
  7404 12-1 13-2 35-1 1/- 
  7408 19 15 36 1/- 
  7410 7-1 1 35-1 1/- 
  7797 21-2 28 37 1/- 
  7798 17 16-3 36 -/1 
  7903 22-1 16-8 36-2 1/- 
  7969 22-1 16-8 36-2 1/- 
  7997 21-2 28 36-1 1/- 
  8001 21-2 28 37 1/- 
  8232 22-1 14 38 1/- 
 cc41-44/Lineage 3 41 7-2 4 37 4/1 
   7-2 4-2 37 1/- 
   ND 13-15 ND 1/- 
   18-1 3 38 1/- 
  43 19 15-1 36 9/5 
   19 15 16 1/- 
   19-2 13-1 36 1/- 
  44 5-1  2-2 36-2 2/- 
   7-1 1 35-1 2/- 
   5-2 10 37-1 1/- 
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Group  cc1 ST2 VR13 VR24 VR35 Frequency
6 
(Phenotypic/PCR) 
B  cc41-44/Lineage 3 44 (cont.) 7-2 13 35-1 1/- 
(cont.) (cont.)  19-1 26 36-2 -/2 
   22 13-1 3-2 1/- 
  136 5-1 2-58 36-2 1/- 
   17 16-3 36 -/1 
   17 16-93 36 1/- 
  170 18-1 3 38 1/- 
   21 16 37-1 1/- 
  180 7-2 13-1 35-1 -/1 
  206 18-3 1 35-1 1/- 
  340 7-2 4 37 -/1 
  437 5-2 10 37-1 1/- 
   7-2 13-1 35-1 1/- 
   22-1 14 38 -/1 
  464 19 15 36 1/- 
  482 21 16 37-1 -/1 
  571 18-7 9 35-1 1/- 
  577 7-2 4 37 8/- 
  833 7 15 36 1/- 
  835 19 35 36 -/1 
  1097 17 23 37 1/- 
   17 23-2 37 1/- 
  1361 12-1 13-1 35-1 -/1 
  1433 7-2 1 35-1 1/- 
  1489 5 2 36-2 1/- 
  1908 7-1 1 35-1 1/- 
  1915 7-2 13-1 35-1 1/- 
  1947 7-2 9 35-1 -/1 
  2120 18-7 9 35-1 1/- 
  2433 19 15-1 36 -/1 
  2459 7-1 1 35-1 1/- 
  2514 18-7 9-3 35-1 -/1 
   19 15 36 1/- 
  2532 18-7 19-5 35-1 1/- 
   18-7 19-17 35-1 1/- 
  2631 7 9 35-1 -/1 
  3296 7-2 13-1 35-1 3/1 
  3866 7-2 4 37 1/- 
  5120 7-2 13-1 35-1 1/- 
  5471 18-7 9 35-1 -/1 
  6034 18-7 9 35-1 1/- 
  6655 7-1 1 35-1 1/- 
  7270 18 25 38-1 1/- 
  7621 18 13-2 35-1 1/- 
  7624 7-1 1 35-1 1/- 
  7720 18-1 34 38 1/- 
  7730 7-2 13-2 35-1 1/- 
  7799 18 25 38-1 1/- 
  8220 22 14-3 36-2 -/1 
 cc60 60 5 2 36-2 1/- 
  allele ND ND ND 1/- 
 cc96 94 5-1 10-4 36-2 -/1 
 cc162 162 22 14 36 1/- 
 cc167 167 5-1 10-4 36-2 1/- 
 cc174 2547 22 26 35-1 1/- 
  7939 22 26 35-1 1/- 
 cc213 213 22 14 36 20/3 
   17 4 37 -/1 
  1218 22 14 36 1/- 
  5951 22 14 36 1/- 
 cc231 1011 7-1 1 35-1 1/- 
 cc254 3294 21 15 36 2/- 
  7991 21 16-13 37-1 1/- 
  8221 12-1 13-1 35-1 1/- 
 cc269 13 19 15 36 1/- 
  269 5-24 2-2 36-2 -/1 
   12-1 13 35-1 1/- 
   18 25 38-1 1/- 
   19 15 36 3/- 
   19-1 15-11 36 1/- 
   19-1 16 37-1 -/1 
   22 9 35-1 1/- 
  275 22 9 35-1 1/1 
  283 7 14 35 1/- 
  352 22 9 35-1 1/- 
  479 19-1 15 36 -/1 
  492 21-13 30-14 36-2 1/- 
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Group  cc1 ST2 VR13 VR24 VR35 Frequency
6 
(Phenotypic/PCR) 
B  cc269 1161 22 9 35-1 1/- 
(cont.) (cont.) 1273 22 9 35-1 1/- 
  1284 22 14 36 -/1 
  1416 22 9 35-1 1/- 
  2166 22 26 35-1 -/1 
  2239 5-2 10 37-1 1/- 
  2592 19 15 36 1/- 
  2803 19-1 3 38 1/- 
  3286 22 9 35-1 -/1 
  5984 19 15 36 1/- 
  6908 5-2 10 37-1 1/- 
  7269 19 13-2 35-1 1/- 
  7992 22 9 35-1 1/- 
  8000 7-2 13 35-1 1/- 
  8231 7-2 13-1 35-1 1/- 
 cc282 1802 5-1 10-1 36-2 1/- 
 cc334 334 5-1 2-2 36-2 1/- 
  2552 7-1 1 35-1 2/- 
  3285 21 16 27-1 1/- 
 cc364 15 12-1 13-7 35-1 1/- 
  413 12-1 13-1 35-1 1/- 
  2534 12-1 13-1 35-1 1/- 
  4650 12-1 13-1 35-1 2/- 
  7965 12-1 13-1 35-1 1/- 
 cc376 7405 19 15 36 -/1 
  7265 19 15 36 1/- 
 cc461 461 19 13-1 36 1/- 
   19 13-2 36 1/- 
   22 9 35-1 1/- 
  6403 19 13-6 36 1/- 
  7972 19 13-1 36 1/- 
 cc865 460 7-1 4-1 37-1 1/- 
  865 7 1 35-1 -/1 
 cc1117 1117 18-1 3 38 -/1 
 cc1157 1157 21-7 16 37-1 -/1 
 Unassigned 284 19 15 36 1/- 
   ND ND ND 1/- 
  288 19 15-1 36 1/- 
   18-1 3 38 1/- 
  336 7-1 1 35-1 1/1 
   19 13 35-1 1/- 
  1162 NEG NEG NEG 5/- 
  2152 5-1 10-9 36-1 1/- 
  2528 18-7 9 35-1 -/1 
  2875 neg neg neg 2/- 
  3621 7-1 1 35-1 1/- 
  4053 19 15 36 -/1 
  4221 19 15 36 -/2 
   19 15-41 36 -/1 
   19 16 37-1 -/1 
   22-1 14 36 -/1 
  4597 5-1 2-2 36-2 1/- 
  5952 21 16 37-1 1/- 
  6654 18 3 38 1/- 
   18-1 3 38 1/- 
  6656 12-1 13 35-1 1/- 
  6659 7 16 35 1/- 
  6661 19 15 36 1/- 
  6663 7-2 1 35-1 -/1 
  7268 17 16-4 36 1/- 
  7398 7-2 4 37-1 1/- 
  7399 12-1 13 35-1 1/- 
  7407 22 9-7 35-1 1/1 
  7411 18-1 3 38 1/- 
  7412 5-4 2 36-2 1/- 
  7620 5 2 36-2 1/- 
  7622 19 15 36 1/- 
  7723 5-1 10-4 36-2 1/- 
  7726 7-1 1 38-1 1/- 
  7727 12-1 13-1 35-1 1/- 
  7729 12-1 13-1 35-1 1/- 
  7801 18 25 38-1 1/- 
  7802 22 14-6 36-2 1/- 
  7905 5 2-2 36-2 1/- 
  7970 18-1 3 38 1/- 
  7990 19 15 36 -/1 
  7998 22 26 35-1 1/- 
  7999 18-1 34 38 -/1 
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Group  cc1 ST2 VR13 VR24 VR35 Frequency
6 
(Phenotypic/PCR) 
B  Unassigned 8003 12-1 13-1 35-1 1/- 
(cont.) (cont.) 8066 7-2 13-1 35-1 -/1 
  abcZ neg neg neg neg 1/- 
C cc8/Cluster A4 8 5 2 36-2 69/- 
   5 3 36-2 1/- 
   5-1 10-4 36-2 1/- 
 cc11/ET-37 11 5 2 36-2 1/- 
   5 2-1 36-2 5/- 
   5 44 36-2 1/- 
  67 5 2 36-2 1/- 
  4677 21 16 37-1 1/- 
 cc22 114 18-1 3 38 1/- 
  289 18 25 38-1 1/- 
   18-1 3 38 6/- 
 cc35 457 12-1 13 35-1 1/- 
   19 15 36 1/- 
   22-1 14 38 1/- 
  3676 17 16-3 36 1/- 
  7264 7-1 1 35-1 1/- 
 cc41-44/Lineage 3 42 22-1 16-8 36-2 1/- 
  206 7 9 35-1 1/- 
   18-3 1 35-1 1/- 
   19 15 35-1 1/- 
  337 18-3 1 35-1 1/- 
  1362 19 15 36 1/- 
  1574 7-2 13-1 35-1 6/- 
  3278 18-1 34 38 -/1 
  6657 5-2 10-57 36-2 3/- 
   19 15 36 1/- 
   19-3 15 36 1/- 
  7266 18 25-11 38-1 -/1 
  7971 19 15 35-1 1/- 
 cc92 7722 5-1 10-4 36-2 1/- 
 cc174 1057 18-1 3 38 1/- 
  3293 18-1 3 38 1/- 
 cc175 7800 5-1 10-4 36-2 1/- 
 cc178 7987 19 15 new -/1 
 cc212 212 7-1 4-1 37-1 -/1 
   19 15 36 1/- 
   19-3 15 36 1/1 
  1229 19-3 15-10 36 -/1 
 cc254 254 21 16 37-1 2/- 
  468 7 16-16 37-1 3/- 
 cc269 283 19-1 15-11 36 -/1 
 cc334 189 5-2 10-3 37-1 2/- 
  334 5-1 2-2 36-2 1/- 
   5-1 10-4 36-2 -/1 
   18-1 3 38 1/- 
   19 15-1 36-2 4/- 
   21 16 37-1 1/- 
  1031 7-4 14-6 35-1 2/- 
  1034 5-3 2 36-2 1/- 
   17 16-4 36 3/- 
  2508 7-4 14-6 35-1 1/- 
  2526 22-1 14 38 1/- 
  3464 7-1 1 35-1 1/- 
 cc364 413 12-1 13-1 35-1 1/1 
  7733 12-16 13 35-1 1/- 
 cc461 461 19-32 13 36 -/1 
  6430 19-33 13-1 36 1/- 
  6910 19-33 13-1 36 1/- 
 Unassigned 344 5-1 10-1 36-2 -/1 
   5-1 10-4 36-2 1/- 
W135 cc11/ET-37 11 5 2 36-2 4/- 
  473 5 2 36-2 1/- 
  1246 5 2 36-2 1/- 
 cc22 22 5-1 2-2 36-2 1/- 
   18 3 38 -/1 
   18-1 3 38 28/4 
  1224 18-1 3 40 1/- 
   18-1 3-1 38 1/- 
  1226 18-1 3 38 1/- 
  2878 18-1 3 38 1/- 
  5948 18-1 30 38 -/1 
  7409 18-1 3 38 2/- 
  7904 18-1 3 38 1/- 
 cc174 185 18-1 3 38 1/- 
 cc198 198 18 25-11 38-1 1/- 
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Group  cc1 ST2 VR13 VR24 VR35 Frequency
6 
(Phenotypic/PCR) 
W135 cc364 462 12-1 13 35-1 1/- 
 Unassigned 1251 18-1 3 38 5/- 
X cc750 24 7 1 35-1 1/- 
  750 21 16 37-1 5/1 
 cc1157 1157 21-7 16 37-1 -/1 
 Unassigned 961 19 15 36 1/- 
  1220 19 15 36 1/- 
  5947 7-1 14-6 36-2 -/1 
  7989 19 15 36 1/- 
Y cc11/ET-37 11 5 2 36-2 2/- 
 cc22 114 18-1 3 38 6/1 
  7409 18-1 3 38 1/- 
 cc23/Cluster A3 23 5-1 2-2 36-2 12/- 
   5-2 10-2 36-1 2/- 
   5-2 10-57 36-2 -/2 
   5-2 10-81 36-2 1/- 
   7-2 13-1 35-1 10/- 
   22 14 36 1/- 
  183 5-18 10-2 36-2 -/1 
  1655 5-1 10-4 36-2 1/1 
  1794 5-1 2-2 36-2 1/- 
  1811 18 3 38 1/- 
  5544 5-2 10-9 36-2 1/- 
  6800 5-2 10-57 36-2 1/- 
  7406 5-1 2-2 36-2 1/- 
  7731 5-1 2-2 36-2 -/2 
 cc41-44/Lineage 3 1097 17-1 23 37 1/- 
  7728 22 9 35-1 1/- 
 cc92 7721 5-29 10-4 36-2 -/1 
 cc167 167 5-1 10-4 36-2 5/- 
   5-11 10-4 36-2 1/- 
   7-2 16 37-1 1/- 
   21 16 37-1 1/- 
  168 5-1 10-4 36-2 ½ 
  766 5-1 10-4 36-2 3/- 
   22 14-6 36-2 -/1 
  2415 5-1 10-4 36-2 1/1 
  6031 5-1 10-4 36-2 1/- 
  7803 5-1 10-4 36-2 1/- 
 cc174 1466 21 16 37-1 2/- 
 cc178 6662 19-15 15 36 1/- 
 cc364 7725 18 25 38-1 1/- 
ctrA Z cc103 103 18-1 1 35-1 -/1 
   18-1 3 38 -/2 
   18-7 9 35-1 -/1 
   21 16 37-1 -/1 
   ND ND ND -/1 
 cc254 1953 19 15 36 -/1 
 Unassigned 1455 7-2 13-1 35-1 -/1 
   19 13 35-1 -/2 
   19-1 13-1 35-1 -/1 
  2154 22 14-6 36-2 -/4 
  4874 5-4 2 36-2 -/1 
  5946 7-2 1 35-1 -/1 
  5953 18-1 30-1 38 -/1 
  7272 7-2 13-1 35-1 -/1 
  7967 18-1 30-3 38 -/1 
  7975 7-1 1 35-1 -/1 
  8647 22-21 9 35-1 -/1 
ctrA 29E cc35 472 21-2 28 37 -/1 
 cc60 60 21 16 37-1 -/9 
  1650 5 2 36-2 -/1 
  1780 21 16 37-1 -/1 
  2104 21 16 37-1 -/1 
  2155 5 2 36-1 -/1 
  6903 19-3 15 36 -/1 
  7724 21 16 37-1 -/1 
 cc178 178 5 2 36-2 -/1 
   18 25-6 38-1 -/1 
   19 15 36 -/6 
  5949 19 15 36 -/1 
  6912 19 15 36 -/1 
  new fumC 19 15 36 -/1 
 cc212 212 19-3 15 36 -/1 
  7618 5-1 10-1 36-2 -/1 
 cc254 254 5-1 2-2 36-2 -/2 
   5-2 10 37-1 -/1 
   5-11 10-8 36-2 -/1 
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Group  cc1 ST2 VR13 VR24 VR35 Frequency
6 
(Phenotypic/PCR) 
ctrA 29E cc254 254 7-4 13-7 35-1 -/1 
(cont.) (cont.) (cont.) 21 16 37-1 -/3 
   21-1 2-2 36-2 -/2 
   21-1 2-5 36-2 -/1 
  1839 5-1 2-2 36-2 -/1 
  2520 7-32 13-1 37-1 -/1 
   21 16 37-1 -/1 
   21 16-96 37-1 -/1 
   22 26 35-1 -/1 
  2701 21 16 37-1 -/1 
  4881 5-1 2-2 36-2 -/1 
  6914 5-1 2-2 36-2 -/1 
  6915 5-1 2-2 36-2 -/1 
  7203 19 15-1 36 -/1 
  7968 5-1 10-8 36-2 -/2 
  new fumC  
& pgm 
21 16 37-1 -/1 
 cc1157 1157 21-1 16 37-1 -/1 
   21-7 16 37-1 -/3 
  7619 21-10 16-5 37-1 -/1 
 Unassigned 4385 5-1 10-1 36-2 -/1 
  6032 7-2 9 35-1 -/1 
ctrA 29E Unassigned 7732 21 16-102 37-1 -/1 
ctrA Z/29E cc60 2002 21 16 37-1 -/1 
cnl cc53 53 7 30 37-1 -/1 
   7 30 38 -/15 
   7 30-1 38 -/2 
   7 30-2 38 -/3 
   7 30-3 38 -/8 
   7-2 30 38 -/1 
  5950 7 30 38 -/1 
 cc198 198 18 25 38-1 -/1 
   18 25-1 38-1 -/2 
   18 25-7 38-1 -/1 
   18 25-25 38-1 -/1 
  823 7-2 13-15 35-1 -/1 
  7782 7-2 13-15 35-1 -/1 
 cc1117 1117 18-1 30-3 35-1 -/1 
 cc1136 8635 18-4 25 38-1 -/1 
ctrA cc23/cluster A3 8002 5-2 10-12 36-2 -/1 
 cc35 7988 22-1 14 38 -/1 
 cc92 7966 7-1 1 35-1 -/1 
 cc167 167 21 16 37-1 -/1 
 Unassigned 3258 18-7 9-14 35-1 -/1 
  7267 18-7 9-5 35-1 -/1 
PCR NEG cc23/cluster A3 23 5-1 2-2 36-2 -/1 
 cc41-44/Lineage 3 577 7-2 4 37 -/1 
 cc103 103 5-2 3 38 -/1 
 cc254 7964 21 16 37-1 -/1 
 Unassigned 4221 19 15 36 -/1 
  8222 5-2 10-23 37-1 -/1 
NG cc53 53 - 30 38 1/- 
 cc269 283 7 13-1 35-1 1/- 
 Unassigned 2539 12-1 23-3 37 1/- 
  4878 - - 38 1/- 
1 cc, clonal complex; 2 ST, Sequence Type; 3 VR1, PorA Variable Region 1; 4 VR2, PorA Variable 
Region 2; 5 VR3, PorA Variable Region 3; 6 Frequency, indicates the number of strains of a 
particular strain type where the “group” was identified phenotypically (to the left of the stroke) or by 
PCR (to the right of the stroke); NG, nongroupable; ND, not determined; PCR NEG, specimens 
failed to give a positive result with any of the serogroup specific, cnl or ctrA PCR tests; 
 
Eleven, four, four, two and two strain types associated with sero- or genogroups 
B, C, Y, W135, 29E, respectively. Two strain types were associated with capsule 
null locus-containing isolates and one strain type was associated with serogroup 
X. The most prevalent strain types, listed in Table 6.3, in rank order were, sixty-
nine specimens of the strain type C:8:8:5,2,36-2 that were isolated during 1985 - 
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1987; thirty-two specimens of the strain type W135/w:22:22:18-1,3,38 (n=28/4) 
that were isolated during 1977 – 2001; twenty-three specimens of the strain type 
B/b:213:213:22,14,36 (n=20/3) that were isolated during 1996 – 2003; fifteen 
specimens of the strain type cnl:53:53:7,30,38 that were isolated during 1984 – 
2003; fourteen specimens of the strain type B/b:41-44:43:19,15-1,36 (n=9/5) 
that were isolated during 1983 - 2002; twelve specimens of the strain type 
Y:23:23:5-1,2-2,36-2 that were isolated during 1979 - 2001; ten specimens of the 
strain type Y:23:23:7-2,13-1,35-1 that were isolated during 1985; nine specimens 
of the strain type ctrA29E:60:60:21,16,37-1 that were isolated during 1984 – 
1988; eight specimens of the strain type B:41-44:577:7-2,4,37 that were isolated 
during 1977 - 1997; eight specimens of the strain type cnl:53:53:7,30-3,38 that 
were isolated during 1984 – 2002; seven specimens of the strain type 
B:32:259:7,16,35 that were isolated during 1987 and seven specimens of the 
strain type Y/y:22:114:18-1,3,38 (n=6/1) that were isolated during 1985 – 1988 
(data not shown). 
A further six specimens of the strain type B/b:35:457:22-1,16-8,36-2 (n=4/2) 
that were isolated during 1985 - 1988; six specimens of the strain type 
B/b:35:457:19,15,36 (n=3/3) that were isolated during 1982 - 1997; six 
specimens of the strain type C:22:289:18-1,3,38 that were isolated during 1985 – 
1988; six specimens of the strain type C:41-44:1574:7-2,13-1,35-1 that were 
isolated during 1985 – 1987; six specimens of the strain type 
X/x:750:750:21,16,37-1 (n=5/1) that were isolated during 1998 – 2001 and six 
specimens of the strain type ctrA29E:178:178:19,15,36 that were isolated during 
1984 – 1987; five specimens of the strain type B:22:289:18-1,3,38 that were 
isolated during 1977 - 1989; five specimens of the strain type B:32:33:19,15,36 
that were isolated during 1982 – 1987; five specimens of the strain type 
B:35:457:22-1,14,38 that were isolated during 1979 - 1987; five specimens of the 
strain type B/b:41-44:41:7-2,4,37 (n=4/1) that were isolated during 1996 - 2001; 
five specimens of the strain type B:UA:1162:neg,neg,neg that were isolated 
during 1984 – 1993; five specimens of the strain type C:11:11:5,2-1,36-2 that 
were isolated during 1986 - 1987; five specimens of the strain type 
W135:UA:1251:18-1,3,38 that were isolated during 1985 – 1986 and five 
specimens of the strain type Y:167:167:5-1,10-4,36-2 that were isolated during 
1985 – 1988 (data not shown).  
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Those STs identified to be associated with multiple sero- or genogroups listed in 
Table 6.2 were examined further by comparing the PorA subtypes to identify 
strains which may have undergone capsule switching. The data indicate that at 
least fourteen capsule switching events may have occurred within the carriage 
strain collection if we are to assume that strains that are of identical ST and 
PorA subtype but of a different sero- or genogroup provides us with evidence of 
a capsule switching event (Table 6.4). 
Table 6.4 – Strain types of the meningococcal carriage strain collection that may have 
undergone capsule switching 
 
cc ST PorA  Group VR1 VR2 VR3  B C W135 Y 29E 
8 8 5 2 36-2  4 70    
11 11 5 2 36-2  1 1 3 1  
  5 2-1 36-2  1 6    
22 22 18-1 3 38  1  32   
 114 18-1 3 38   1  7  
 289 18-1 3 38  4 7    
35 457 22-1 14 38  5 1    
 472 21-2 28 37  3    1 
41-44 206 18-3 1 35-1  1 1    
167 167 5-1 10-4 36-2  1   6  
212 212 19-3 15 36   2   1 
254 254 21 16 37-1   2   3 
334 334 5-1 2-2 36-2  1 1    
 413 12-1 13-1 35-1  1 2    
1162 1162 - - -  5 1    
 
cc, clonal complex; ST, sequence type; VR, variable region; Group, sero- or genogroup; numbers 
in the columns below “Group” indicate the number of carried meningococci of a particular strain 
type that is associated with a particular serogroup. 
 
Within the carriage strain collection nine capsule switching events may have 
occurred involving serogroups B and C; two capsule switching events may have 
occurred involving serogroups C and 29E; one capsule switching event may have 
occurred involving serogroups B and W135; one capsule switching event may 
have occurred involving serogroups B and Y; one capsule switching event may 
have occurred involving serogroups B and 29E and two capsule switching events 
may have occurred involving serogroups C and Y. Interestingly, strains of 
ST11:5,2,36-2 may have undergone more than one capsule switching event as 
three isolates were of serogroup W135 and one strain each of the serogroups B, 
C and Y were observed within the strain collection (Table 6.4). 
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6.5 Prevalence and temporal distribution of the major 
strain types amongst the carriage and IMD strain 
collections in Scotland, 1974 - 2004 
The IMD strain collection was examined for the prevalence of the common strain 
types previously identified in the carriage strain collection (Table 6.5). Eight of 
the common strain types identified in the carriage strain collection were not 
present in the IMD strain collection. These were two related cnl strains that 
differed only in VR2 cnl:53:53:7,30,38 and cnl:53:53:7,30-3,38; as well as the 
strains Y:23:23:5-1,2-2,36-2; ctrA29E:60:60:21,16,37-1; Y:22:114:18-1,3,38; 
B:35:457:22-1,16-8,36-2; ctrA29E:178:178:19,15,36 and B:UA:1162:-:-:-. 
Table 6.5 – Association of prevalent strain types identified in carried meningococci in 
Scotland, 1974 - 2004 & comparison with a carriage phenotype 
 
Strain type  Prevalence (%) OR (95% CI) Group cc ST VR1 VR2 VR3  NIV  IMD  
C 8 8 5 2 36-2  69 (8.64) 147 (5.31) 1.68 (1.25, 2.27) 
W135/w 22 22 18-1 3 38  32 (4.00) 11 (0.40) 10.45 (5.24, 20.83) 
B/b 213 213 22 14 36  23 (2.88) 34 (1.23) 2.38 (1.40, 4.07) 
cnl 53 53 7 30 38  15 (1.87) - - 
B/b 41-44 43 19 15-1 36  14 (1.75) 17 (0.61) 2.88 (1.42, 5.88) 
Y 23 23 5-1 2-2 36-2  12 (1.50) - - 
Y 23 23 7-2 13-1 35-1  10 (1.25) 4 (0.14) 8.75 (2.74, 27.99) 
ctrA29E 60 60 21 16 37-1  9 (1.13) 35 (1.26)1 - 
B 41-44 577 7-2 4 37  8 (1.00) 1 (0.04) 27.97 (3.49, 224.01) 
cnl 53 53 7 30-3 38  8 (1.00) - - 
B 32 259 7 16 35  7 (0.88) 27 (0.98) 0.90 (0.39, 2.07) 
Y/y 22 114 18-1 3 38  7 (0.88) - - 
B/b 35 457 22-1 16-8 36-2  6 (0.75) - - 
B/b 35 457 19 15 36  6 (0.75) 19 (0.69) 1.09 (0.44, 2.75) 
C 22 289 18-1 3 38  6 (0.75) 4 (0.14) 5.23 (1.47, 18.57) 
C 41-44 1574 7-2 13-1 35-1  6 (0.75) 9 (0.33) 2.32 (2.22, 17.75) 
X/x 750 750 21 16 37-1  6 (0.75) 3 (0.11) 6.97 (1.74, 27.94) 
ctrA29E 178 178 19 15 36  6 (0.75) - - 
B 22 289 18-1 3 38  5 (0.63) 5 (0.18) 3.48 (1.00, 12.05) 
B 32 33 19 15 36  5 (0.63) 69 (2.49) 0.25 (0.10, 0.61) 
B 35 457 22-1 14 38  5 (0.63) 2 (0.07) 8.71 (1.69, 44.96) 
B 41-44 41 7-2 4 37  5 (0.63) 220 (7.95) 0.07 (0.03, 0.18) 
B UA 1162 - - -  5 (0.63) 19 (0.69)2 - 
C 11 11 5 2-1 36-2  5 (0.63) 59 (2.13)3 0.29 (0.12, 0.72) 
W135 UA 1251 18-1 3 38  5 (0.63) 4 (0.14) 4.35 (1.17, 16.24) 
Y 167 167 5-1 10-4 36-2  5 (0.63) 2 (0.07) 8.71 (1.69, 44.96) 
 
Group, serogroup or genogroup; cc, clonal complex; ST, sequence type; VR1, PorA variable region 
1; VR2, PorA variable region 2; VR3, PorA variable region 3, IMD, invasive meningococcal disease 
isolates; NIV, non-invasive meningococcal isolates; OR, odds ratio; CI, confidence interval; ORs & 
95% CIs in bold indicate statistical significance; 1 Serogroup B:60:60:21,16,37-1; 2 B:UA:1162:5-
1,2-2,36-2; 3 C:11:11:any subtype = 400 (14.45%) 
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Fourteen strain types were more prevalent amongst the carriage strain 
collection than the IMD strain collection. Three strain types accounted for a 
greater proportion of the IMD strain collection than the carriage strain 
collection; these were B:32:33:19,15,36 (2.49% vs. 0.63%), B:41-44:41:7-2,4,37 
(7.95% vs. 0.63%) and C:11:11:5,2-1,36-2 (2.13% vs. 0.63%). Estimation of the 
carried or invasive potential of strain types by odds ratios (ORs) indicated that 
twelve strain types were significantly associated with a carriage phenotype and 
a three further strain types were significantly associated with invasive disease 
(Table 6.5). 
The carriage strain collection was examined for the prevalence of the common 
strain types previously identified in the IMD strain collection (Table 6.6). Five of 
the common strain types identified in the IMD strain collection were not present 
in the carriage strain collection; these were B:8:8:5-1,2-2,36-2; C:11:11:5-1,10-
4,36-2; B:32:32:7-1,16,35; C:8:8:5-1,2-2,36-2 and C:11:11:5-1,10-8,36-2. 
Table 6.6 – Association of prevalent strain types identified in invasive meningococcal 
disease isolates in Scotland, 1974 - 2004 with an invasive phenotype 
 
Strain type  Prevalence (%) OR (95% CI) Group cc ST VR1 VR2 VR3  IMD  NIV  
B 41-44 41 7-2 4 37  220 (7.95) 5 (0.63) 13.72 (5.63, 33.40) 
C 11 11 5 2 36-2  188 (6.79) 1 (0.04) 58.17 (8.14, 415.80) 
C 8 8 5 2 36-2  147 (5.31) 69 (8.64) 0.59 (0.44, 0.79) 
A 1 1 5-2 10 37-1  117 (4.23) 1 (0.04) 35.23 (4.91, 252.67) 
C 11 11 5-1 10-4 36-2  71 (2.57) - - 
B 32 33 19 15 36  69 (2.49) 5 (0.63) 4.06 (1.63, 10.10) 
C 11 11 5 2-1 36-2  59 (2.13) 5 (0.63) 3.46 (1.38, 8.65) 
B 269 269 19-1 15-11 36  55 (2.00) 1 (0.04) 16.18 (2.24, 117.13) 
B 32 32 7-1 16 35  43 (1.55) - - 
C 41-44 206 any any any  41 (1.48) 3 (0.38) 3.99 (1.23, 12.92) 
B 269 275 22 9 35-1  39 (1.41) 1 (0.04) 11.41 (1.56, 83.17) 
B 32 32 7 16 35  36 (1.30) 4 (0.50) 2.62 (0.93, 7.38) 
C 8 8 5-1 2-2 36-2  35 (1.26) - - 
W135 11 11 5 2 36-2  35 (1.26) 4 (0.50)1 2.55 (0.90, 7.19) 
C 11 11 5-1 10-8 36-2  34 (1.23) - - 
B 213 213 22 14 36  34 (1.23) 23 (2.88) 0.42 (0.25, 0.72) 
B 32 259 7 16 35  27 (0.98) 7 (0.88) 1.11 (0.48, 2.57) 
 
Group, serogroup; cc, clonal complex; ST, sequence type; VR1, PorA variable region 1; VR2, PorA 
variable region 2; VR3, PorA variable region 3, IMD, invasive meningococcal disease isolates; NIV, 
non-invasive meningococcal isolates; OR, odds ratio; CI, confidence interval; 1 including NCTC 
11203; ORs & 95% CIs in bold indicate statistical significance 
 
Fifteen of the prevalent strain types were more common in the IMD strain 
collection compare to the carriage strain collection. The strain types 
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C:8:8:5,2,36-2 and B:213:213:22,14,36 accounted for a greater proportion of the 
carriage strain collection than the IMD strain collection (Table 6.6). Estimation 
of the carriage or invasive potential of strain types by odds ratios (ORs) 
indicated that eight strain types were significantly associated with invasive 
disease and a further two strain types were significantly associated with a 
carriage phenotype (Table 6.6). Temporal changes in the distribution of 
prevalent strain types amongst the IMD strain collection are evident from Figures 
6.8 – 6.12. An apparent lack of prevalent strain types was observed during 1982 – 
1984; however, this is likely a reflection in the reduced number of samples from 
these years in the strain collection, as seen in Figure 3.1.  
 
 
Figure 6.8 - Temporal distribution of prevalent strain types identified in the IMD strain 
collection in Scotland, 1974 - 2004 
Y-axis, number of isolates; x-axis, year of isolation 
 
The temporal distribution of strain types is characterised by a number of peaks 
in prevalence and for some strains this appears to be a cyclic occurrence every 
3-5 years (Figures 6.8 – 6.12). No individual strain type has persisted throughout 
the full 31-year period however antigenic or capsular alterations in the 
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predominant lineages have been observed throughout the 31-year period (Figure 
6.8 – 6.12). Despite the recent decline of cc8, it is clear that major changes in 
this lineage have occurred during the period covered by the strain collections 
(Figure 6.9). Sixty-five percent (356/547) of strains of cc8 were ST-8; 
predominantly of serogroups B (n=145) and C (n=206). Further, subtype 5,2,36-2 
(n=167) and 5-1,2-2,36-2 (n=136) predominated. ST-8:5,2,36-2 isolates were 
predominantly serogroup C rather than B; 147 and 20 respectively. In contrast, 
ST-8:5-1,2-2,36-2 isolates were predominantly of serogroup B rather than C; 101 
and 35 respectively.  
 
 
 
Figure 6.9 - Temporal distribution of the major cc8 strain types identified in the IMD strain 
collection in Scotland, 1974 - 2004 
 
The temporal distribution of these strains indicates that during the first 10-year 
period B:8:8:5-1,2-2,36-2 strains declined while C:8:8:5-1,2-2,36-2 strains 
increased; although not to the same numbers. The strains appear to have been 
replaced, first by C:8:8:5,2,36-2 and then B:8:153:5-2,20,37-1 strains during the 
subsequent decade; however cc8 appears to have declined rapidly during the 
late 1990s and accounted for only a small number of the IMD strain collection 
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thereafter (Figure 6.9). ST-11 isolates were of serogroup W135 during the 1970s 
and early 1980s. Subsequently ST-11 isolates were of serogroup C (Figure 6.10).  
 
 
Figure 6.10 - Temporal distribution of the major cc11 strain types identified in the IMD strain 
collection in Scotland, 1974 - 2004 
 
During the latter 20 year period a number of subtypes were associated with 
serogroup C ST-11 isolates; 5,2-1,36-2 predominate in the mid 1980s to early 
1990s; succeeded by 5,2,36-2 from the late 1980s peaking in 1990 and again 
later that decade; succeeded by 5-1,10-4,36-2 and 5-1,10-8,36-2 in the late 
1990s. However following the introduction of the MCC vaccine in 1999 there was 
a dramatic reduction in C:11:11 strains regardless of subtype (Figure 6.10). 
Serogroup B isolates are genetically more diverse and patterns in the temporal 
distribution of strain types are less apparent.  As noted earlier, cc32 has been in 
decline throughout the 31 year period (Figure 6.11). However, within this cc, the 
B:32:259:7,16,35 strain would appear to have emerged more recently in 
Scotland than the three other major cc32 strains displayed in Figure 6.11. 
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Figure 6.11 - Temporal distribution of the major cc32 strain types identified in the IMD strain 
collection in Scotland, 1974 - 2004 
 
 
 
In contrast, cc269 has been increasing in prevalence due to two major strain 
types; B:269:269:19-1,15-11,36 and B:269:275:22,9,35-1 (Figure 6.12). 
Interestingly, the temporal distribution of strain type B:41-44:41:7-2,4,37 is 
characterised by two peaks; the first, in 1976 was, followed by a period of 
decline over the next 6 years. During the early 1990s the strain appears to have 
re-emerged, with a peak in 1994 which was again followed by a period of decline 
(Figure 6.12).  
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Figure 6.12 - Temporal distribution of the other major strain types identified in the IMD strain 
collection in Scotland, 1974 - 2004 
 
 
Temporal patterns in the carriage strain collection are less apparent. However, 
as highlighted in Figure 6.13, the temporal distribution of the three most 
common strain types illustrates some interesting features. The distribution of 
the strain type C:8:8:5,2,36-2 in the carriage strain collection is punctuated by a 
large peak in prevalence that is short-lived (Figure 6.13) and occurs just prior to 
a peak in prevalence of this strain type amongst the IMD strain collection 
(Figures 6.8 & 6.9). The strain type W135:22:22:18-1,3,38 has been observed 
throughout each decade of the period covered by the carriage strain collection 
(Figure 6.13). However, this strain was not commonly identified amongst the IMD 
strain collection. Contrastingly, the strain type B:213:213:22,14,36 was only 
found in the latter period of the carriage strain collection (Figure 6.13) and 
strains belonging to cc213, as a whole, were not identified prior to 1994 and 
1996 in the IMD and carriage strain collections, respectively. Moreover this cc 
was only recently assigned as a recognised cc during 2004 
(http://pubmlst.org/neisseria). 
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Figure 6.13 - Temporal distribution of the major strain types identified in the carriage strain 
collection in Scotland, 1974 – 2004 
 
 
6.6 Potential coverage of serogroup B meningococci by 
licensed or experimental PorA-based outer 
membrane vesicle vaccines 
The potential coverage by licensed or experimental PorA-based OMV vaccines of 
the strains of the carriage and IMD strain collections was assessed in the previous 
chapter. However, the PorA-based vaccines were developed to target 
predominant serogroup B strains causing disease in different geographic areas, 
therefore only serogroup B or NG siaD B PCR-positive strains from each of the 
strain collections was reassessed for coverage by these vaccines (Table 6.7). An 
increase in coverage by all vaccines was observed when each strain collection 
was limited to serogroup B and NG siaD B PCR-positive strains; coverage was 
highest with the NonaMen vaccine however this still only accounted for just over 
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one third or just under half of sero- or genogroup B isolates for the carriage and 
IMD strain collections, respectively. Regarding serogroup or genogroup B strains 
only; a potential PorA-based OMV vaccine using the six or nine most prevalent 
subtypes would achieve 36.4% and 46.4% coverage, respectively, of the carriage 
strain collection. 
Table 6.7 – Differences in potential coverage of PorA VR1,2 subtypes identified in 
meningococci in Scotland, 1974 – 2004 by experimental or licensed PorA-based OMV 
vaccines: with emphasis on serogroup B meningococci 
 
Vaccine 
(Manufacturer) PorA subtype(s) 
Strain Coverage(%)1 
carriage2 IMD3 
all 
strains 
B  
only 
all 
strains 
B  
only 
Cuban  
VA-MENGOC-BC 
(Finlay Institute) 
P1.19,15 6.9% 10.2% 7.5% 10.4% 
Norwegian  
(NIPH)4 P1.7,16 1.5% 3.6% 2.5% 4.3% 
New Zealand MeNZB  
(NZMH5 & Chiron) P1.7-2,4 2.1% 4.8% 10.1% 17.0% 
Bivalent (Finlay 
Institute & GSK) 
P1.19,15 & 
P1.7-2, 4 9.0% 15.1% 17.6% 27.5% 
HexaMen 
(NVI)6 
P1.5-2,10; P1.12-1,13: P1.7-2,4; 
P1.19,15-1; P1.7,16 & P1.5-1,2-2 12.6% 17.5% 31.9% 41.0% 
NonaMen 
(NVI) 
HexaMen + P1.22,14;  
P1.7-1,1; P1.18-1,3 28.9% 34.0% 38.1% 48.3% 
 
1 Based on the prevalence of the homologous PorA subtype; 2 carriage strain collection; 3 invasive 
meningococcal disease strain collection; 4 NIPH, Norwegian Institute of Public Health; 5 NZMH, 
New Zealand Ministry of Health; 6 NVI, Netherlands Vaccine Institute 
 
 
6.7 Discussion 
The observation that several distinct meningococcal lineages were composed of 
isolates of more than one sero- or genogroup initially suggested the widespread 
occurrence of capsule switching events within these lineages. However, closer 
inspection of the data did not support this possibility as the association of 
serogroup was, in most cases, restricted to individual STs within these clonal 
complexes. Whilst carried meningococci were characterised into 297 STs (see 
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Chapter 4) during this study, only twenty-one (7.07%) STs were associated with 
more than one serogroup. Further analysis of individual strain types provided 
evidence that capsule switching may have occurred within a small number of 
strains of the carriage strain collection. 
Statistically significant associations with IMD or with a carriage phenotype were 
observed for prevalent strain types amongst carried meningococci and IMD 
isolates isolated in Scotland during the period 1974 - 2004. Unexpectedly, the 
strain type C:8:8:5,2,36-2 was significantly associated with a carriage phenotype 
despite its high prevalence and its longevity over a period of 15 years from 1983 
- 1998 in the IMD strain collection; contrastingly this strain type was only present 
in the carriage strain collection over a three-year period, 1984 – 1987. This may 
indicate bias in the carriage strain collection, perhaps as a result of the 
increased swabbing of individuals in the community during a period of increased 
disease in the Lanarkshire area.   
In their updated report, Jolley et al. speculated that the observed high 
prevalence of serogroup C isolates may have been due to the recent circulation 
of the ST-11/ET-37 lineage within the Czech Republic following a period of 
absence  (Jolley, Kalmusova et al. 2002). This explanation may also be 
applicable to the high prevalence of serogroup C isolates amongst the carriage 
strain collection in Scotland. MLST and subtyping data indicates the strain 
C:8:8:5,2,36-2 was responsible for the majority of carried serogroup C isolates. 
Temporal analysis of this strain type indicates this strain rapidly increased in 
prevalence in the period following the first observation of this strain from a case 
of IMD in 1981. Subsequently this strain peaked in prevalence during 1985 
amongst the carriage strain collection and then during 1986 amongst the IMD 
strains collection, before declining over the following 20-year period.  As 
previously noted in Chapter 3, a large proportion of the carriage strain collection 
was received during the period 1984 – 1993; many of which were isolated in the 
Lanarkshire region. During 1984 – 1986 an unexpectedly high number of cases of 
meningococcal disease occurred (Mathew and Chaudhuri 1986; Thomson and 
Jackson 1987). 
It is possible that some of the isolates from this period of the carriage strain 
collection were obtained following further detailed investigations by Lanarkshire 
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health board, and these isolates were subsequently forwarded to the reference 
laboratory. Investigations into the carriage of meningococci among teenagers 
aged 15-18 years in one region of Germany found that carriage rates were 
typical of that age group. However, considerable variation in carriage was 
observed between different schools, towns or counties and between collection 
periods (Glitza, Ehrhard et al. 2008). It may be the case that the perceived 
increase in cases of meningococcal disease in Lanarkshire during 1984 - 1986 was 
a regional phenomenon and was not experienced throughout the country. 
Similarly, in the USA during the 1990s, the state of Oregon experienced an 
unusually high incidence of cases of serogroup B ET-5; particularly in teenagers 
(Diermayer, Hedberg et al. 1999; Tondella, Popovic et al. 2000). 
Changes in the prevalence of different lineages in Scotland appear to have 
occurred over relatively short time periods and this feature may not be fully 
observed by the short time-frame covered in the study by Yazdankhah and 
colleagues. Two thirds of the Norwegian carriage isolates were obtained in 
response to a disease outbreak due to the cc32/ET-5 (Yazdankhah, Kriz et al. 
2004). Carriage of meningococci is known to be influenced by epidemics and is 
often higher in contacts of disease cases (Cardenosa, Dominguez et al. 2001). 
The outbreak lineage was not detected in significantly high numbers in carriage 
by Yazdankhah and colleagues (Yazdankhah, Kriz et al. 2004). However isolates 
obtained from close family contacts of cases of IMD are often identical 
(Cardenosa, Dominguez et al. 2001; Tzanakaki, Urwin et al. 2001). Other 
lineages associated with increased disease potential have been found not to be 
prevalent in high numbers in carriage studies; i.e. serogroup C and/or cc11/ET-
37 (Jolley, Kalmusova et al. 2000; Yazdankhah, Kriz et al. 2004) suggesting the 
prevalence of individual lineages in carriage is not mirrored in the circulating 
disease lineages over equivalent periods in time. However, the updated report 
by Jolley et al. suggests otherwise (Jolley, Kalmusova et al. 2002).  
Different lineages may be distinct in their capacity for and duration of carriage 
and in their pathogenic potential. Glitza and colleagues found over a quarter of 
colonised teenagers were carriers over at least 23 weeks, of which greater than 
20% carried the same strain. Furthermore, carriage was observed in over a third 
of colonised teenagers for at least 15 weeks. Acquisition of a new strain was 
observed in over a third of colonised teenagers (Glitza, Ehrhard et al. 2008). 
Chapter 6  222 
Variations in the duration of carriage of strains and the replacement by a 
different lineage have also been observed amongst military recruits (Jones, 
Christodoulides et al. 1998; Caugant, Tzanakaki et al. 2007). Trotter and 
colleagues concluded that phenotype (i.e. C:2a) and increasing age of the host 
to be associated with death in cases of IMD (Trotter, Fox et al. 2002). It is 
possible the predominant disease-causing lineage in Norway (Yazdankhah, Kriz et 
al. 2004) may have been lost or replaced by other meningococci in these 
individuals. As previously discussed the serogroup C ST-11/ET-37 lineage is not 
often carried. This lineage has been described as having a higher attack-rate 
than the serogroup B ST-41-44/Lineage 3 meningococci; indeed, even within the 
ST-41-44/Lineage 3, which was named as a result of the joining of two individual 
clonal complexes, ST-41 is more often associated with disease, while ST-43 is 
more often associated with a carriage phenotype (see Chapter 4). A naturally 
shortened period of carriage by C:ST-11/ET-37 strains could explain why this 
lineage is not detected, to the same extent as other lineages, during carriage 
studies or in carriage isolate strain collections. In Scotland during the 1990s, 
when C:ST-11/ET-37 strains were increasingly causing IMD, case-fatality rates for 
serogroup C strains in general were higher than for serogroup B strains (Mooney, 
Christie et al. 2004). 
Previous work by the reference laboratory using phenotypic methods indicated 
the prevalence of serotypes and serosubtypes had changed in Scotland during a 
15-20 year period (Clarke 1999b). Amongst serogroup C strains serotype 2b 
strains decreased while 2a:P1.5 strains increased. Serogroup B strains are more 
diverse in their antigenic combinations; however 2b:P1.10 and 15:P1.7,P1.16 
declined during the 1990s while 4:P1.4 increased (Clarke 1999b; Kyaw, Clarke et 
al. 2002). Similar observations were made in England and Wales around the same 
period. There was a decline in C:2b, B:2b and B:15:P1.7,16 strains and increases 
in B:4:P1.4 and B:NT:P1.9 strains during an eleven year period from 1993-1994 
onwards (Gray, Trotter et al. 2006).  
Published and unpublished studies conducted at the SHLMPRL since then have 
identified a number of correlations between the phenotypic serotyping and 
serosubtyping OMP ELISA data and MLST lineages and porA variable region 
sequencing data (Clarke, Diggle et al. 2002; Diggle 2004; Sullivan 2008). 
Serotype 2a was predominantly associated with cc11/ET-37. Further, 2a:P1.5 
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strains were predominantly 5-1,10-4,36-2 or 5-1,10-8,36-2; whereas 2a:P1.2,P1.5 
strains were predominantly 5,2,36-2 by porA VR sequencing. Serotype 2b was 
predominantly associated with cc8/Cluster A4; specifically 2b:P1.10 strains were 
predominantly ST-153. In addition, B:15:P1.7,P1.16 strains were predominantly 
cc32/ET-5; importantly meningococci of this cc have since been recognised as 
the cause of increased periods of disease in England during the 1980s (Bygraves, 
Urwin et al. 1999). B:4:P1.4 strains were predominantly ST-41:7-2,4,37 and 
B:NT:P1.9 strains were predominantly of cc269. PorA variable region sequencing 
of N. meningitidis isolates by the SHLMPRL commenced around 1999. For a short 
time the serotyping and serosubtyping OMP ELISA and PorA variable region 
sequencing was performed concurrently, however during October 2002 the 
decision was taken to cease the use of the OMP ELISA. There are currently no 
plans by the SHLMPRL to undertake DNA sequencing of porB alleles; previous 
evaluations concluded that this would provide little extra information in strain 
discrimination in return for the time and cost invested in such analyses (Dr. M. 
Diggle, personal communication). 
PorA-based OMV vaccines were tailor-made to be effective against predominant 
disease-causing serogroup B strains. Furthermore, vaccination campaigns will 
likely target those most at risk from disease; i.e. children and young 
adolescents. As such, one must also consider the target age group and the 
association of PorA subtype with serogroup when discussing potential coverage 
by vaccines as the assessment of strain coverage may be altered by the inclusion 
of strains of other serogroups or strains isolated from individuals outside the 
target age groups. The coverage data presented herein is based only upon the 
prevalence of the homologous subtypes; coverage would increase if one was to 
account for strains possessing only one identical VR compared with those vaccine 
subtypes. Similarly, if antibodies against particular variants were cross-reactive 
with other variants within PorA families then coverage may be expected to 
increase. However, since strains of meningococci are frequently characterised as 
NST due to reduced expression of PorA or because they do not react with the 
available MAbs, this would require knowledge of the cross-reactivity of 
antibodies directed against individual variable loop epitopes and should also 
consider the level of PorA expression within individual strains.  
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7 Conclusions and future prospects 
Prior knowledge of the circulating meningococcal lineages in Scotland has 
focused on the characterisation of isolates obtained from persons with 
meningococcal disease. Whilst this has provided valuable information, disease 
isolates represent only the tip of the iceberg of the overall population biology of 
the meningococcus. For the meningococcus the progression from commensalism 
to the disease-state merely results in the interruption of transmission between 
hosts. Only recently has there been an acceptance by the wider scientific 
community that more attention should be paid to the study of meningococcal 
isolates not obtained from cases of IMD. This study is the first of its kind in 
Scotland, to my knowledge, to characterise a large collection of carried 
meningococci covering a 31-year period by MLST and porA VR subtyping and to 
subsequently perform a comparison of the generated data with that of an IMD 
strain collection over the same period in Scotland.  
Serological classification methods are phenotypically based and suffer from the 
deficiency that groupings based on them may contain strains that are 
genotypically dissimilar. Furthermore the panel of MAbs utilised by serological 
classification methods is also not comprehensive and strains frequently do not 
react; this was evident during this study since 23.8% of isolates of the carriage 
strain collection were NG (Chapter 3) whilst 63.8% of the carriage strain 
collection were NST (by OMP ELISA that was previously performed by the 
reference laboratory; data not shown). Serogroup-specific and serogroup non-
specific PCR tests were successfully utilised to characterise the majority of 
phenotypically NG carried meningococci. In addition, molecular subtyping of the 
porA VRs 1, 2 and 3 was able to re-characterise the majority of the carriage 
strain collection into distinct porA subtypes. Non-groupable isolates [OR 17.66; 
95% CI (12.71 to 24.54)] and those of sero- or genogroups W135 [OR 2.49; 95% CI 
(1.72 to 3.60)], Y [OR 6.26; 95% CI (4.18 to 9.39)], X [OR 3.13; 95% CI (1.20 to 
8.14)], Z [OR 131.89; 95% CI (18.00 to 960.76)] and 29E [OR 21.30; 95% CI (4.76 
to 95.36)] were significantly associated with a carriage phenotype. In contrast, 
serogroups A [OR 3.64; 95% CI (1.96 to 6.76)], B [OR 2.65; 95% CI (2.25 to 3.12)] 
and C [OR 1.92; 95% CI (1.58 to 2.33)] were significantly associated with invasive 
disease. 
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The prevalence of different serogroups amongst carried meningococci in 
Scotland has changed over time. For example, no isolates of serogroup A were 
isolated during the last 15 years of the period covered by the carriage strain 
collection in this study. This is consistent with the observations of the reference 
laboratory in Scotland that have documented a decline in the prevalence of 
serogroup A meningococci from cases of IMD (Fallon, Brown et al. 1984; Kyaw, 
Christie et al. 2002; Kyaw, Clarke et al. 2002; Clarke, Reid et al. 2002a; Clarke 
2005; Sullivan 2008). Furthermore, this trend has been observed elsewhere in 
the UK and in other industrialised countries where serogroup A meningococci are 
seldom the cause of invasive disease (Jones 1995; Rosenstein, Perkins et al. 
2001; Gray, Trotter et al. 2006; Russell, Urwin et al. 2008). Despite this, 
serogroup A meningococci are still prevalent in other regions of the world, 
causing significant levels of disease in Asia (Zhang, Shao et al. 2008; Yang, Zhang 
et al. 2009), parts of Russia (Koroleva, Beloshitskij et al. 2009) and in Africa 
(Nicolas, Norheim et al. 2005). Recently, a new serogroup A conjugate vaccine 
has been developed for use in Africa (Lee, Kuo et al. 2009) in the hope that it 
can achieve reductions in disease comparable with those previously observed in 
countries using MenC conjugate vaccine (Balmer, Borrow et al. 2002; Maiden and 
Stuart 2002; Mooney, Christie et al. 2004; Larrauri, Cano et al. 2005; de Greeff, 
de Melker et al. 2006; Booy, Jelfs et al. 2007). 
A large number of STs identified during this study were characterised for the 
first time, some of which contained novel allele sequences. The carriage strain 
collection reported herein was also observed to be highly diverse with the 
majority of STs identified only once.  This diversity observed within the carriage 
strain collection [0.981; 95% CI (0.955, 1.006)] was significantly greater than the 
diversity within an IMD strain collection [0.938; 95%CI (0.934, 0.942)] from the 
same period. Although no significant change in diversity throughout the 31-year 
period was observed within the carriage strain collection, this was observed 
within the IMD strain collection; 0.900 (95% CI 0.892, 0.907) for the period 1974-
1983; compared to 0.938 (95% CI 0.929, 0.946) for the period 1984-1993; and 
0.892 (95% CI 0.881, 0.903) for the period 1994-2004. Hence, the level of 
diversity, D, of the IMD strain collection for the periods 1974-1983 and 1994-2004 
can be said to be significantly less compared with that for the period 1984-1993. 
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Temporal changes in the most prevalent clonal complexes were observed 
throughout the 31-year period; increases in cc22, cc41/44 and cc269 and 
decreases in cc1, cc5, cc8, cc11, cc32, cc35, cc37, cc254, cc334 and cc364 were 
observed. Whilst cc213 was formally assigned during 2004 (Ibarz-Pavon, Brehony 
et al. 2004) the data presented herein indicate cc213 emerged in Scotland 
during the early 1990s. This cc is now prevalent in Scotland in meningococci 
isolated from both carriage and in cases of IMD. Furthermore, for several clonal 
complexes a significant association with a carriage phenotype (cc22, cc23, cc35, 
cc92, cc167, cc174, cc212, cc213, cc254, cc461, cc750, cc1157 and 
meningococci unassigned to a clonal complex) or with invasive disease (cc1, cc8, 
cc11, cc32, cc41-44 and cc269) was observed. Despite significant associations at 
the level of cc, distinct differences in those associations were apparent for 
individual STs within a given clonal complex; most notably the significant 
association of ST41 and both ST43 and ST44 with invasive disease and a carriage 
phenotype, respectively. 
Merging sero- or genogrouping data, MLST data and porA subtyping data allowed 
observation of the temporal changes that have occurred within the most 
prevalent carriage strain types and IMD strain types in Scotland over the 31-year 
period 1974 - 2004. Significant associations with invasive disease or with a 
carriage phenotype remained down to the level of strain type for eight and 
twelve of the most prevalent strain types, respectively. In addition several other 
strain types prevalent in one strain collection were absent from the other and 
could not be compared using the same method. The strain types B:213:22,14,36 
[OR 2.38 (95%CI 1.40, 4.07)] and B:43:19,15-1,36 [OR 2.88 (1.42, 5.88)] were 
significantly associated with a carriage phenotype.  
A feature of the carriage strain collection was the concentration of cc8 isolates 
during the period 1984 – 1986 and the high proportion of isolates obtained from 
individuals identified as resident in Lanarkshire at a time when an episode of 
increased disease was experienced within that region (Mathew and Chaudhuri 
1986; Thomson and Jackson 1987). This was first noted in Lanarkshire in 1984 
(Thomson and Jackson 1987) and was also noted in both east and west Scotland. 
However, unlike in England and Wales there were no reported local outbreaks of 
disease. Furthermore, serogroup C notifications/isolations increased during this 
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time period and subsequently predominated for the first time in Scotland since 
laboratory surveillance of infections commenced. 
In this study, cc8 was found to be significantly associated with invasive disease, 
in agreement with the findings of others (Ure, Gray et al. 2004). Furthermore, 
whilst ST8 was also significantly associated with invasive disease, the most 
common strain type within cc8, C:8:8:5,2,36-2, [OR 1.68; 95% CI (1.25, 2.27)] 
was however, significantly associated with a carriage phenotype. Moreover, 
other prevalent cc8 strain types, C:8:8:5-1,2-2,36-2 and B:8:8:5-1:2-2:36-2, 
were absent from the carriage strain collection and could not be tested by the 
same method. Carriage of the meningococcus is reportedly higher among 
subjects during disease outbreaks or epidemics and this may explain the 
overrepresentation of this cc amongst the carriage strain collection. However, 
other lineages possessing the serogroup C capsular polysaccharide have been 
described as being carried for only a short duration. The emergence of an ET-15 
C2a strain in Canada during the late 1980s reportedly had a short carriage period 
prior to infection given that these ET-15 isolates could not be found in group C 
meningococcal carriers during the outbreak in Victoria County in 1989 (Ashton, 
Ryan et al. 1991). Similarly during an outbreak of serogroup C disease in British 
Columbia, a carriage study of the local population revealed carriage of 
serogroup C was only 4% (Patrick, Champagne et al. 2003). 
Cc269 was also reported to have emerged in Canada (Law, Lorange et al. 2006). 
MLST revealed its presence in a variety of EU countries in during 2000 – 2002 
(Brehony, Jolley et al. 2007). This lineage has been identified in IMD and in the 
carriage strain collection in Scotland over 30 years ago suggesting that the 
emergence of this lineage is not a recent event. Nevertheless, the prevalence of 
this cc amongst IMD strains has increased in recent years and along with cc41-44 
constitutes the majority of IMD cases in Scotland (Ure 2008). Interestingly, as 
observed during this study, cc269 is highly diverse with respect to PorA subtype. 
Similarly, in England and Wales, Russell and colleagues identified that this 
lineage had been prevalent at least as early as 1975 (Russell, Urwin et al. 2008). 
More recently, one third of serogroup B meningococci isolated in England and 
Wales are of cc269 (Lucidarme, Comanducci et al. 2009). 
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During the 1990s, serogroup C meningococci of the ST-11/ET-37 complex were 
an increasing problem in Europe, particularly in the UK (Clarke, Reid et al. 
2002a). The emergence and transmission of serogroup W135 meningococci also 
of this cc was associated with the Hajj pilgrimage in 2000 (Taha, Achtman et al. 
2000; Aguilera, Perrocheau et al. 2002). Although carriage of this lineage is low, 
analysis of the SHLMPRL meningococcal isolate collection during this study has 
revealed the presence of this lineage in Scotland since at least as early as 1974; 
initially associated with IMD due to serogroup W135 until the early 1980s 
followed by serogroup B or predominantly C from the early 1980s. Russell and 
colleagues also identified this lineage in isolates from England and Wales as far 
back as 1975, predominantly of serogroup W135, and then increasingly of 
serogroup C (Russell, Urwin et al. 2008). Furthermore, the temporal analysis of 
ST11 meningococci isolated from cases of IMD in Scotland also indicates several 
changes have occurred in the subtypes associated with this lineage (Chapter 6); 
ST11 strains were initially W135:5,2,36-2 during the 1970s to early 1980s, 
subsequently the C:5,2-1,36-2 strain was prevalent during the period 1984 – 
1993. This strain was then succeeded by the C:5,2,36-2 strain that began 
increasing from around 1987 and subsequently dominated during the 1990s. More 
recently, two more ST11 strain types emerged; C:5-1,10-4,36-2 and C:5-1,10-
8,36-1 which both peaked in around 1999 – 2000. Interestingly these latter three 
C:11 strains were all circulating in Scotland at the same time.  
The exchange of DNA coding for the sialyltransferase by meningococci enables 
clones to express different capsular polysaccharide (Swartley, Marfin et al. 
1997). Fortunately, capsule switching has not been reported as yet in the UK 
(Maiden and Stuart 2002; Mooney, Christie et al. 2004; Diggle and Clarke 2005). 
However, reports from continental Europe and North America suggests that 
capsule switching in clinical isolates of N. meningitidis may be a common 
occurrence (Stefanelli, Fazio et al. 2003; Tsang, Law et al. 2005; Lancellotti, 
Guiyoule et al. 2006; Harrison 2008; Beddek, Li et al. 2009; Castilla, Vazquez et 
al. 2009; Simoes, Cunha et al. 2009; Harrison, Shutt et al. 2010). Evidence for 
capsule switching in an isolate was defined by Harrison and colleagues “as the 
presence of an unusual ST-serogroup combination; specifically a genetic 
sequence type (ST)/clonal complex in an isolate of a serogroup more generally 
associated with another serogroup”. The authors presented data indicating 35 B-
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to-C, seven C-to-B, two W135-to-Y and one W135-to-B capsule switching events 
(Harrison 2008; Harrison, Shutt et al. 2010). However, it is not clear what 
observations directed Harrison and colleagues, or others, when deciding 
“normal” serogroup-ST associations. Are they using local surveillance data (i.e. 
ABCs data, in the case of Harrison et al.) only or are they using global data? Are 
they using the MLST website?  
The assumption that an uncommon ST:serogroup association must be the result 
of some recent recombination event is perhaps misleading, particularly in 
countries using capsular-based vaccines. In countries using MCC vaccines, for 
example, one would reasonably expect to observe a reduction in disease cases 
due to serogroup C strains.  In turn, this may allow for the emergence of other 
less virulent strains which would have previously been out-competed by more 
virulent serogroup C strains. Furthermore, geographic and temporal variations in 
the prevalence of meningococcal serogroups are well documented. 
Consequently, a rare ST-serogroup association in one geographic location may 
not necessarily be rare in another location. Thus, a rare ST:serogroup association 
could indicate the emergence of an existing strain into a geographic niche where 
the strain had previously been at undetectable levels or absent. 
The association of sero- and genogrouping data with cc in this study initially 
indicated the potential existence of multiple cases of capsule switching within 
the carriage strain collection. However, closer inspection of the association of 
sero- or genogroup with individual STs revealed that the majority of STs were of 
a single serogroup. There were a small number of exceptions; for twenty-one STs 
at least two different serogroups were observed. Moreover, once subtyping data 
were included into the analysis this reduced the potential number of capsule 
switching events amongst the carriage strain collection. From the data, it is not 
possible to predict the direction (i.e. C-to-B or B-to-C) of these potential capsule 
switching events and in some instances the data suggest that the strain types 
were not mutually exclusive. It may be beneficial to re-test the isolates 
implicated in possible capsule switching by agglutination and serogroup-specific 
PCR to confirm these results, given that some isolates initially recorded as 
serogroup Z were later found to be genogroup 29E by PCR. Only nongroupable 
isolates from the carriage strain collection were systematically tested using the 
serogroup-specific PCR tests to characterise these strains by genogroup. 
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Simultaneous carriage of more than one strain of N. meningitidis has been 
documented (Caugant, Tzanakaki et al. 2007); however the extent to which this 
occurs is not fully apparent. On the basis that meningococcal strains of identical 
genetic lineages may possess different capsular polysaccharides (Swartley, 
Marfin et al. 1997) or antigenic profiles presumably, carriage of more than one 
strain must occur to allow horizontal genetic exchange of the capsule locus. 
Nasopharyngeal carriage of more than one strain of pneumococci, in some cases 
three, has been observed on the basis of serotyping (Kaltoft, Skov Sorensen et 
al. 2008; Brugger, Hathaway et al. 2009; Brugger, Frey et al. 2010) although it is 
not clear whether these strains were of the same genetic type. 
Uncertainty remains regarding the optimal sampling method to identify 
meningococcal carriage. Different carriage studies often use different methods 
and, as such, are difficult to compare. The choice of sampling site, transport 
medium or direct plating of swabs, single or multiple swabs and length of time 
between swabbing and plating can influence the level of carriage. A recent 
review by Roberts and colleagues (Roberts, Greenwood et al. 2009) of the 
published literature concluded that meningococcal carriage would be best 
assessed by swabbing the posterior pharyngeal wall through the mouth with 
direct plating or keeping transport time to below five hours. Additionally the use 
of charcoal swabs and selective antibiotics to inhibit the growth of non-
meningococcal bacteria has also been recommended to improve the yield of 
meningococci in the sample (Caugant, Hoiby et al. 1992; Roberts, Greenwood et 
al. 2009). 
Characterisation of the meningococcal capsule-synthesis cluster in carried 
meningococci isolated from healthy subjects in Bavaria, Germany has shown that 
a significant proportion of isolates harbour a non-coding intergenic region of 
either 113 or 114bp in length, termed the capsule null locus (cnl) (Claus, Maiden 
et al. 2002). Four lineages containing the cnl were identified amongst the 
carriage strain collection during this study. Interestingly, two of these lineages 
contained a novel cnl allele distinct from that sequenced in Bavarian carriage 
isolates of the same lineages. Recent reports of cnl-possessing meningococci 
causing disease in immunocompromised and, more remarkably, 
immunocompetent individuals (Vogel, Claus et al. 2004b; Hoang, Thomas et al. 
2005; Findlow, Vogel et al. 2007) has challenged our understanding of the 
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necessity for the meningococcus to be encapsulated in order to survive in the 
bloodstream and evade the host immune system (Klein, Ison et al. 1996; van 
Deuren, Brandtzaeg et al. 2000; Spinosa, Progida et al. 2007). 
PorA is a candidate for inclusion in meningococcal vaccines (Devoy, Dyet et al. 
2005; Oster, Lennon et al. 2005; Martin, Ruijne et al. 2006); therefore it is 
important to monitor the variation within this protein in the meningococcal 
population both during and following the introduction of strain-specific vaccines. 
A small number of laboratories, including the SHLMPRL, characterise the VR3 
(Loop V) of porA (Molling, Unemo et al. 2000; Molling, Backman et al. 2001; 
Clarke, Diggle et al. 2003b; de Filippis, de Andrade et al. 2007). Although 
variation is less diverse, sequencing has shown that carriage strains possessing 
identical VR1 and VR2 may have a different VR3. Recently, recommendations for 
the typing of N. meningitidis isolates were proposed. The strain designation for 
meningococci, recommended by the European Meningococcal Disease Society 
(EMGM), is to include the serogroup, PorA VRs, FetA VR, MLST sequence type and 
clonal complex. An example is C: P1.5,2-1: F5-4: ST-11 (cc11) (Jolley, Brehony 
et al. 2007). 
Due to the heterogeneity of PorA subtypes in meningococci in Scotland the 
potential coverage by experimental or licensed PorA-based OMV vaccines would 
be limited. Therefore the introduction of monovalent or multivalent PorA-based 
vaccines in Scotland may be of little benefit. Improved strain coverage as a 
whole, not just against those of serogroup B, may require the addition of other 
vaccine antigens.  
Meningococcal vaccines targeting particular polysaccharide capsules have been 
available in Scotland for a number of years (Danzig 2004). Knowledge of vaccine 
uptake and vaccine efficiency would aid in the interpretation of any effect of 
vaccination on the distribution of particular meningococcal serogroups. The 
deficiencies of polysaccharide vaccines are well documented so it may be 
difficult to speculate that these vaccines could have contributed significantly to 
changes in meningococcal population structure, particularly since these plain 
polysaccharide vaccines were made available or were recommended for distinct 
subsets of the population i.e. immunosuppressed individuals, contacts of IMD 
cases or to travellers (DoH 2006b). 
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Vaccination remains the best form of disease prevention, however currently 
licensed vaccines do not offer broad protection against all serogroups, or are not 
immunogenic in those individuals most at risk of IMD (i.e. infants <2 years). The 
serogroup B capsule is poorly immunogenic and is known to be structurally 
homologous with human cell lines (NCAM, neural cell adhesion molecule) (Finne, 
Leinonen et al. 1983; Finne, Bitter-Suermann et al. 1987). Consequently, 
alternative means must be sought when developing vaccines to target serogroup 
B meningococcal disease. The genomes of a small number of strains of N. 
meningitidis have been fully sequenced; the serogroup B strain MC58, the 
serogroup A strain Z2491, the serogroup C strain FAM18 and the serogroup C 
strain 053442 (Parkhill, Achtman et al. 2000; Tettelin, Saunders et al. 2000; 
Bentley, Vernikos et al. 2007; Peng, Yang et al. 2008). Genome-sequencing 
projects have facilitated the discovery of new vaccine antigen targets (Pizza, 
Scarlato et al. 2000). 
A number of candidate antigens are currently being investigated, including 
factor H-binding protein (fHbp). Extensive prevalence and sequence analyses of 
fHbp from a variety of serogroup B N. meningitidis lineages indicates that all 
isolates have a fHbp gene and that variants so far identified can be classified 
into two or three distinct groups; subfamilies A and B (Fletcher, Bernfield et al. 
2004; Murphy, Andrew et al. 2009) or groups 1, 2 and 3 (Masignani, Comanducci 
et al. 2003; Brehony, Wilson et al. 2009) respectively, in all countries surveyed.  
Pfizer and Novartis are currently investigating a bivalent fHbp vaccine (based on 
one family A and one family B variant) in clinical trials and the 5 Component 
Vaccine against Meningococcus B (5CVMB) respectively, in clinical trials. The 
5CVMB is composed of the New Zealand OMV (Oster, Lennon et al. 2005) plus 
five other antigens; Factor H-binding protein (fHbp; GNA 1870: LP2086) variant 
1; Neisserial adhesion A (NadA; GNA 1994), GNA 2091, GNA 2132 (Neisseria 
Heparin-binding antigen; NHBA) and GNA 1030 (Rappuoli 2008; Snape 2008).  
Accurate and timely surveillance is essential in order to assess the impact that 
future vaccination campaigns will have on the circulating meningococcal 
lineages. I would recommend that, dependent upon the progress of the 
investigational vaccines, the SHLMPRL considers the introduction of prospective 
and retrospective molecular surveillance of the candidate vaccine antigens in 
meningococcal carriage and disease isolates from Scotland. Enhanced 
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surveillance of meningococcal disease in Scotland, through the Meningococcal 
Infectious Disease Augmented Surveillance (MIDAS) scheme, was implemented in 
November 1999 (Clarke 1999a) to coincide with the MenC immunisation 
campaign, whilst during the same year the Enhanced Surveillance of 
Meningococcal Disease (ESMD) was established in England, Wales and Northern 
Ireland (Shigematsu, Davison et al. 2002) to obtain accurate incidence data and 
monitor the impact of the MenC vaccine during and following its introduction in 
the UK from November 1999. Worldwide, many countries undertake active 
meningococcal surveillance programmes, however they are biased in favour of 
disease isolates. Furthermore, individual surveillance programmes may vary from 
country to country. Robust and accurate surveillance systems will facilitate the 
observation of circulating meningococcal lineages and also enable the 
identification of new clonal complexes, such as cc213 (Ibarz-Pavon, Brehony et 
al. 2004). Despite the ease of access to the MLST website and the data it holds, 
the scientific community is not duty-bound to deposit all their surveillance data 
on this publicly-accessible database.  Moreover, data on the MLST website may 
be further biased towards novel sequence types. Strain data is an absolute 
requirement of the submission procedure for new allele sequences prior to 
assignment of a new ST by the database curator.  However, the scientific 
community is not duty-bound to submit strain data for those strains of previously 
characterised STs and as such the data on the neisseria MLST database cannot 
replace the surveillance systems already in place in many countries.  
A downward trend in cases of IMD is occurring across much of Europe and North 
America, irrespective of serogroup and with or without the introduction of 
conjugate vaccination campaigns. Undoubtedly conjugate vaccination campaigns 
have reduced the burden of disease due to the serogroup(s) targeted in the 
countries where the vaccines have been implemented. For instance, around 80% 
or more of disease cases in Scotland are now due to serogroup B following over a 
decade of using the MCC vaccine. Since 2003 few cases of serogroup C IMD have 
been reported; the recent surveillance data in Scotland puts the rate for all 
disease at 2.69 cases per 100,000 population and for the last two calendar years, 
2008-2009, no case of serogroup C disease has been reported to HPS (McDonald 
2010a; 2010b). In other countries where the actual numbers of disease cases due 
to serogroup C are low, there are no plans to introduce the MenC vaccine. 
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Cases of meningococcal disease are increasingly being confirmed by non-culture 
methods. This is due in part to improvements in disease recognition and 
subsequent early intervention with antibiotic therapy. Consequently fewer 
meningococcal isolates are being cultured and ultimately submitted to the 
SHLMPRL by regional bacteriology laboratories. The SHLMPRL currently uses ctrA 
as a target for the identification of meningococcal DNA in clinical samples from 
individuals suspected of having meningococcal disease. However, as previously 
mentioned, this gene is absent from meningococci possessing the cnl. Although 
reports of cnl-containing meningococci causing invasive disease are limited, if 
these strains were to become a more prominent cause of IMD then the ctrA PCR 
would not detect the strains in clinical samples. Indeed, these strains have only 
recently been recognised and they may be more prevalent in IMD cases than 
previously thought; especially in immunocompromised individuals or in 
individuals suffering from less severe symptoms.  Research conducted by the 
CDC has identified a species-specific PCR target (sodC) that accurately identifies 
meningococcal DNA, irrespective of capsular status, in clinical specimens (Dolan 
2008; Dolan, Hatcher et al. 2009) and in a carriage study (J. Dolan, personal 
communication).  This assay could be readily introduced into the repertoire of 
molecular tests utilised by the SHLMPRL.  
Whilst one must concede there are imperfections with the carriage strain 
collection characterised during this study, in the absence of a structured 
sampling programme to fully (and regularly) investigate meningococcal carriage 
irrespective of age, sex, geographic location, socio-economic status etc, the 
analysis of a carriage strain collection assembled from the isolate archive of the 
SHLMPRL constitutes a step in the right direction. Existing culture collections are 
often not representative of biological populations as they are composed of 
mostly virulent isolates. This is a circumstance which is reflected in Scotland by 
the disparity between the characterisation of disease versus carriage isolates by 
the SHLMPRL. Furthermore, this disparity is also apparent in the global data 
deposited on the Neisseria MLST website.  
More recently, efforts have been made to redress the balance. However, 
carriage studies are technically demanding, expensive and time consuming and 
agreement has yet be reached on the methods of best practice; although 
recommendations have been proposed (Roberts, Greenwood et al. 2009). 
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Moreover, carriage studies are difficult to compare as they often assess different 
human populations of restricted age, ethnic origin or socio-economic status and 
are often performed following different methods. To my knowledge, a carriage 
study has not been performed since that which coincided with the 
implementation of the MenC polysaccharide-conjugate vaccine in the UK in 1999 
(Balmer, Borrow et al. 2002; Maiden and Stuart 2002). However, the MenC-
associated carriage study in 1999 only focused on the carriage of N. meningitidis 
in teenagers aged 15 - 17 years at the start of the first year of the study 
(Balmer, Borrow et al. 2002; Maiden and Stuart 2002). A carriage study in the UK 
involving Novartis is due to commence at the start of the academic year in 2010 
(personal communication, Dr Mathew Diggle) however, the details regarding this 
were not known to the author at the time of writing.    
The SHLMPRL is a fully accredited via the Clinical Pathology Accreditation (UK) 
Ltd. (CPA) scheme and the high standards by which the SHLMPRL currently 
operate may not have been in place during the reference laboratory’s infancy. 
The meningococcal reference laboratory was born out of the special interest, 
exceptional dedication and labours of a few key individuals (chiefly Dr. R. Fallon 
and subsequently Dr. L. Smart) at a time when funding for such a laboratory, if 
at all in place, was very limited (Dr M. Diggle, personal communication). 
Moreover, without their endeavours the reference laboratory would likely never 
have existed.  
Nevertheless, a number of matters regarding the SHLMPRL strain archive and 
database require attention. For the isolates obtained during the earlier years of 
the period covered by this study the availability of samples was an issue. An 
entry recorded on the meningococcal isolate database did not guarantee that a 
corresponding isolate was present amongst the laboratory isolate archive. 
Several hundred isolates listed in the meningococcal isolate database were 
absent from the laboratory isolate archive; presumably they were either never 
archived at the time the samples were processed or they have since been 
expended or discarded. Furthermore, during isolate recovery it was noted that 
isolates missing from the strain collection were frequently those recorded as NG. 
Were these isolates considered of lesser importance and not archived or were 
they discarded during a previous re-location of the reference laboratory?  It is 
my opinion that the N. meningitidis isolate database is in need of improvement 
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and I would recommend that the database be updated in order to match the 
archived freeze-dried/lyophilised samples with their corresponding database 
record such that the precise location and condition of each specimen are 
recorded. 
Related to this issue was that of the number of specimens that were not viable 
following attempts to sub-culture; particularly those isolates stored as freeze-
dried/lyophilised specimens (those dating from 1974 – 1995). One of the 
functions of the reference laboratory is to maintain the meningococcal isolate 
archive. During the course of this study the quality and quantity of the currently 
archived lyophilised/freeze-dried specimens varied enormously and specimens 
were often not viable following resuscitation and sub-culturing. Therefore, 
based on the difficulties encountered with the resuscitation and recovery of N. 
meningitidis isolates, I would also recommend to the SHLMPRL to plan and 
implement the resuscitation and recovery of stored lyophilised/freeze-dried 
specimens (perhaps also older isolates stored on 5% glycerol or on ProtectTM 
beads) and prepare fresh stocks to re-archive.   Moreover, future research by the 
reference laboratory or its collaborators may benefit in using this extensive 
isolate archive and it would be regrettable if this valuable resource was put in 
jeopardy. 
Long-term storage of N. meningitidis is best achieved by either lyophilisation or 
freezing.  Lyophilised bacteria can be stored for long periods at 4ºC or at -20ºC 
(Popovic, Ajello et al. 1999). Contrastingly, however, freeze-dried (lyophilised) 
specimens have been securely stored at ambient temperature at the SHLMPRL 
for at least the previous nine years, if not longer. Consequently, this may have 
been detrimental to the viability of stored N. meningitidis cultures.  Although a 
number of factors may all influence viability; from growth media, growth phase 
and cell concentration, the use of protective agents, the drying methodology, 
re-hydration of the specimen, as well as specimen storage and packaging 
(Morgan, Herman et al. 2006). Maintenance of the isolate archive and accurate 
documentation describing it is of particular importance given the proposed re-
location of the Stobhill Microbiology Reference laboratories (including the 
SHLMPRL) to another site in Glasgow (Glasgow Royal Infirmary) in the next 2-3 
years. At the time of writing no definite decision regarding re-location had been 
approved, nevertheless moving all the laboratory resources, not just the isolate 
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archive, and tracking its constituent parts would be aided by a more detailed 
laboratory inventory. 
The exemplary surveillance system (MIDAS) in place in Scotland in the modern 
era does not extend to the earlier years of the period covered by this study. For 
some samples a comprehensive epidemiological record was not available; age-
group data was not recorded for around 40% and 15% of the carriage and IMD 
strain collections, respectively. Although attempts were made to contact Health 
Protection Scotland and NHS health boards to seek their assistance, 
ascertainment of missing information could not be achieved. 
This study cannot be directly compared with those more traditional carriage 
studies because the methodology employed is slightly different. Carriage of the 
meningococcus is known to vary in relation to the age-group of the population 
sampled (Cartwright, Stuart et al. 1987; Caugant, Kristiansen et al. 1988; 
Caugant, Hoiby et al. 1994; Pavlopoulou, Daikos et al. 2004; Bogaert, Hermans 
et al. 2005; Claus, Maiden et al. 2005) and the isolates are frequently non-
serogroupable (Cartwright, Stuart et al. 1987; Caugant, Kristiansen et al. 1988; 
Caugant, Hoiby et al. 1994; Jolley, Kalmusova et al. 2000). The carriage strain 
collection in this study also displays these typical features. The isolates of the 
reference laboratory strain archive were assembled over the course of the past 
four or five decades. Isolates in this study were selected from the strain archive 
on the basis of the criteria set out in chapter two, and as such, isolates were not 
actively obtained by swabbing from a defined community during a defined time 
period. Therefore the determination of carriage rates, both regional and 
national, in Scotland of different serogroups, STs or ccs is not possible.   
In this study, the criteria used to define a carried meningococcal isolate was set 
in order to exclude any bias that may occur due to the influence of any disease 
outbreaks.  Furthermore, although this study has compared carriage strains with 
IMD strains the distinction between the two is, in situ, surely less clear-cut.  
Following acquisition of the meningococcus by a host the next step in the 
sequence of events leading to disease is adhesion (i.e. carriage) of the 
meningococcus to host cells; therefore all isolates causing disease would initially 
have been carried by the host.  
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Around a decade has passed since the UK meningococcal carriage study was 
undertaken and, while much has been gained from this study, the time may be 
right to implement a new carriage study given that changes in the 
meningococcal population can be observed to occur over a relatively short time 
frame. Carriage rates vary considerably according to the age-group studied 
(Cartwright, Stuart et al. 1987; Yazdankhah and Caugant 2004), however if we 
assume an average rate of carriage in Scotland equivalent to that reported 
during the Stonehouse survey of 10.9% (Cartwright, Stuart et al. 1987) then this 
would be equivalent to swabbing in excess of 7,250 individuals to obtain a strain 
collection of the same size as the carriage strain collection reported herein. 
Furthermore, to obtain a carriage strain collection of comparable size to the IMD 
strain collection would require swabbing nearly 25,400 individuals.  
It is presumed that most cases of meningococcal disease occur due to the 
acquisition of the bacterium from a healthy carrier since contact with an 
individual with IMD will be rare; certainly in more industrialised countries where 
disease tends to be more sporadic and outbreaks occur infrequently. In the 
meningitis belt in sub-Saharan Africa, where disease incidence rates are typically 
higher and outbreaks are often large, the importance of transmission via an 
individual with IMD may be more significant.  Furthermore, disease incidence in 
temperate countries peaks during the winter or early spring, whereas in sub-
Saharan Africa disease incidence is usually highest during the dry season. This 
raises the question how does seasonality influence transmission? Are there 
variations in the transmission or duration of carriage of different meningococcal 
lineages? 
Following exposure to the bacterium, adhesion to host cells is the critical first 
stage in the sequence of events necessary for colonisation and the possible 
subsequent dissemination throughout the body. Damage to the ciliated epithelial 
layer is known to be a contributing risk factor towards meningococcal infection. 
This may be due to preceding viral infection or active or passive smoking 
(Cartwright 1995b; Fischer, Hedberg et al. 1997; Yusuf, Rochat et al. 1999; Kriz, 
Bobak et al. 2000). Since 2006 the Smoking, Health and Social Care (Scotland) 
Bill has been in force making it illegal to smoke in enclosed public spaces. One 
wonders how this legislation will impact on the transmission and carriage of N. 
meningitidis and the incidence of meningococcal disease in Scotland. Whilst 
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exposure to cigarette smoke in enclosed public spaces should be reduced how 
would exposure in a household setting change and, in turn, would this impact on 
transmission amongst household members? 
As observed in the SHLMPRL isolate database, meningococci can be obtained 
from various sites on the human host, not just from a variety of sites within the 
upper respiratory tract, but also from other mucosal surfaces such as those 
found in the ano-genital tract and from the conjunctiva. It would be of interest 
to characterise the non-respiratory tract isolates as it would add to our 
understanding on the circulating meningococcal lineages. Acapsulate, capsule 
null locus-containing strains of meningococci have been identified in individuals 
with infections of the conjunctiva (SHLMPRL; unpublished data).  Moreover, 
distinct acapsulate pneumococcal lineages have also been found to cause 
infections of the conjunctiva (Hanage, Kaijalainen et al. 2006). The study by 
Young and colleagues described 1156 strains of meningococci isolated from 
carriers forwarded to the reference laboratory during 1972 - 1982; many from a 
study of meningococcal carriage in patients attending a department for sexually 
transmitted diseases. Most strains were isolated from the respiratory tract, and 
many were isolated from genital sources (Young, Harris et al. 1983).   
The study by Young et al. concluded that among patients attending a clinic for 
sexually transmitted diseases, women without gonorrhoea were significantly less 
likely to be colonised with meningococci than were women with gonorrhoea and 
men with or without gonorrhoea. Women without gonorrhoea were also 
significantly less likely to be colonised with groupable meningococci but there 
were no significant differences in carriage rates of non-groupable meningococci. 
The authors discussed the effect of behavioural differences and therefore 
relative-risk on the different groups based on their results. Many of the women 
from which throat swabs were taken were asymptomatic contacts (of men with 
gonorrhoea) while the vast majority of males from whom throat swabs were 
taken attended the clinic with symptomatic urethritis. It was suggested that a 
higher incidence of meningococcal colonisation of the pharynx appears to be 
associated with the greater rate of recent mouth-to-mouth contact in the more 
sexually active and hence ‘high-risk’ patients rather than directly correlated 
with gonococcal infection. Furthermore, the authors suggested that these results 
may be explained if predominantly different transmission routes for groupable 
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and non-groupable isolates were to exist. If non-groupable isolates were 
primarily spread via droplet spray then most individuals would be exposed to a 
similar extent. In contrast, if groupable meningococci were primarily spread 
from direct salivary spread then they would be expected to be of higher 
incidence in their ‘high risk’ patients by virtue of their greater degree of mouth-
to-mouth contact.  
The progression of a strain from commensalism to disease is intimately linked to 
the host-pathogen interactions and it is becoming increasingly apparent that to 
fully understand why the meningococcus causes disease in one individual but not 
in another we must learn more about the influence of host genetics on immunity 
to bacterial pathogens. A number of genetic polymorphisms have been described 
which are associated with increased risk of meningococcal disease. For example, 
diversity in CEACAM genes (Callaghan, Rockett et al. 2008); Caucasian paediatric 
meningococcal disease patients carrying the functional Plasminogen-activator-
inhibitor (PAI)-1 gene 4G/4G genotype are at an increased risk of developing 
vascular complications and dying from meningococcal disease (Haralambous, 
Hibberd et al. 2003); a polymorphism in the Factor H (fH) gene have been 
described in UK Caucasians that can result in reduced bactericidal activity 
against meningococci and an increased risk of contracting meningococcal disease 
(Haralambous, Dolly et al. 2006). Genetic polymorphism of the binding domain 
of surfactant protein-A2 has been described that increases the risk of 
meningococcal disease and risk of death (Jack, Cole et al. 2006). Interleukin-1 
(IL-1) genotype also can influence the severity of meningococcal disease (Read, 
Camp et al. 2000). Other risk factors include those previously mentioned which 
are associated with increased risk of carriage; i.e. contact with an IMD case, 
overcrowding, ethnicity (e.g. Maori or Pacific Islanders), preceding viral 
infection, or age-group. Interestingly, bacterial load has been linked to disease 
severity (Darton, Guiver et al. 2009); possibly an indication of over-stimulation 
of immune system.  Retrospective analyses of IMD patients and matched controls 
may reveal the extent of disease-associated host genetic polymorphisms in the 
Scottish population. 
Microarray technology has been used to assess gene expression during 
meningeal-meningococcal interaction providing evidence for the release of host 
factors including cytokines and chemokines in response to bacterial challenge 
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(Wells, Tighe et al. 2001).  Neisserial genome comparisons based on microarray 
hybridisation experiments has also prompted attempts to identify virulence gene 
candidates that were restricted to invasive isolates. Differences in the 
pathogenic potential of different meningococci (carried or invasive), gonococci 
or other Neisseria spp. were measured by the mere presence/absence of a 
particular genetic determinant. Conflicting results regarding the association of a 
filamentous phage Nf1 (MDA) with invasive isolates suggests this phage is not a 
characteristic of all invasive meningococcal strains (Bille et al 2005; Hotopp et al 
2006).  Nevertheless, it is currently not known what MDA encodes. 
Characterisation of the individual porA VRs and the precise determination of the 
level of expression of the constituent PorA subtypes are warranted particularly 
since a number of prospective vaccines are at various stages of development.  
Furthermore, an assessment of the dominant epitopes would also be required to 
aid in the assessment of the immune response generated towards vaccine-
associated subtypes. Serum bactericidal assays (SBAs) in vaccinees or using 
convalescent sera from patients (such as is performed by the Vaccine Evaluation 
Unit, Meningococcal Reference Laboratory, Manchester, UK) combined with DNA 
sequencing of the porA promoter region could be utilised to assess this. 
Currently, the SHLMPRL performs Minimum Inhibitory Concentration (M.I.C.) 
assays on all N. meningitidis isolates for the following antibiotics; 
Sulphamethoxazole, Penicillin G, Chloramphenicol, Ciprofloxacin, Cefotaxime 
and Rifampicin. However, as previously mentioned, progressive laboratory 
practice meant that isolates obtained during the earlier period of the strain 
collection were not exposed to such rigorous protocols as those of a more 
contemporary period. Consequently not every isolate in the archive has been 
tested for its susceptibility to all the aforementioned antibiotics. This is one 
avenue worth further exploration, particularly since several of these antibiotics 
can be used to treat primary cases of meningococcal disease and oral Rifampicin 
is recommended in the UK for the prevention of secondary cases of 
meningococcal meningitis (and to facilitate eradication of the meningococcus 
from the nasopharynx). However, there is no widely adopted definition across 
Europe for breakpoints for antimicrobial resistance in N. meningitidis despite 
the efforts of the EMGM (Vázquez 2007; Vázquez, Enriquez et al. 2007). In 
addition, previous studies by the SHLMPRL on the prevalence of antibiotic 
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resistance has only focused on isolates of Streptococcus pneumoniae (Clarke, 
Scott et al. 2004; Clarke, Reid et al. 2005; Smith, Jefferies et al. 2006; Cooke 
2010). 
The Meningococcus remains an important pathogen of man despite the best 
efforts of the medical and scientific community over the preceding century and 
longer. Further study regarding carriage of the bacterium is warranted as there 
is much we have yet to learn. Diagnosis of IMD is problematic as initial symptoms 
are often non-specific and resemble other respiratory illnesses. The progression 
of disease is rapid, case-fatality rates exceed 10% and permanent sequelae are 
even more common. Isolation of the causative organism is not always possible, 
particularly if antibiotics have been administered prior to hospital admission, 
and laboratory-confirmed cases of IMD are increasingly being diagnosed by non-
culture methods. As the complexity of this bacterium is unravelled, perhaps a 
more potent method for the eradication of meningococcal disease can be 
discovered. Meanwhile, current strategies to control the burden of N. 
meningitidis should not be taken for granted; vaccination and antibiotic use has 
been shown to be effective in high-risk populations. However, continued 
surveillance is required to establish the long-term effect on individual lineages 
should they undergo genetic changes that render a particular vaccine or 
antibiotic obsolete and we must remain vigilant despite a downward trend in 
cases of meningococcal disease in more industrialised countries. 
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9 Appendix 
9.1 N. meningitidis carriage strain collection database 
An electronic record of the carried N. meningitidis strain collection 
characterised during this study was created from the meningococcal isolate 
database at SHLMPRL. All results of the genogroup-specific and genogroup non-
specific PCR tests, the MLST allelic profiles and STs, the porA VRs and capsule 
null locus allele sequencing were recorded onto the electronic record.  This 
database is stored as a Microsoft Excel file named “KScott-PhD” located in the 
folder “Common” within the SHLMPRL network and is only accessible by 
SHLMPRL staff. 
 
9.2 N. meningitidis carriage strain collection sequence 
electropherograms 
At the SHLMPRL, sequence trace files were routinely archived in duplicate.  One 
copy was archived to a remote server and one copy was archived locally onto 
compact disc. This was also performed for sequence trace files for all MLST 
alleles, porA VRs and cnl alleles obtained during this project.  A paper record of 
the sequencing results was also maintained during the project. To allow 
retrospective identification of the individual trace files details of the individual 
MegaBACE 1000 sequencing run file (or files) which contained the individual DNA 
sequence electropherograms for each MLST allele, porA VR or cnl allele was 
recorded in the paper record. At the time of writing this paper record was 
located in room 8 of the SHLMPRL. The archived sequence data files and the 
paper record of the sequencing results can only be accessed by SHLMPRL staff. 
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9.3 Examples of agarose gel electrophoresis pictures for 
the genotypic serogrouping, porA and MLST PCRs 
 
 
Figure 9.1 – Example of an agarose gel electrophoresis gel picture for the genotypic 
serogroup B (siaDB) PCR of N. meningitidis strains 
All rows; Lane 1: N. meningitidis serogroup B strain ATCC 13090 positive control, Lane 2: 18MΩ 
H2O negative control, Lanes 3 – 8, N. meningitidis isolates; Lane 9: N. meningitidis serogroup B 
strain ATCC 13090 positive control, Lane 10: 18MΩ H2O negative control, Lanes 11 – 16: N. 
meningitidis isolates. 
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Figure 9.2 – Example of an agarose gel electrophoresis gel picture for the genotypic 
serogroup C (siaDC) PCR of N. meningitidis strains 
Lane 1: N. meningitidis serogroup A strain ATCC 13077, Lane 2: N. meningitidis serogroup B strain 
ATCC 13090, Lane 3: N. meningitidis serogroup C strain ATCC 13102, Lane 4: N. meningitidis 
serogroup W135 strain NCTC 11203, Lane 5: N. meningitidis serogroup Y strain ATCC 35561, 
Lane 6: N. meningitidis cnl strain GL0101366, Lane 7: 18MΩ H2O negative control, Lane 8: siaDC 
PCR mix only. 
 
 
 
Figure 9.3 – Example of an agarose gel electrophoresis picture for the genotypic serogroup 
Y or W135 (siaDY/W135) PCR of N. meningitidis strains 
Lane 1: N. meningitidis serogroup W135 strain NCTC 11203 positive control, Lane 2: N. 
meningitidis serogroup Y strain ATCC 35561 positive control, Lane 3: 18MΩ H2O negative control, 
Lane 4: N. meningitidis strain 85-06321, Lane 5: N. meningitidis strain 85-09251, Lane 6: N. 
meningitidis strain 85-09253, Lane 7: N. meningitidis strain 85-09254, Lane 8: N. meningitidis strain 
85-09260, Lane 9: N. meningitidis strain 85-09262, Lane 10: N. meningitidis strain 85-09264, Lane 
11: N. meningitidis strain 85-09266, Lane 12: N. meningitidis strain 85-09274, Lane 13: N. 
meningitidis strain 85-11256. 
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Figure 9.4 – An example of an agarose gel electrophoresis picture of XbaI-digested 
siaDY/W135 PCR-positive products 
Top row: undigested siaD Y/W135 PCR-positive amplicons, Bottom row: XbaI-digested siaD 
Y/W135 PCR-positive products, Lane 1: N. meningitidis serogroup W135 strain NCTC 11203 
(positive control), Lane 2: N. meningitidis serogroup Y strain ATCC 35561 (positive control), Lane 
3: N. meningitidis strain 85-09254, Lane 4: N. meningitidis strain 85-09266, Lane 5: N. meningitidis 
strain 85-11256. 
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Figure 9.5 – Example of an agarose gel electrophoresis picture for the genotypic serogroup 
X, Z & 29E (ctrAX, ctrAZ & ctrA29E) PCRs of N. meningitidis strains 
Top row: ctrA X PCR, Middle row: ctrA Z PCR, Bottom row: ctrA 29E PCR, Lane 1: 100bp DNA 
Ladder, Lane 2: N. meningitidis serogroup A strain ATCC 13077, Lane 3: N. meningitidis serogroup 
B strain ATCC 13090, Lane 4: N. meningitidis serogroup C strain ATCC 13102, Lane 5: N. 
meningitidis serogroup W135 strain NCTC 11203, Lane 6: N. meningitidis serogroup Y strain 
ATCC 35561, Lane 7: N. meningitidis serogroup X strain NCTC 10790, Lane 8: N. meningitidis 
serogroup Z strain NCTC 10792, Lane 9: N. meningitidis serogroup 29E strain NCTC 11202, Lane 
10: N. meningitidis cnl strain GL0101366, Lane 11: ctrA PCR mix + 18MΩ H2O, Lane 12: ctrA PCR 
mix only, Lane 13: 100bp DNA Ladder. 
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Figure 9.6 – Example of an agarose gel picture for the capsule null locus (cnl) PCR of N. 
meningitidis strains 
Lane 1: N. meningitidis cnl strain GL0101366 (positive control), Lane 2: N. meningitidis serogroup 
B strain ATCC 13090 (negative control), Lane 3: 18MΩ H2O (negative control), Lane 4: N. 
meningitidis strain 99-3792, Lane 5: N. meningitidis strain 02-4098. 
 
 
 
Figure 9.7 – Example of an agarose gel electrophoresis picture for the serogroup non-
specific ctrA PCR on N. meningitidis strains 
Lane 1: N. meningitidis serogroup A strain ATCC 13077, Lane 2: N. meningitidis serogroup B strain 
ATCC 13090, Lane 3: N. meningitidis serogroup C strain ATCC 13102, Lane 4: N. meningitidis 
serogroup W135 strain NCTC 11203, Lane 5: N. meningitidis serogroup Y strain ATCC 35561, 
Lane 6: N. meningitidis serogroup X strain NCTC 10790, Lane 7: N. meningitidis serogroup Z strain 
NCTC 10792, Lane 8: N. meningitidis serogroup 29E strain NCTC 11202, Lane 9: N. meningitidis 
cnl strain GL0101366, Lane 10: N. meningitidis strain 96-0628, Lane 11: N. meningitidis strain 97-
1386, Lane 12: serogroup non-specific ctrA PCR mix + 18MΩ H2O, Lane 13: serogroup non-
specific ctrA PCR mix only. 
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Figure 9.8 – Example of an agarose gel electrophoresis picture for the amplification of porA 
and MLST PCR products on N. meningitidis strains 
Order of amplified gene fragments repeats every 8 lanes: porA, abcZ, adk, aroE, fumC, gdh, pdhC 
and pgm, Top row Lanes 1 – 8: N. meningitidis serogroup A strain ATCC 13077, Top row Lanes 9 
– 16: N. meningitidis serogroup B strain ATCC 13090, Middle row Lanes 1 – 8: N. meningitidis 
serogroup W135 strain NCTC 11203, Middle row Lanes 9 – 16: N. meningitidis serogroup Y strain 
ATCC 35561, Bottom row Lanes 1 – 8: N. meningitidis serogroup X strain NCTC 10790, Bottom 
row Lanes 9 – 16: N. meningitidis serogroup Z strain NCTC 10792. 
 
